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APASL/Poster/Abstract/1
Expression of co-inhibitory molecules in PBMC from chronic
hepatitis C patients
Youn-Jae Lee1,2, Sung-Jae Park1,2, Sam Ryong Jee1, Sang Hyuk
Lee1, Sang Young Seol1, Jung Myung Chung1, Hye-Young
Jeong2,3, Hyoun-Mi Seo2,3, Su-Kil Seo2,3, Sae-Gwang Park2,3,
Jeong-Nyeo Lee2,3 and In-Hak Choi2,3
1Department of Internal Medicine,
2Research Center for Immune Modulation,
3Department of Microbiology, Inje University College of
Medicine, Busan, Korea
We reasoned that B7-H1 and B7-H4, co-inhibitory molecules,
may be involved in the defective T cell immunity to hepatitis C
virus (HCV) in chronic hepatitis C (CHC) patients. First, we
measured the expression proﬁles of B7-H1 and B7-H4 in
unstimulated or stimulated PBMCs with PHA or LPS by
FACS. The percentage of B7-H1-expressing unstimulated
CD41, CD81 T cells, B cells, and monocytes was signiﬁcantly
increased in CHC patients compared to normal donors. How-
ever, B7-H4 expression appeared considerably high only in
CD191B cells and monocytes from CHC patients. In contrast,
B7-H1 and B7-H4 expression in stimulated CD41 and CD81 T
cells with PHA were upregulated in normal donors rather than
in CHC patients, implying that a proliferating activity of T cells
was inhibited by unknown mechanisms. We also examined the
expression of regulatory molecules associated with tolerance
such as immunoglobulin-like transcript 3 (ILT3), ILT4, TGF-
b3, and indolamine 2,3-deoxygenase (IDO). Expression of all
these genes was upregulated in CHC patients untreated with
IFN-a/ribavirin compared with normal donors. The ﬁndings of
high expression of co-inhibitory molecules, B7-H1 and B7-H4,
and regulatory molecules associated with tolerance suggest that
these molecules may be involved in the pathogenesis of chronic
hepatitis C.
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APASL/Poster/Abstract/3
Endoscopic mucosal resection of a long Barrett’s esophagus with
intramucosal cancer in a patient with decompensated HCV liver
cirrhosis (Child–Pugh B) and esophageal varices (grade I)
S. Seewald, T. L. Ang, B. Bestari, I. Marki, T. Sookpaisal,
S. Omar, S. Groth, U. Seitz, Y. Zhong, F. Thonke and
N. Soehendra
Department of Interdisciplinary Endoscopy, University Hospi-
tal Hamburg-Eppendorf, Hamburg, Germany
Endoscopic mucosal resection (EMR) has emerged as a viable
alternative form of curative therapy to surgery for early eso-
phageal cancers, especially in patients with a high surgical risk.
One of the limitations of EMR is coexisting esophageal varices.
We describe a case of intramucosal cancer in a 10-cm long
segment Barrett’s esophagus arising in a 63-year-old patient
with esophageal varices (grade I) due to hepatitis C liver
cirrhosis (Child–Pugh B). Early Barrett’s cancer and esophageal
varices were diagnosed during his pre-liver transplantation
evaluation. To qualify for liver transplantation listing, the
Barrett’s cancer had to be treated but he was deemed to have
too high a surgical risk on account of his cirrhosis and as such
was referred for treatment with EMR. Prior to EMR, the portal
system was decompressed by transjugular intrahepatic porto-
systemic shunting (TIPS). Complete ablation of Barrett’s eso-
phagus was then successfully achieved with circumferential
EMR using the newly introduced multi-band ligation (MBL)
technique (Duette Multi band mucosectomy kit - CE0123, Cook
Ireland Ltd., Ireland) supplemented by snare resection using a
30-mm Erlangen-type polypectomy snare made of monoﬁla-
ment 0.28-mm-thick stainless-steel wire (Medwork, Germany)
in ﬁve sessions. The total number of resected mucosa pieces was
25 and the size ranged from 0.3 to 2.4 cm2. Histological evalua-
tion revealed high-grade intraepithelial neoplasia (HGIN) and
well-differentiated intramucosal cancer (IMC) (pT1 m2; G2).
Bleeding from a small varix occurred only once during the ﬁrst
EMR session, and was controlled immediately by intravariceal
injection with 0.5ml of the N-butyl-2-cyanoacrylate (Histoa-
cryls): Lipiodols mixture (0.5ml: 0.8ml). During the entire
follow-up of 4 months, no recurrence of Barrett’s esophagus or
malignancy was observed. The patient is currently doing well
and is awaiting liver transplantation.
APASL/Poster/Abstract/4
Long-term safety and efﬁcacy of N-butyl-2-cyanoacrylate injec-
tion for bleeding fundal varices using a standardized injection
technique
S. Seewald, H. Imazu, I. Marki, B. Bestari, S. Omar, S. Groth,
U. Seitz, Y. Zhong, S. Sikka, F. Thonke and N. Soehendra
Department of Interdisciplinary Endoscopy, University Hospi-
tal Hamburg-Eppendorf, Hamburg, Germany
Introduction: The tissue glue N-butyl-2-cyanoacrylate (CA)
has been successfully used in many countries for the treatment
of gastric fundal variceal (FV) bleeding. However, signiﬁcant
rebleeding rates and serious complications including embolism
have been reported, which hinders approval in the US.
Aims: To analyze the long-term safety and efﬁcacy of CA
for FV bleeding using a standardized injection technique and
regimen. Methods: (1) 0.5ml CA was mixed with 0.8ml Lipio-
dol. (2) To minimize the risk of embolism, not more than 1.0ml
of CA–Lipiodol mixture was injected into fundal varices at any
one time and repeated if necessary until hemostasis was
achieved. (3) Simultaneous obliteration of all tributaries was
carried out. (4) Endoscopy was repeated after 4 days to check
for patent varices by palpation method to prevent rebleeding.
Results: Fighty-eight patients with FV underwent endoscopic
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obliteration with CA from 1994 to 2003. Eleven presented with
active bleeding and 47 had elective sessions. Cirrhosis was
present in 54 patients and non-cirrhotic portal ﬁbrosis in 4.
Initial hemostasis and eradication were achieved in all patients.
The total number of sessions was 1.3  0.5. The total volume of
CA was 3.7  2.3ml. The cumulative rebleeding free rate at 1-,
3- and 5-year periods was 97.9, 93.9 and 78.0%, respectively.
The cumulative survival rate at 1-, 3- and 5 year periods was
75.1, 51.7 and 40.8%, respectively. There was no procedure-
related complication. Rebleeding free rate was not inﬂuenced by
the type of FV or by liver function. However, mortality rate was
signiﬁcantly related to Child–Pugh class. Conclusion: Endo-
scopic obliteration with CA is safe and effective for treatment
of bleeding FV. The side effects can be minimized by the
standardized injection technique and regimen. Future studies
of primary prophylaxis for gastric fundal varices with CA are
warranted to prevent early mortality.
APASL/Poster/Abstract/5
May three to four months’ treatment with pegylated interferon and
ribavirin for chronic hepatitis C be an alternative basic therapy?
M. Tantoro Harmono
Internal Medicine Laboratory, Dr. Muwardi District General
Hospital, Faculty of Medicine, Surakarta University, Surakarta,
Indonesia
Following the case of a woman, 60 years old with chronic C
hepatitis, treated with interferon thrice a week and ribavirin
1000mg daily, one can stop the therapeutic program after 4
weeks of treatment. When her qualitative serological marker was
checked for its HCV RNA, the result was negative. These data
suggest that it may be possible to treat chronic hepatitis C in a
shorter time. Another reason is that Interferon is too expensive
for our people. Based on these data, I tried to treat the patients in
two groups: the ﬁrst group consisted of those with type I virus
and the other group had those with the other genotype virus. The
ﬁrst group was treated for 3 months and then the qualitative
HCV RNA was checked. While we waited for the results from
the laboratory, which took a month’s time, the patients were still
being treated. If the result was negative, it meant that the virus
was negative in 3 months of treatment, but I still continued the
treatment for a month then. The second group, which was of the
other genotype, was treated with the regimen for 2 months and
the qualitative HCV RNA was checked. While we waited for the
results, the patients were still under treatment for a month. If the
HCV RNA was negative, the patients still followed their regimen
of treatment for 1 month. I realize there is the danger of relapse,
but for economic reasons, treating the ﬁrst group (genotype I)
for 4 months and the second group for 3 months, is reasonable as
an alternative basic therapy for chronic hepatitis C, particularly
for a poor country. Certainly this study needs a longer time and
many more patients.
APASL/Poster/Abstract/6
Liver diseases in private hospitals in Jakarta
K. Marcellus Simadibrata1, Unggul Budihusodo Soemarno2
and Bunyamin Aries3
1Department of Internal Medicine, Faculty of Medicine,
University of Indonesia/Dr. Cipto Mangunkusumo Hospital,
2Department of Internal Medicine, St. Carolus Hospital,
3Department of Internal Medicine, Pluit Hospital, Jakarta,
Indonesia
Background: Liver disease can be drug induced, caused by viral
or bacterial infection, fatty inﬁltration, malignancy, etc. Hepa-
titis can be acute or chronic. Hepatitis may be drug induced or
caused by viral or bacterial infection. Patients and Meth-
ods: This is a retrospective study. All data from the medical
records of the liver disease patients related to viral hepatitis
infection in three hospitals in Jakarta (Abdi Waluyo, Pluit, and
St. Carolus) from the year 2001 to 2003 were included in this
study. Incomplete data were excluded. Diagnosis of patients was
made on the basis of history of illness, physical examination,
supporting laboratory (liver function tests), liver ultrasound or
CT-scan examination, and liver biopsy for chronic liver disease/
hepatoma. The diagnosis of viral hepatitis infection was made
according to the results of viral serological marker (IgM anti
HAV, HBsAg, IgM anti-HBc, HBeAg, total anti-HCV, IgM
anti-HCV) examinations. Results: There were 278 data of liver
disease related to viral hepatitis infection patients from the year
2001 to 2003. The most frequent liver disease was acute hepatitis
(55.39%). The characteristics of the patients were male (64.75%),
mean age 39.38  17.21 years old and Javanese (24.10%). In
acute hepatitis, there was no correlation with sex (P40.05). The
male patient was more frequent in the chronic hepatitis, liver
disease, and hepatoma groups (Po0.001). The mean age in the
acute hepatitis group was less than in the chronic hepatitis, liver
cirrhosis and hepatoma groups (Po0.001). The hepatitis A viral
infection was the most frequent cause of acute hepatitis in 121
patients (85.21%). The hepatitis C viral infection was the most
frequent cause of chronic hepatitis (63.89%), liver cirrhosis
(53.33%), and hepatoma/HCC (60%). Conclusion: The most
frequent liver disease is acute hepatitis.
APASL/Poster/Abstract/7
Endoscopic retrograde cholangio pancreatography (ERCP) ex-
amination in patients with biliary obstruction due to common bile
duct (CBD) stone
Marcellus Simadibrata, Dadang Makung Soemarno, Abdullah
Murdani, Syam Ari Fahrial, Manan Chudahman, H. Daldiyono
and A. A. Rani
Department of Internal Medicine, Faculty of Medicine, Uni-
versity of Indonesia/Dr. Cipto Mangunkusumo Hospital,
Jakarta, Indonesia
Background: Biliary obstruction can be caused by CBD stone,
CBD stricture, cholangio carcinoma, etc. In this study, we
wanted to assess the role of ERCP examination (diagnostic
and therapeutic) in cases with CBD stone. Patients and Meth-
ods: All patients with common bile duct stone found in ERCP
examination from 2000 to 2004 were included in this study. This
is a retrospective study, using the patients’ medical records from
Cipto Mangunkusumo Hospital and St. Carolus Hospital.
Results: We found 67 patients with biliary obstruction due to
CBD stone from 138 ERCP examinations. The most frequent
complaint was jaundice in 44 (65.67%) patients. The most
frequent age group is 40–49 years (29.85%). The biliary stones
were found both in the CBD and the gall bladder in 18 (26.87%)
patients. Sphincterotomy and stone extraction were done in
31 (46.27%) patients. Mechanical lithotripsy was done in 2
patients. Stenting was done in 17 (25.37%) patients. The failure
of therapeutic ERCP was found in 13 (19.40%) patients.
Conclusion: We frequently found CBD stones in biliary ob-
struction with ERCP examination. Therapeutic ERCP was
successful in 80.60% of patients.
APASL/Poster/Abstract/8
Efﬁcacy of analog of schizandrine C in management of acute viral
hepatitis
A. Fuad Bakry, Suyata Syadra Bardiman, Taufan Hermansyah
and Erwin Azmar
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Division of Gastroenterohepatology, Department of Internal
Medicine, University of Sriwijaya School of Medicine/Moh.
Hoesin General Hospital, Palembang, Indonesia
Background: Acute viral hepatitis is still the main health pro-
blem in many countries all over the world, including Indonesia,
because of high incidence, morbidity, and mortality rates. Until
now, there is no speciﬁc treatment for acute viral hepatitis.
Management therapy is carried out by giving rest, a sufﬁcient-
calorie diet, and avoiding hepatotoxic drugs. Nowadays, scien-
tists are interested in using alternative medicines such as herbal
plants or phytopharmacy, which is already known as medicine
for healing the liver after trauma or infection (hepatoprotector).
Objective: To determine the efﬁcacy of analogue of schizan-
drine C on acute viral hepatitis patients. Patients and Meth-
ods: This study was a double-blind controlled study. Sample
was adapted based on simple randomization. Subjects were
inpatients with acute viral hepatitis in Dr. Moh. Hoesin General
Hospital, Palembang during July–December 2004, with age
range 15–65 years; clinically, they had acute viral hepatitis A
and B features, positive serologic markers (IgM anti-HAV for
hepatitis, acute viral hepatitis A, HBsAg and IgM anti-HBc for
acute viral hepatitis B) and agreed to participate in this study.
Results: We had 39 acute viral hepatitis patients, 36 patients
were included in the study and three patients dropped out. Out
of 36 patients, 32 patients had acute viral hepatitis A, and 4
patients had acute viral hepatitis B. Subjects are divided into
two groups by simple randomization; each group included 18
patients, composed of 16 acute viral hepatitis A patients and
two acute viral hepatitis B patients. There were no signiﬁcant
differences on database characteristics of both groups (P4
0.05). Improvement on liver function parameters showed signiﬁ-
cant differences in both groups in the second, third and fourth
weeks after treatment (Po0.05). At the end of the fourth week,
in group I, SGOT and SGPT levels declined and were 94.56%
and 95.79%, respectively, and almost all patients achieved
clinical improvement except for 1 patient who still had jaundice.
In group II, SGOT and SGPT levels declined and were 79.29%
and 83.80%, respectively, and eight patients still had jaundice,
two of them with nausea, one patient with vomitus and one
patient with epigastric pain. During this study period, there were
no side effects found on using analogue of schizandrine C or
worsening of the course of acute viral hepatitis patients in both
groups. Conclusions: Analogue of schizandrine C improved the
clinical healing and recovery period and also liver function
parameters in acute viral hepatitis patients.
APASL/Poster/Abstract/9
Multistage stratiﬁed random sampling of HbsAg in rural area of
Pagar Alam South Sumatra, Indonesia
Fuad Bakry, Syadra Bardiman, Suyata and Mumasi Silitonga
Gastroenterohepatology Division, Internal Medicine Depart-
ment, Medical Faculty of Sriwijaya University/RSMH Palem-
bang, Indonesia
Background: The data available in gastroenterohepatology di-
vision of internal medicine department of Dr. Moh. Hoesin
Hospital Palembang showed that hepatitis, liver cirrhosis and
hepatoma patients with HBsAg positive mostly come from
Pagar Alam town, South Sumatra, Indonesia. Therefore, the
research was carried out in that town in order to know the
prevalence and risk factors inﬂuencing the cause of hepatitis B in
that particular area. Methods: A cross-sectional study was
carried out from May to October 2004 in Pagar Alam, a
mountainous area 350 km from Palembang. The subjects of
the research were 1000 people taken by using the multi-stage
stratiﬁed random sampling technique. Results: Mean age of the
respondent was 38.9 years (range 65–72 years old), mostly 30
years old; the youngest was 17 and the oldest one was 95 years
old. They had the following characteristics: female 52.1% (521
people), farmers 49.4% (494 people), elementary graduate,
Basemah ethnic 62% (628 people). A total of 1000 subjects
were examined: 71 people suffered from HBsAg positive (7.1%),
42 of them had HBsAg positive and 19 subjects had families
with positive HBsAg. There were 71 subjects with HBsAg
positive; the male to female ratio was 7.16%:6.9% but was
not signiﬁcant statistically. In terms of occupation 10.6% (67
subjects), had one permanent job, and most of them were junior
high school graduates (11.5%). Pagar Alam ethnics have a 1.8-
fold risk of getting infected by hepatitis B compared to other
ethnics (P5 0.04). There was no statistically signiﬁcant correla-
tion among speciﬁc anamnesis, injection and tranfusion history
and positive HBsAg (P5 0.146 and 0.146). The history of
subjects with fever and icteric symptom and subjects with family
jaundice history show a signiﬁcant relation to positive HBsAg
examination (P5 0.03 and 0.02 ). Multiple heterosexual subjects
and drug users had a statistically signiﬁcant relationship with
hepatitis B prevalence in Pagar Alam (P5 0.002 and 0.001).
Based on physical examination, there were 27 subjects suffering
from icteric eyes (2.72%) and 54 subjects with hepatomegaly
(5.4%). The HBeAg positive were 59.16% of HBsAg positive
patients. Conclusion: Prevalence of HBV (positive HBsAg) was
7.1% in Pagar Alam. Risk factors of HBsAg positive in Pagar
Alam were poor socioeconomics status and knowledge, HBV
positive family members, sexual behavior, and drug user.
APASL/Poster/Abstract/10
Utility of serum a-fetoprotein in predicting survival of patients
diagnosed with hepatocellular carcinoma
D. A. Payawal, I. A. Lapus, J. M. Co and G. Nilo
Cardinal Santos Medical Center, Wilson St., San Juan, Metro
Manila, Philippines
Introduction: Hepatocellular carcinoma (HCC) represents the
third most common cancer in the Philippines. a-fetoprotein
(AFP) is a widely used marker to screen for early HCC. Its role
in predicting survival has not been established. Objective: The
aim of this study is to determine the utility of AFP in predicting
survival among patients with HCC. General Study Design:
Prospective cohort. Participants: All patients from 1997 to
2004 who were referred to our clinic due to liver mass and
underwent liver biopsy were analyzed and followed up. Analy-
sis: Demographic data, tumor characteristics and Child–Pugh
Classiﬁcation were analyzed and correlated with AFP levels
using multivariate analysis. Patients were classiﬁed into Group I
(AFPo10 ng/ml) and Group II (AFP410 ng/ml). Kaplan–
Meier method of analysis was used to determine the survival
difference. Results: One hundred and four patients were in-
cluded. Demographic data and tumor characteristics of the two
groups were comparable. Group I (N5 25) had 1-, 3- and 5-year
survival rates of 88%, 65% and 65%, respectively. Group II
(N5 63) had a 1-, 3- and 5-year survival rates of 79%, 44% and
20%, respectively (P5 0.60). Furthermore, substratifying pa-
tients based on treatment showed no signiﬁcant difference in
survival rates between Group I and Group II (P5 0.60).
Conclusions: sAFP is not a good predictor for survival of
patients with HCC. Furthermore, it does not correlate with
patient or tumor characteristics.
APASL/Free Paper/Abstract/11
Titers of antibody to Hepatitis B surface antigen after the
implementation of expanded program on immunization in Cica-
lengka subdistrict Bandung
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Iesje Martiza, Sri Sudarwati, Yasmar Alfa and Dwi Prasetyo
Department of Pediatric, Medical Faculty, Padjadjaran Uni-
versity/Hasan Sadikin General Hospital, Bandung, Indonesia
To evaluate the immunologic response and the long-term
protection provided by a Biofarma’s yeast-derived recombinant
Hepatitis B (HB) vaccine that was implemented by Expanded
Program on Immunization since 1995, we examined titers of
antibody to Hepatitis B surface antigen (anti-HBs) on 61
children aged 9–66 months old who were recipients of that
vaccine in Cicalengka subdistrict Bandung West Java. Our
sample consisted of 31 (50.8%) males and 30 (49.2%) females.
All of the subjects had received three doses of intramuscular HB
vaccine according to the recommended dose and schedule (the
last dose was given at age 6). These subjects were divided into six
age groups, i.e. 9, 18, 30, 42, 54 and months old, respectively.
Blood samples were examined for anti-HBs using the Immulite
Diagnostic Kit (Enzyme-linked immunosorbent assay).
Mothers’ HBsAg status were unknown. The geometric means
of anti-HBs titers (GMTs) were calculated by taking the log of
anti-HBs titers for each subject and then taking the antilog of
the mean of these values. There was a high signiﬁcant difference
of the GMTs in all groups with the values 539.6, 62.0, 30.2,
119.7, 132.5 and 11.6mIU/ml, respectively (F5 5.998; Po
0.001). A further analysis by the Duncan’s mean difference test
showed that signiﬁcant groups were the ﬁrst compared to the sixth
group. To assess the association between the duration after im-
munization and antibody titers using the cubic regression formula,
we had obtained the GMT’s estimate of each group as 592.2,
44.7, 44.2, 108.1, 122.9 and 12.3mIU/ml, respectively (r5 0.585;
Po0.001). The GMTs of anti-HBs after HB vaccination by
Expanded Program on Immunization had ﬂuctuated during 5
years after the last dose; seroprotective level had been obtained
in 100% of the ﬁrst group and 55% of the sixth group. However,
all of the subjects with no protective anti-HBs titers remained
protected against acute infection as well as chronic Hepatitis B
carrier. It seems that immunologic memory remains intact up to
5 years after immunization.
APASL/Free Paper/Abstract/12
Association of Hepatitis C infection among thalassemic children
with number of blood unit transfusions after donor blood screening
in Hasan Sadikin General Hospital Bandung
Dwi Prasetyo, Diah Asri Wulandari, Iesje Martiza and
Yasmar Alfa
Department of Pediatrics, Medical Faculty, Padjadjaran Uni-
versity/Hasan Sadikin General Hospital, Bandung, Indonesia
Introduction: Donor blood screening test for HCV antibody by
third generation ELISA is widely used. However, there is still a
window period during which a donor can be infected, but still
have a negative screening test. The positive predictive value of
this test is only 50–61% in patients who are at low risk for HCV
infection. With PCR, this window period is reduced approxi-
mately to 12 days. Objectives: To ﬁnd the association of HCV
infection with the number of blood unit transfusions, and
prevalence of hepatitis C infection in thalassemic children
receiving screened donor blood. Patients and Methods: This
was an analytic cross-sectional study. Sixty-seven children
receiving third generation ELISA screened donor blood were
examined for HCV antibody using UBI EIA 4.0 consecutively.
The study was conducted in Hasan Sadikin General Hospital,
Bandung, from January to March 2004. The prevalence of
Hepatitis C was presented in percentage, and the association
of HCV infection with the number of unit transfusions was
presented using logistic regression analysis. Results: There was
an association between the quantities of transfused blood and
positive HCV antibody (Po0.001). The magnitude of associa-
tion was 1.08 for each blood unit transfusion. The prevalence of
Hepatitis C in thalassemic children receiving third generation
ELISA-screened blood was 22.4% (95% CI 12.4–32.4%).
Comparison with the prevalence of HCV infection from pre-
vious studies before and after the advent routine screening
for HCV using third generation ELISA (50.8% and 22.4%,
respectively) showed signiﬁcant difference by w2 (Po0.001).
Conclusion: There is an association between HCV infection
and the number of blood unit transfusions, and donor
blood screening test with third generation ELISA will decrease
the prevalence of Hepatitis C infection among thalassemic
children.
APASL/Free Paper/Abstract/13
Eupatilin, a pharmacologically active ﬂavone derived from Arte-
misia asiatica, suppresses death receptor-mediated hepatocyte
apoptosis
J. H. Yoon, G. Y. Gwak, S. H. Lee, S. M. Lee, Y. J. Kim and
H. S. Lee
Department of Internal Medicine and Liver Research Institute,
Seoul National University College of Medicine, Seoul, Korea
Background: In cholestasis, bile acids induce hepatocyte apop-
tosis primarily via activating death receptor (DR)-mediated pro-
apoptotic signaling cascades. Eupatilin (5,7-dihydroxy-3,4,6-
trimethoxyﬂavone), an active ingredient of Artemisia asiatica,
has anti-oxidative and anti-inﬂammatory activities, and exhibits
cytoprotective effects against experimentally-induced gastroin-
testinal, hepatic and pancreatic damage. Objectives: This study
was conducted to examine if Eupatilin might modulate DR-
mediated hepatocyte apoptosis. Methods: Huh-BAT cells, a
human hepatocellular carcinoma cell line stably transfected
with a bile acid transporter, were used in this study. Hepatocyte
apoptosis was quantiﬁed using DAPI staining, and its signaling
cascades were explored by immunoblot. MAPK signals were
evaluated using immunoblot and their selective inhibitors.
Results: Eupatilin signiﬁcantly attenuated DR-mediated hepa-
tocyte apoptosis, which was either induced by bile acid or
TRAIL. Speciﬁcally, Eupatilin diminished bile acid-induced
caspase 8 cleavage and subsequent activation of its downstream
pro-apoptotic signals. The reduced caspase 8 activation was not
due to the modulation of TRAIL-R2/DR5 expression levels.
Instead, Eupatilin attenuated bile acid-induced activation of
pro-apoptotic MAPKs including p38 MAPK and JNK. In
particular, the Eupatilin-mediated inhibition of bile acid-in-
duced JNK activation was responsible for the attenuation of
caspase 8 cleavage. Contrary to Eupatilin, N-acetylcysteine, an
anti-oxidant, did not affect the bile acid-induced pro-apoptotic
signals. Conclusions: The results demonstrate that Eupatilin
attenuates DR-mediated hepatocyte apoptosis by decreasing
bile acid-induced pro-apoptotic JNK activation, independent of
its anti- oxidative function. Therefore, Eupatilin might be ther-
apeutically efﬁcacious in a variety of human liver diseases
associated with cholestasis.
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APASL/Poster/Abstract/18
Coadministration of albumin and furosemide for the treatment of
cirrhosis patients with ascites and hypoalbuminemia
Ivan L. Toruan, A. Fuad Bakry, Syadra B. Suyata
Division of Gastroenterohepatology, Department of Internal
Medicine, Sriwijaya University, Faculty of Medicine/Moh.
Hoesin General Hospital, Palembang, Indonesia
Introduction: Hypoalbuminemia in cirrhosis patients often re-
sults in sufﬁcient ﬂuid accumulation to mandate diuretic therapy
but is often resistant to diuresis. Studies have suggested that
hypoalbuminemia itself diminishes the amount of albumin-
bound furosemide and diminishes furosemide delivery to the
ascending limb of the loop of the Henle. Therefore, administra-
tion of mixtures of albumin and furosemide may enhance
diuretic and natriuretic responses. Objectives: The aim of this
crossover study was to investigate whether albumin/furosemide
mixture could increase the diuretic and natriuretic action of
furosemide. Patients and Methods: Eleven patients with cirrho-
sis and ascites (age, 54.4  16.5 years; Child–Pugh score,
10.2  0.9; Child–Pugh class B/C, 2/9; serum albumin,
2.1  0.4 g/dl; serum bilirubin, 1.3  0.7mg/dl; serum creati-
nine, 0.9  0.3mg/dl; serum ALT, 58.0  27.3 IU/L) were
enrolled in the study. Sodium balance was maintained through-
out the study with a metabolic diet. All patients received
spironolactone, but administration of all other diuretic agents
was discontinued. Each patient received all of the following two
treatments intravenously: (1) 40mg of furosemide, (2) 40mg of
furosemide and 25 g of albumin premix ex vivo. Results: Both
furosemide alone and albumin/furosemide mixture increased
urine volume signiﬁcantly as compared with each basal state
(673  254ml/24 h vs 2273  969ml/24 h, Po0.05; and
818  338ml/24 h vs 3009  907ml/24 h, Po0.05). The vo-
lumes of urine between the two groups were of statistical
signiﬁcance (Po0.05). Sodium excretions were signiﬁcantly
increased in both groups, compared with each basal state
(35.0  22.1 mEq/24 h vs 161.5  86.3 mEq/24 h, Po0.05;
and 34.3  20.5 mEq/24 h vs 192.0  106.6 mEq/24 h,
Po0.05). The amounts of sodium excretion between the two
groups were of statistical signiﬁcance (Po0.05). Conclusion-
s: Albumin enhanced the diuretic and natriuretic effects of
furosemide in cirrhosis patients with ascites and hypoalbumi-
nemia. Therefore, the coadministration of albumin and furose-
mide for the treatment of cirrhosis patients with ascites and
hypoalbuminemia should be consider clinically.
19
Abstract withdrawn
20
Abstract withdrawn
21
Abstract withdrawn
APASL/Poster/Abstract/22
Prevalence of HCV genotype
Ho Tan Dat and Pham Thi Thu Thuy
Medic Medical Center, Vietnam
Background: Hepatitis C virus (HCV) genotypes are distributed
differently depending on geography and etiology of infection.
The incidence of HCV isolates found in clinical practice is of
great clinical signiﬁcance to the treatment of HCV infected
patients as different subtypes may respond unequally to therapy.
Objectives: To evaluate the prevalence of HCV genotypes in
Vietnamese patients. Comparison of serum virus loads among
patients infected with Hepatitis C Virus genotypes 1, 2, and 6.
Methods: A total of 327 HCV RNA-positive patients with
chronic hepatitis were enrolled (male 57.5%, female 42.5% with
mean age of patients 47.9  10.58 years) from April 2004 to
January 2005. HCV genotypes were determined by LiPA (Bayer
Corporation). At the same time, we collected 229 random serums
in this group to perform Branched DNA for HCV RNA
quantiﬁcation. Results: Genotypes 1 and 6 were the commonest
genotypes, followed by type 2, while the rare genotype 3 was
found in a lone patient. Genotype 1 was seen in 58.4% (type 1:
5.8%; 1a: 6.4%; 1a/1b: 0.3%; 1b: 45.9%) genotype 6a in 23.9%,
genotype 2 in 13.1% (type 2: 1.5%; type 2a/2c: 11.6%), and
genotype 3b in 0.3%. 14 samples (4.3%) were unclassiﬁed. We
then performed sequencing based on 50UT with the Trugene
system, identiﬁed genotype 1 (two cases), 1b (two cases), 2a (one
case), 2c (one case), and 6a (eight cases) but not typed by LiPA.
In all, 229 patients had viral loads. HCV genotypes 1, 2, and 6
had quantities of HCV above 2  106 copies/ml in 91, 18, and 32
cases, and below 2  106 copies/ml in 46, 15, and 27 cases,
respectively. We observed no signiﬁcant difference in virus load
between patients infected with genotypes 1, 2, and 6 (P40.05).
Conclusions: Our study indicated that HCV genotypes 1 and 6
are common in Vietnam, while subtype 1b is the most common.
A unique genotype 3b was detected in our patients. There is no
relationship between HCV genotype and viremia levels. The
TruGene system, a direct sequencing method, is more efﬁcient
in the identiﬁcation of the HCV genotype.
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APASL/Plenary/Abstract/25
Genotype C HBV has two subgroups with distinct epidemiological
and virological characteristics
H. L. Y. Chan, S. K. W. Tsui, C. H. Tse, E. Y. T. Ng, T. C. C.
Au, L. Yuen, A. Bartholomeusz, K. S. Leung, K. H. Lee,
S. Lorcarnini and J. J. Y. Sung
Department of Medicine and Therapeutics, Biochemistry and
Department of Computer Science and Engineering, The Chinese
University of Hong Kong, Hong Kong and Victorian Infectious
Disease Research Laboratory, Melbourne, Australia
Background: Genotype C hepatitis B virus (HBV) is associated
with more aggressive disease and possibly higher risk of
hepatocellular carcinoma than genotype B HBV in Asia.
Objectives: We aimed to investigate the characteristics of
HBV genotype C subgroups in Hong Kong and its relationship
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with HBV genotype C in other parts of Asia. Methods: Full-
genome nucleotide sequences of 49 HBV genotype C isolates
from Chinese chronic hepatitis B patients were compared with
the sequences of 69 HBV genotype C isolates and 12 genotype
non-C isolates in GenBank database. Phylogenetic analysis was
performed to deﬁne the subgroups of HBV genotype C based on
44% heterogeneity of the entire HBV genome. Results: Eighty
percent of patients in Hong Kong belonged to a subgroup
predominantly found in Southeast Asia (Vietnam, Thailand,
Myanmar and Southern China) designated as HBV genotype Cs
and the remaining 20% of patients belonged to another sub-
group predominantly found in the Far East (Korea, Japan and
Northern China) designated as HBV genotype Ce. Overall, the
number of differences in nucleotide sequence between HBV
genotype Cs and HBV genotype Ce was 4.2  0.3%. Both
genotypes Cs and Ce have over 8% nucleotide difference from
other HBV genotypes. Comparing HBV genotype Cs and HBV
genotype Ce among patients in Hong Kong, HBV genotype Cs
was associated with a higher tendency to develop basal core
promoter mutations (80% vs 50%, P5 0.14), C at nucleotide
1858 (95% vs 0%, Po0.001) and fewer precore stop codon
mutation (5% versus 50%, P5 0.002). On comparing with the
reference amino acid sequences of other HBV genotypes, lysine
at amino acid 85 in the terminal protein region of the poly-
merase gene was most speciﬁc for HBV genotype Cs, while
lysine at amino acid 143 in the terminal protein region was most
speciﬁc for HBV genotype Ce. Conclusions: We have identiﬁed
two subgroups of genotype C HBV, namely genotypes Ce and
genotype Cs, which have different epidemiological distributions
and virological characteristics. Further research is required to
investigate the clinical outcome associated with these two
genotype C HBV subgroups.
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APASL/Poster/Abstract/28
Prevalence of hepatitis C virus infection in health care workers
B. J. Waleleng, N. T. Wenas, M. C. P. Wongkar and C. Wibowo
Gastroentero Hepatology Division, Internal Medicine Depart-
ment of Medical School Sam Ratulangi University, Manado,
Indonesia
Objectives: To investigate the prevalence of hepatitis C virus
(HCV) infection in health care workers who work in Prof. Dr. R.
D. Kandou Manado General Hospital and Bethesda Hospital in
Tomohon. Methods: This is a descriptive study of 3 months
(July–October 2002). Diagnosis of HCV infection was based on
positive antibody of HCV by Entebe Dipstick Anti HCV.
Results: We found 14 of 239 subjects (5.9%) infected by HCV.
Distribution rates of HVC on medical nurses and non-medical
nurses were 11 and 3, respectively (P40.05). Two (2.9%) and
nine (13.0%) subjects, respectively, who worked in the ward and
intensive care room were infected by HCV (Po0.005). Four
(3.6%) of 110 subjects who worked foro5 years, and 10 (7.8%)
subjects who worked for45 years were infected by HVC. The
relationship between duration of working as nurse and prevalence
of HVC infection was not signiﬁcant statistically (P40.05).
Nevertheless, there was a tendency of increased risk of HVC
infection in health care workers who had worked 45 years as
nurses. We did not ﬁnd a relationship between contact frequency
with prevalence of HVC infection, but subjects who worked 45
times with needlesticks showed 2.3 times higher transmitted HCV
than those who had worked o5 times with needlesticks. There
was a signiﬁcant difference on health care workers who had
worked45 times with needlesticks with duration of working45
years Po0.01. Conclusions: There was no difference of HCV
infection in medical nurses and non-medical nurses. We did not
ﬁnd a relationship between HCV infection and duration of
working as nurse. Nevertheless, this study found a relationship
between nurses who worked in the ward and intensive care room.
Suggestions: Health care workers should universally take pre-
cautions during their duties in the hospital.
APASL/Poster/Abstract/29
Platelet count/spleen diameter ratio: can it predict the presence of
varices in patients with cirrhosis of liver?
Shahid Sarwar, Anwaar A. Khan, Altaf Alam, Arshad Kamal
Butt, Farzana Shafqat, Kashif Malik, Irfan Ahmad, Aamir
Khan Niazi and Aakif Dilshad
Department of Gastroenterology and Hepatology, Shaikh
Zayed Post-Graduate Medical Institute, Lahore, Pakistan
Introduction and Objective: Ratio of platelet count and spleen
diameter has recently been proposed as a predictor of the
presence of esophageal varices in patients with cirrhosis. This
study was carried out to evaluate the predictive value of this
ratio for the presence of varices. Patients and Methods: One
hundred and one patients with established cirrhosis and no
history of variceal bleed were included. Diagnosis of cirrhosis
was based on clinical, laboratory, and ultrasonographic fea-
tures. Data on physical examination, hematological, biochem-
ical, and abdominal ultrasound examination were recorded for
all patients. All patients underwent upper GI endoscopy.
Varices were recorded as low- and high-grade. The presence of
varices on EGD was correlated with platelet count/spleen
diameter ratio. Results: Total number of cased included were
101, 54 of whom were males and 47 were females. Mean age of
patients was 52.48 ( 11.11) years. Thirty-ﬁve patients were in
Child–Pugh class A, 49 in Child class B and 17 patients in Child
class C. Esophageal varices were seen in 65 patients while 36
patients had no varices. High-grade varices were seen in 15
patients and 50 patients had low-grade varices. Mean value of
platelet count/spleen diameter in patients with varices was
798.09 compared to 617.08 in those without varices. Value
of platelet count/spleen diameter ratio was not signiﬁcantly
different among patients with and without varices (P5 0.117).
Conclusions: The ratio of platelet count/spleen diameter cannot
be used to predict the presence of esophageal varices.
APASL/Poster/Abstract/30
Value of quantitative HCV RNA in management of chronic
hepatitis C patients with genotypes 2 and 3
Shahid Sarwar, Anwaar A. Khan, Altaf Alam, Arshad Kamal
Butt, Farzana Shafqat, Kashif Malik, Irfan Ahmad, Aamir
Khan Niazi and Aakif Dilshad
Department of Gastroenterology and Hepatology, Shaikh
Zayed Post-Graduate Medical Institute, Lahore, Pakistan
Introduction and Objective: Viral load of hepatitis C virus is used
to predict early viral response in genotypes 1 and 4. Its value in
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predicting response in genotypes 2 and 3 is still questionable. This
study was carried out to assess the value of quantitative PCR in
genotypes 2 and 3 in predicting response to therapy. Patients and
Methods: Patients with positive HCVRNA and genotypes 2 and
3 were included. Baseline liver function tests, complete blood
count, clotting proﬁle, viral load and liver biopsy were carried
out. Viral load was checked by quantitative HCV RNA in all
patients before commencing therapy. All patients were treated
with standard interferon a-2b with ribavirin for 6 months.
Patients with completed therapy were checked for sustained viral
response 6 months after completion of treatment. Correlation
between sustained viral response (SVR) and baseline viral load
was determined using Student’s t-test and w2 test. Results: Of the
55 patients included, six patients were of genotype 2 while 49 had
virus of genotype 3. Male to female ratio was 1.11:1 (29/26).
Mean baseline viral load was 4.8 million copies/ml. Fifty patients
completed the treatment. Sustained viral response was seen in 31
patients while 19 patients were positive for HCV RNA 6 months
posttherapy. Viral load at start of therapy was not signiﬁcantly
different in those with SVR compared to those with no response
to therapy (P5 0.478). Conclusion: Viral load of hepatitis C virus
at start of therapy is not predictive of response to combination
therapy in patients with viral genotypes 2 and 3.
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Real-time virtual sonography, an integrated system of computer
tomography with ultrasound images: value in radiofrequency
ablation guidance
Yasunori Minami1, Hobyung Chung1, Masatoshi Kudo1, Toyo-
kazu Fukunaga1, Tatsuo Inoue1, Kazuomi Ueshima1, Satoru
Hagiwara1, Yasuhiro Sakaguchi1, Kinuyo Hatanaka1 and Hi-
toshi Shiozaki2
1Division of Gastroenterology and Hepatology, Department of
Internal Medicine,
2Department of Surgery, Kinki University School of Medicine,
Osaka-Sayama, Japan
Background: Recently, the real-time visualization system that
combines ultrasound cross section and CT has been invented
and introduced into the clinical practice of hepatology. The
system, Real-time Virtual Sonography, can display the same
cross sectional view of US image with CT in real-time fashion
using CT volume data. Purpose: We examined the feasibility
and safety of percutaneous radiofrequency (RF) ablation guided
by Real-time Virtual Sonography for hepatic malignancies.
Subjects and methods: Between September 2004 and November
2004, nine patients with 15 nodules have been treated using
Real-time Virtual Sonography. The patient population included
seven men and two women, with a mean age of 65.6 years. RF
ablation was used to treat primary liver cancer in seven patients
(78%); two patients (23%) were treated for metastatic lesions
from colorectal adenocarcinoma (n5 1), and rectal carcinoid
(n5 1). The maximum diameter of nodules ranged from 1.0 to
5.0 cm (mean  SD; 1.8  1.3 cm). Real-time Virtual Sonogra-
phy can display a multi planar reconstruction (MPR) image,
which indicates the same cross section as ultrasound image from
the CT volume data in real time. The system is composed of an
ultrasound scanner with probe, a PC that generates MPR image
from CT volume data and magnetic positioning unit that detects
the position of probe. During ultrasound scanning, the PC
detects the position of probe by the using magnetic positioning
sensor. After that, the PC generates an MPR image from the CT
volume data and display. As a result, it became possible
to compare ultrasound image with MPR image in real time.
The cool-tip needle RF system was used for RF ablation.
Results: The relationship between a tumor and surrounding
vessels was easily recognized by referring to the image of virtual
sonography in all nodules. The synergic effect which not only
virtual MPR image helps understanding of US image but US
helps understanding of CT image affected. The overall success
rate in puncturing lesions that were unrecognized by US was
100%. Complete tumor necrosis was achieved in a single session
in 13 lesions (86%), while two sessions were required for the
remaining two lesions (14%). No serious side effects or proce-
dure-related complications were observed. Conclusion: In our
experience of 15 hepatic malignancies, Real-time Virtual Sono-
graphy-guided RF ablation could be used safely and success-
fully for hepatic masses. It even made possible treatment of
hepatic nodules poorly deﬁned on B-mode US.
APASL/Plenary/Abstract/33
Changes of expression of Toll-like receptors 2 and 4 in HepG2
cells before and after hepatitis B virus infection
Jin Sheng, Zhang Da-Zhi, Ren Hong, Guo Hui,
Chen Ya-Xi and Liu Qi
Institute for Viral Hepatitis, the Second Afﬁliated Hospital of
Chongqing University of Medical Sciences, Chongqing, China
Background: Toll-like receptors (TLR) have been identiﬁed to
mediate cell stimulation by microbial antigens. The recent
discovery of the TLR family has focused attention on the
disease processes as TLR mediate pathogen recognition and
immune activation. However, only TLR2 and TLR4 were
shown to transmit lipopolysaccharide (LPS) effects via immune
signal transmittal. Recent publications show that regulation of
TLR2, TLR4 and their associated downstream pathways are
both involved and crucial for LPS tolerance. Regulation of
TLR2 and TLR4 can affect a mechanism to modify LPS
responses in patients with chronic endotoxemia due to liver
diseases. However, more evidence has shown that endotoxin/
lipopolysaccharide from the gut playsan important role in liver
damage in chronic hepatitis patients. Objective: In order to
explore the roles of TLR2 and TLR4 in hepatocyte damage after
hepatitis B virus infection, and to discover whether LPS can
affect hepatocytes without immuno-mechanism pre- and post-
HBV infection, we detected the changes of TLR2 and TLR4
expression in human hepatocyte lines using HepG2 cells and
2.2.15 cells. Methods: HepG2 cells are most similar to normal
human hepatocytes and 2.2.15 cells are HepG2 cells infected
with HBV. We selected these two cell lines to study the
differences of TLR2 and TLR4 expression between HepG2 cells
before and after HBV infection. In this research, both HepG2
and 2.2.15 cells were stimulated with 1 mg/ml, 10mg/ml, 100 mg/
ml, 1mg/ml and 10mg/ml LPS. Then the expressions of proteins
of TLR2 and TLR4 were examined by immunohistochemistry
(IHC), the mRNA was examined by reversal transcription-
polymerase chain reaction (RT-PCR), apoptosis was examined
by ﬂow cytometry (FC), and the expressions of HBsAg
and HBeAg of 2.2.15 cells were tested with Abbott kits.
Results: IHC and RT-PCR analysis revealed that TLR2 and
TLR4 expressions were detected in both HepG2 and 2.2.15 cells.
Moreover, without immune activation, TLR2 and TLR4 ex-
pressions were higher when the concentrations of LPS were
higher. FC analysis revealed that no apoptosis was detected in
HepG2 cells stimulated with LPS in this research, but apoptosis
was detected in 2.2.15 cells when treated with the same factors.
Furthermore, the apoptosis ratios increased with the increase in
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concentrations of LPS. When concentrations of LPS were 1 mg/
ml, 10mg/ml, 100 mg/ml, 1mg/ml and 10mg/ml, the apoptosis
ratios were 1.94%, 3.03%, 3.50%, 3.72% and 5.30%, respec-
tively. Abbott analysis revealed that expressions of HBsAg and
HBeAg of 2.2.15 cells stimulated with LPS were lower than
those not stimulated with LPS (Po0.05). Conclusions: HBV
can affect expressions of TLR2 and TLR4 in HepG2 cell lines.
LPS can lead 2.2.15 cells to apoptosis but not HepG2 cells.
Although LPS cannot damage normal hepatocytes, it might
aggravate hepatocyte damage when their microenvironment is
changed by HBV infection. Therefore, we feel the mechanism
involved in this phenomenon needs to be identiﬁed through
more research.
APASL/Poster/Abstract/34
Serum ALT levels do not correlate with response to interferon–
ribavirin combination in patients with chronic hepatitis C
Shahid Sarwar, Anwaar A. Khan, Altaf Alam, Arshad Kamal
Butt, Farzana Shafqat, Kashif Malik, Irfan Ahmad, Aamir
Khan Niazi and Aakif Dilshad
Department of Gastroenterology and Hepatology, Shaikh
Zayed Post-Graduate Medical Institute, Lahore, Pakistan
Introduction and Objective: A signiﬁcant proportion of indivi-
duals with chronic hepatitis C virus (HCV) infection have
persistently normal alanine aminotransferase (ALT) levels.
This study was conducted to see the effect of baseline ALT in
chronic hepatitis C patients on response to interferon–ribavirin
combination therapy. Patients and Methods: Patients with po-
sitive anti HCV and HCV RNA by PCR with no signs of
decompensated liver disease were included. Depending on base-
line ALT, patients were divided in two groups. One group with
ALT below the upper normal limit and a second group with
raised ALT (41.5 times the upper limit of normal value). Both
groups were treated with interferon and ribavirin therapy. All
patients were evaluated for sustained viral response (SVR) at 6
months after treatment completion with HCV RNA by PCR.
Both groups were compared for response to therapy with the
w2 test. Results: The total number of patients was 70, 25 patients
with normal ALT and 45 patients with ALT above the upper
normal limit. Male to female ratio was 1.1:1 (37/33). Mean age
was 35.61 ( 10.59) years. Sixty-three patients completed treat-
ment. Sustained viral response (SVR) was seen in 35 patients.
Comparison of patients with normal ALT and those with raised
ALT revealed 13 of 25 patients with normal ALT and 22 of 45
patients with raised ALT. Difference in SVR in the two groups
was not signiﬁcant (P5 0.679). When patients with raised ALT
were sub-classiﬁed, a signiﬁcantly better response was seen in
patients with ALT twice the upper normal limit. (P5 0.021).
Conclusions: Patients with normal ALT level have a good
response to combination therapy, equivalent to those with a
raised ALT level.
APASL/Free Paper/Abstract/35
Cost–beneﬁt analysis of living-donor liver transplantation (LDLT)
timing in hepatocellular carcinoma patient within Milan criteria:
an outcome-oriented decision analysis
Hironori Tanaka, Yoshiyuki Kobayashi, Shinichiro Nakamura,
Kazuhiro Nouso, Kenji Miyoshi, Hideki Ohnishi, Syouta
Iwado, Bon Shoji, Yasuhiro Miyake, Yoshiaki Iwasaki,
Haruhiko Kobashi, Kohsaku Sakaguchi and Yasushi
Shiratori
Department of Gastroenterology, Hepatology, and Infectious
Disease, Okayama University School of Medicine, Okayama,
Japan
Background: Liver transplantation (LT) is the optimal treat-
ment of hepatocellular carcinoma (HCC) and living-donor liver
transplantation (LDLT) is an alternative way to overcome
donor shortage. However, there are several problems for
LDLT, such as the frequent complications and injury to the
donor. Therefore, it is important to decide the timing of LDLT
for HCC patients. Aim: The aim of this study is to determine
the economical effects of LDLT for HCC patients with a
Markov-based decision analytic model according to the times
of LDLT. Method: (1) Between January 1994 and October
2004, 230 HCC patients within Milan criteria treated by resec-
tion and/or local ablation therapy were enrolled. We analyzed
their liver functions and tumor parameters when there was HCC
recurrence. (2) A Markov model was constructed simulating the
natural history of HCC patients within Milan criteria. We
compared the data following three strategies according to the
times when LDLT was selected (‘‘LDLT at ﬁrst’’ was deﬁned as
LDLT at the time of HCC diagnosis, ‘‘LDLT at recurrence’’
was deﬁned as that when HCC was initially resected/ablated,
and LDLT was performed at the time of recurrence with a
strategy that did not select liver transplantation (No LT).
Transition probabilities and all costs were drawn from pub-
lished data. Simulation and analysis were performed using
TreeAge pro 2004. Results: (1) Out of 230 HCC patients, 104
patients (45%) showed recurrence of HCC during the follow-up
period. The number of patients within Milan criteria at recur-
rence and second recurrence were 81 patients (79%). (2) When
we analyzed this model using our recurrence data, the life
expectancy of each of the strategies was as follows: 9.9 years
for LDLT at ﬁrst, 9.6 years for LDLT at recurrence and
6.8 years for No LT. Incremental cost-effectiveness ratio
(ICER) was $46,232 for LDLT at ﬁrst and $34,864 for
LDLT at recurrence, when we compared these with No LT.
Conclusion: Primary local therapy and following LDLT at
HCC recurrence is the cost-effective strategy for HCC patients
within Milan criteria.
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EGCG and resveratrol protect human hepatocytes (Hep G2 and
Chang liver cells) from oxidative stress
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H. Y. Nah1, W. S. Lee1, C. H. Park1, Y. E. Joo1, H. S. Kim1,
S. K. Choi1, J. S. Rew1, B. A. Shin2 and S. J. Kim1
1Department of Internal Medicine,
2Department of Microbiology, Chonnam University Medical
School, Gwangju, Korea
Backgrounds and Objectives: Increasing evidence regarding
free-radical generating agents and the inﬂammatory process
suggests that accumulation of reactive oxygen species (ROS)
can involve hepatotoxicity, and direct oxidative injury serves as
a general trigger for apoptosis in the liver. Although the under-
lying mechanisms remain incompletely understood, it is widely
accepted that oxidative stress also plays a critical role in liver
ﬁbrogenesis. In this study, the protective effects of the antiox-
idants, epigallocatechin-3-gallate (EGCG) and resveratrol on
oxidative stress in human hepatocyte Hep G2 and Chang liver
cells were investigated.Methods: Cytotoxicity was measured by
MTT assay. Intracellular oxidative activity was detected in
dihydrodichloro-ﬂuorescein diacetate (DCF-DA) loading cells
by ﬂuorescent spectrophotometer. GSH/GSSG ratio was mea-
sured with commercially available kit according to the manu-
facture’s instructions. The lipid peroxidation and protein
carbonylation assay kits were used to analyze oxidation damage
to lipids and proteins. Cell cycle was analyzed by ﬂow cytometry.
The expression of cell cycle-related nuclear factors was analyzed
by Western blotting. Results: Exposure to a concentration of
200mM hydrogen peroxide or 500mM ethanol induced cytotoxi-
cities to hepatocytes, as shown by cell toxicity assay. Hydrogen
peroxide and ethanol administration induced increases of ROS
generation, lipid peroxidation and protein carbonylation either
by enhancing the production of oxygen-reactive species and/or by
decreasing the level of endogenous antioxidants. EGCG and
resveratrol were found to reduce the ROS generation, lipid
peroxidation and protein carbonylation in oxidative-stressed
cells. They also prevented hepatocytes from depletion of
GSH. Flow cytometric analysis revealed that both EGCG and
resveratrol protect the cells from oxidative stress-induced cell
death in appropriate conditions but Western blot analysis de-
monstrated that addition of EGCG and resveratrol upon oxida-
tive-stressed cells led to marked reduction of mitotic Cdk (Cdk1).
Conclusions: EGCG and resveratrol could prevent Chang liver
and Hep G2 cells from oxidative damages of lipids and proteins
caused by hydrogen peroxide or ethanol. They might inhibit the
proliferative capacities of Chang liver and Hep G2 cells but
protect them from oxidative stress-induced cell death.
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Hepatitis B virus-neutralizing anti-pre-S1 human antibody frag-
ments from large naı¨ve antibody phage library
Sung Jae Park1, Sam Ryong Jee1, Eun Taek Park1, Youn Jae
Lee1, Sang Hyuk Lee1, Sang Young Seol1, Jung Myung Chung1,
Sae-Gwang Park2 and In-Hak Choi2
1Department of Internal Medicine and
2Department of Microbiology, College of Medicine, Inje Uni-
versity, Korea
We report the construction of a large nonimmunized phage anti-
body library in single-chain variable region fragment (scFv)
format, which allowed the selection of antibodies that neutralize
hepatitis B virus (HBV). We generated 1.1  1010 independent
scFv clones using the cDNA of functional variable (V) gene
segments of heavy and light chains puriﬁed from the peripheral
blood mononuclear cells of 50 nonimmunized human donors.
Using BIAcore, we selected two clones that recognized pre-S1
and neutralized pre-S1- and HBV binding of Chang liver cells.
Clone G10 had the highest afﬁnity (KD5 1.69  10 7M), which
was higher than that of clone 1E4 that was generated previously
from a heavy chain-shufﬂed antibody library. The off-rates of
clones were within 10 3 s 1 as determined by BIAcore and are
comparable to those of antibodies derived from a secondary
immune response. In the inhibition assays of pre-S1 and virus
binding to Chang liver cells using ﬂuorescence-activated cell
sorting and the polymerase chain reaction, G10 had better
neutralizing activity than 1E4. The new phage library may be a
valuable source of antibodies with reasonable afﬁnities to differ-
ent targets, and the anti-pre-S1 antibody fragment G10 may be a
good candidate for immunoprophylaxis of HBV infection.
APASL/Free Paper/Abstract/44
Is Gilbert syndrome really more prevalent in schizophrenic patients?
L. Vı´tek1,2, M. Novotna´3, J. Eberova´4, M. Lenı´cek1 and
M. Jirsa4
1Institute of Clinical Biochemistry and Laboratory Diagnosis,
24th Department of Internal Medicine,
3Department of Psychiatry, Charles University,
4Laboratory of Experimental Hepatology, IKEM, Prague,
Czech Republic
Background: Controversy exists on the issue of serum bilirubin
in schizophrenia. Although the majority of published studies
have demonstrated high prevalence of unconjugated hyperbilir-
ubinemia in schizophrenic patients, none of these studies have
investigated the UGT1A1n28 polymorphism (a genotypic mar-
ker of GS in Caucasians). The aim of our study was to analyze
both serum bilirubin and GS genotype in schizophrenic patients.
Methods: Our study was performed on 88 patients with schizo-
phrenia (56 males, median age5 39 years, 32 females, median
age5 45.5 years) and 110 healthy age and sex-matched controls.
Standard serum biochemical tests and UGT1A1n28 polymorph-
ism were determined in all subjects. Results: Substantially lower
serum bilirubin levels were detected in schizophrenic patients
than in controls ([median; 25–75% range], total population: 6.6;
4.9–8.5 vs 12.2; 9–15.6mM/l, Po0.001; males: 7.1; 4.8–9.4 vs
12.9; 9–16.8 mM/l, Po0.001; females: 6.1; 5.0–7.4 vs. 10.3; 8.4–
13.5 mM/l, Po0.001). Similarly, the prevalence rates of GS
genotype and bilirubinemia 417 mM/l were also markedly low
in all schizophrenic patients vs controls (TATA box 7/75 9.1%
vs 16.3%, P5 0.196 [not signiﬁcant presumably due to low
numbers of subjects], and 2.3% vs. 18.2%, Po0.001, respec-
tively). Conclusions: Patients with schizophrenia do not have
higher prevalence of either the common UGT1A1 polymorph-
ism or hyperbilirubinemia above 17mM/l. In contrast, they
exhibit substantially lower levels of serum bilirubin levels. Since
bilirubin is a potent antioxidant it seems that low levels of serum
bilirubin may predispose patients to oxidative stress-mediated
diseases such as schizophrenia.
APASL/Poster/Abstract/45
Prevalence and factors associated with insulin resistance among
patients with non-alcoholic fatty liver: a prospective study
D. A. Payawal, R. Y. Cobankiat, R. A. Sy
Cardinal Santos Medical Center, San Juan, Metro Manila,
Philippines
Objective: To determine prevalence of insulin resistance among
patients with fatty liver. Methods: The study employed a cross-
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sectional survey design among adult patients with fatty liver
seen at Cardinal Santos Medical Center for executive check up
from September 2003 to September 2004 using a non-probabil-
ity, purposive, prospective sampling. Ultrasound was utilized to
detect patients with non-alcoholic fatty liver disease (NAFLD)
who would be prospectively recruited using purposive sampling.
Baseline sociodemographic and clinical data were collected.
Insulin resistance (IR) was measured using the homeostatic
model assessment for insulin resistance (HOMA-IR). Descrip-
tive statistics was then employed to describe the cases and
prevalence of insulin resistance was computed. Results: Of the
24 patients with NAFLD recruited for the study, 15 (67%) were
shown to have insulin resistance (IR) as computed by HOMA-
IR. Variables noted to be signiﬁcant and conﬁrmed using
correlation coefﬁcient by linear regression in contributing to
IR among these patients included waist circumference
(Po0.009), waist-to-hip ratio (Po0.003) and fasting insulin
levels (Po0.001). Conclusion: Based on the initial data, pre-
valence of insulin resistance among patients with NAFLD was
high at 62.5%. Factors associated with insulin resistance among
patients with NAFLD include higher fasting insulin levels,
bigger waist circumference and waist-to-hip ratio.
APASL/Poster/Abstract/46
Hepatitis E in rural England
H. R. Dalton1, H. J. Fellows1, S. H. Hussaini1, R. Peiris1,
J. Mitchell1, M. Banks2, R. Bendall1 and D. F. Levine1
1Royal Cornwall Hospital, Truro, UK,
2Veterinary Laboratory Agency, Addlestone, Surrey, UK
Introduction: Hepatitis E (HEV) is rare in developed countries
and was previously thought to be conﬁned to travelers returning
from endemic areas. Recently there have been reports from a
number of developed countries of HEV infection in non-trave-
lers. However, the epidemiology of autochthonous (locally ac-
quired) HEV infection (aHEV) in the developed world is unclear.
Objectives: To evaluate the incidence and natural history of
aHEV infection in Cornwall UK. Methods: Eighty-seven pa-
tients with unexplained hepatitis were tested for HEV over a 6-
year period by HEV IgM serology and/or RT-PCR RNA
assays. A case of HEV infection was deﬁned as an
ALT4500U/l and strongly positive HEV IgM serology (test:
cut-off ratio45) or HEV PCR positive. Results: A total of 7/87
of patients tested was found to have aHEV infection, giving an
incidence of 2.9 cases/million population/year. None of the
cases had traveled to an endemic area. All patients were
middle-aged or elderly (median age 63, range 48–81 years),
and males were more commonly affected (M:F ratio 5:2). The
range of expression of aHEV varied from asymptomatic anic-
teric disease to severe hepatitis requiring in-patient care. All
patients recovered within 6 weeks except for one patient who
died of an unrelated cause. None were vegetarian and two had
regular contact with uncooked pork, including daily exposure in
one patient who works as a butcher. All cases were caused by
genotype III HEV, and in two cases the HEV RNA bore close
sequence homology to genotype III HEV RNA isolated from a
UK pig. Conclusions: The incidence of aHEV is 2.9/million/
year. Unlike endemic HEV it causes a hepatitic illness in the
middle-aged and elderly. The mode of transmission remains to
be determined, but could be a zoonosis from a pig reservoir.
aHEV is a Public Health issue in the UK.
APASL/Free Paper/Abstract/47
The expression of CD 137(4-1BB) and serum concentration of
soluble 4-1BB (s4-1BB) in patients with hepatocellular carcinoma
Jung Woo Shin1, Neung Hwa Park1, Noh Eui Kyu2, Hyun Su
Kim1, Hyung Hyup Choi1, Dong Ha Han1, In Du Jeong1,
Sung-Jo Bang1 and Do Ha Kim1
1Division of Gastroenterology, Department of Internal Medi-
cine, University of Ulsan College of Medicine,
2Biomedical Research Center, Ulsan University Hospital,
Ulsan, Korea
Background/Aims: The 4-1BB, a member of the TNF receptor
superfamily, is expressed on activated T cells and antigen
presenting cells. 4-1BB generates costimulatory signals, which
involve T cell activation and proliferation, and tumor suppres-
sion. s4-1BB, which is generated by proteolytic cleavage or
alternative splicing, inhibits biological activities of 4-1BB. High
circulating levels of s4-1BB have been suggested to suppress
immune response and this ﬁnding was observed in hematologic
malignancy. In this study, we investigated expression of 4-1BB
on peripheral blood mononuclear cell (PBMC) and serum
concentration of s4-1BB in patients with hepatocellular carci-
noma (HCC) and in healthy controls. We also analyzed correla-
tions between s4-1BB concentrations and clinical characteristics
of HCC patients. Methods: 4-1BB expressions on PBMC from
23 HCC patients and 24 healthy controls were analyzed by ﬂow
cytometry after stimulation with CD3. Serum levels of s4-1BB
were measured by an enzyme-linked immunosorbent assay.
Results: The expression of 4-1BB was signiﬁcantly lower on
PBMC of HCC patients than that of healthy controls (10.35 
5.3% vs 23.08  6.73%; Po0.01). PBMC with CD414-1BB1 of
HCC patients was higher than that of controls (36.6  12.9% vs
21.9  4.3%. Po0.01). But, PBMC with CD814-1BB1 was not
different between HCC patients and controls (30.2  13.1%
vs 25.3  12.1%; P5 0.18). Serum level of s4-1BB was
signiﬁcantly higher in HCC patients than in healthy controls
(4455  2194 pg/ml vs 1575  990 pg/ml). There was no
difference in expression of 4-1BB and serum levels of s4-1BB
according to the Child–Pugh classiﬁcation. The s4-1BB levels in
HCC patients were correlated with AFP levels (r5 0.64;
Po0.01). Conclusions: We have demonstrated low expression of
4-1BB and high level of s4-1BB in patients with HCC. These results
suggest that poor costimulatory effects of 4-1BB may be associated
with escape of immune surveillance in patients with HCC.
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Association of hepatic ﬁbrosis or inﬂammation with serum iron
indices and hepatic iron concentration in patients with nonalco-
holic fatty liver disease
Kyoung Oh Kim, Sang Hoon Park, Joon Ho Moon, Jae One
Jung, Jong Pyo Kim, Cheol Hee Park, Tai Ho Han, Kyo-Sang
Yoo, Dong Jun Kim, Myung Seok Lee and Choong Kee Park
Department of Internal Medicine, Hallym University College of
Medicine, Anyang, Korea
Background/Objectives: Nonalcoholic fatty liver disease
(NAFLD) may progress to advance liver disease. Increased
iron is suspected to enhance hepatic injury associated with
NAFLD. The aims of this study are to evaluate the relation
of serum iron indices and hepatic iron concentration (HIC) with
hepatic ﬁbrosis or inﬂammation, and to assess whether the
increased HIC is an independent predictor of progression to
liver ﬁbrosis.Methods: The clinicodemographic, laboratory and
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histopathological data on 31 subjects with a ﬁnal diagnosis of
NAFLD seen between July 2001 and March 2004 at our
hospital were analyzed. Liver biopsy specimens were graded
according to methods described by Brunt et al. Hepatic iron
concentration was available in 25 NAFLD patients. Results: Li-
ver biopsy specimens showed grade 1 and 2 inﬂammations in 12
(38.7%)patients and grade 3 inﬂammation in 2 (6.6%). It
revealed stage 1 ﬁbrosis in 10 (32.3%) patients and stage 2
ﬁbrosis in 12 (38.7%). Advanced ﬁbrosis (stage 3) was observed
in 2 (6.6%) patients, but there was no cirrhosis. HIC and hepatic
iron index (HII) were 1426–1188 mg/g dry weight and 0.79–
0.69mg/g/age. Serum ferritin and body mass index (BMI) were
associated with hepatic inﬂammation (correlation coefﬁ-
cient5 0.591, 0.428, P valueo0.05, Spearman’s correlation
analysis). Serum ferritin, BMI and AST/ALT ratio were asso-
ciated with hepatic ﬁbrosis (correlation coefﬁcient5 0.497,
0.437, 0.456, P valueo0.05, Spearman’s correlation analysis).
But, multivariate analysis did not identify serum ferritin, BMI,
transferrin saturation, HIC as an independent predictor of
hepatic ﬁbrosis or inﬂammation (multiple logistic regression
model). Conclusions: Hepatic iron accumulation had no corre-
lation with the degree of hepatic inﬂammation or ﬁbrosis. Thus,
hepatic iron may not be an independent predictor of hepatic
ﬁbrogenesis in patients with NAFLD.
APASL/Poster/Abstract/50
Clevudine therapy for 24 weeks reduced serum HBV DNA levels
and increased ALT normalization rates further than 12-week
clevudine therapy
K. S. Lee1, K. S. Byun2, Y. H. Chung3, S. W. Paik4, J. Y. Han5,
K. Yoo6, H.-W. Yoo7, B. C. Yoo4, H.-S. Lee8
1Yonsei University Hospital,
2Korea University Hospital,
3Asan Medical Center,
4Samsung Medical Center,
5The Catholic University Hospital,
6Ewha Womans University Hospital,
7Bukwang Pharm. Co., Ltd.,
8Seoul National University Hospital, Seoul, Korea
Background: In a phase II clinical study (Hepatology
24;40:652A), clevudine 30mg QD for 12 weeks was well toler-
ated and produced a potent antiviral activity during the dosing
period and maintained a viral suppression through 24 weeks
after the end of dosing. Objectives: The primary objectives of
the study were to evaluate the safety and tolerability and to
assess the antiviral activity of 24-week treatment with clevudine
30mg QD. Biochemical and serological responses were also
assessed. Method: All of 21 eligible patients received clevudine
30mg QD for 24 weeks and were followed up for another 24
weeks off therapy. Eligible patients were HBeAg-positive
chronic hepatitis B patients who had previously received pla-
cebo in the previous phase II 12-week treatment study and
whose HBeAgs were not seroconverted to anti-HBe. The anti-
viral activity was deﬁned as median log10 decrease from the
baseline. Results: Median decreases from baseline in serum
HBV DNA were 4.65 and 1.96 log10 copies/ml at week 24
(the end of treatment) and week 48(24 weeks off therapy),
respectively. Analysis of individual data showed that serum
HBV DNA levels were below the lower limit of detection (300
copies/ml) by Amplicor PCR assay in 19%, 57%, 19% and 0%
at weeks 12, 24, 34 and 48, respectively. ALT levels were
normalized in 67% at week 24 and the ALT normalization
rates further increased after the cessation of therapy up to 81%
at week 34 and then slightly decreased thereafter to 75% at week
48. The rates of HBeAg loss were 24 and 20% at weeks 24 and
48, respectively. Genotypic analysis did not show any mutation
at the HBV pol domain except one (rt 183V/I); however, it was
not associated with a viral breakthrough. Conclusion: Clevu-
dine 30mg treatment for 24 weeks was well tolerated with an
excellent safety proﬁle and exhibited more potent antiviral
activity and a higher ALT normalization rate than 12-week
treatment with durable vial suppression and normalization of
ALT levels at week 24 off therapy.
APASL/Poster/Abstract/51
Estimation of intravenous frusemide-induced natriuresis for early
detection of refractory ascites
S. Alam, M. Khan, N. Ahmad, K. Alam and S. Rahman
Department of Hepatology, Bangabandhu Sheikh Mujib
Medical University, Shahbag, Dhaka, Bangladesh
Background: Ascites is a common major complication of cir-
rhosis. About 5–10% patients of ascites eventually becomes
refractory. Identiﬁcation of patients who are refractory
usually requires several weeks of observation with diuretics.
Objective: To exploremethods for earlier detection of refractory
ascites. Materials and Methods: This study is a prospective
study. Consecutive patients of cirrhosis with ascites were in-
cluded in the study, which was carried out during the period
from January 2001 to January 2003. All the patients were kept
on low sodium diet and all diuretics were withdrawn for 3 days.
Then 24- h urinary sodium was estimated. Patients having 24-h
urinary sodium excretion less than 50mmol were included in the
study. Eighty milligrams frusemide was then injected intrave-
nously. Urine was collected for 8 h for measurements of sodium
and o50mmol were suspected refractory ascites group and
450mmol were responsive group. Both the groups were fol-
lowed with oral diuretics therapy. Results: A total of 30 patients
of cirrhosis with ascites, 24 male and six female, were included in
the study. Cirrhosis was related to hepatitis B virus in 22
patients, hepatitis C virus in two patients and six patients
were non-B, non-C related. All the patients were in Child B
and C grade. The intravenous injection of frusemide was not
associated with any adverse effect. There were no signiﬁcant
differences between two groups for age, sex, etiology of liver
disease and Child–Pugh score. At the end of the study, 24
patients were detected as responsive ascites and six patients
were detected as refractory ascites with oral diuretics.
But the prediction was 27 and three with frusemide injection.
Conclusion: The present study showed that 50% of patients
with refractory ascites could be identiﬁed reliably by this
method. The availability of a simple test that can be admini-
strated in a day care unit. We recommend further study of a
larger group with this test.
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Interventional US on liver diseases, diagnostic, and treatment
H. Sidharta
Ultrasound Unit, Division of Gastroenterology, Department of
Internal Medicine, Graha Medika Hospital, Jakarta, Indonesia
Many liver diseases, diagnosed by ultrasound or by clinicians,
need more information for an accurate ﬁnal diagnosis and
adequate treatment as well. As Color Doppler, 3D and 4D
not always could provide an accurate diagnosis, interventional
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US (IUS) is the procedure of choice. For these purposes, various
types of needles and procedures are available which are con-
venient for the patients as well as for the operator. In Graha
Medika Medika hospital, during the last years, IUSs were
performed in 24 liver diseases, 22 HCC, six cysts and 31
abscesses. The samples were sent to pathologists for histological
or cytological study or both. More accurate treatment or
surgery could then be realized. During US follow-up after
treatment or surgery with conventional US, color Doppler
and/or 3D/4D, a second or more IUS could be performed, as
needed, before arriving at ﬁnal complete healing. In conclusion,
performing IUS is necessary to establish an accurate ﬁnal
diagnosis and treatment with convenient techniques that aree-
conomical and could replace surgery.
APASL/Poster/Abstract/54
The role of zinc, copper, ratio Cu/Zn, and lymphocytes in liver
cirrhotic and hepatocellular carcinoma patients
Neneng Ratnasari, Siti Nurdjanah, Putut Bayupurnama,
Sutanto Maduseno, Eko Bacharibjatoen and Wiwid Agung
Sub Division of Gastroentero-Hepatology, Internal Medicine,
Faculty of Medicine, Gadjah Mada University, Yogyakarta,
Indonesia
Background: Hypozincemia has been described in many chronic
liver diseases including liver cirrhotic (LC) and hepatocellular
carcinoma (HCC). The hypozincemia is always followed by
hypercopperemia and the ratio Cu/Zn increased as the malig-
nant process prediction. The hypozincemia has a place in
immune function impairment and encephalopathy caused by a
malnutrition status. The hallmark of protein–calorie deﬁciency
and zinc deﬁciency are thymic atrophy and lymphopenia.
Objective: Exploring hypozincemia and the increase in ratio
Cu/Zn as the predictor of malignant process in HCC and LC
patients. Studying the role of hypozincemia and lymphopenia as
predictors of immune function impairment and encephalopathy.
Design: A cross-sectional study was conducted with subjects
from inpatient and outpatient Gastroentero-hepatology Depart-
ment, Dr. Sardjito Hospital, Yogyakarta, Indonesia. The study
was carried out from March to August 2004. Diagnosis of LC is
performed by ultrasound and clinical examination, and diag-
nosis of HCC is performed by a-fetoprotein, ultrasound and ﬁne
needle biopsy. Measuring of zinc and copper serum by spectro-
photometer atom absorber (SAA). Hepatic encephalopathy was
predicted by numeric connection test (NCT). Data were ana-
lyzed with computer system (t-test, Wilcoxon rank test, and
linear regression). Results: Total LC patients are 20 (four
patients Child–Pugh A; six patients Child–Pugh B; 10 patients
Child–Pugh C). Total HCC patient are 15. There is no difference
of age and sex between HCC and LC patients (P40.05). The
decreasing of zinc serum in LC patients is signiﬁcantly heavier
than in HCC(LC 48.97  8.74mg/dl; HCC 35.89  40.45 mg/
day; P5 0.012; normal Zn5 50–150 mg/dl). The increasing
of copper serum in LC patients is not different compared with
HCC patients (LC 131.99  24.85 mg/day; HCC 126.50 
32.75 mg/day; P40.05; normal Cu5 100–200 mg/dl). The ratio
Cu/Zn in KHS is signiﬁcantly higher than in LC patients (8.57
vs 3.15; Po0.05; cut off 1.15). The total lymphocyte counts in
LC and HCC patients are not different statistically (P40.05),
but the leucocyte count in HCC is higher than in LC (12.9 vs 7.8;
103/mm3: P5 0.26). By non parametrical analysis, there are
correlations between lymphopenia–hypozincemia and increas-
ing Cu–lymphopenia both in LC and HCC patients, with
Po0.05. There are correlations between hypozincemia-encepha-
lopathy and increasing of NCT-hypozincemia in LC patients,
with Po0.05. Conclusions: Our data indicate that hypozince-
mia and increasing of ratio Cu/Zn may occurr in LC and HCC
patients as a predictor of malignant process. Decreasing im-
mune function may be predicted by lymphopenia combined with
hypozincemia, and occurring of encephalophaty may be corre-
lated with hypozincemia too.
APASL/Poster/Abstract/55
Detection of hepatitis B virus DNA on ﬁlter paper: comparison
between serum and whole blood
A. D. Handayu, Rino A. Gani, Reny Mulatsih, Ali Sulaiman,
Nurul Akbar and L. A. Lesmana
Division of Hepatology, Department of Internal Medicine,
Faculty of Medicine, University of Indonesia/Dr. Cipto Man-
gunkusumo Hospital, Jakarta, Indonesia
Hepatitis B virus infection is still a major public health problem
in Indonesia. More than 11 million people have been infected by
this virus. To provide good treatment for HBV infection, as the
ﬁrst step we need to detect HBV DNA. However, detection of
HBV DNA can be done only in big cities because geographical
limitations have caused some difﬁculties in transporting blood
samples in Indonesia. The goal of this study is to prove that
HBVDNA can be detected from serum or a whole blood sample
that is dried on ﬁlter paper, which makes it easier to transport a
specimen to the laboratory. We examined 20 serum and whole
blood samples with positive HBV DNA. These samples had
been quantiﬁed with COBAS AMPLICOR HBV Monitor
reagent and dripped on ﬁlter papers. We used Nested-PCR
method for detection of HBV DNA. A comparison was made
between serum and blood samples. Out of 20 specimens, we got
100% positive results on serum and 75% on whole blood, with
the quantitative result lying between log 2 and 4log 5. In
conclusion, examination of HBV DNA with the Nested-PCR
method on ﬁlter paper was better when using serum than when
using whole blood samples.
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Malaria with hyperbilirubinemia in Minahasa, Indonesia
Carta A. Gunawan1, Paul N. Harijanto2 and Agung Nugroho2
1Division of Infectious Disease and Tropical Medicine, Depart-
ment of Internal Medicine, Mulawarman University School of
Medicine/A. Wahab Sjahranie General Hospital, Samarinda,
2Division of Infectious Disease and Tropical Medicine, Depart-
ment of Internal Medicine, Sam Ratulangi University School of
Medicine/Manado General Hospital, Manado, Indonesia
Background: Malaria remains the most important parasitic
disease in the world, including Indonesia. In Minahasa, North
Sulawesi, jaundice is the most frequent presentation found in
severe malaria patients. Objectives: To explore the features of
malaria patients with hyperbilirubinemia, and its correlation
with other complications. Methods: A retrospective study was
performed by collecting data of severe malaria patients treated at
the Bethesda Hospital and Gunung Maria Hospital in Mina-
hasa, North Sulawesi from January 1991 until December 2000.
Statistical analysis was carried out using the z test, w2 test and
t-test for regression. Results: In the period of 10 years, there
were 271 severe malaria patients treated at these two hospitals.
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Of 271 severe malaria patients, 209 patients (77.1%) had total
bilirubin level41mg/dl and 147 patients (54.2%) fulﬁlled WHO
criteria for jaundice (total bilirubin level 43mg/dl). Total
bilirubin level ranged from 1.01 to 36.40mg/dl with mean value
6.64mg/dl. Mean conjugated bilirubin level was 3.99mg/dl and
mean unconjugated bilirubin level was 2.65mg/dl. Malaria with
hyperbilirubinemia was frequently accompanied with renal dys-
function/acute renal failure (56.9%). Mean SGOT level was
57.8 IU/l and mean SGPT level was 37.9 IU/l. Mean alkaline
phosphatase level was 176.5 IU/l. There were signiﬁcant positive
correlations between total bilirubin level and SGOT, SGPT,
alkaline phosphatase, creatinine levels, parasite count (Po0.05)
and signiﬁcant negative correlation between total bilirubin level
and platelet count (Po0.05). There was no correlation between
total bilirubin level and level of consciousness (GCS), hemoglo-
bin level and reticulocyte count (P40.05). Mortality rate was
17.2% (36/209). There was no correlation between total bilirubin
level and mortality rate, although the highest mortality rate was
found among patients with total bilirubin level 4 10mg/dl
(32.6%) and those with three or more complications (40.4%).
There was no signiﬁcant difference in the efﬁcacy of parenteral
quinine and artemether used in treating severe malaria patients
(86.8% vs 86.2%; P40.05). Conclusions: Malaria with hyperbi-
lirubinemia/jaundice is the most common complication of severe
malaria patients in Minahasa, Indonesia. Total bilirubin level
correlates positively with SGOT, SGPT, alkaline phosphatase,
creatinine levels and parasite count, but it correlates negatively
with platelet count. Liver parenchymal disorder and cholestasis
seem to play a more important role compared with hemolysis in
the development of jaundice in severe malaria patients. More
than 50% of hyperbilirubinemia patients develop accompanying
acute renal failure. The mortality rate of hyperbilirubinemia
patients is 17.2%.
APASL/Poster/Abstract/59
Protective effect of captopril and losartan against liver cell injury
induced by paracetamol, CCL4, and ethanol in rats
Nafrialdi, Edi TM Gultom, Rianto Setiabudy, Fransiscus D
Suyatna
Department of Pharmacology, Faculty of Medicine, University
of Indonesia, Jakarta
Background: ACE-inhibitor and angiotensin receptor blockers
have been shown to be protective against ischemia-reperfusion
injury in various tissues including heart and liver. Aim: The
present study was aimed to evaluate whether inhibition of renin-
angiotensin system (RAS) by captopril and losartan also pro-
tective against liver cells injury induced toxic dose of paraceta-
mol, CCl4, and ethanol. Methods: Fifty four male Sprague-
Dawley rats of 200–250 g BW were devided into 3 groups of 18
rats. The ﬁrst group was given a single dose of paracetamol
2500mg/kg p.o, the second group received a single dose of CCl4
2mg/kg p.o, and the third group received a four days admin-
istration of 10ml/kg/d of ethanol solution with escalating
concentration (35%, 50%, 60%, and 70%). Each group was
further devided into 3 subgroups each receiving pretreatment
with aquadest (10ml/kg/d) for 3 days (control group), captopril
2mg/kg/d for 3 days, or losartan 4mg/kg/d for 3 consecutive
days prior to paracetamol or CCl4. For those receiving ethanol,
captopril and losartan were given for 4 days. One day
after administration of the toxic substances, laparotomy
was performed under pentobarbital anesthesia. Blood samples
were withdrawn from vein cava for the measurement of SGOT
and SGPT level representing the parameter of liver inuury. The
liver was excised for MDA measurement as the parameter of
oxidative stress. One way ANOVA or Krusskal-Wallis were
applied (as appropriate) for between group comparison.
Results: Mean  SD of SGOT, SGPT, and liver MDA levels
in control (Ctl) and captopril- and losartan protected groups are
shown in the following table:
Groups
Subgroups
Paracetamol CCl4 Ethanol
Ctl Capt Los Ctl Capt Los Ctl Capt Los
SGOT
(U/l)  SD
212.8 100.2n 102.8n 285.2 179.6n 144.5n 116.3 91.7n 90.8n
54.3 10.2 7.8 39.5 18.4 45.3 2.6 5.4 8.6
SGPT
(U/l)  SD
216.3 71.7n 90.2n 272.2 161.0n 156.9n 58.6 46.6n 46.5n
63.8 14.4 34.6 3.8 47.8 40.9 2.9 4.3 4.4
MDA  SD
(nmol/ml)
24.4 16.7n 15.9n 47.9 26.1n 27.4n 34.1 18.9n 20.0n
3.5 1.9 3.3 9.1 4.8 2.4 5.9 3.3 2.7
nPo0.05 versus respective control groups.
Conclusions: Reduction of SGOT and SGPT levels indicated
that captopril and losartan have protective effects against liver
injury induced by paracetamol, CCl4, or ethanol. Reduction of
MDA levels suggests that this protective effect is (at least partly)
mediated by antioxidant effects RAS-inhibition.
APASL/Free Paper/Abstract/60
Protective effect of renin–angiotensin system inhibition on is-
chemic reperfusion of the liver
Nafrialdi, Nunung P. Waluyatiningsih and Fransiscus D.
Suyatna
Department of Pharmacology, Faculty of Medicine, University
of Indonesia, Jakarta, Indonesia
Aim of the Study: Inhibition of the renin–angiotensin system
(RAS) by ACE-inhibitors or angiotensin receptor blocker
(ARB) has been widely used in the treatment of myocardial
infarction. In the following study, the inﬂuence of RAS block-
ade on ischemic reperfusion injury of the liver was evaluated as a
preliminary model to further learn the role of RAS in liver
failure such as that encountered during multiple organ failure.
Methods: Thirty male Wistar rats weighing 200–250mg were
divided into ﬁve groups of six rats. Ischemic reperfusion was
performed by a 30-min ligation of the portal vein followed by 30
reperfusions in situ. All procedures were performed under
anesthesia with intraperitoneal injection of penthobarbital so-
dium (60mg/kg). ALT and AST were measured from the
plasma before and after ischemia as indicators of liver damage.
Malondialdehyde (MDA) and superoxide dismutase (SOD)
were assayed from liver homogenate after the reperfusion
period, and were taken as the parameters of free radical attack.
The control group underwent ischemic reperfusion without
previous treatment. Treated groups received Captopril 2mg/
kgBW/day, Benazepril 0.1mg/kg BW/day, Valsartan 4mg/
kgBW/day or N-acetyl cystein (NAC) 15mg/kgBW/day for
three consecutive days before the procedure. Results: The table
shows the results of ALT, AST, MDA and SOD.
Control Captopril Benazepril Valsartan NAC
Pre Post Pre Post Pre Post Pre Post Pre Post
ALT 54.46 348.5 42.55 60.03 65.69 83.84 82.86 75.27 55.53 62.90
 SE 6.57 33.99 7.49 5.78 7.85 8.09 6.02 5.49 3.33 9.43
AST 23.01 306.25 31.8 41.34 56.61 67.85 72.97 67.22 31.81 39.36
 SE 2.12 17.18 5.52 5.53 7.90 16.32 4.0 6.11 3.62 4.90
MDA 11.64 7.24 8.21 9.03 9.83
 SE 0.65 0.64 0.79 0.57 0.66
SOD 19.52 11.60 12.99 17.86 12.80
 SE 1.34 1.50 1.80 1.92 1.91
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It is concluded that 1. ACE-inhibitor and ARB reversed the
increase of ALT and AST after ischemic-reperfusion to a value
approaching baseline level. 2. The reduction of MDA and SOD
suggests that the protective effect of ACE-I and ARB is
mediated by the antioxidant effect of these substances.
APASL/Free Paper/Abstract/61
Functional roles of ubiquitin hybrid genes in hepatoma cell
proliferation and apoptosis
X.-J. Han1, K.-R. You1, S.-S. Kim2, Young-II Yeom2,
W.-X. Xu3 and T. D.-G. Kim1
1Division of Gastroenterology and Hepatology, Department of
Internal Medicine, Chonbuk National University Medical
School and Hospital, Jeonju, Jeonbuk, Korea,
2Korea Research Institute of Bioscience and Biotechnology,
Daejeon, Korea,
3Department of Physiology, Shanghai Jlao Tong University
School of Medicine, Shanghai, China
Using the cDNA microarray method, we found that the
ubiquitin–ribosomal protein hybrid genes, Uba80 and Uba52,
were preferentially expressed in hepatocellular carcinomas com-
pared with corresponding nontumor samples. This overexpres-
sion seems to be correlated with tumor cell proliferation (cell-
cycle progression). However, the ubiquitin hybrid genes are
further overexpressed during tumor cell apoptosis induced by
various apoptogenic agents. Cells that ectopically overexpress
Uba80 or Uba52 show a higher susceptibility to apoptosis and
are even occasionally induced to apoptosis when cultured in the
absence of apoptogenic agents. Apoptogenic insults enhance the
nuclear targeting of ubiquitin–nibosomal proteins and elicit the
aggregation of ubiquitin proteins in the nucleus during the early
stage of apoptosis. However, further insult results in a decrease
in histone ubiquitination, and, subsequently, to the abnormal
ubiquitination of the nuclear envelope, and a change to an
apoptotic cell morphology during the late stage of apoptosis.
Each fused nibosomal protein may function as a carrier for
rapid nuclear targeting and is localized in nucleoll. These results
suggest that ubiquitin hybrid genes may be associated with
tumor cell proliferation, but are further targeted during apop-
tosis and are responsible for the abnormal ubiquitination of the
nuclear envelope instead of nucleosomal histones.
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Characteristic clinical features of sarcomatoid hepatocellular
carcinoma: a suggestion of a different carcinogenic process from
trabecular type of hepatocellular carcinoma
J. M. Kang, Y.-H. Chung, S. H. Lee, T. S. Kim, J. M. Ahn,
Y. S. Lee, S. W. Jung, K. M. Kim, Y. S. Lim, Y. S. Lee and
D. J. Suh
Department of Internal Medicine, University of Ulsan College
of Medicine, Asan Medical Center, Seoul, Korea
Background/Aims: Although the histological characteristics of
sarcomatoid type of hepatocellular carcinoma (scHCC) have
been occasionally reported, the clinical features of patients with
scHCC are still unclear. Thus, in this study, we analyzed the
clinical and radiological features of scHCC, comparing it with
trabecular HCC (trHCC), which is the most common histolo-
gical type, to get an insight into the biology of it. Methods: Fif-
teen patients with scHCC who were diagnosed at our institution
from August 1997 to August 2004 were the subjects. Their
clinical and radiological features were compared with those of
96 patients with trHCC diagnosed histologically from January
to December 2004. Results: The age and gender of patients with
scHCC were not different from those with trHCC. The etiolo-
gies of underlying chronic liver disease were not different bet-
ween scHCC and trHCC (HBV; HCV; NBNC; 80%:7%:13%
vs. 70%:19%:11%; P40.05). Sarcomatoid HCC associated
with liver cirrhosis infrequently compared with trHCC (13%
vs. 81%; Po0.01). Serum a-fetoprotein (AFP) levels of patients
with scHCC were much lower than those of patients with trHCC
(median: 9.9 vs. 17.1 ng/ml; Po0.05). The size of scHCC was
much larger than that of trHCC (9.4  4.9 vs. 4.1  2.8 cm in
diameter; Po0.001). At the time of diagnosis, scHCC also
associated more frequently with extrahepatic metastases com-
pared with trHCC (47% vs. 4%; Po0.01). However, the
frequency of portal vein invasion in scHCC is not signiﬁcantly
different from that of trHCC. Consequently, patients with
scHCC appeared to have much shorter survival periods than
patients with trHCC (Po0.01). Conclusions: Sarcomatoid HCC
presents as a larger-sized tumor that produces less AFP, more
frequently associating with extrahepatic metastases and result-
ing in a shorter survival period than trHCC. A majority of
scHCC seems to arise from an underlying non-cirrhotic liver,
suggesting pathogenic mechanisms of scHCC that are different
from those of trHCC.
APASL/Free Paper/Abstract/64
Effects of long-term ribavirin monotherapy on progression of liver
cirrhosis and occurrence of hepatocellular carcinoma in patients
with chronic hepatitis C
S. H. Ryu1, Y.-H. Chung2, J. A. Kim2, M. H. Choi2, Y. S. Lee2,
S. W. Jung2, S. H. Kim2, Y. S. Lim2, Y. S. Lee2 and D. J. Suh2
1Department of Internal Medicine, University of Inje College of
Medicine,
2Department of Internal Medicine, University of Ulsan College
of Medicine, Asan Medical Center, Seoul, Korea
Background/Aims: Although ribavirin (RBV) has been used for
the treatment of chronic hepatitis C (CHC) in combination of
interferon (IFN), the efﬁcacy and safety of long-term RBV
monotherapy remain to be clariﬁed. In this study, we evaluated
the clinical outcomes of long-term RBV monotherapy in terms
of progression of liver cirrhosis (LQ and occurrence of hepato-
cellular carcinoma (HCC). Methods: Sixty-ﬁve CHC patients
(37 CH and 28 LC of Child–Pugh class A) with serum alanine
aminotransferase (ALT) level42 upper limit of normal (ULN)
over 6 months, who did not respond or relapsed following IFN-
(X therapy, were administered RBV at a dose of 900–1200mg/
day and followed up for 412 months (median 47; range 12–88
months). Female patients aged o45 and patients with hemo-
globin levels o10 g/dl were excluded. We compared the cumu-
lative occurrence rates of decompensation and HCC according
to the response to RBV monotherapy. Results: Serum ALT
levels of 40 patients (62%) wereo2 ULN (responders); those of
the other 25 (38%) were  2 ULN (non-responders) at 12
months following RBV monotherapy. Female gender appeared
to be more common in responders (Po0.05). However, there
were no differences in age, duration of therapy, percentage of
LC, initial ALT, albumin, bilirubin levels and Child–Pugh
scores between the responders and non-responders. The cumu-
lative occurrence rates of decompensation at 1, 3 and 5 years
tended to be lower in responders than in non-responders (8.3%,
25% and 25% vs. 21%, 32% and 40%; P 5 0.07). The
cumulative occurrence rates of HCC at 1, 3 and 5 years were
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signiﬁcantly lower in responders than in non–responders (2.5%,
5.8% and 5.8% vs. 14%, 29% and 39%; Po0.05). During
follow-up periods, ﬁve patients (81/6) need to reduce the dosage
of ribavirin because of hemolytic anemia. Conclusion: Long-
term RBV monotherapy may retard the progression of LC and
reduce occurrence of HCC in patients with chronic hepatitis C
who arc responsive to the therapy.
APASL/Young Investigator/Abstract/65
Different cut-off values of serum a-fetoprotein should be used for
the diagnosis of hepatocellular carcinoma in accordance with the
etiology of associated chronic liver disease
S. W. Jung1, Y.-H. Chung1, J. A. Kim1, M. H. Choi1, Y. S. Lee1,
S. H. Kim1, M. K. Jang2, S. H. Ryu3, K. M. Kim, Y. S. Lim1,
Y. S. Lee1 and D. J. Suh1
1Department of Internal Medicine, University of Ulsan College
of Medicine, Asan Medical Center,
2Department of Internal Medicine, College of Medicine, Hallym
University,
3Department of Internal Medicine, University of Inje College of
Medicine, Seoul, Korea
Background/Aims: Although a-fetoprotein (AFP) has been re-
garded as a useful serologic marker of hepatocellular carcinoma
(HCC), the usefulness of it is limited because of frequent
elevation of serum AFP levels in patients with chronic liver
disease (CLD), which is commonly associated with HCC. Serum
AFP levels of patients with CLD have been reported to be
different in relation to the etiology of CLD, affecting the
speciﬁcities of serum AFP in diagnosing HCC. Thus, in this
study, we evaluated the efﬁcacies of serum AFP in the diagnosis
of HCC in accordance with the etiology of associated CLD.
Methods: A total of 443 consecutive patients with HCC (340
HBV, 43 HCV, 57 NBNC, 3 HBV1HCV) were the subjects; 552
patients with liver cirrhosis (LC) were also examined as non–
tumor controls (359 HBV, 42 HCV, 143 NBNC, 8 HBV1HCV).
Using serum AFP levels measured at the time of diagnosis, the
sensitivities and speciﬁcities of serum AFP in diagnosing HCC
were calculated and compared in accordance with the etiology
of associated CLD. Results: Serum AFP levels in HBV-asso-
ciated HCC were signiﬁcantly higher than those in HCV-
associated HCC or NBNC HCC. (Po0.00 1) Moreover, serum
AFP levels of patients with LC were also signiﬁcantly different
in relation to the etiology (Po0.001) The calculated cut-off
values of serum AFP in diagnosing HBV-associated HCC,
where the speciﬁcities were over 95%, were 400 ng/ml; l00 ng/
ml in HCV-associated HCC and 20 ng/ml in NBNC HCC. At
the cut-off level of serum AFP, the sensitivities were 44%, 33%
and 49%, respectively. Conclusion: HBV infection frequently
associates with elevated serum AFP levels, compared with HCV
infection or other causes of CLD. Therefore, different cut-off
values of serum AFP should be used for the diagnosis of HCC,
in accordance with the etiology of associated CLD.
APASL/Young Investigator/Abstract/66
The effects of long-term continuous administration of lamivudine
in patients with YMDD mutants of genotype C hepatitis B virus:
in relation to type of YMDD variants
Y. S. Lee1, Y.-H. Chung1, J. A. Kim1, M. H. Choi1, S. H. Lee1,
S. W Jung1, S. H. Kim1, M. K. Jang2, S. H. Ryu3, K. M. Kim1,
Y. S. Lim1, Y. S. Lee1 and D. J. Suh1
1Department of Internal Medicine, University of Ulsan College
of Medicine, Asan Medical Center,
2Department of Internal Medicine, College of Medicine, Hallym
University,
3Department of Internal Medicine, University of Inje College of
Medicine, Seoul, Korea
Background/Aim: Prolonged lamivudine (LAM) therapy fre-
quently associates with YMDD mutants of hepatitis B virus
(HBV). The long-term outcome of patients with YMDD muta-
tions is not clear so far, especially when they are treated with
lainivudine continuously. We analyzed the effects of long-term
continuous LAM therapy in patients with YMDD mutants of
genotype C HBV. Method: Out of 92 with viral resistance
during prolonged larnivudine therapy, 82 patients with the
YMDD mutant (63 CK 19 LC; 47 YIDD, 20 YVDD and 15
mixed) were administered lamivudine continuously at a dose of
100mg/day and followed for 412 months (median, range; 61,
16–96 months). The cumulative rates of serum ALT normal-
ization, negative serum HBV-DNA and loss of serum HBeAg
were calculated. The clinical, biochemical and virological fea-
tures were compared, especially in relation to the type of
YMDD variant. Result: The 1-, 2- and 3-year cumulative rates
of normal serum ALT were 41%, 82% and 90% and those of
negative serum HBV-DNA were 27%, 59% and 80%, respec-
tively Moreover, 5%, 13% and 27% of patients with YMDD
mutants lost their serum HBeAg at 1, 2 and 3 years following the
appearance of the YMDD mutant, respectively During the
periods of follow-up, two patients (2.4%) underwent liver
transplantation because of serious decompensation, two patients
(2.4%) developed hepatocellular carcinoma and four patients
(4.9%) died of liver-related complications. There were no differ-
ences of age, gender, initial serum ALT, HBV-DNA levels and
HBeAg-positivity ,in accordance with the type of YMDD
variants (YIDD, YVDD and mixed type). Also, the cumulative
rates of normal serum ALT, negative serum HBV-DNA and loss
of serum HBeAg were not different among the three groups of
YMDD variants. Conclusion: Long-term continuous LAM ther-
apy gives a substantial proportion of patients with the YMDD
mutant favorable viral responses. However, the type of YMDD
variant may not inﬂuence the clinical outcomes induced by the
continuous LAM therapy.
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APASL/Poster/Abstract/68
Efﬁcacy of oral branched-chain amino acid supplement in liver
cirrhosis
Lae Hyun Phyun, Kwang Hyun Ko, Ji Hyun Lee, Chang Il
Gwoun, Sung Pyo Hong, Sung Kyu Hwang, Pil Won Park and
Kyu Sung Rim
Department of Internal Medicine, Pochon CHA University
Bundang CHA General Hospital, Sung Nam, Korea
Background/Aim: Nutritional supports with branched-chain
amino acids (BCAA) might prevent disease progression in
patients with liver cirrhosis. We investigated the efﬁcacy of
oral BCAA supplementation in patients with liver cirrhosis.
Materials and Methods: Thirty-eight cirrhotic patients, from
January 2001 to July 2003, prescribed oral BCAA supplementa-
tion for more than 12 months, were included retrospectively. We
compared the parameters associated with cirrhotic complications
such as incidence of HCC, laboratory data, Child–Pugh score,
number of admissions and mortality rate, with parameters in
those who had not received BCAA (control group, N5 100).
Results: Mean age of the patients was 51.7  10.2 Y/O and the
male–female ratio was 29:9. Average follow-up period and
duration of oral supplementation with BCAA in these patients
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were 16.6  5.8 months and 12.8  4.6 months, respectively.
There were no differences in baseline characteristics. In the
patients group, the total number of HCC was less frequent
(BCAA vs not BCAA 5 0/38:6/100), but no statistical signiﬁ-
cance was noted. Cirrhotic patients with oral BCAA supplemen-
tation had higher serum albumin (3.3  0.5mg/dl vs
2.8  0.6mg/dl, Po0.001) and a lower Child–Pugh score
(7.7  2.1 vs 9.7  2.9, Po0.001) than those in the control
group. Although statistically not signiﬁcant, the BACC group
showed more improvement with PT( change of PT,  1.85mg/dl
vs  0.27mg/dl, Po0.439) and T.B( change of BT, 0.2mg/dl vs
3.3mg/dl, Po0.121) than the control group. Conclusions: Oral
BCAA supplementation would prevent cirrhotic progression and
trend to a decreased risk of HCC. But a long term, prospective,
randomized study, to clarify the effects of oral BCAA supple-
mentation, is warranted.
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APASL/Poster/Abstract/70
Does Celecoxib have anti cancer activity against hepatocellular
carcinoma cells? A case report
Harmono M. Tantoro
Internal Medicine Laboratory, Dr. Muwardi District General
Hospital, Faculty of Medicine Surakarta University, Indonesia
Objectives: To report the possibility that celecoxib has
anti cancer activity against hepatocellular carcinoma cells.
Materials: A man, 58 years old and weighing 51 kg, was
clinically diagnosed with hepatocellular carcinoma (HCC),
based on the pain he was suffering, a mass in the right upper
quadrant of his abdomen and a weight loss of about 11 kg in 3
months. The clinical pathology: Hb 13.7 gr%, leucocytes at
11 600 cells/ml, thrombocytes at 214 000 cells/ml, albumin 4.2
gr%, globulin 3.7 gr%, g-globulin15.2%, HBsAg negative, anti
HBs positive, anti HCV negative and AFP 62, PIVKA II
42000. Sonography showed a mass that was hyper and hypoe-
choic, with a diameter of more than 6 cm. He had comorbidity
with hypertensive heart disease, treated with one tablet 40mg
propranolol at night, 10mg nifedipin at dawn, and tablets of
25mg captopril and 25mg hydrochlorothiazide in the morning.
The HCC was treated with celecoxib 100mg twice a day,and
after 6 months of treatment, his weight increased to 61 kg and he
was without limited activity. In the 13 months of treatment, he is
still alive, with normal activity. Results: Now, in the 13 months
of the celecoxib treatment, the patient is still alive, with 57 kg
body weight and normal activity. Conclusion: Perhaps celecoxib
has activity against HCC cells;this needs further conﬁrmation.
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APASL/Poster/Abstract/80
Durability of effectiveness after cessation of lamivudine treatment
in patients with chronic hepatitis B
Wang Lei, Liu Feng, Yan Jie, Li Xiaoying, Wang Jingbo,
Ma Ping and Wang Yaozong
Jinan Infectious Disease Hospital, Jinan, China
Objective: To investigate the durability of effectiveness after
cessation of lamivudine treatment in HbeAg-positive CHB
patients and HbeAg-negative CHB patients, as well as the
factors inﬂuencing it. Methods: Fifty-nine HBeAg-positive
CHB patients who met the cessation criteria of lamivudine
therapy (deﬁned as total duration  12 months and HBeAg
seroconversion maintained  6 months) and 29 HBeAg-nega-
tive CHB patients (total duration  24 months) were included
in the study. HBVDNA (Lightcycler, Roche), and biochemical
parameters (Architect Ci8200, Abbott) were tested at months 1–
4, 6, 9, and 12 of year 1, and every 6 months thereafter. Relapse
was deﬁned as HBVDNA  104 copies/ml. The endpoint of the
study was relapse. The statistical analysis was performed by the
software SPSS for windows 10.0. Results: 1. For HBeAg-
positive CHB patients, the duration of lamivudine treatment
was 12-60 months (median 23m). During follow-up 20 patients
relapsed, all the relapses occurring within 18 months after
cessation of lamivudine, The cumulative relapse rates (Ka-
plan–Meier method) were 22.0%, 27.2%, 31.3% and 36.3% at
months 3, 6, 12 and 24, respectively; the ratios of cumulative
relapse cases to all relapse cases at months 4, 6 and 12 were
75.0%, 80.0% and 90.0%, respectively. The ages of the relapse
cases were signiﬁcantly higher than those of the nonrelapse cases
(36.7  15.6 years, 22.7  9.3 years, P5 0.039). The relapse rate
of patients aged  18y was signiﬁcantly lower than that of
patients aged 418 years, 6.7% (1/15) vs. 43.2% (19/44),
Po0.01; for patients whose treatment duration was o18
months, the overall relapse rate was 66.7% (6/9); for those
 18 months, the cumulative relapse rates at months 3, 6, 12
and 24 were 18.0%, 20.0%, 24.8% and 30.4%, respectively. 2.
For HBeAg-negative CHB patients, the treatment duration of
lamivudine was 24–42 months (median 27m).Of these patients,
12 relapsed, 11 (91.7%) relapses occurring within 18 months
after cessation of lamivudine. The cumulative relapse rates at
months 3, 6, 12 and 24 were 17.2%, 21.2%, 41.5% and 47.4%,
respectively; the ratios of cumulative relapse cases to all relapse
cases at months 4, 6 and 12 were 41.7%, 50.0% and 83.3%,
respectively. The durability of effectiveness has no association
with age and duration of treatment. Conclusion: 1. The dur-
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ability of effectiveness after cessation of lamivudine treatment in
patients with HBeAg-positive chronic hepatitis B is different
from that of those with HBeAg-negative CHB. 2. For patients
with HBeAg-positive chronic hepatitis B, the durability of
effectiveness after cessation of lamivudine treatment is asso-
ciated with age and duration of treatment. It was especially
noted that the relapse rate of patients aged  18 years was
signiﬁcantly lower than that of patients aged 418 years. 3. For
patients with HBeAg-positive chronic hepatitis B, it is recom-
mended that the duration of lamivudine therapy should be
 18 months. 4. Follow-up was essential after cessation of
lamivudine and biochemical analysis and HBVDNA should be
tested periodically within 18 months, especially within the ﬁrst 4
months. For patients with HBeAg-negative chronic hepatitis B,
the follow-up period should be properly prolonged.
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APASL/Poster/Abstract/84
The brain natriuretic peptide and diastolic dysfunction of cirrhosis
with ascites
Chang Wook Kim1, Woo Seung Shin2, Chang Don Lee1, Jung
Won Jang1, Soon Woo Nam1, Young Seok Jo1, Nam Ik Han1,
Sang Wook Choi1, Sang Bok Cha1, Kyu Won Chung1 and
Hee Sik Sun1
1Department of Internal Medicine,
2The Division of Hepatology-Gastroenterology and Cardiol-
ogy, The Catholic University of Korea, Seoul, Korea
Background: Cirrhotic cardiomyopathy is generally deﬁned as
subnormal ventricular response to stress, and subtle cardiac
abnormalities have been described in patients with cirrhosis.
Especially, diastolic dysfunction can be seen in cirrhotic
cardiomyopathy. Natriuretic peptide hormones have been
reported to be sensitive markers of early cardiac disease. We
evaluated the relationship between brain natriuretic peptide
(BNP) and cardiac diastolic function in cirrhosis with ascites.
Methods: Prospectively, eight patients of cirrhosis with ascites
and four patients of hepatitis without cirrhosis as controls were
enrolled in this study. Each patient was examined for determi-
nation of serum BNP level, which was followed by echocardio-
graphy within 3 days. Results: Between cirrhosis and hepatitis
without cirrhosis, there were signiﬁcant differences of ALT,
albumin, prothrombin time and platelets. But, there were no
signiﬁcant differences of serum BNP level and diastolic dysfunc-
tion of echocardiogram. Correlation between BNP and diastolic
dysfunction of heart was not seen in this study. Among 12 cases,
ﬁve were alcohol-related liver diseases and seven were not
alcohol-related liver diseases. Between alcohol-related liver dis-
ease and alcohol-unrelated liver disease, there were no signiﬁcant
differences of BNP level and diastolic dysfunction. Conclu-
sion: BNP of cirrhosis showed an increased tendency compared
to that of hepatitis without cirrhosis butit was not signiﬁcant. The
relationship between serum BNP level and cardiac diastolic
dysfunction of echocardiogram was not seen in this study.
APASL/Poster/Abstract/85
The associations between polymorphisms of some candidate genes
and outcomes of hepatitis B virus infection
Xinxin Zhang, Zhitao Yang, Xiaofei Kong, Zhimeng Lu,
Jiehong Jiang, Donghua Zhang, Qiming Gong, Dengdi and
Jing Shenying Zhang
Department of Infectious Diseases, Rui Jin Hospital, Shanghai,
China
The outcomes of HBV infection are thought to be correlated
with the individual immune status and HBV-speciﬁc cellular
immune response. The immune-related genes may play impor-
tant roles in conquering viral replication and clearing the viral
infection. SNPs (single nucleotide polymorphisms), which can
serve as genetic markers, may inﬂuence the expression and
function of the genes. 253 cases of self-limited HBV infection
and 308 cases with persistent HBV infection from patients of
Chinese HAN ethnicity were enrolled in this study. The ratio of
male to female in the persistent HBV group was much higher
than that of self-limited infected subjects (P5 0.001). The
average age of self-limited infected patients was much more
than that of persistent HBV infected patients (Po0.001). A
panel of nine SNPs in seven important genes was determined by
allele-speciﬁc PCR. The distribution of MxA -88 SNP genotypes
was not in accord with the Hardy–Weinberg equilibrium. This
might have been caused by technical problems and will be re-
analyzed later. As the multiplicative logistic model was used to
exclude the inﬂuence of age and sex, the distribution of
genotypes of MTP H297Q in the self-limited HBV infection
group is higher than that in the persistent HBV infection group
(OR of CC genotype is 1.80, 95% CI: 1.011–1.769, P5 0.042).
As the dominant/recessive logistic model was used, the domi-
nant G allele of OAS1 30UTR, the dominant T allele of MTP-
493 and the dominant G allele of MTP H297Q in the self-limited
group were much higher than those in the persistent group (OR
is 0.37, 0.13 and 0.53, respectively; 95% CI 0.164–0.814, 0.026–
0.666 and 0.285–0.995, respectively). These results implied for
the ﬁrst time that the polymorphism of these genes might be
involved in determining the outcomes of HBV infection. The
combination of several SNPs could serve as the predictor for the
evolution of HBV infection, leading to new therapeutic methods
for HBV infection.
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APASL/Free Paper/Abstract/87
Hepato renal Syndrome in late extrahepatic obstructive jaundice
after internal drainage in experimental rats
M. Soemarko
Department of Surgery, Brawijaya University School of Med-
icine, Malang, East Java, Indonesia
Delayed extrahepatic obstructive jaundiced patients undergoing
internal biliary drainage have an increased risk of acute ischemic
renal dysfunction that ends in renal failure, with potentially high
morbidity and mortality. The aim of this study was to investigate
the signiﬁcance of acute ischemic renal failure caused by ANF
and ET-1 balance disturbance after internal biliary drainage (ID)
in an experimental animal model of delayed extra hepatic
obstructive jaundice. Adult male Wistar rats (weight: 190–220 g
and age: 20–24 weeks), n5 20 (ﬁve pairs) rats were used: ﬁrst pair
(four rats) for control (C), second pair for sham operation (SO),
third , fourth, and ﬁfth pair of rats for bile duct ligation (BDL).
The third pair was used as BDL control (BDLC), second
laparotomy was performed on the fourth pair for ID to perform
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a stenting choledocho-duodenostomy in the 14 days after BDL
and the ﬁfth pair underwent a second laparotomy to perform ID
in the same way in 35days after BDL. In the 38days after BDL,
all the 20 Wistar rats were sacriﬁed. All the Wistar rats were
assigned to the systemic blood ANF and ET-1 investigation with
Enzyme linked immunoabsorbent assay (ELISA), and renal
parenchymal ANF and ET-1 investigation with immunohisto-
chemistry staining (HIS). The concentration of ANF and ET-1
in systemic blood and renal parenchyma in the ﬁrst, second, and
fourth pairs was balance (in normal value), but the concentration
of ET-1 in renal glomeruli was higher than the normal value
(P5 0.0001) and the concentration of ANF in renal glomeruli
was much lower than the normal value (P5 0.0001) in the ﬁfth
pair. The data from this experimental animal study was evidence
that delayed extrahepatal obstructive jaundice internal drainage
caused disturbance of the ANF and ET-1 balance and triggered
acute ischemic renal failure.
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APASL/Free Paper/Abstract/92
HBV genes induce cytotoxic T lymphocyte response upon adeno-
associated virus (AAV) vector delivery into dendritic cells
You Hong, Cong Min, Wang Ping, Liu Tianhui, Wang Baoen
and Jia Jidong
Liver Research Center, Beijing Friendship Hospital, Capital
University of Medical Sciences, Beijing, China
Objective: The hepatitis B virus (HBV) has been an expanding
problem throughout the world and it remains difﬁcult to treat.
Immunotherapeutic approaches may offer new, effective treat-
ments. The study is to show that multiple HBV genes delivered
by recombinant adeno-associated virus (AAV) virus into den-
dritic cells (DC) are able to elicit a strong antigen-speciﬁc and
MHC class I-restricted CTL response. Methods: Three recom-
binant AAV type 2 vectors, which carry one of HBV S, C or X
genes, were used to transduce professional antigen-presenting
DC for the purpose of stimulating cytotoxic T lymphocytes
(CTL) in vitro. Monocytes, isolated from 10 healthy donors or
seven chronic hepatitis B patients, were pulsed by rAAV-HBV-
S, X, C or 293 lysate as control at the ﬁrst day of isolation, then
the DC were cultured for 7 days in vitro. The transcription and
expression of HBV-S, C or X genes were analyzed by reverse
transcription-polymerase chain reaction (RT-PCR) or intracel-
lular staining ﬂuorescence-actived cell sorter (FACS), respec-
tively. Results: It was found that all three recombinant AAV/
HBV antigen viruses could load DC at approximately 90%
transduction efﬁciency. Most importantly, all three AAV-
loaded DC stimulated rapid, antigen-speciﬁc and major histo-
compatability complex (MHC)-restricted CTL. In vitro, these
CTL killed (30–50%) synthetic antigen-positive autologous
targets as well as Hep3B liver cell targets. In comparing the
three antigens, it was found that AAV/HBV-C-derived CTL
consistently had the highest killing efﬁciency. Conclusion: These
data suggest that AAV/HBV antigen gene-loading of DC may
be useful for immunotherapeutic protocols against hepatitis B
virus infection and that the HBV C antigen may be the most
useful for this purpose.
APASL/Free Paper/Abstract/93
The effective infection of recombinant adeno-associated virus on
hepatic oval cells in vitro
Wang Ping, Cong Min, Liu Tianhui, Jia Jidong, Wang Baoen
and You Hong
Liver Research Center, Beijing Friendship Hospital, Capital
University of Medical Sciences, Beijing, China
Objective: Hepatic oval cells, the progenitors for liver regenera-
tion, are ideal target cells for gene therapy. As one of the main
gene therapy vectors, adeno-associated virus (AAV) has shown
the high ability to infect differentiated liver cells. This study is to
evaluate the infection efﬁciency and gene expression on hepatic
oval cells in vitro. Methods: Two marker genes, neomycin (neo)
or green ﬂuorescence protein (GFP) were constructed into AAV
type 2 vector and packaged into rAAV-neo or rAAV-GFP virus
in 293 cells. Hepatic oval cells were isolated from rats fed with
choline-deﬁcient diet supplement with 0.1% (w/w) ethonine for
6 weeks and identiﬁed by electromicrology, immunohistochem-
istry, RT-PCR, Western blot and cell differentiation. The
cultured hepatic oval cells were infected by rAAV-Neo virus
or rAAV-GFP virus at the MOI of 25. The rAAV-Neo virus-
infected cells and uninfected control cells were selected by
100 mg/ml G418 after 3 days of infection for 6 days and reduced
to 50mg/ml thereafter. The rAAV-GFP virus-infected cells
and the control cells were observed by both ﬂuorescence micro-
scope and ﬂuorescence-activated cell sorter (FACS) for GFP
expression. Results: Electron microscope, immunohistochemis-
try, RT-PCR and Western blot results showed the isolated cells
had the characteristics of mature hepatocytes, bile duct cells,
fetal liver cells and stem cells and could differentiate under
appropriate circumstances. So these cells were hepatic oval cells.
There were no obvious phenotypic changes after hepatic oval
cells were infected either by rAAV-Neo or by rAAV-GFP.
Under G418 selection, about 80% of the cells infected by the
rAAV-Neo virus could survive while the uninfected control
cells gradually died out, which indicated that the infection
efﬁciency of rAAV-Neo on hepatic oval cells was around
80%. The rAAV-GFP virus-infected oval cells showed a green
ﬂuorescence signal after 4 days of infection by ﬂuorescence
microscope. The infection efﬁciency was 93.5% by FACS
analysis. Conclusion: Hepatic oval cells could be infected by
recombinant adeno-associated virus signiﬁcantly, with the efﬁ-
ciency above 80%.
APASL/Plenary/Abstract/94
Real-time PCR determines extracellular matrix mRNA levels in
experimental rat liver ﬁbrosis
Y. J. Zhang, Y. Wang, P. Wang, M. Cong, H. You, J. D. Jia,
H. Ma and B. E. Wang
Liver Research Center, Capital University of Medical Sciences
Beijing Friendship Hospital, Beijing, China
Objectives: To study the expression of procollagen I mRNA,
TIMP-1 mRNA and CTGF mRNA in bile duct occlusive rat
liver ﬁbrosis by real-time PCR.Methods: (1) One hundred male
SD rats weighing 150–200 g were randomly divided into ﬁve
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groups: sham-operation group, bile duct occlusive ﬁbrosis
model group, silymarin (SIL) treatment group (intragastric
gavage of SIL 50mg/kg/day), Pentoxifyline (PTX) treatment
group (intragastric gavage of PTX 16mg/kg/day) and SIL/PTX
combination treatment group (intragastric gavage of SIL 50mg/
kg/day and PTX 16mg/kg/day). (2) Total RNA was extracted
from frozen rat liver tissue by using TRIzol reagent and was
reverse transcribed to cDNA. (3) The mRNA levels of procolla-
gen I, TIMP-1 and CTGF were determined by real-time PCR
(TaqMan technique). For each sample, the mRNA levels of
procollagen I, TIMP-1 and CTGF were normalized by GAPDH
mRNA. Results: After 6 weeks of bile duct occlusion (BDO),
the model group displayed 14-, 7- and 8-fold increases for
procollagen I mRNA, TIMP-1 mRNA and CTGF mRNA,
respectively. After treatment with SIL, PTX and a combination
of both, ﬁbrous septa became discontinuous and thinner.
Compared with the model group (procol-I mRNA: 1.54 
0.29; TIMP-1 mRNA: 4.08  1.36; CTGF mRNA:24.14 
5.08), SIL could downregulate the expression of procol-I
mRNA (0.59  0.15), TIMP-1 mRNA (1.49  0.60) and
CTGF mRNA (6.43  2.01). The difference between the SIL
group and the model group is statistically signiﬁcant (Po0.05).
PTX could also downregulate the expression of procol-I mRNA
(0.68  0.18) and CTGF mRNA (8.12  2.27); however, it
upregulated TIMP-1 mRNA (6.16  2.14) signiﬁcantly. Procol-
lagen I mRNA level and CTGF mRNA level in the combination
group were similar to the monotherapy groups (Po0.05),
although TIMP-1 mRNA level in the combination group was
lower than that in the PTX group (Po0.05). Conclusions: We
conclude that in rat ﬁbrosis induced by bile duct occlusion, SIL
or PTX could attenuate hepatic ﬁbrosis by downregulating
procollagen I and CTGF mRNA expression. However, there
is no further beneﬁt of combination therapy, perhaps because of
the upregulation of TIMP1 by PTX.
APASL/Free Paper/Abstract/95
Hepatic hemodynamic change after percutaneous radiofrequency
ablation of hepatocellular carcinoma
S. Sato, H. Miyakawa, H. Fujikawa, E. Kitazawa, A. Takai
Y. Kawashima, T. Matsushita, K. Kikuchi, T. Watabe,
M. Omata and Y. Murakawa
Department of Internal Medicine, University of Teikyo-mizo-
nokuchi, Japan
Objective: Radiofrequency thermal ablation (RFA) is a mini-
mally invasive treatment widely used for the treatment of liver
neoplasms. The purpose of this study was to evaluate the changes
in hepatic hemodynamics after percutaneous RFA treatment of
hepatocellular carcinoma using pulsed Doppler sonography.
Materials and Methods: Between April 2004 and November
2004, 40 subjects with hepatocellular carcinoma (1.2–4.3 cm in
diameter, 1–3 nodules) were treated by RFA. The RFA was
performed percutaneously using a monopolar cooled-tip elec-
trode needle under US guidance with local anesthesia. Hepatic
hemodynamic change was examined in each patient 2 days
before and after the RFA. The statistical analysis was per-
formed on hemodynamic measurements recorded in the fasting
state by pulsed Doppler sonography. The time-averaged velo-
city and cross-sectional area of the portal vein and maximum
velocity of the hepatic artery were recorded. Portal vein blood
ﬂow was calculated. Hepatic venous ﬂow was classiﬁed into
normal or abnormal patterns. Results: In the ablation zone,
hepatic arterial velocity was signiﬁcantly elevated after RFA,
compared to pre-treatment level (35.5 cm/s vs 26.4 cm/s),
Po0.05, while portal vein ﬂow and hepatic venous ﬂow were
not signiﬁcantly altered. In the non-ablated zone, there was no
signiﬁcant change in the hepatic hemodynamics before and after
RFA. Conclusion: RFA-treated zone had elevated hepatic ar-
terial velocity. But in the non-ablated zone, no signiﬁcant
change was observed in the hemodynamics of artery, portal
and hepatic veins, indicating that RFA is a safe and minimally
invasive treatment, with no untoward effect on hepatic hemo-
dynamics outside the locoregional area.
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Combination therapy of intra-arterial 5-ﬂourouracil and systemic
interferon hepatocellular carcinoma with portal venous invasion
Shuntaro Obi
Kyoundo Hospital Chiyoda-ku, Tokyo, Japan
Background: Hepatocellular carcinoma (HCC) with portal ve-
nous invasion (PVI) presents an ominous prognosis. The com-
bination of intra-arterial 5-ﬂuorouracil (FU) and systemic
interferon was recently reported to be effective against
HCC with PVI, although only in small-sized pilot studies.
Methods: One hundred and sixteen patients with HCC with
PVI received IFN (5 000 000U intramuscularly on days 1, 3, and
5 of each week) and 5-FU (500mg into the hepatic artery on
days 1 through 5 of the ﬁrst and second week of each 4-week
cycle). The therapy was terminated at the end of the ﬁrst cycle in
case of progressive disease, or repeated for at least three cycles
otherwise, when the response to treatment was evaluated by
Eastern Cooperative Oncology Group criteria. The survival was
compared with that of historical controls (n5 42). Results: Ni-
neteen (16%) patients showed a complete response, and the
other 42 (36%) showed a partial response. The untoward effects
were limited to controllable nausea and appetite loss. The
survival rates at 12 and 24 months among patients overall
were 34% and 18%, respectively, in contrast to 15% and 5%
among the historical controls. Survival rates at 12 and 24
months were 81% and 59% among complete responders,
respectively, and 43% and 18% among partial responders.
Conclusions: The combination therapy with 5-FU and IFN
was safe, and substantially improved survival among the com-
plete responders.
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Efﬁcacy of glycyrrhizin in the treatment of non-alcoholic steato-
hepatitis
T. Nakashima
Department of Internal Medicine, Saiseikai Kyoto Hospital,
Nagaoka-kyo, Japan
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Stronger Neo-Minophagen C (SNMC) is a registered Japanese
medicine in the form of an intravenous injecting solution, which
contains 0.2% glycyrrhizin, a major saponin component in an
aqueous extract from licorice roots. SNMC has proven effective
in improving serum transaminase levels in patients with chronic
viral hepatitis. We used SNMC in the treatment of non-alco-
holic steatohepatitis (NASH). Five NASH patients (two males
and three females, aged 48  6 years) received SNMC (Mino-
phagen Pharmaceutical Co., Tokyo, Japan, 40 ml/day) alone
intravenously three times/week for 3 months or more. NASH
was diagnosed clinically on the basis of the laboratory data and
histological ﬁndings in the liver. Both the alanine aminotrans-
ferase (ALT) and gamma-glutamyl transpeptidase (r-GTP)
levels (mean, IU/l) signiﬁcantly improved from 112 and 89
before SNMC treatment, respectively, to 49 and 55 after
treatment, respectively (Po0.01). Serum ferritin levels (mean,
ng/ml) also signiﬁcantly improved from 210 before, to 116 after
SNMC treatment (Po0.01). NASH, which is characterized by
fatty change associated with necroinﬂammation, occasionally
progresses to cirrhosis and hepatic failure. Oxidative stress may
contribute to the progression of NASH. We have found that
SNMC increases the levels of glutathione in human lympho-
cytes, thereby decreasing oxidative stress of the body (Antiox
Redox Signal, 2:687, 2000). The present data clearly indicate
that SNMC improves the levels of ALT, r-GTP, and serum
ferritin as a marker of oxidative stress (Liver, 2001; 21:295) in
NASH patients. In conclusion, the decrease in oxidative stress
may be one mechanism that accounts for the therapeutic effects
of SNMC on NASH.
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Time course of cell-cycle-related proteins in rat hepatic stellate
cells isolated from dimethynitrosamine-induced hepatic ﬁbrosis
Kyoung Bun Lee, Min Jae Lee and Ja June Jang
Department of Pathology, Seoul National University College of
Medicine, Seoul, Korea
DMN (dimethynitrosamine)-induced rat liver cirrhosis model
appears appropriate for the study of the early events of hepatic
ﬁbrosis. Hepatic stellate cells (HSCs) are the primary
cellular source of the matrix components in liver ﬁbrosis. This
study was designed to decipher the expression pattern of the
cell cycle and apoptosis regulatory proteins in HSCs during
DMN-induced rat hepatic ﬁbrosis. Six-week-old female
Sprague–Dawley rats were intraperitoneally injected 10 ml of
DMN/kg body weight, 3 consecutive days a week for 4 weeks.
The animals were sacriﬁced in the ﬁrst, second, third and fourth
weeks and HSCs were puriﬁed. The expression of cell-
cycle control proteins such as CDK2, CDK4, cdc2, cyclin B,
cyclin D, cyclin E and apoptosis-related proteins (bcl-2 and Fas)
was examined by Western blotting. The proliferation and
apoptosis fractions of the isolated HSCs were examined by
ﬂow cytometry. The portions of S-phase cells and apoptotic cells
dramatically increased in the ﬁrst week and rose again in the
fourth week. Expression pattern of cyclins, CDKs, PCNA, Fas
and bcl-2 was diverse. Cyclin A, cyclin D and PCNA showed
increased expression in the ﬁrst week but cyclin B steadily
increased up to the fourth week. The expression of other cyclins
and CDKs remained unchanged or decreased slightly. Bcl-2
and Fas were increased from the ﬁrst week until the fourth
week. The HSCs in DMN-induced rat hepatic ﬁbrosis had
a high proliferation rate in the early stage of ﬁbrosis, with
high apoptotic activity. These early events were correlated
with increased cyclin A and D expression and increased Fas
expression.
105
Abstract withdrawn
106
Abstract withdrawn
107
Abstract withdrawn
APASL/Free Paper/Abstract/108
Prognostic determinants of survival and effect of transarterial
chemoembolization in patients with hepatocellular carcinoma
Z. Abbas, A. R. Siddiqui, N. H. Luck, Z. A. Khan, M. Hassan,
R. Mirza, S. Aziz, A. Naqvi and Sah Rizvi
Department of Hepatogastroenterology, Sindh Institute of
Urology and Transplantation, Karachi, Pakistan
Introduction: The aim of the present study was to identify
independent prognostic markers for survival in patients of
hepatocellular carcinoma (HCC) and cirrhosis of liver and to
evaluate the effect of transarterial chemoembolization (TACE)
on overall survival. Methods: We conducted a study on 50
patients with HCC and cirrhosis where baseline characteristics
and follow-ups were available. The diagnosis of HCC was
established by ultrasound, computerized tomography, magnetic
resonance imaging, histologic or a-fetoprotein levels. Survival
rates were calculated by means of the Kaplan–Meier method.
Univariate analyses of the effect of different characteristics were
based on comparison of survival by the log-rank test. Statisti-
cally signiﬁcant variables were introduced into a multivariate
Cox’s proportional-hazard regression analysis. Survival curves
were compared using different classiﬁcation systems (Child’s
Class, CLIP, Okuda, BCLC). Because TACE was performed
in 21 patients, its effect on survival was also analyzed.
Results: Males were 78%, median age 51 years(range 13–70
years). Median follow-up was 7.5 months (range 2–26 months).
HCV was the etiology in 50%. At the time of analysis of data, 23
patients had died (46%) and 21 (42%) had undergone TACE.
Overall survival rates at 2, 6, 12 and 22 months were 98% (95%
Cl, 97–99%), 78% (95% Cl, 72–84%), 45% (95% Cl, 37–53%)
and 26% (95% Cl. 16–36%), respectively. Univariate analyses
showed that etiology (P5 0.0001), sex (P5 0.01), tumor type
(P5 0.02), hepatomegaly (P5 0.04), portal vein thrombosis
(P5 0.05), hemoglobin (P5 0.06), age (P5 0.07), splenic
varices (P5 0.09) and serum levels of alkaline phosphatase
(P5 0.09) and CLIP scoring (P5 0.0004) were signiﬁcantly
related to survival. The multivariate Cox regression model
showed that hepatitis C etiology (P5 0.009) and portal vein
thrombosis (P5 0.061) were independent prognostic determi-
nants of survival. In addition, patients, 21 (42%) of whom were
offered TACE, also yielded a beneﬁcial effect on the survival in
the total population (relative risk (RR), 1.95; 95% CI, 0.84–
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4.54) and showed improved 1-year survival compared with those
who were not offered TACE (57% vs 37%). Conclusion: Hepa-
titis C as the etiology of HCC is associated with poor prognosis.
Portal vein involvement adversely affects survival. TACE inﬂu-
ences favorably 1-year survival. The CLIP scoring system seems
to be a better choice in our patients.
APASL/Poster/Abstract/109
Pyogenic liver abscess in Southeast Asian patients
Vui Heng Chong
RIPAS Hospital, Negara Brunei Darussalam, Brunei
Background: Liver abscess (LA) can cause signiﬁcant
morbidity and the organisms vary between different regions.
Objective: This study assesses the characteristics of LA in
Southeast Asian patients. Material and Methods: Patients trea-
ted for LA (1999–2004) were identiﬁed and retrospectively
reviewed. Results: Forty-two patients (mean age 47.6 years
(range 22–79 years), male5 38%, 91%) were treated for 49
episodes of LA. Two patients (post-Whipple’s and diabetes,
respectively) had recurrent abscesses. Predisposing factors were
diabetes (47.7% (known diabetes 31% and newly diagnosed
16.7%)) and biliary pathologies (21.4%). The most common
manifestations were fever (95.6%) and abdominal pain (69%).
LA was located at the right lobe (80%), left lobe (11%) and both
lobes (9%). Eighty-one percent had a solitary abscess. The
commonest organisms isolated were Klebsiella (46.8%) and
Mellioidosis (21.3%). No organisms (cryptogenic) were isolated
in 21.3%. Klebsiella abscess patients were older (54.9 vs. 38.1
years old, P5 0.021) and more likely to have diabetes (93.3%
vs. 6.7%, P5 0.005) compared to patients with cryptogenic
abscesses. Mellioidosis patients were more likely to have dia-
betes compared to patients with cryptogenic abscess (90% vs.
10%, P5 0.000) and other organisms (81.8% vs. 18.2%,
P5 0.039). Others organism-related abscesses were more
likely to have biliary pathologies. Sixty-six percent required
aspirations of the abscess and 33% need a drainage catheter
inserted. Complications were seen in 37%, with 12.2% needing
intensive care admissions. All responded to antibiotics with or
without drainage. There was no mortality associated with LA.
Conclusions: Klebsiella andMellioidosis are common organisms
causing pyrogenic LA in Southeast Asian patients. Both Kleb-
siella and Mellioidosis abscesses were associated with diabetes.
Other organisms group was more likely to have biliary pathol-
ogies. All responded to treatment with antibiotics with or
without drainage/aspiration.
APASL/Poster/Abstract/110
Characteristics of hepatitis C in Negara Brunei Darussalam
V. H. CHONG, A. Z. F. Jamaludin, A. P. Jacob, M. Alexander
and A. Jalihal
Gastroenterology Unit, RIPAS Hospital, Negara Brunei Dar-
ussalam, Brunei
Introductions: A combination therapy for chronic hepatitis C
(CHCV) has improved the treatment outcome. The patients’
and viral characteristics are important predictors of the re-
sponse. We aim to assess these characteristics in our patients.
Methods: CHCV patients (positive serum RNA) followed up in
the hepatology clinics were identiﬁed and retrospectively re-
viewed. Results: There were 81 patients (male (n5 67%, 83%))
with a mean age of 41.3  10.9 years (range 25–80 years). Fifty-
six percent were  40 years old. The etiologies of CHCV were
intravenous drug use (IDU) – 55.6%, hemodialysis related –
13.6% and others – 13.6%. Unknown etiology accounted for
17.3%. The associated factors for disease progression were
hepatitis B co-infection (n5 3%, 3.7%) and history of alcohol
use (n5 15%, 18.5%). All were negative for HIV. Serum ALT
was persistently elevated in 61.5%, ﬂuctuating in 20% and
persistently normal in 18.5%. Genotype testing (n5 14) showed
genotype 1 (n5 5%, 35.7%), genotype 2 (n5 1%, 7.1%),
genotype 3 (n5 8%, 57.1%) and genotype 4 (n5 2%, 14.3%).
Two patients had dual genotypes (genotypes 2/4 and 1/4,
respectively). Liver biopsy was carried out in 42% (n5 34),
showing grade (1.9  0.91/4) and stage (1.9  0.98/4). Com-
pared to non-IDU patients, more IDU patients were 40 years
old (75.6% vs. 30.6%, Po0.001) with favorable genotypes
(80% vs. 25%, P5 0.052), although not signiﬁcant. There
were no differences between the genders, except that
female patients had more unfavorable genotypes (P5 0.040).
Conclusions: Our results show that our patients have favorable
factors such as low co-infection rate, alcohol use, mild histolo-
gical activities and favorable genotypes. Majority of the IDU
patients were younger than 40 years old and had favorable
genotypes. There were no differences in the serum ALT and
histological activities.
APASL Bali/Poster/Abstract/111
Hepatitis C in Negara Brunei Darussalam: response to combina-
tion therapy
Azf Jamaludin, V.H. Chong, A.P. Jacob, M. Alexander,
A. Jalihal
Gastroenterology Unit, RIPAS Hospital, Negara Brunei
Darussalam
Introductions: Treatment of chronic hepatitis C (CHCV) has
improved with combination therapy. Currently, there is debate
regarding treatment of CHCV in intravenous drug users (IDU).
We review our experience with combination therapy in CHCV
patients.
Methods: All patients who had completed at least one course of
combination therapy (46 months of therapy) and had longer
than 6 months of follow-up were identiﬁed and reviewed.
Results: There were 28 patients (22 males, mean age of
40.7  9.9 years old) who completed one course of treatment
(standard IFN/ribavirin, n5 23 and pegylated IFN/ribavirin,
n5 5). IDU accounted for 61% of the etiology. All IDU were
undergoing drug rehabilitation before treatment. The end of the
treatment biochemical response was 93%. The overall sustained
viral response (SVR) was 64.3%. Comparing IDU with others
(non-IDU), there was no difference in treatment response
(64.7% vs. 63.6%, P5 0.954). IDU patients were younger
(37.2  6.7 vs. 46.2  11.7 years old, P5 0.025) and had higher
pretreatment serum alanine aminotrasferase (ALT) (P5 0.790).
Responders had signiﬁcantly higher pretreatment ALT
(P5 0.018). Overall side effects of treatment were seen in 64%
(ﬂu-like symptoms 58.3%, hematological 50% and depressive
related 8%).
Conclusions: Our response rates for combination therapy are
comparable with published data. There was no difference in
treatment response rate between the IDU and non-IDU. This
suggests that the CHCV-infected IDU should be offered treat-
ment whenever possible after rehabilitation.
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Correlation between the degree of hepatic disfunction and the
degree of cognitive deﬁcits in patients with liver cirrhosis
Tri Astawa, Idn Wibawa, N. Purwadi and Iga Suryadharma
Division of Gastroentero-Hepatology, Department of Internal
Medicine, Faculty of Medicine, Udayana University of Denpa-
sar, Denpasar, Indonesia
Background: Cirrhotic patients may present a degree of cogni-
tive alterations, which is related to the degree of hepatic
dysfunction. The number connection test (NCT) and digit
symbol test (DST) have been used to assess the degree of
cognitive deﬁcits in liver cirrhosis. However, the test
may potentially be attributed to the education level and
age, although some authors found their role insigniﬁcant.
Methods: In order to ﬁnd the relationship between the degree
of hepatic dysfunction as assessed by Child–Pugh score and the
degree of cognitive deﬁcits as assessed by percentage of increase
of NCT score or percentage of decrease of DST score with
respect to age and education level predicted score, a cross-
sectional analytic study was conducted among cirrhotic patients
in several hospitals in Denpasar. A normal control group was
selected to set the formula for age and education level predicted
NCT or DST score. Spearman’s corelation test was used to
assess the relationship between variables. Results: A total of 97
cirrhotic patients, aged 51.96  11.15, male 84.5%, female
15.5% and 40 normal controls, aged 49.18  10.53, male
50%, female 50%, were involved in this study. The mean
NCT, DST and Child–Pugh score of cirrhotic patients were
106.24  75.56, 21.62  9.41 and 7.87  1.63, respectively. The
mean NCT and DST of normal controls were 42.95  13.62 and
42.81  9.23, respectively. The formula for predicted NCT score
is 48.2561(0.343  age) (6.987  education level) and that
for predicted DST is 49.423 (0.336  age)1(3.119 
education level). Child–Pugh score was positively and signiﬁ-
cantly correlated with percentage of increase of NCT score
(R5 0.221; P5 0.029), and also Child–Pugh score was nega-
tively and signiﬁcantly correlated with percentage of decrease of
DST score (R5  0.328; P5 0.001). Conclusion: In liver cir-
rhosis, the degree of hepatic dysfunction was correlated with the
degree of cognitive deﬁcits.
APASL/Poster/Abstract/116
The seroepidemiological investigation of hepatitis B in Chinese
over 3-years-old
Liang Xiaofeng1, Chen Yuansheng1, Wang Xiaojun1,
He Xiong2 and Chen Lijuan2
1National Immunization Program, Chinese Center for Disease
Control and Prevention,
2Beijing Center for Disease Control and Prevention, Beijing,
China
Objective: In order to know about the epidemic situation of
hepatitis B and the effect of hepatitis B vaccine, which was
brought into the Expanded Program on Immunization from
1992, and provide the theoretical basis for prevention and
control of hepatitis B in China. Methods: (1) A total of 62 029
specimens were selected from the sampling of the Investigation
of Nutrition and Health in Chinese residents in 2002. (2)
HBsAg, anti-HBs and anti-HBc in blood samples were detected
using ELISA reagents and revised by SPRIA and Abbott
ELISA reagents. (3) The software used for the analysis of the
data above is SAS 8.2. Results: (1) The standardized prevalence
rate of HBsAg, anti-HBs and anti-HBc is 9.09%, 37.48% and
50.04% in humans aged over 3-years-old and 5.03%, 45.33%
and 29.10% in children from 3 to 12 years, respectively. (2) The
prevalence rate of HBsAg and HBV in urban areas is 4.61% and
43.51%, respectively. Comparing with 1992 (HBsAg 8.08% and
HBV 59.46%), the rate of HBsAg has declined to 42.95% and
the rate of HBV has declined to 26.82%. The prevalence rate of
HBsAg and HBV in villages is 9.41% and 56.77%, respectively.
Comparing with 1992 (HBsAg 10.49%), the rate of HBsAg has
declined to 27.63%. (3) In humans aged over 3-years-old,
comparing with 1992 (HBsAg 9.75%), the rate of HBsAg
(5.28%) in the vaccinated area has declined to 45.85%, while
the rate of HBsAg (9.51%) in the unvaccinated area has not
obviously changed. (4) The prevalence rate of HBsAg and HBV
in the vaccinated children from 3 years to 12 years is 3.63% and
26.88%, respectively. Comparing with 1992 (HBsAg 10.22–
11.27% and HBV 52–55%), the rate of HBsAg and HBV has
declined by 64–68% and 40–52%, respectively. In the vacci-
nated children from 3 to 12 years, the prevalence rate of HBsAg
in the urban areas is 1.96%, but the rate of HBsAg in villages is
6.65%. In the unvaccinated children, the prevalence rate
of HBsAg and HBV is 11.19% and 47.03%, respectively.
Conclusion: The results reveal that some changes have hap-
pened in the epidemic character of hepatitis B in China and
suggest that since the hepatitis B vaccine was brought into
the expanded program on immunization (EPI) from 1992, the
prevalence rate of the HBsAg and HBV, especially in the
children from 3 years to 12 years, has obviously declined.
Note: The ﬁnal data should be the result of further analysis.
APASL/Poster/Abstract/117
Aetiology of cirrhosis in a tertiary referral centre in Sri Lanka
A. S. Dassanayake, K. C. D. Mettananda, A. P. De Silva and
H. J. De Silva
Departments of Medicine and Pharmacology, Faculty of Med-
icine, University of Kelaniya, Ragama, Sri Lanka
Introduction: Alcoholic liver disease is widely believed to be the
commonest cause of cirrhosis in Sri Lanka. However, with the
rising prevalence of obesity and diabetes, non-alcoholic steato-
hepatitis (NASH) is increasingly being diagnosed. Despite being
situated in an intermediate to high transmission region, the
prevalence of both hepatitis B (o2%) and C ( 1%) is low in
our population. Aims: To study the aetiology of cirrhosis in a
tertiary referral centre in Sri Lanka. Methods: We analysed the
database of outpatients with cirrhosis maintained since 2001,
reviewing records with regard to aetiology. A diagnosis of
cirrhosis was established on clinical, biochemical and radiolo-
gical evidence, and conﬁrmed histologically when required.
A detailed alcohol and drug history was obtained from all
cirrhotic patients. Hepatitis B and C serology, iron and copper
studies, and an autoimmune screen were also performed.
Results: Records of 101 patients were analysed (male:female5
78:23, mean age 38.3 years (SD 17.5)). The aetiology of cirrhosis
was as follows: alcohol 64 patients (63.4%, male:female5 60:4),
cryptogenic 24 (23.8%, male:female5 12:12), chronic hepatitis
B four (all males), autoimmune hepatitis four (all females),
Wilson’s disease two (both females), previously diagnosed
NASH two (one male, one female), and chronic hepatitis C
one (male). The prevalence of diabetes was 45% among patients
with cryptogenic cirrhosis compared to 27% among patients
with other causes. Conclusions: Alcohol remains the commonest
cause of cirrhosis in our patients. Cryptogenic cirrhosis was the
second commonest cause overall, and the commonest among
females. The high prevalence of diabetes among patients with
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cryptogenic cirrhosis suggests an aetiology of previously un-
detected NASH.
APASL/Poster/Abstract/118
Effects of fatty liver and related factors on the efﬁcacy of
combination antiviral therapy in patients with chronic hepatitis C
Yu Jianwu1, Li Shuchen1 and Wang Guiqiang2
1Department of Infectious Diseases, The Second Afﬁliated
Hospital, Harbin Medical University, Harbin, China,
2Department of Infectious Diseases, The First Hospital of
Peiking University, Peiking, China
Hepatic steatosis is a histological feature in patients with
chronic hepatitis C and adversely affects the virologic response
rates to anti-HCV therapy. This study is to investigate whether
the fatty liver and related factors have an impact on the efﬁcacy
in chronic hepatitis C treated with peginterferon and ribavirin,
and the associations between HCV genotyping and fatty liver.
Ninety patients received, subcutaneously, 180 mg peginterferon
a-2a once a week plus ribavirin. HCV genotypes and the level of
serum insulin of patients were measured, fatty liver was detected
by B ultrasound, and the body mass index (BMI) and waist-to-
hip ratio (WHR) were calculated. Of the 90 chronic hepatitis C
patients, 35 (38.9%) were genotype 1, 41 (45.6%) were genotype
2, 5 (5.6%) were genotype 3 and 9 (10.0%) were undetermined.
The incidence of fatty liver in HCV genotypes 1, 2, 3 and
undetermined genotype was 11.4%, 9.8%, 60.0% and 11.1%,
respectively, which suggested that the distribution of fatty liver
in different HCV genotypes was imbalanced (w25 9.95,
Po0.05). In a multivariate analysis, the efﬁcacy of combination
therapy was signiﬁcantly associated with BMI (P5 0.011),
WHR (P5 0.024), the level of serum insulin (P5 0.001), and
the fatty liver (P5 0.028). With multivariate regression analysis,
the serum insulin level proved to be an independent predictor of
the efﬁcacy of antiviral therapy. The incidence of fatty liver in
HCV genotype 3 was signiﬁcantly higher than that of other
genotypes. The BMI, WHR, the level of serum insulin, and fatty
liver were associated with the sustained virologic response. The
level of serum insulin was an independent factor for predicting
the effect of antiviral therapy.
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Description function of the liver in malaria and the factors that
inﬂuence it
Armen Ahmad, Nuzirwan Acang, Nasrul Zubir and Saharman
Leman
Sub Division of Tropical Medicine and Infection Diseases,
Department of Internal Medicine, Faculty of Medicine Uni-
versity Andalas, Dr. M. Jamil General Hospital, Indonesia
Introduction: There are 300–500 million malaria cases in the
world with an annual death rate of 3 million. In Indonesia, 95%
of malaria is caused by Plasmodium falciparum, vivax and a
mixture of both. This research tried to observe the function of
the liver in malarial cases and the factors that inﬂuence it.
Materials and Methods: This research used a cross-sectional
method to evaluate the feature of the function of the liver, in Dr.
M. Jamil General Hospital. The inclusion criteria were patients with
clinical symptoms, with or without anemia, with or without liver
enlargement, with or without enlargement of spleen, age exceeding
12 years, whohad P. falciparum in the sexual stage, and agreed to
participate in the research. The exclusion criteria were age less than
12 years, damage of the function of the liver caused by other
malaria, peripheral routine blood examination, SGOT, SGPT,
bilirubin, and the parasitic count. For data analysis the SPSS
version 11 was used with a P-value o0,05. Results: From the 172
cases of malaria, the following results were obtained: falciparum
parasitic 168 (97%), vivax 3 (4%,16%), mixture 1 (0%, 58%), males
were affected more than females 117:55 (68.02:31.98%), the most
common age group 21–30 years old 63 (36%, 62%), the area
background, middle incidence area 8 (4%,65%) and low area 164
(95%, 35%), the fever lasted up to 7 days 89 (51%, 74%) , icteric 8
(4%, 65%), anemia 21 (12%, 21%),enlargement of the liver 78
(45%,35%) and spleen 74 (43%, 02%), the increasing SGOT
39.83  39, 42U/l, SGPT 38.99  33.5U/l. The parasitic
count5120–165.000par/ml in tropozoid form. Conclusion: In this
research, the damage function of the liver was found with increase of
SGOT, SGPT, and bilirubin. No correlation was found with the
increase of SGOT, SGPT with parasitic count. There was correla-
tion between bilirubin with parasitic count. The was no correlation
between SGOT, SGPT, bilirubin with long periods of fever and no
correlation between SGOT, SGPT with hemoglobin. There was
negative correlation between bilirubin and hemoglobin.
APASL/Poster/Abstract/121
Inﬂuence of storage duration on sensitivity of HBV-DNA detec-
tion among samples stored in ﬁlter paper
Reny Mulatsih, Rino A. Gani, A. D. Handayu, Ali Sulaiman,
Nurul Akbar and L. A. Lesmana
Division of Hepatology, Department of Internal Medicine,
Faculty of Medicine, University of Indonesia/Dr. Cipto Man-
gunkusumo Hospital, Jakarta, Indonesia
Hepatitis B virus (HBV) DNA detection plays an important role
in ensuring a proper management of HBV infections, which is
becoming a major health problem in Indonesia. However, taking
the geographic condition of Indonesian territory into considera-
tion, transportation of samples from remote areas to major cities
where DNA detection is available may take a considerable
amount of time. The objective of this study was to determine
the sensitivity of HBV-DNA detection on samples stored in ﬁlter
paper as a medium, and the inﬂuences of storage duration on
detection sensitivity. A total amount of 20 HBV-DNA serum
samples previously quantiﬁed using COBAS Amplicore was
dripped onto ﬁlter papers. Half of the samples were stored for
a week, and the other half for 2 weeks, after which the samples
were analyzed for the presence of HBV-DNA by means of nested
PCR. The group which was stored for 1 week was 95% positive
and the groups stored for 2 weeks were 85% positive; with
quantitative results 2  105–3.05  102. Detection of HBV-
DNA on samples stored in ﬁlter papers should be performed
before 1 week of storage, since a decline in sensitivity was
observed in samples stored for more than 1 week. However,
detection should still be positive on samples stored for over 2
weeks if viral load is high.
APASL/Poster/Abstract/122
Genotype determination of hepatitis B virus from dried serum on
ﬁlter paper
Rino A. Gani, Handayu , Reny Mulatsih, Ali Sulaiman and
Nurul Akbar
Division of Hepatology, Department of Internal Medicine,
University of Indonesia, Indonesia
Background: Genotype of hepatitis B virus (HBV) is an im-
portant test in clinical epidemiology as well in the management
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of patients. In our institution, we determined the HBV genotype
with primer-speciﬁc method, which can reveal 100% HBV
genotype from serum of chronic hepatitis patients and 80%
from hepatoma patients. Filter paper can preserve HBV-DNA
and this method can be used to transport the specimen from a
remote area. We determined the HBV-DNA from dried serum on
ﬁlter paper and use this for genotype analysis.Method: A volume
of 100ml sera from patients that already quantitated for HBV
DNA with Amplicor HBV DNA (Roche) was dropped onto a
ﬁlter paper (9 cm2 of Whatman No. 1). After drying at room
temperature, the paper was put in a plastic clip and kept in a
closed cabinet with room temperatures of 25–33 1C and humidity
of 90–96% for 1 week. HBV-DNA determinations were done
with nested PCR. Genotypes of HBV were determined by means
of speciﬁc primers in the region of Pre-S1, Pre-S2 and S for
detection of genotypes A, B, C, D, E and F. Results: Twenty-
three sera quantitated for DNA of HBV were obtained. Eighteen
(78.3%) of these sera were successfully determined for genotype.
Genotypes B were the most frequent (13/18%, 72.2%) and the
rest were genotype C (5/18%, 27.7%). The proportions of HBV
genotypes in our study were comparable to the other studies in
our country that used serum and sequencing of the whole genome
for genotyping of HBV. Five samples that could not be deter-
mined by this method showed positive with nested PCR and
mostly had o103 copy/ml. Conclusion: Filter paper can be a
good alternative method to transport HBV-DNA for genotype
determination in most cases of HBV infection. However, a small
number of HBV-DNA in serum can hamper the results and other
methods of genotyping must be used.
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APASL/Poster/Abstract/125
Endoscopic injection of N-butyl-2-cyanoacrylate (Histoacryl) vs
transjugular intrahepatic portosystemic shunt (TIPS) for the
treatment of gastric variceal bleeding: comparison of short-term
results
K. M. Kim, J. H. Park, Y. S. Lim, H. C. Lee, Y. H. Chung,
Y. S. Lee and D. J. Suh
Department of Internal Medicine, Asan Medical Center, Uni-
versity of Ulsan, College of Medicine, Seoul, Korea
Background and Aims: Transjugular intrahepatic portosystemic
shunt (TIPS) has been widely used for the treatment of gastric
variceal bleeding in many centers and, more recently, the
endoscopic injection of N-butyl-2-cyanoacrylate (Histoacryl)
was reported to be effective. This study was to compare the
efﬁcacy and safety of the two treatments as the initial treatment
of gastric variceal bleeding. Patients and Methods: From July
2003 to January 2004, 27 patients with gastric variceal bleeding
were treated with endoscopic Histoacryl injections in our
institution (Histoacryl group). Twelve weeks after treatment,
survival rate, rebleeding rate and complications of these patients
were compared with the historical control group of 37 patients
who were treated with TIPS between January 2001 and April
2004 (TIPS group). Results: Basal characteristics of the patients
were not different between the two groups. The number of
patients with hepatocellular carcinoma was signiﬁcantly higher
in the Histoacryl group (44.4%) than in the TIPS group (13.5%)
(P5 0.006). Overall survival rates in 12 weeks after treatment
were not different between the two groups (Histoacryl, 85.2%,
TIPS, 89.2%, P5 0.712). The rebleeding rates were 11.1% in
the Histoacryl group and 18.9% in the TIPS group and the
incidences of PSE after treatment were 18.5% and 21.6%,
respectively, which were not different between the two groups
(P5 0.498, 0.761, respectively). Conclusions: Endoscopic His-
toacryl injection was effective and the safe initial treatment
modality for bleeding gastric varices comparing TIPS, although
the follow-up period was not long enough. Long-term prospec-
tive study of Histoacryl injection versus TIPS on gastric variceal
bleeding is warranted.
APASL/Poster/Abstract/126
The relationship of VII factor with the degree of liver functional
status based on Child–Pugh criteria on liver cirrhosis
Bistok Sihombing1, Rosnawaty2, Iman Sukiman and
Abiran Nababan1
1Department of Internal Medicine University of North
Sumatra,
2Department of Clinical Pathology, University of North
Sumatra, Indonesia
It is predictable that haemostatic disturbances will be found
in the liver cirrhosis patient. This is due to the fact that
coagulation factor, inhibitor and ﬁbrinolysis factor are
produced in the liver. The VII factor will decrease progres-
sively, and it is the most sensitive to the damage of liver
parenchyme in cirrhosis. The aim of this study is to examine
the VII factor concentration in liver cirrhosis, and to know
whether this factor can be used to change the grade/stage/
severity of liver cirrhosis. Methods: A cross-sectional study
was conducted in 29 ambulatory and non-ambulatory liver
cirrhosis patients in two hospitals, RSPM and RSHAM Medan
in September 2002. It consisted of 21(72%, 4%) men and 8
(27%, 6%) women and the mean ages were 56 and 14 years. The
matched age control was taken from 15 healthy subjects who
had a mean age of 50.27 years. For control subjects, data were
taken after the interview, physical examination, and normal
laboratory tests. The examination of the VII factor is the VII-C
(pro coagulant) activity, which is based on one-stage assay with
the VII-depleted plasma. Results: Differences were observed in
the VII factor value and thrombocyte count in the case and
control groups. While the ﬁrst decreased continually for
the control group, Child–Pugh A, B, C, the second did not
show signiﬁcance relations to these observations. The values
were 138.71  13.77%, 103.98  10.43%, 78.13  10.42%,
and 38.97  14.77%, respectively for the decrease of mean
concentration of factor VII. The thrombocyte concentrations
were 259.80  58.47, 125.40  50.92, 134.38  71.96, and
135.56  59.30, respectively. To conclude, there is a
signiﬁcant decrease of the VII factor in the control group and
liver cirrhosis patients regardless of the stage of Child–Pugh
criteria. However, it was not shown in the prothrombin time
changes by these observations. The other result is that there is
no signiﬁcant relationship between the thrombocyte count and
the VII factor.
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APASL/Poster/Abstract/129
Serum adiponectin correlates with viral characteristics but not
histologic features in patients with chronic hepatitis C
C. J. Liu1, P. J. Chen1,2, Y. M. Jeng3, W. L. Huang2,
W. S. Yang1,2, M. Y. Lai1,2, J. H. Kao1,2,4,5 and D. S. Chen1,
1Department of Internal Medicine,
2Graduate Institute of Clinical Medicine,
3Department of Pathology,
4Hepatitis Research Center,
5Department of Medical Research National Taiwan University
Hospital and National Taiwan University College of Medicine,
Taipei, Taiwan
Introduction: Adiponectin induces insulin sensitivity and mod-
ulates inﬂammatory responses. We thus studied the implications
of adiponectin in patients with chronic hepatitis C virus (HCV)
infection inherently linked to insulin resistance. Patients and
Methods: We analyzed the association of serum adiponectin
levels with clinical, virologic and histologic ﬁndings in 95 naı¨ve
Taiwanese patients with chronic hepatitis C before and after
antiviral therapy. Results: At baseline, 14 (15%) of the 95
patients were obese and 26 (27%) had type 2 diabetes mellitus.
Fifty-seven patients were infected with HCV genotype 1 and 38
with genotype 2. Steatosis and periportal ﬁbrosis was present in
44 (46%) and 69 (73%), respectively. In multivariate analysis,
male gender, insulin resistance, high HCV load and genotype 2
were signiﬁcantly associated with a lower serum adiponectin
level. In contrast, intrahepatic gene expression of adiponectin
receptors was higher in genotype 2 compared with genotype 1.
Serum adiponectin level did not correlate with other clinical or
histologic parameters. After treatment, change of steatosis also
did not correlate with the change of adiponectin level (P5 0.61).
Conclusion: Adiponectin correlated with hepatitis C viral fac-
tors at both serum and liver tissue levels. The interactions
among adiponectin, insulin resistance and chronic HCV infec-
tion merit further studies.
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Durability of response to peginterferon a-2a (40 kDa) 1 year after
the end of treatment in patients with HBeAg-negative chronic
hepatitis B: results from a large multicentre trial
C. Yurdaydin1, P. Marcellin2, G. K. K. Lau3, P. Farci4, R. Jin5,
S. Gurel6, T. Piratvisuth7, S. Hadziyannis8, Z.-M. Lu9 and
M. Popescu10
1University of Ankara, Ankara, Turkey,
2Hoˆpital Beaujon, Clichy, France,
3Queen Mary Hospital, Hong Kong, China,
4Universita di Cagliari, Cagliari, Italy,
5Beijing You An Hospital, Beijing, China,
6Medical School of Uludag University, Bursa, Turkey,
7Songklanakarin Hospital, Songkla, Thailand,
8Henry Dunant Hospital, Athens, Greece,
9Ruijin Hospital, Shanghai, China,
10Roche, Basel, Switzerland
Introduction: In patients with HBHBHBeAg-negative CHB, pe-
ginterferon a-2a (40kDa) provides signiﬁcantly higher sustained
response rates 6 months after the end of treatment than lamivu-
dine (LAM) (Marcellin, N Engl J Med 2004). The combination of
peginterferon a-2a and LAM did not provide an advantage over
peginterferon a-2a alone. This analysis aims to evaluate the
durability of response 1 year after the end of treatment in patients
treated with peginterferon a-2a alone. Patients and Methods: In
the initial study, 177 patients with HBeAg-negative CHB received
48 weeks of peginterferon a-2a 180 mg once weekly and were
assessed 6 months post-treatment. Results generated 12 months
post-treatment in a roll-over long-term observational study (LT-
study) are presented. Results: In total, 62% of the patients
participating in the original study opted to participate in the
LT-study. The rates of biochemical and virologic response mea-
sured 12 months after the end of treatment with peginterferon a-
2a monotherapy were similar to those reported 6 months after the
end of treatment: 59% vs 59% for ALT normalization; 42% vs
43% for HBV-DNA o20000copies/ml; and 17% vs 19% for
HBV-DNA o400 copies/ml. In a sub-analysis of those patients
who responded to peginterferon a-2a monotherapy at the end of
treatment, more than half (55%) had HBV-DNA levels
o100 000copies/ml for most of the 12-month follow-up; 30%
had HBV-DNA levels o20000 copies/ml, and 15% had HBV-
DNA levels permanentlyo400copies/ml.Conclusion: A ﬁnite 48-
week course of peginterferon a-2a can induce high rates of
biochemical and virologic response that are sustained 1 year after
the end of treatment.
APASL/Free Paper/Abstract/132
HBe-antigen negative chronic hepatitis B: cost-effectiveness of
peginterferon a-2a compared with lamivudine treatment in Taiwan
D. L. Veenstra1, S. D. Sullivan1, M. Y. Lai2, C. M. Lee3,
C. M. Tsai4 and K. Patel5
1University of Washington, Seattle, WA, USA,
2National Taiwan University Hospital, Taipei, Taiwan,
3Chang Gung Memorial Hospital, Kaohsiung, Taiwan,
4Roche Products Ltd., Taipei, Taiwan,
5Hoffmann-La Roche, Nutley, NJ
Introduction: In Taiwan, the carrier rate of HBsAg is 15–20%,
one of the highest in the world. Among those patients with
chronic hepatitis B (CHB), HBeAg-negative disease accounts
for approximately 40–50% patients. A recent study found that
peginterferon a-2a (40 kDa) is more effective than lamivudine in
treating HBeAg-negative CHB, but its cost-effectiveness has not
been evaluated. We aimed to evaluate the incremental cost-
effectiveness of 48 weeks of peginterferon a-2a compared to 48
weeks of LAM, from the perspective of the Taiwan Bureau of
National Health Insurance. Patients and Methods: We devel-
oped a Markov model to simulate the natural history of
HBeAg-negative CHB in a cohort of 40-year-old patients.
Efﬁcacy, disease progression, economic, and quality of life
data were derived from the published literature and a survey
of clinical experts in Taiwan. Life expectancy, quality-adjusted
life expectancy, lifetime costs (NTD$), and incremental cost-
effectiveness ratios (ICERs) were calculated. Results: The gain
in quality-adjusted life years (QALYs) for 48 weeks of pegin-
terferon a-2a compared to 48 weeks of LAM was 0.45 at an
additional cost of NTD$157 000 (US$5000), resulting in an
ICER of NTD$347 000 (US$11 000) per QALY gained. Despite
the variation in each parameter used in the analysis, the ICER
did not exceed NTD$448 000 (US$14 000) per QALY gained.
Conclusion: In HBeAg-negative CHB, 48 weeks of treatment
with peginterferon a-2a compared to 48 weeks of LAM appears
to offer life expectancy and quality of life improvements at a
favorable cost-effectiveness ratio.
APASL/Poster/Abstract/133
More potent on-treatment viral suppression with lamivudi-
ne  peginterferon a-2a (40 kDa) [is not associated with increased
rates of sustained response: results from two large randomised
trials
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E. Gane1, G. Cooksley2, G. Germanidis3, M.-Y. Lai4, P. Farci5,
S. W. Paik6, W. C. Chow7, G. K. K. Lau8, P. Marcellin9 and
P. Button10
1Middlemore Hospital, Otahuhu, New Zealand,
2Royal Brisbane Hospital, Herston, Australia,
3Papageorgiou General Hospital, Thessaloniki, Greece,
4National Taiwan University Hospital, Taipei, Taiwan,
5Universita di Cagliari, Cagliari, Italy,
6Samsung Medical Center, Sungkyunkwan University School of
Medicine, Korea,
7Singapore General Hospital, Singapore,
8Queen Mary Hospital, Hong Kong, China,
9Hoˆpital Beaujon, Clichy, France,
10Roche, Dee Why, Australia
Introduction: Nucleos(t)ide analogues are associated with high
on-treatment HBV-DNA suppression. However, the effect of
on-therapy viral suppression on HBeAg seroconversion and off-
therapy sustained response is unclear. We investigated the effect
of on-treatment HBV-DNA suppression on sustained response
in two large, randomised trials of patients with HBeAg-positive
or HBeAg-negative CHB. Patients and Methods: HBeAg-posi-
tive (n5 814) and -negative (n5 537) patients received 48 weeks
of peginterferon a-2a (40 kDa) (180 mg once-weekly)1placebo,
peginterferon a-2a1lamivudine (LAM) (100mg once-daily) or
LAM. Patients were assessed 24 weeks post-treatment (week
72). Results: In the HBeAg-positive and -negative studies, viral
suppression by week 48 was greater with peginterferon a-
2a1LAM ( 7.2 log and  5.0 log, respectively) and LAM
alone ( 5.8 log and  4.2 log) than with peginterferon a-2a
alone ( 4.5 log and  4.1 log). However, at week 72, responses
with peginterferon a-2a (32% HBeAg seroconversion (HBeAg-
positive) and 59% ALT normalisation (HBeAg-negative)) were
similar to peginterferon a-2a1LAM (27% and 60%), but
signiﬁcantly superior to LAM (19% and 44%; P  0.004).
HBsAg seroconversion rates with peginterferon a-2a (3%
(HBeAg-positive) and 3% (HBeAg-negative)) and peginterferon
a-2a1LAM (3% and 2%) were also superior to LAM (0% and
0%; P5 0.004 and 0.029). More potent HBV-DNA suppression
resulted in lower rates of LAM-resistant YMDD mutation
development. Conclusion: Despite greater viral reduction with
LAM  peginterferon a-2a, off-therapy response was highest
with peginterferon a-2a alone, suggesting that more potent on-
treatment HBV-DNA suppression does not always translate
into improved sustained response. This indicates that the
immunomodulatory activity of peginterferon a-2a contributes
considerably in sustaining response post-treatment.
APASL/Poster/Abstract/134
Histologic improvement and sustained response in patients with
HBeAg-positive or HBeAg-negative chronic hepatitis B treated
with peginterferon a-2a (40 kDa)
G. Cooksley1, P. Marcellin2, F. Bonino3, G. K. K. Lau4, Y. F.
Liaw5, M.-Y. Lai6, Z.-M. Lu7, R. Flisiak8, M. Fried9 and
N. Pluck10
1Royal Brisbane Hospital, Herston, Australia,
2Hoˆpital Beaujon, Clichy, France,
3IRCCS, Ospedale Maggiore di Milano Policlinico, Milan,
Italy,
4Queen Mary Hospital, Hong Kong, China,
5Chang Gung Memorial Hospital, Linkou, Taiwan,
6National Taiwan University Hospital, Taipei, Taiwan,
7Ruijin Hospital, Shanghai, China,
8Medical University of Bialystok, Bialystok, Poland,
9University of North Carolina, Chapel Hill, NC, USA,
10Roche, Welwyn, UK
Introduction: Established treatments for CHB have been shown
to promote improvements in liver histology that are generally
associated with virologic and biochemical response. We inves-
tigated the relationship between histologic improvement and
off-therapy sustained responses in patients receiving peginter-
feron a-2a (40 kDa) monotherapy in two large, randomised
studies. Patients and Methods: HBeAg-positive (n5 271) and
HBeAg-negative (n5 177) patients received peginterferon a-2a
(180 mg once-weekly)  placebo for 48 weeks and were assessed
24 weeks after the end of treatment (week 72). Histologic
response was deﬁned as a reduction in the modiﬁed HAI score
of at least 2 points, compared with the pre-treatment score.
Results: Among patients with a paired biopsy, rates of histolo-
gic improvement 24 weeks after the end of treatment were 49%
and 59% in the HBeAg-positive and HBeAg-negative studies,
respectively. In both studies, there was a signiﬁcant association
between improved histologic activity and sustained virologic
and biochemical responses at week 72 (P  0.001). In the
HBeAg-positive study, a histologic response occurred in 73%
of patients with sustained HBeAg seroconversion vs 36% of
patients without HBeAg seroconversion. In the HBeAg-nega-
tive study, a histologic response occurred in 71% of patients
with sustained normal ALT vs 43% of patients without normal-
ised ALT. Conclusion: A ﬁnite 48-week course of peginterferon
a-2a was able to induce histologic improvements 24 weeks after
the end of treatment in around a half of all patients, regardless
of whether they had HBeAg-positive or HBeAg-negative CHB.
In patients treated with peginterferon a-2a, there is a signiﬁcant
association between improved histology and sustained response.
APASL/Free Paper/Abstract/135
Cost-effectiveness of peginterferon a-2a compared with lamivu-
dine treatment in patients with HBe-antigen positive chronic
hepatitis B in Taiwan.
S. D. Sullivan1, D. L. Veenstra1, P. J. Chen2, T. T. Chang3,
W. L. Chuang4, C. M. Tsai5 and K. Patel6
1University of Washington, Seattle, WA, USA,
2National Taiwan University Hospital, Taipei, Taiwan,
3National Cheng Kung University Hospital, Tainan, Taiwan,
4Kaohsiung Medical University Hospital, Kaohsiung, Taiwan,
5Roche Products Ltd., Taipei, Taiwan,
6Hoffmann-La Roche, Nutley, NJ
Introduction: Peginterferon a-2a (40 kDa), a new treatment
option for patients with chronic hepatitis B (CHB), offers
improved efﬁcacy with a deﬁned treatment duration compared
with lamivudine (LAM), but at a higher cost. We undertook an
economic evaluation from the perspective of the Taiwan Bureau
of National Health Insurance to assess the clinical outcomes and
costs of peginterferon a-2a for the treatment of patients with
HBeAg-positive CHB, compared with LAM treatment for 48
weeks. Patients and Methods: A cost-effectiveness analysis was
carried out using a state-transition Markov model simulating
the natural history of HBeAg-positive CHB. Efﬁcacy data were
obtained from a randomized clinical trial of 820 patients (87%
were Oriental) comparing peginterferon a-2a to LAM. We
modeled a hypothetical cohort of 32-year-old patients with
HBeAg-positive CHB. Life expectancy, quality-adjusted life
expectancy, lifetime costs (NTD$), and incremental cost-effec-
tiveness ratios (ICERs) were estimated. Results: A 48 week
treatment with peginterferon a-2a compared to LAM resulted
in higher total costs, but longer quality-adjusted life expectancy,
yielding an ICER of NTD$381 000 (US$12 000) per quality-
adjusted life year (QALY) gained. Although there is uncertainty
associated with the prognosis of HBeAg-positive CHB, the
ICER did not exceed NTD$485 000 (US$15 000) per QALY
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gained despite variation in each parameter used in the analysis.
Conclusion: A 48 week treatment with peginterferon a-2a com-
pared to 48 weeks of LAM treatment in CHB patients who are
HBeAg-positive appears to offer life expectancy beneﬁts at a
favorable cost-effectiveness ratio.
APASL/Free Paper/Abstract/136
Effect of age, gender, prior anti-HBV therapy and drug exposure
on sustained response in Asian patients enrolled in a large multi-
national study of peginterferon a-2a (40 kDa)  lamivudine vs
lamivudine for chronic hepatitis B
G. K. K Lau1, K.-X. Luo2, S. W. Paik3, W. Y. Chang4,
T. Piratvisuth5, A. Chutaputti6, Y. K. Yin7 and P. Mccloud8
1Queen Mary Hospital, Hong Kong, China,
2Nanfang Hospital, Guangzhou, China,
3Samsung Medical Center, Sungkyunkwan University School of
Medicine, Korea,
4Kaohsiung Medical University Hospital, Kaohsiung, Taiwan,
5Songklanakarin Hospital, Songkla, Thailand,
6Pramongkutklao Hospital, Bangkok, Thailand,
7Huashan Hospital, Shanghai, China,
8Roche, Dee Why, Australia
Introduction: This analysis examined the effect of age, gender,
prior anti-HBV therapy and drug exposure on sustained response
in Asian patients enrolled in a large, randomised clinical trial.
Patients and Methods: Asian patients (n5 708) HBeAg-positive
CHB received 48 weeks of peginterferon a-2a (40kDa) peginter-
feron a-2a([180mg once weekly1placebo), peginterferon a-2a1la-
mivudine (LAM) (100mg once-daily) or LAM. Patients were
assessed 24 weeks post-treatment (week 72). Results: Rates of
HBeAg seroconversion 24 weeks post-treatment were signiﬁcantly
higher with peginterferon a-2a containing treatment than with
LAM: 31%, 29% and 19% for peginterferon a-2a, peginterferon
a-2a1LAM and LAM, respectively (Po0.02) in patients receiving
peginterferon a-2a monotherapy, age did not affect the rate of
sustained HBeAg seroconversion , but response was slightly higher
in female (35%) vs male (30%) patients; rates of HBeAg serocon-
version in patients without prior anti-HBV therapy, with prior
LAMor prior conventional IFN treatment were comparable to the
overall rate (30%, 27%,36%, and 31%, respectively). In the
peginterferon a-2a monotherapy arm, drug exposure was very
high, with 79% of patients receiving 490% of the total peginter-
feron a-2a dose. HBeAg seroconversion rates in patients receiving
o90% or 490% of the total peginterferon a-2a dose were 22%
(95% CI: 9–34%) and 33% (95% CI: 26–40%). Conclusion: In
Asian patients, peginterferon a-2a provided higher rates of HBeAg
seroconversion than LAM, irrespective of prior anti-HBV therapy,
age or gender. Exposure to peginterferon a-2a among Asian
patients in the study was high, reﬂecting the good tolerability of
the drug. The extent of peginterferon a-2a exposure did not
signiﬁcantly affect HBeAg seroconversion rates.
APASL/Plenary/Abstract/137
Sustained response in Asian patients enrolled in two large, multi-
national studies of peginterferon a-2a (40 kDa)  lamivudine vs
lamivudine for chronic hepatitis B
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Introduction: The inﬂuence of ethnicity on treatment response
in patients with chronic hepatitis B (CHB) has been a subject of
recent debate, Asian patients have traditionally been considered
to have more ‘difﬁcult-to-treat’ CHB. We investigated treatment
response in Asian patients enrolled in two large, randomised
clinical trials. Patients and Methods: Asian patients with
HBeAg-positive (n5 708) or –negative (n5 332) CHB received
48 weeks of peginterferon a-2a (40 kDa) (180 mg once-week-
ly)1placebo, peginterferon a-2a1lamivudine (LAM) (100mg
once daily) or LAM. Patients were assessed 24 weeks post-
treatment (week 72). Results: Asian patients were enrolled at
centres throughout Asia, Europe and America. The predominant
infecting HBV genotypes in Asian patients from both studies
were C (63%) and B (35%). In the HBeAg-positive study,
sustained HBeAg seroconversion rates were signiﬁcantly higher
with peginterferon a-2a (31%; P5 0.005) or peginterferon
a-2a1LAM (29%; P5 0.02) than with LAM (19%). In
the HBeAg-negative study, rates of sustained HBV-DNA
o400 copies/ml were signiﬁcantly higher with peginterferon
a-2a (26%; P5 0.003) or peginterferon a-2a1LAM (24%; P5
0.012) than with LAM (11%). Among Asian patients treated with
peginterferon a-2a ( LAM), 8 of 476 (2%) patients in the
HBeAg-positive study and 5 of 220 (2%) patients in the HBeAg-
negative study achieved sustained HbsAg seroconversion after
only 6-month treatment-free follow-up. No patients treated with
LAM alone achieved HbsAg seroconversion. Conclusions: In
Asian patients, peginterferon a-2a provides signiﬁcantly higher
rates of off-therapy sustained response than LAM. The results
demonstrates the possibility of sustained HbsAg response in
Asian patients after a ﬁnite duration of peginterferon a-2a, an
outcome that was not seen with LAM.
APASL/Poster/Abstract/138
Predicting response in a large, multinational trial of peginterferon
a-2a (40 kDa  lamivudine vs lamivudine alone for HBeAg-posi-
tive chronic hepatitis B
W. C. Chow1, G. Cooksley2, W. Y. Chang3, M. Manns4,
S. Thongsawat5, H.-F. Zhang6, M. Fried7, Y. F. Liaw8,
Y.-R. Zhao9 and F. Zahm10
1Singapore General Hospital, Singapore,
2Royal Brisbane Hospital, Herston, Australia,
3Kaohsiung Medical University Hospital, Kaohsiung, Taiwan,
4Medizinischen Hochschule, Hannover, Germany,
5Chiang Mai University, Chiang Mai, Thailand,
6Beijing 302 Hospital, Beijing, China,
7University of North Carolina, Chapel Hill, NC, USA,
8Chang Gung Memorial Hospital, Linkou, Taiwan,
9Chongqing Medical College, Chongqing, China,
10Roche, Basel, Switzerland
Introduction: Baseline and on-treatment predictors of response
are used in the treatment of hepatitis C to improve the chance of
response, enhance patient motivation and avoid unnecessary
treatment. We investigated predictors of response in patients
with CHB receiving peginterferon a-2a (40 kDa)  lamivudine
(LAM) or LAM alone. Patients and Methods: HBeAg-positive
patients (n5 814) received 48 weeks of peginterferon a-2a (180mg
once-weekly)1placebo, peginterferon a-2a1LAM (100 mg once-
daily) or LAM. Response was deﬁned as HBeAg seroconversion
24 weeks post-treatment (week 72). Results: Rates of HBeAg
seroconversion at week 72 were signiﬁcantly higher with pegin-
terferon a-2a alone (32%; Po0.001) and combination therapy
(27%; Po0.023) than with LAM alone(19%). In multivariate
analyses, high ALT, low HBV-DNA and low HBeAg levels at
baseline were signiﬁcant predictors of HBeAg seroconversion
(Po0.001). Among patients receiving peginterferon a-2a alone,
the rate of HBeAg seroconversion was 41% if baseline ALT levels
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were 45  ULN, and 53% if HBV-DNA levels were o9.1 log
copies/ml. HBV genotype was not signiﬁcantly predictive of
response. Of note, response in genotype C patients receiving
peginterferon a-2a alone (31%) was similar to genotype B
patients (30%). Quantitative HBeAg was a better on-treatment
predictor than HBV-DNA; HBeAg-seroconversion rates at week
72 were 14% in patients with week 12 HBeAg levels4100 IU/ml,
but were 53% in patients with week 12 HBeAg levelso10 IU/ml.
Conclusions: High ALT, low HBV-DNA and low HBeAg at
baseline were independently predictive of sustained response in
patients with HBeAg-positive CHB. In contrast to results with
conventional IFN-a, peginterferon a-2a provides equally good
response rates in patients with genotypes B and C.
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Pitfalls in management of symptomatic simple liver cysts: report
of two cases
Yasin Leonardi and Benny Phillipi
Subdivision of Digestive Surgery, RSUPNCM, Jakarta,
Indonesia
Management options for symptomatic non-parasitic simple liver
cyst vary widely. Therapeutic options range from percutaneous
cyst aspiration, aspiration and instillation of sclerosing agent,
open cyst unrooﬁng, laparoscopic cyst unrooﬁng, cystenterost-
omy, and cyst excision. Despite improved imaging modality, the
presence of neoplasia is still difﬁcult to be determined before
and during surgery. The management of neoplastic cyst is
totally different. To achieve a satisfactory result, a good
preoperative evaluation and a tailored patient approach is
very important before considering any intervention. Similar to
the widely and rapidly accepted laparoscopic cholecystectomy,
laparoscopic wide cyst unrooﬁng is performed with great
enthusiasm for any symptomatic simple liver cyst. After a period
of time, there are some unsuccessful cases with laparoscopic
unrooﬁng. A retrospective review was done for our two un-
successful simple liver cyst cases in the hope that it can be
avoided in the future.
APASL/Poster/Abstract/143
Clinical and laboratory features of non-cirrhotic portal hyperten-
sion in Cipto Mangunkusumo Hospital
Julﬁna Bisanto, Wahyuni Indawati and Hanifah Oswari
Department of Child Health, School of Medicine, University of
Indonesia, Indonesia
Objective: To describe clinical and laboratory features of oeso-
phageal varices due to non-cirrhotic portal hypertension in chil-
dren. Methods: We describe six patients of non-cirrhotic portal
hypertension admitted to Cipto Mangunkusumo Hospital during
1999–2004. Result: Six of 25 portal hypertension patients were
diagnosed as non-cirrhotic portal hypertension based on clinical
manifestations, laboratory ﬁndings and Doppler ultrasound ex-
aminations. Five boys and one girl ranging from 4 to 14 years old
were registered as this group during 1999–2004. Recurrent haema-
temesis and melaena were the main problems of all cases.
Splenomegaly was found in all cases but only three cases showed
hepatomegaly. Peripheral blood test revealed anaemia and throm-
bocytopenia. Liver function tests were within normal limits except
for prolonged prothrombin time in two cases, which was not
persistent. Only three patients underwent liver biopsy, which
showed hydropic degeneration and mild piece necrosis. Three
patients showed third to fourth grade of oesophageal varices and
two patients were with ﬁrst to second grade. One patient was only
clinically diagnosed. We performed ligation in three cases and
sclerotherapy in two cases. All patients were given isosorbide
mononitrate and propanolol for long-term management. Conclu-
sion: Non-cirrhotic portal hypertension showed recurrent haema-
temesis and melaena, normal liver function and splenomegaly. In
spite of oesophageal varices in endoscopic ﬁndings, no sign of liver
cirrhotic was found in liver biopsy.
APASL/Poster/Abstract/144
Prevalence of hepatitis B virus infection among children of HBV
carrier or infected mothers
Julﬁna Bisanto, Nababan Rouli, Hanifah Oswari, Diah
Istikowati and Imral Chair
Child Health Department, Medical Faculty University of
Indonesia, Jakarta, Indonesia
Objective: Hepatitis B is endemic in several regions of the world
including Indonesia with the carrier rate as much as 3–20%.
This high prevalence has occurred because of vertical transmis-
sion and horizontal infection since an early age. The aim of this
study was to determine the prevalence of hepatitis B virus
infection among children of HBV carrier or infected mothers.
Methods: This study was carried out descriptively cross-sec-
tional on children of HBV carrier or infected mothers who came
to the Hepatology Subdivision, Internal Medicine Department
Dr. Cipto Mangunkusumo Hospital during January 2002–April
2003. Serologic tests of HBsAg, anti-HBs and anti HBc were
done using ELISA method. Results: There were 59 children of
32 HBV carrier/infected mothers who matched the inclusion
criteria with the age range of 9 months to 18 years. We found
HBsAg positive in 13.6%, anti HBs positive in 62.7% and anti
HBc positive in 6.8% of the children. Conclusion: Prevalence of
hepatitis B virus infection among children of carrier/infected
mothers was 13.6%.
APASL/Poster/Abstract/145
Pancreatic metastasis from breast carcinoma presenting as
obstructive jaundice: serial case reports
Ari F. Syam, M. Abdullah, D. Makmun, M. S. Kolopaking,
D. Djojoningrat, C. Manan, A. A. Rani and Daldiyono
Division of Gastroenterology, Department of Internal medicine,
Medical Faculty University of Indonesia, Medical Faculty
University of Indonesia, Indonesia
Metastatic pancreatic tumors from breast cancer are uncommon
and rare cases. Most tumors in the breast are slow growing so it is
possible to ﬁnd this metastasize to other regions. Two cases of
jaundice are reported that were secondary to obstruction of the
common bile duct by metastatic carcinoma of the breast. Our ﬁrst
patient, a 43-year-old woman, was admitted with unexpected
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obstructive jaundice. She also felt right breast mass and pain.
Physical examination showed a mass 7  7  5 cm3 in the right
breast, suggestive of breast cancer. No lymph node metastasis
was observed. Laboratory ﬁndings showed that the carcinoem-
bryonic antigen (CEA), AFP and Ca 19-9 levels were still in
normal range. We diagnosed obstructive jaundice due to pan-
creatic tumor demonstrated on computed tomography and then
performed ERCP plus endoscopic stenting. Resolution of jaun-
dice was achieved in this patient. Chemotherapy was given to the
patient using six courses of chemotherapyusing ﬂuorouracil,
adryamicin and cyclophosphamide (FAC), intravenously. The
second patient, a 44-year-old woman, was hospitalized for
obstructive jaundice 2 years after extended mastectomy. Labora-
tory ﬁndings showed that the carcinoembryonic antigen (CEA),
Ca 15-3 and Ca 19-9 levels increased to 22.9 ng/ml, 76.2U/ml and
15887U/ml, respectively. Abdominal ultrasound found dilatation
of common bile duct due to a tumor in the head of the pancreas.
ERCP examination showed dilatation of common bile duct with
dorsal narrowing. Conclusion: This clinical picture was a late
manifestation and the ﬁrst evidence of spread of the disease. In
patients with a history of carcinoma of the breast, the possibility
of extrahepatic biliary metastasis should always be considered in
the differential diagnosis of jaundice before concluding that
extensive hepatic involvement is the cause of jaundice.
APASL/Poster/Abstract/146
Ten year follow-up of a liver cirrhosis patient following transju-
gular intrahepatic portosystemic shunt (TIPS)
Ari Fahrial Syam and Aziz Rani
Division of Gastroenterology, Department of Internal Medi-
cine, Faculty of Medicine, University of Indonesia, Indonesia
The transjugular intrahepatic portosystemic shunt (TIPS) is an
advance management in the complications of portal hyperten-
sion. It is most commonly used in the management of refractory
variceal bleeding, where it can prevent rebleeding. TIPS useful-
ness is limited by two major problems: shunt dysfunction and
hepatic encephalopathy. Patients who bled from gastric varices
had lower mortality than those who bled from esophageal
varices. Hepatic encephalopathy is a frequent event after trans-
jugular intrahepatic portosystemic shunt (TIPS). We report a
68-year-old female with liver cirrhosis who underwent TIPS 11
years ago. She had liver cirrhosis presenting with complications
of portal hypertension since 1 year before the TIPS procedure.
The diagnosis of cirrhosis was conﬁrmed by biopsy and was
basedon clinical, radiological and laboratory ﬁndings. This
patient was without hepatic encephalopathy history and ascites
before. Pre-TIPS assessment showed that her bilirubin, creatine
and albumin were within normal limits. We evaluated that this
patient had Child–Pugh class A before the TIPS procedure. Her
main problem before the TIPS procedure was esophageal
varices and thrombocytopenia with platelet count 40 000. The
indication of TIPS for this patient was recurrent variceal
bleeding. Ten years follow-up found that the patient had
variceal rebleeding only once during 7 years after the TIPS
insertion. Esophageal band ligation had succeeded to eradicate
esophageal varices. She had hepatic encephalopathy only twice
in 10 years after the TIPS procedure. In this patient, this
problem can be overcome with conservative treatment. At
present, even after 11 years of the TIPS procedure, the condition
of this patient is still good. Conclusions: This case report has
demonstrated that TIPS has been used successfully in the
management of variceal bleeding, and has a low complication
rate after 10 years follow-up for a patient with Child–Pugh class
A. The evaluation of prognostic factors is the key towards
evaluatingclinical interventions in liver cirrhosis.
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Lower serum viral loads in young patients with hepatitis B virus-
related hepatocellular carcinoma
F. C. Tsai1, C. J. Liu1, C. L. Chen2, P. J. Chen1,2,3, M. Y. Lai1,2,
J. H. Kao1,2,3,4 and D. S. Chen1,2
1Division of Gastroenterology, Department of Internal Medi-
cine,
2Graduate Institute of Clinical Medicine,
3Department of Medical Research,
4Hepatitis Research Center, National Taiwan University Col-
lege of Medicine and National Taiwan University Hospital,
Taipei, Taiwan
Introduction: Advanced age and high hepatitis B virus (HBV)
DNA level are risk factors associated with the development of
HBV-related hepatocellular carcinoma (HCC). However, little
is known about the role of viral load in the carcinogenesis of
HCC in young people. Patients and Methods: A total of 183
HBV-related HCC patients and 202 HBV carriers were enrolled.
Serum viral loads in young ( 40 years of age) and old (440
years of age) HCC patients were compared with those in HBV
carriers. Other factors associated with the development of HCC
were also analyzed. Results: Serum alanine aminotransferase
(38.7  24.1 vs. 58.4  65.4 IU/l, Po0.05) and HBV DNA
levels (log10 titer: 4.20  1.33 vs. 4.80  1.39, P5 0.05) were
lower in young HCC patients than in old HCC patients. There
was a positive correlation between the age and serum HBV
DNA loads in HCC patients but a negative correlation in HBV
carriers. Young HCC patients with HBV genotype B infection
had higher viral loads than those with genotype C (log10titer:
4.79  1.34 vs. 3.27  0.60, Po0.05). By multivariate logistic
regression analyses, high serum HBV DNA levels were asso-
ciated with the development of HCC in old patients (odds ratio
(OR) 1.584, 95% conﬁdence interval (CI) 1.075–2.333) rather
than in young patients (OR 0.848, 95% CI 0.645–1.116).
Conclusion: Viral factors in association with the development
of HBV-related HCC in young patients are different from their
old counterparts. The complicated interplay between host and
virus could be responsible for the emergence and aggressive
outcome of early-onset HCC.
APASL/Poster/Abstract/150
Clinical signiﬁcance of intrahepatic HCV RNA level in chronic
HCV infection
J. Y. Jang1, Y. S. Kim1, C. H. Han1, S. H. Eun1, Y. K. Chun1,
Y. Kim1, J. H. Moon1, Y. D. Cho1, C. S. Shim1, B. S. Kim1,
S. Y. Jin2 and J. K. Lee3
1Department of Gastroenterology and Hepatology, Soonchun-
hyang University Hospital,
2Department of Pathology,
3Roche Diagnostics, Korea, Seoul, Korea
Introduction: There was a correlation between serum and in-
trahepatic HCV RNA levels in chronic HCV infection. How-
ever, the debate continues on whether intrahepatic HCV viral
load correlates with the severity of liver disease activity. This
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study was carried out to identify the clinical signiﬁcance of
intrahepatic HCV RNA level in chronic HCV infection. Patients
and Methods: Thirty-eight anti-HCV positive patients were in-
cluded (M:F5 24:14, mean age: 51.3 y.o.) (CH:LC5 29:9).
Percutaneous liver biopsy was performed and remaining tissue
was stored in liquid nitrogen. HCV RNA was extracted by
QIAamps RNA Micro Kit and quantiﬁcation of serum and
hepatic HCV RNA were performed using the AMPLICORt
HCVMONITOR Kit. Seventeen of them were treated with INF-
a and ribavirin for chronic hepatitis C. Results: (1) There was a
signiﬁcant correlation between intrahepatic and serum HCV
RNA levels (intrahepatic HCV RNA:1.9  3.1  107 copies/g
vs serum HCV RNA: 3.2  3.2  106 copies/ml) (R5 0.538,
Po0.05). (2) Histologically, total HAI score (R5 0.346,
Po0.05) and periportal inﬂammation (R5 0.398, Po0.05) were
weakly correlated with intrahepatic HCV RNA level. (3) Serum
ALT level was not correlated with intrahepatic HCV RNA level.
(4) Intrahepatic HCV RNA level was not different according to
HCV genotype. (5) Intrahepatic HCV RNA level was not
different according to treatment response. Conclusion: Intrahepa-
tic HCV RNA level was correlated with serum HCV RNA level
and weakly correlated with periportal inﬂammation. However, it
was not associated with serum ALT, HCV genotype or response
to antiviral therapy. Therefore, it seems unlikely that measure-
ment of intrahepatic HCV RNA level provides additional infor-
mation in anti-HCV positive patients.
APASL/Poster/Abstract/151
Clinical and laboratory proﬁle of hepatitis C in hemophiliac
children
Hanifah Oswari, Ferry Damardjati, Djajadiman Gatot, Julﬁna
Bisanto and Zakiudin Munasir
Department of Child Health, Faculty of Medicine of University
of Indonesia, Dr. Cipto Mangunkusumo General Hospital,
Jakarta, Indonesia
Many hemophiliacs were infected with hepatitis C virus (HCV)
in childhood after transfusions with inadequately or non-virus-
inactivated clotting factor products. There is still limited in-
formation available on the clinical course of HCV infection in
children. Patients registered in hemophilia society who tested
anti-HCV positive at Pediatric Department Dr. Cipto Mangun-
kusumo Hospital were enrolled. None of them received antiviral
treatment. All of the subjects were infected with HCV before the
age of 18 years and after at least 6 months of acute infection
clinical examination, ALT, platelets and HCV RNA test were
performed. Thirty-nine subjects were enrolled. Current median
age was 15 years. The median age for ﬁrst time transfusion was
15 months. Twenty-two (56%) of 39 subjects showed clinical
manifestations. Liver and spleen enlargement were not found in
all of the subjects. Ten (26%) of the 39 subjects had elevated
ALT. Platelet counts were within normal limits in all subjects.
Twenty-four (61%) patients had chronic hepatitis, whereas the
remaining 15 (39%) subjects spontaneously cleared HCV. In
conclusion: HCV infection in pediatric patients had mild clinical
manifestations and laboratory abnormality. Sixty-one percent
of the subjects developed chronic hepatitis.
APASL/Poster/Abstract/152
Efﬁcacy of low-dose peginterferon a 2b with ribavirin in chronic
hepatitis C – an Indian experience
Rajesh Gupta, C. H. Ramakrishna, Sandeep Lakhtakia, Manu
Tandan, Rupa Banerjee and D. Nageshwar Reddy
Department of Medical Gastroenterology & Hepatology, Asian
Institute of Gastroenterology, Hyderabad, India
Introduction: The combination of peginterferon and ribavirin is
the main stay of treatment in chronic hepatitis C. Peginterferon
a-2b is recommended in a dose of 1.5mcg/kg body
weight weekly in combination with ribavirin. We conducted a
non randomized pilot study to assess the efﬁcacy of peginter-
feron a-2b in doses of 50 and 80mcg weekly (based on body
weight) plus ribavirin in HCV genotype 2 and genotype 3
chronic hepatitis C patients. Methods: During the study period
of January 2002 to December 2003, all patients diagnosed as
chronic hepatitis C or HCV-related compensated cirrhosis were
treated with peginterferon a-2b 50mcg S/C weekly (body
weight o60kg) or 80mcg S/C weekly (body weight 460kg)
plus ribavirin 800mg/day for 24 weeks. Results: Overall 28
patients, 14 patients in each group (based on body weight) were
treated during this period. Out of 28 patients, 75% were genotype
3, 18% were genotype 2 and 7% were genotype 1. The mean
doses of peginterferon a-2b were 0.91mcg/kg in group 1 and
1.23mcg/kg in group 2, respectively. The end of treatment (ETR)
and sustained virologic response (SVR) were 82% and 78%,
respectively. Serious adverse effects were seen in 3.5% patients.
Conclusion: Low-dose peginterferon a-2b in combination with
ribavirin for 24 weeks is effective in HCV genotypes 2 and 3
chronic hepatitis C patients.
APASL/Poster/Abstract/153
Liver disorders in children with malignancy in RSCM
Hanifah Oswari, Elsye Souvriyanti and Julﬁna Bisanto
Department of Child Health, Faculty of Medicine of University
of Indonesia, Dr. Cipto Mangunkusumo General Hospital,
Jakarta, Indonesia
Liver disorders in children with malignancy can be caused by liver
necrosis due to administration of cytostatic agents and other
medicines, inﬁltration of tumor cells into the liver, infection by
hepatitis virus obtained through transfusion, sepsis, and others.
The aim of this study was to ﬁnd out the clinical patterns of liver
disorders in children with malignancy. This study used retro-
spective data. Data were obtained from the Pediatric Hema-
Oncological Division of FKUI-RSCM from March 1 2004 until
March 31 2005. Of the 39 patients, 18 patients were diagnosed as
having acute lymphoblastic leukemia (ALL), eight patients had
acute myeloblastic leukemia (AML), and 13 patients had solid
tumors. Patients with ALL were given therapy as follows: nine
patients for induction therapy, four patients for CNS-prevention
therapy, one patient for maintenance therapy, and four patients
had no therapy. Patients with AMLwere given therapy as follows:
seven patients for induction therapy and one patient for con-
solidation therapy. Liver disorders were found in 25 patients with
hepatitis, 11 patients with cholestasis, two patients with both of
the diseases and one patient with hepatomegaly due to hepato-
blastoma. Of the 39 patients with liver disorders, the disorders in
28 patients were caused by cytostatic agents, in seven patients due
to inﬁltration of tumor cells, in three patients suspected of viral
infection and of inﬁltration of tumor cells, and in one patient due
to sepsis. The following medications were given for ALL:
methotrexate, cytosine arabinoside, L-asparaginoside, daunorubi-
cin, vincristine, 6-mercaptopurine, cyclophospamide, and for
AML: methotrexate, cytosine arabinoside, vincristine, cyclophos-
pamide, adryamicin. Fourteen patients on cytostatic agents had
reduced doses, 10 patients had strict follow-up, and ﬁve patients
had delayed treatment. These results showed that patients with
malignancy should be regularly followed up to detect any liver
disorders due to cytostatic agents, tumor cell inﬁltration, viral
infection, and sepsis, or a combination of these factors. Treatment
could be delayed or the doses reduced or continued under
monitoring.
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Neonatal liver disease in Ciptomangunkusumo Hospital
Hanifah Oswari, Mutiara Siagian and Julﬁna Bisanto
Child Health Department, Faculty of Medicine, University of
Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Primary liver disease in neonates is rare. Much of the liver
dysfunction seen in the neonatal period is secondary to systemic
illness such as sepsis or hypoxic injury. Early intervention to
address the cause of dysfunction is critical to successful manage-
ment of liver disease. A retrospective descriptive study has been
done by evaluating the medical records of hepatic diseases in the
neonatal ward, which had been consulted to the Gastroenter-
ohepatology Division from January 2004 until February 2005 in
Child Health Department, Cipto Mangunkusumo Hospital,
Jakarta. Of 523 neonates in the perinatology ward, we reviewed
47 (9%) cases of neonatal liver diseases, which had been
consulted to the Gastrohepatology Division. There were 42 girls
and ﬁve boys, aged between 5 and 31 days old. There were 12
(25.5%) preterm infants and 35 (74.5%) term infants. The
diagnosis of these patients was 35 cholestasis alone, two
hepatitis, seven cholestasis and hepatitis, three others (one
ascites, one unconjugated hyperbilirubinemia, one suspected
neonatal hemochromatosis). Cholestasis were due to sepsis
alone in 32, antifungal therapy alone in six, both sepsis and
antifungal therapy in three, suspected Crigler–Najjar type-2 in
one patient. Two patients underwent colostomy due to atresia
ani and malrotation. Of 42 patients with cholestasis, 29 patients
underwent blood culture. We found 17 Acinetobacter calcoace-
ticus, one Enterobacter aerogenes, one Staphylococcus epidermi-
dis, one Klebsiela pneumonia, one Escherichia coli, one Serratia
marcessens, one Candida albicans, yeast cell in one patient and
ﬁve sterile. Of the 523 patients, 47 (9%) neonates had been
consulted to the Gastroenterohepatology Division with presen-
tation of cholestasis in 42 patients (89%). The etiology of liver
disease in neonates in our department was mainly sepsis (74.5%)
and mainly caused by Acinetobacter calcoaceticus (58.6%).
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Signiﬁcance of caput medusa in Budd–Chiari Syndrome: Our
experience of 12 patients and collateral pathways as compared
with post-necrotic cirrhosis
Heon Young Lee, Won Seok Heo, Kyung Hoon Chae, Jae
Hoon Jung, Yoon Sae Kang, Yeon Soo Kim, Seok Hyun Kim,
Jae Kyu Seong and Byung Seok Lee
Department of Internal Medicine, Chungnam National Uni-
versity Hospital, Taejeon, Korea
Background/Aims: The Budd–Chiari syndrome is an unusual
form of portal hypertension caused by occlusion of the hepatic
venous ﬂow and it is often frequently complicated by inferior
vena caval occlusion with a potentially dismal outcome if not
treated optimally. Our study is to review etiogical, clinical
features and especially collateral pathways in the Budd–Chiari
syndrome. Methods: From 1990 to 2004, 12 patients were
diagnosed with the Budd–Chiari syndrome in our hospital.
Results: Seven patients were males and ﬁve were females.
Median age at presentation was 48 years (range 20–74 years).
Four patients (33%) have membranous obstruction of vena
cava, but the other six patients (50%) do not have any etiologic
factors or associated disorders. Generalized swelling and ab-
dominal distension were the most common symptoms. Spleno-
megaly and ascites were the common signs. The diagnosis of this
syndrome was performed by abdominal CT scans and in six
patients, vena cavography through femoral vein catheterization
was conﬁrmed. Eighty-three percent of the patients showed
obstructing lesions of the hepatic portion of the inferior vena
cava. Only two patients (17%) had hepatic vein obstruction
without caval lesions. The collateral pathways in abdominal CT
scans showed vertebrolumbar-azygous pathway and intrahepa-
tic collaterals at seven patients (58.3%), respectively. Especially,
para-umbilical collaterals of the abdominal wall (Caput Me-
dusa) were shown in six patients (50%) and theirs occurrence
rate was signiﬁcantly higher in two patients among the 149
patients with post-necrotic cirrhosis from January to March
2004 in our hospital (P5 0.00028). Conclusion: The Budd–
Chiari syndrome is a rare form of portal hypertension. There-
fore, diagnosis of the syndrome was delayed and resulted in
poor prognosis. If para-umbilical collaterals of the abdominal
wall were presented, especially in the early period of cirrhosis,
we should think of the Budd–Chiari syndrome as a cause of liver
cirrhosis.
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Clinical assesment of transarterial chemoembolization using poly-
vinyl alcohol for management of hepatocellular carcinoma: con-
cern about hepatic damage
Young Seok Kim1, Sang Hoon Han1, Sang Gyune Kim1, Jae
Young Jang1, Bong Min Ko1, Su Jin Hong1, Chang Beom Ryu1,
Joon Hee Jho2, Jong Ho Moon1, Young Deok Cho1, Yun Soo
Kim1, Moon Sung Lee1, Chan Sup Shim1 and Boo Sung Kim1
1Institute for Digestive Research, Department of Internal Medicine,
Soon Chun Hyang University College of Medicine, Seoul, Korea,
2Department of Radiology, Soon Chun Hyang University College
of Medicine, Bucheon, Korea
Background: Polyvinyl alcohol (PVA) has seldom been used for
the embolic agents during transarterial chemoembolization
(TACE). It may completely occlude the vessels and might
compromise the patient’s hepatic functions and distort arterial
access for subsequent TACE. But, several experimental and
clinical reports have shown that the occluded vessels with PVA
particles also recanalize with another mechanism rather than with
gelfoam. Aim: To assess the liver function and the initial results
after arterial embolization using PVA during TACE.Material and
Methods: The authors performed arterial embolization using
PVA particles, instead of commonly using gelfoam pledgets at
the end of TACE after infusion of chemotherapeutic agent and
lipiodol emulsion for 28 HCCs in 27 patients. Three patients were
excluded in this study because of lack of follow-up computed
tomography (CT) after TACE. Eighteen patients were men. The
mean age of the patients was 59.8 years.Twenty patients were in
class A and 4 patients were in class B according a Child–Pugh
classiﬁcation. The cause of cirrhosis was hepatitis B (13),
hepatitis C (four) and alcohol or unknown (seven). The inclusion
criteria for embolization with PVA were viable single or
lesser than three nodular HCCs having visible feeder(s)
and possible segmental or subsegmental embolization. The
longest diameter of nodules varied from 12.9 to 135.7 mm
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(mean: 31.8 mm) and the mean amount of cisplatin and lipiodol
used were 61.3 mg and 5.3 ml. Follow-up was done with
contrast-enhanced spiral CT in all patients and continuing
TACE in four patients. Mean follow-up period was 13.5 weeks.
Results: Complete embolization was achieved in all patients and
compact lipiodol accumulation was noted in 19 nodules, faint
accumulation in four nodules and partial accumulation in two
nodules on a post-TACE spot shot. Two of the faintly accumu-
lated nodules and the other two partially accumulated nodules
became compact on follow-up CT. All nodules except three were
stable compact during the follow-up periods. The mean tumor
reduction ratio was 17% at 2 weeks and 63.5% at last follow-up
CT after TACE (Po0.001). The decline of the level of AFP
between a baseline value and that of last follow-up was signiﬁcant
(P50.006). The elevation of AST, ALT and total bilirubin levels
between baseline and that of early follow-up period within
2 weeks after TACE was signiﬁcant (Po0.05), but it was restored
after that period. This pattern was similar regardless of the
tumor size, Child–Pugh class or size of PVA particle. No severe
adverse reactions or complications were noted. Conclusion: Ad-
junctive embolization with PVA particles during TACE is effective
in getting stabilization of HCC. It may deteriorate hepatic functions
for at least 2 weeks, but after that hepatic function is recovered.
APASL/Poster/Abstract/160
Combination of peginterferon a-2b (12 kDa) and lamivudine in
HBeAg negative chronic hepatitis B – an Indian experience
D. N. Amarapurkar and N. D. Patel
Department of Gastroenterology, Bombay Hospital and Med-
ical Research Center, Mumbai, India
Introduction: Treatment of HBeAg negative chronic hepatitis B
infection (e-CHB) is associated with poor sustained response
(SR). Recently, Marcellin et al. showed SR of 44% with
peginterferon (40 kDa)–lamivudine combination therapy in
treatment naı¨ve e-CHB. We undertook this open-labeled pro-
spective study to study the response of peginterferon a-2b
(12 kDa)–lamivudine combination in Indian patients of e-CHB.
Methods: Patients of e-CHB with persistently elevated transa-
minases (42 times upper limit of normal) were treated with
lamivudine 100mg PO daily and peginterferon 1.5 mg/kg SC
once a week for 12 months. These patients were divided into (1)
treatment naı¨ve group and (2) treatment failure group – patients
who were non-responsive to at least two treatment regimens.
Patients were tested for LFT, HBeAg, antiHBe, quantitative
HBVDNA and liver biopsy when possible at inclusion. During
the treatment period, LFT was tested at monthly intervals and
HBeAg, antiHBe and HBVDNA at 3 monthly intervals. End of
treatment response (EOR) was assessed at the end of the
treatment period and SR at 6-months post treatment. Treatment
response was deﬁned as normalization of enzymes and loss
of detectable HBVDNA. Results: A total of 18 patients with
e-CHB was included in this study with mean age of 34.7  6.2
years (range 20–54 years) and male:female5 8:1. (1) In treat-
ment naı¨ve e-CHB, 8/11 patients achieved EOR (72.7%),
whereas 6/11 patients (54.5%) had SR. (2) In treatment failure
e-CHB, 4/7 patients had EOR (57.1%) and 3/7 patients achieved
SR (42.8%). Conclusion: SR was achieved in 9/18 e-CHB
patients (50%) with combination of peginterferon and lamivu-
dine.
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Angiomyolipoma in the liver: a case report
Evelina1, Teguh Kuncoro2, Ardiana Hendrasti2, Vera Yuwono,
S Ening Krisnuhoni1, H. Diah Rini1 and Wirasmi Marwoto1
1Department of Pathological Anatomic, Faculty of Medicine,
University of Indonesia/Dr. Cipto Mangunkusumo Hospital,
Indonesia,
2Department of Pathological Anatomic, Gatot Subroto Army
Hospital, Jakarta, Indonesia
Angiomyolipoma is very rare in the liver. It is more frequent in the
kidney than in the liver. This is the ﬁrst liver case found in
Indonesia. Biologic behavior is another problem. Although con-
sidered benign, we found in the literature that a renal angiomyo-
lipoma that had extended into the liver and metastasized to the
lung exhibited typical angiomyolipoma along with other foci of
transformation into a high-grade spindle cell carcinoma. In the
liver, the case is also similar. It is curative with adequate surgical
excision. One patient whose tumor was not excised was followed
for 4 years with CT examinations; the diameter of this tumor
increased by 10%. One report mentioned a case of hepatic
angiomyolipoma that underwent malignant change.
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Comparison grading and staging at chronic hepatitis C using
Knodell and METAVIR system: a retrospective study
Sony Sugiharto, S. Ening Krisnuhoni and Wirasmi Marwoto
Pathology Anatomical Department of FKUI/RSUPNCM,
Jakarta, Indonesia
Interpretation of liver biopsy done on chronic hepatitis with the
Knodell system did not satisfy the clinician because of disconti-
nuity of the scale/range. In this system, ﬁbrous septa that were
also used as standard therapy were not mentioned. Some experts
suggest that the Metavir system has continuity of the scale to
interpret chronic hepatitis C. The aim of this study is looking for
a better system that can interpret histological activity and
ﬁbrosis comparing the Knodell and Metavir systems. Samples
from 27 cases of chronic hepatitis C patients were taken from
2000 to 2003. The slides were stained by hematoxylin and eosin
(H&E), Van Gieson (VG), Victorian Blue (VB) and Retikulin
staining. Interpretation was done by two observers individually,
and then interpreted again together using the Knodell and
Metavir systems. If discrepancies were found, a discussion
towards the most agreeable ﬁgure is tried. In conclusion, the
Metavir system is better than the Knodell system in histological
activity and ﬁbrosis because the Metavir system has less vari-
ables than the Knodell system and the scale is continuous.
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Hepatocellular carcinoma in infant: a case report
Nunung Ainur Rahmah1, Wirasmi Marwoto1, Vera Yoewono1
Ening Krisnuhoni1, Diah Rini Handjari1, Darmawan Kartono2
and David Handojo Muljono3
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3Faculty of Medicine, University of Indonesia/Dr. Cipto Man-
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sia Eijkman Institute for Molecular Biology, Jakarta, Indonesia
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Hepatocellular carcinoma is one of the most common tumors in
the world. The incidence of hepatocellular carcinoma generally
increases with age in all populations but it has a tendency to
decrease in the elderly and is very rare in children. This is a case
report of hepatocellular carcinoma in a 9-month-old boy, ad-
mitted with palpable abdominal mass in the right upper quad-
rant. Imaging modalities by USG could not adequately
demonstrate deﬁnite ﬁndings of the tumor arising from the liver
and the patient was diagnosed with neuroblastoma. Intra-opera-
tively, the tumor mass was found to arise from the surface of
the posterior edge of the liver; it was a pedunculated tumor.
The histopathological examination revealed a pedunculated
hepatocellular carcinoma grade 3. The Victorian Blue staining
and immunohistochemistry staining done afterward showed
HBsAg positivity in non-tumor as well as in neoplastic liver
tissue.
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Prevalence, virological and clinical characteristics of hepatitis B
virus genotypes in Pakistan
Saeed Hamid1, Tariq Moatter2, Khalid Mumtaz1, Wasim Jafri1,
Yasuhito Tanaka1 and Masashi Mizokami1
1Department of Clinical Molecular Informative Medicine, Na-
goya City University Graduate School of Medical Sciences,
Nagoya, Japan,
2Departments of Medicine and Pathology, Aga Khan Univer-
sity, Karachi, Pakistan
Background: Hepatitis B virus (HBV) genotypes are gaining
importance in terms of epidemiology and clinical signiﬁcance.
Currently, eight HBV genotypes (A–H) and their serial subtypes
are known and seem to be distributed along particular geogra-
phical locations globally. However, data are scanty from many
parts of the world. Aims: To investigate the prevalence of HBV
genotypes in Pakistan and their relationship to the pattern of
HBV-related liver disease. Methods: The HBV genotype was
determined in 257 HBV DNA-positive patients using PCR-
RFLP. Four of these isolates were then fully sequenced and
compared to isolates from other parts of the world using mole-
cular evolutionary analysis. Results: Four patients had acute and
253 had chronic HBV infection. Mean age was 28 years and there
were 201 (78%) males and 56 (22%) females. HBeAg was positive
in 219 (85%) patients (wild type infection) and was negative in 38
(15%) patients (pre core/ core promoter mutant infection).
Patients with wild type infection were younger than patients
with mutant infection (95% vs 21% patients  30 years,
Po0.001). Mean ALT level in chronic HBV patients was
103  26 IU and there was no difference in the two groups.
Overall, HBV genotype D was found in 247 (96.2%) cases,
followed by a combined infection with HBV genotype B1D in
9 (3.3%) and one (0.5%) case of genotype A. Seven of eight
patients with mixed B1D genotype had wild type infection and
only one had mutant infection. Sequence and phylogenetic ana-
lysis did not show signiﬁcant differences between HBV type D
isolates from Pakistan and other parts of the world. Conclusions:
Genotype D is the most common genotype in Pakistani patients
with acute and chronic hepatitis B, irrespective of the presence of
wild type or mutant infection. A mixed genotype (B1D) was
found in some patients, mainly with wild type infection.
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Hepatic vein waveforms revisited
K. C. Sudhamshu1, Shoichi Matsutani2, Hitoshi Maruyama2
and Hiromitsu Saisho2
1Liver Unit, National Academy of Medical Sciences, Nepal,
2Department of Medicine and Clinical Oncology, Graduate
School of Medicine, Chiba University, Japan
Purpose: Changes in Doppler waveforms of hepatic veins have
been studied in cirrhotic liver and it is postulated that dampening
of phasic oscillations appears with worsening of liver function. We
aimed to reevaluate the signiﬁcance of Doppler waveforms of
hepatic vein in cirrhotic patients and to correlate them with
hepatic blood ﬂow. Patients and Method: One hundred and
twenty-six consecutive patients of liver cirrhosis and 60 non-
cirrhotic controls were enrolled in this study. The diagnosis was
conﬁrmed by histopathological examinations and/or imaging
diagnosis together with clinical and biochemical parameters.
Doppler waveforms were obtained from the right hepatic vein.
Other parameters measured were ﬂow volume of portal trunk,
right portal vein and the hepatic artery. Result: Waveforms of the
hepatic vein were classiﬁed into triphasic, biphasic and ﬂat
patterns. Flat waveform was rare. There was no correlation
between liver dysfunction and patterns of waveforms. Inﬂow
was elevated in cases associated with non-triphasic waveforms.
Conclusion: Flat waves, which are postulated to be diagnostic of
worsening liver function, are independent of liver function and
have no diagnostic value. The role of hepatic blood ﬂow seems to
be important, suggesting hemodynamic changes rather than liver
dysfunction as a plausible cause of change in waveforms.
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Proﬁle of increasing serum transaminase in adult dengue fever and
dengue hemorrhagic fever
Khie Chen, Herdiman T. Pohan and Iskandar Zulkarnain
Division of Tropical Medicine and Infectious Diseases, Depart-
ment of Internal Medicine Faculty of Medicine University of
Indonesia/Dr. Cipto Mangunkusumo National General Hospi-
tal, Jakarta, Indonesia
Introduction: Dengue virus mainly infects mononuclear phago-
cyte cells, but it is also present in other non-hematopoietic
cells including hepatocytes. Increased levels of serum transami-
nase, alanine aminotransferase (ALT) and aspartate amino-
transferase (AST), have been reported in severe dengue
infection and related to liver cell damage. In this study, we
will report a proﬁle of increasing ALT and AST in primary or
secondary adult dengue fever and dengue hemorrhagic fever,
and its relation to other liver functions (bilirubin direct, gamma-
glutamyl transferase (gGT) and alkaline phosphatase (ALP)).
Method: A retrospective study was conducted in Dr. Cipto
Mangunkusumo National General Hospital and private (Pluit)
hospital, Jakarta, in 2004. Data were selected from medical
records according to these criteria: age above 14 years old,
primary or secondary dengue fever conﬁrmed by positive rapid
dengue immunochromatographic test, and liver function test
were performed on the ﬁrst day of admission. The deﬁnition of
dengue fever or dengue hemorrhagic fever was determined by
WHO criteria. Results: Eighty-four cases fulﬁlled the enroll-
ment criteria; they consisted of 54 males and 30 females aged
between 14 and 72 years old. Primary infection and secondary
dengue infection was present in 26 and 74% cases; dengue fever
was present in 62% and dengue hemorrhagic fever in 38% cases
(grade I 25% and grade II 13%). ALT and AST were increased
in 78 and 60% cases, respectively; most increasing of ALT
and AST was below threefold of upper normal limit (63% and
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75%). Bilirubin direct, gGT and ALP were also increased in
27%, 36% and 9%, respectively. There were signiﬁcant correla-
tions between increasing of ALT and AST with GI symptoms:
nausea, vomiting and abdominal pain (Po0.05), but no sig-
niﬁcant correlation with type of infection (primary or second-
ary) and severity (dengue/hemorrhagic fever grade I or II).
Conclusion: ALT and AST were increased in 78% and 60%,
and related to the presence of GI symptoms in dengue fever or
dengue hemorrhagic fever. Other liver function tests (bilirubin
direct, gGT and ALP) also showed an increase in some cases.
Further study is needed to know the correlation between dengue
virus serotype and abnormalities of liver function tests in dengue
infection.
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Liver function proﬁle of leptospirosis in Tarakan Hospital,
Jakarta, during heavy and local ﬂoods
J. S. Widayat1, T. P. Herdiman1 and Nazir2
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Internal Medicine, Medical Faculty University of Indonesia/
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2SMF of Internal Medicine Tarakan Hospital, Indonesia
Introduction: Leptospirosis is a health problem which is corre-
lated with the environment. Floods cause Leptospira to spread
out to new areas and new hosts. The aim of this study was to
compare liver function in leptospirosis during heavy ﬂoods (in
2002) with local ﬂoods (in 2003–2005). Methods: Secondary
data were from Tarakan Hospital, with inclusion criteria: fever
and positive serology of leptospira (leptotek/MAT), and exclu-
sion criteria: no data available at the end of hospitalization.
Results: In 2002, 26 samples were gained from 43 suspected
cases of leptospirosis, nine had died (three positive serology). In
2003, there were 63 cases of suspected leptospirosis (no serology,
all excluded). In 2004, 29 samples were gained from 31 suspected
cases of leptospirosis, and there were four deaths. Recent data
(2005), from 47 cases of suspected leptospirosis, were all
included, and there was one death. The liver function tests
were signiﬁcantly different between cases in 2002 compared with
cases in 2004–2005: mean AST of cured cases was 188.55 
240.20 (fatal: 386.67  295.55), in 2004–2005: 39.57  42.74
(fatal: 178.00  205.59). ALT in 2002: 106.82  113.85 (fatal:
256.67  219.5), in 2004–2005: 56.12  68.03 (fatal: 58.00 
33.06). Direct bilirubin 7.99  8.65 (fatal: 1.45  0.92), in 2004–
2005: 2.29  3.78 (fatal: 5.99  5.74). Indirect bilirubin
4.76  5.88 (fatal: 3.25), in 2004–2005: 2.46  3.87 (fatal:
0.93). Platelet count: 123.000  117.146 (fatal: 104.000 
147.254), in 2004–2005: 124.757  81.248 (fatal: 46.400 
33.93). Conclusions: The elevation of AST, ALT, and indirect
bilirubin and thrombocytopenia were found more severe in 2002
when leptospirosis outbreak occurred during heavy ﬂood in
Jakarta.
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Is there still a need for early virological response evaluation in anti
viral therapy for chronic hepatitis C?
Dolvy Girawan, S. A. Abdurachman, Ali Djumhana, S. Juke
Roslia and M. Begawan Bestari
Division of Gastroentero-hepatology, Department of Internal
Medicine, Faculty of Medicine Padjadjaran University,
Dr. Hasan Sadikin Hospital, Bandung, Indonesia
The combination of interferon a and ribavirin provides sus-
tained virological response (SVR) in approximately 40% of
chronic hepatitis C naı¨ve patients. SVR is deﬁned as the absence
of detectable HCV RNA at 24 weeks after cessation of therapy.
Analysis of patients who were treated with interferon-a demon-
strated that HCV RNA levels measured at week 12 of therapy
(early virological response, EVR) in genotype 1 infection were
extremely useful in predicting SVR. This study represented
clinical experience used of peginterferon a-2a plus ribavirin for
the therapy of hepatitis C, 48 weeks for genotype 1 and 24 weeks
for genotype non-1. This is to report preliminary data of
ongoing evaluation and observation covering viral load, HCV
genotypes and subtypes, ALT, AST, GGT, hematology, and
side effects. The study was conducted from March 2003 to
March 2005. There were 24 patients of hepatitis C who received
180mcg peginterferon a-2a plus 1000mg ribavirin. At the start
of therapy, 19 patients (79.17%) had genotype 1 (Subtype 1a:
14 patients, 1b: ﬁve patients) with viral load 2.71  105–
1.85  106 copies/ml, three patients had genotype 2 (2a) with
viral load 3.70  105–5.99  105 copies/ml, one patient had
genotype 3 (3a) with viral load 8.71  105, and one patient of
genotype 4 (4b) with viral load 1.7  103 copies/ml. Twenty-four
patients (100%) had ALT  1, 5 times upper normal limit
(UNL), and one patient had normal AST. Nineteen patients
had GGT normal and ﬁve patients (20.83%) had  1, 5 times
UNL. At the start of therapy, all patients had normal Hb,
leucocytes, and platelets. At week 12, all patients had undetect-
able viral load, ﬁve patients (20.83%) had normal ALT and four
patients (16.67%) had normal AST, three patients (13.40%) had
neutropenia and ﬁve patients (21.74%) had thrombocytopenia.
One patient with genotype 1 at week 23 discontinued therapy
because of allergic reaction and 1 patient of genotype 1
discontinued therapy at week 35 because of extreme thrombo-
cytopenia. At the end of therapy, all patients had undetectable
viral load, 19 patients (86.36%) had normal ALT and AST.
SVR evaluation was offered but was not done as it was
expensive. EVR is a reliable predictor of therapeutic outcome,
and could serve to justify avoiding unnecessary continuation of
therapy. Patients with negative EVR may be advised to stop
therapy as the burden of therapy may outweigh the beneﬁts. In
this study, all patients had low viral load (o2  106 copies/ml)
and after 12 weeks therapy all patients showed positive EVR.
Therapy for hepatitis C with peginterferon a-2a plus ribavirin
repaired liver function which showed normalization of ALT and
AST. Hematologic side effects due to the treatment were
anemia, neutropenia, and thrombocytopenia. One patient had
extreme thrombocytopenia and stopped therapy. Cessation of
therapy is recommended if platelet count decreases to levels
 25000/mm3. The evaluation of EVR in low viral load geno-
type 1 hepatitis C infection is probably not cost-effective. This
assumption should be clariﬁed with additional large-scale data.
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Endoscopic management of bleeding oesophageal varices with N
butyl cyanoacrylate (Histoacryl) – preliminary experience in a
tertiary centre
A. George, R. Ponnudurai, K. Ganesalingam, S. Sachitanan-
dan, L. Sanker, A. Abdullah, S. S. Tan, H. Razlan, O. K. Tan
and I. Merican
Selayang Hospital, Malaysia
1303
Abstracts
Background: Insufﬁcient data exist on efﬁcacy of treating bleed-
ing (OV) with Histoacryl. Objectives: To analyse the efﬁcacy of
Histoacryl in controlling bleeding OV.Methods: We performed
a retrospective analysis of all patients who presented to the
hepatology service of our hospital with bleeding OV who were
treated with Histoacryl as a primary method of achieving
haemostasis. Patient records from 1 January 2004 to 1 April
2005 were reviewed. All patients underwent emergency upper
gastrointestinal (GI) endoscopy within 24 h of admission. All
patients received the same standard of care including transfu-
sion of blood products, pharmacologic therapy (octreotide or
terlipressin) and prophylactic antibiotic therapy. Assessment of
rebleeding was made using standard clinical and endoscopic
parameters. Results: Thirteen patients were treated with His-
toacryl for bleeding OV. Immediate haemostasis was achieved in
all patients. Rebleeding within the ﬁrst 24 h occurred in 0
patients in the Histoacryl arm. During the ﬁrst 2 weeks, no
patients in the Histoacryl arm had evidence of rebleeding. No
patients in the Histoacryl arm showed clinical and/or radiolo-
gical signs of pulmonary embolism. Conclusion: Histoacryl
injection for the management of bleeding OV appears to be
efﬁcacious in achieving primary haemostasis and preventing
rebleeding within the ﬁrst 2 weeks. Thus, our data support the
use of Histoacryl injection in patients with acute OV bleeding. A
prospective randomised trial comparing Histoacryl to endo-
scopic variceal ligation is needed before this can be recom-
mended as routine therapy.
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Unusual low prevalence of hepatitis B infection in Tahuna,
Sangihe island, the northern part of Indonesia – a preliminary
report
Wenny Astuti Achwan1, Haris Widita1, Zainul Muttaqin1,
Sulaiman Ngongu2, Bambang Fajar Suryadi1, Edy Zakaria1,
Mulyanto2 and Suwignyo Sumoharjo1
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Indonesia consists of thousands of islands inhabited by hundreds
of ethnic groups. The prevalence of HBV infection varies widely
from one part to the other, ranging from moderate to high
prevalence. The most frequent HBsAg carrier rate reported from
each area was 5–10%. Tahuna is the capital of Sangihe island in a
relatively isolated archipelago located 150km north of Manado,
Sulawesi with a population of 35000. There is no previous report
on the prevalence of hepatitis B infection in the population.
Hepatitis B universal immunization program in Tahuna was
started 3 years ago. The HBsAg carrier rate reported in the
blood donors in Manado is 4.7%. This study was done to
measure HBsAg carrier rate and HBsAg subtype in Tahuna.
The population of the study was elementary, secondary, and high
school students in Tahuna city, inhabitants of a small village
inside Tahuna, and a group of adults gathered in the hepatitis
presentation given by our team. Venous blood sample was taken,
and then HBsAg was assayed using RPHA and IC method.
Blood samples were collected from a total of 836 persons (658
students, 6–18 years, 117 villagers and 61 other persons gathered
in the presentation). The oldest was 76 years old. HBsAg was
positive in 8 persons (0.96%). Of the 658 school children, HBsAg
was positive in 2 (0.24%). HBsAg was positive in adults excepting
school children in 6 (0.72%). HBsAg subtypes found in Tahuna
were adw (37.5%), ayw (12.5%), and adyw (25%). The subtype
pattern was different from a previous study in Menado that
showed adr (50.0%), adw (35.0%), ayw (5.0%), and ayr (10.0%).
The HBsAg carrier rate of 0.92% in Tahuna is much lower than
the carrier rate reported from the other parts of Indonesia. The
low prevalence of HBsAg in Tahuna is unusual. The HBsAg
carrier rate was even lower than the Anti-HCV rate in the same
population (1.2%). Study in the other islands of Indonesia
showed a higher HBsAg carrier rate in the inhabitants of small
islands than in those of the main island. The higher HBsAg
carrier rate in the small islands was thought to be caused by the
relatively closed environment in the small islands. The different
pattern of HBsAg subtype in Tahuna, especially the absence of
sub determinant ‘‘r’’, may reﬂect the different ancestors of the
population of Manado and Tahuna. The low prevalence of
Hepatitis B infection in the Tahuna population should be
explored by further more detailed study.
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HBsAg carrier rate in pediatric patients in Mataram General
Hospital (12 years after universal vaccination program)
Haris Widita1, Sukardi2, Rina Rosalina3, Stephanus Gunawan3,
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Suwignyo Sumoharjo1,3
1Department of Internal Medicine, Mataram General Hospital,
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4Eijkman Institute of Molecular Biology, Jakarta, Indonesia
In 1988, before hepatitis B universal vaccination performed in
Mataram, a study in pediatric patients admitted to the pediatric
ward of Mataram General Hospital showed 4.3% of the
children were HBsAg positive using reversed passive hemagglu-
tination (RPHA). Universal hepatitis B immunization program
had been performed in the whole of Lombok Island including
Mataram since 1991. The study was done to determine HBsAg
carrier rate in pediatric patients of Mataram General Hospital
12 years after hepatitis B universal vaccination program. In the
present study, blood samples were taken from all the new
patients admitted to the pediatric ward and were assayed for
HBsAg using the same method (RPHA) in Biomedical Research
Unit, Mataram General Hospital. Data on sex, age, diagnosis,
and vaccination status were recorded. Of 436 patients consisting
of 185 (42.4%) female and 251 (57.6%) male, aged from 1
month to 14 years old, 23 (5.3%) were HBsAg positive. The
carrier rate among female patients was 10 (5.4%) and carrier
rate among male patients was 13 (5.2%). The carrier rate child
from the urban area was 7/175 (4%) and from the rural area was
16/261 (6%). The carrier rate of 5.3% in the pediatric patients in
the current study was not lower than the carrier rate in a similar
population reported in 1988 before universal vaccination pro-
gram was performed in Mataram. The ineffectiveness of uni-
versal hepatitis B vaccination in this population is unusual, and
the reason for this should be investigated cautiously.
APASL/Poster/Abstract/178
HBsAg antigenemia in male applicants for a job in a foreign
country: the HBeAg and ALT status
Stephanus Gunawan1, Vera Veriyal1, Iskandar Zulkarnain1,
Haris Widita2 and Suwignyo Sumoharjo3
1Department of Clinical Laboratory,
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The prevalence of HBsAg antigenemia in adults from several
locations in Lombok Island ranges from 8.5% to 20.3%. Mass
neonatal HBV vaccinations in Lombok Island have been con-
ducted since 1991 and this project was successful because within 4
years the project lowered the HBsAg carrier rate in vaccinated
childrenby as much as 70% of the carrier rate of the same age
group before the vaccination program. At the time of the study,
the oldest individual who received mass neonatal immunization
was 15 years old. Most of the job applicants are 19–40 years old
and one of the important health qualiﬁcations of the applicants is
negative HBsAg. The objective of the study was to determine the
rate of HBsAg antigenemia, the HBeAg and the ALT status in
male job applicants for a foreign country in Mataram.
In this study, blood samples were taken from 1586 male job
applicants for a foreign country in Mataram General Hospital
Laboratory, assayed for HBsAg (ELISA), HBeAg (ELISA) and
ALT (spectrophotometric). The results of this study showed that
of 1586 male applicants aged 19–40 years, 167 (10.53%) were
HBsAg positive and (33.53%) of the HBsAg-positive applicants
were also HBeAg positive. The ALT of42  normal upper limit
was found in 1.8% of HBeAg-positive individuals. More than
10% of male job applicants lost the opportunity for getting a job
in the foreign country due to positive HBsAg. More than a third
of them were very infectious and have a possibility of getting
chronic liver disease in the future. However, most of the HBsAg-
positive individuals showed normal ALT.
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The factor associated with liver abscess recurrence
Kim Suk Bae, Yun Se Young, Kim Byung Ha, Shin Jung Eun,
Kim Hong Ja and Song Il Han
Department of Internal Medicine, DanKook University School
of Medicine, CheonAn, Korea
We studied retrospectively 57 patients who were admitted to
DanKook hospital. Liver abscess recurred in six of 57 patients.
The male:female ratio was 1.3:1 in the nonrecurred group but in
the recurred group all were male. The mean average age was
58.6 years in both groups. The duration of symptoms was 12.8
days in the nonrecurred group and 21 days in the recurred group.
The right lobe was the most frequent site in both groups. The
mean size of abscess was 6.3 cm in the nonrecurred group and
3.5 cm in the recurred group. PCD insertion rate was lower, with
decreased abscess size and a statistical signiﬁcance of Po0.01.
PCD insertion duration was 12.2 days in the nonrecurred group
and 8.75 days in the recurred group, but there was no statistical
signiﬁcance. Klebesiella pneumoniae (50%) was the most frequent
bacteria in the nonrecurred group followed by Streptococcus,
Escherichia coli. E. coli (60%) was most frequent in the recurred
group followed by K. pneumoniae. E. coli was more often seen in
the recurred group. Admission period was 22.8 days in the
nonrecurred group and 19.8 days in the recurred group. The
nonrecurred group showed a higher PCD insertion rate and
longer duration than the recurred group. The larger the abscess,
the higher the PCD insertion rate was, leading to a lower
recurrence rate. E. coli was isolated in the recurred group
more often than in the nonrecurred group. Aggressive PCD
insertion and thorough drainage seemed to be helpful to prevent
abscess recurrence. When E. coli is isolated, careful follow-up is
necessary.
180
Abstract withdrawn
APASL/Free Paper/Abstract/181
Effect of interferon-b on the regulatory mechanism in activation of
hepatic stellate cells
Hui-Ying Rao, Lai Wei, Ran Fei, Yan Sun, Jiang-Hua Wang
and Dong Jiang
Institute of Hepatology, People’s Hospital, Peking University,
Beijing, China
Objective: To investigate the regulatory effect of interferon-beta
(IFN-b) on the activation of hepatic stellate cells (HSC) through
transforming growth factor-b (TGF-b) and platelet-derived
growth factor (PDGF) pathways.Materials and Methods: HSC
(rHSC-99 cell lines and LX-2 cell lines) were cultured in DMEM
supplemented with 10% fetal bovine serum. HSC were incu-
bated with 1000 IU/ml IFN-b for 24, 48 and 72 h in groups 1–3;
HSC were incubated with 2000 IU/ml IFN-b for 24, 48 and 72 h
in groups 4–6; HSC were incubated with 4000 IU/ml IFN-b for
24, 48 and 72 h in groups 7–9. Western blots were used to detect
the protein expression of collagen type I, desmin, TGF-b1, TbR-
I, Smad7, Smad4, PDGF-BB, PDGFR-b and b-actin in HSC.
Results: Compared with the control group, expression of col-
lagen type I, desmin, TGF-b1, Smad4 and PDGF-BB of groups
1–9 in rHSC-99 was signiﬁcantly lower (F values were 26.235,
15.456, 27.312, 10.576 and 28.179 respectively, Po0.01), ex-
pression of Smad7 of groups 1–9 in rHSC-99 was signiﬁcantly
higher (F values were 2.492, P5 0.033). Compared with the
control group, expression of collagen type I, desmin, TGF-b1,
Smad4 and PDGF-BB of groups 1–9 in LX-2 was signiﬁcantly
lower (F values were 35.346, 21.237, 5.526, 120.740 and 24.125
respectively, Po0.05), expression of Smad7 of groups 1–9 in
LX-2 was signiﬁcantly higher (F values were 39.988, Po0.001).
Conclusion: IFN-b inhibits the ﬁbrosis of the liver and inhibits
the activation of HSC through the TGF-b and PDGF pathway.
APASL/Free Paper/Abstract/182
The function of G-CSF mobilized hematopoietic stem cells on
50% orthotopic partial liver transplantation
Liu Feng, Wei Lai, Chen Guo-dong, Pan Xiao-ben, Jiang Dong,
Cong Xu, Fei Ran
Hepatology Institute, People’s Hospital, Peking University,
Bejing, China
Background: On the basis of the recently recognized potential of
hematopoietic stem cells (HSC) to give rise to hepatocytes, we
investigated the possibility that HSC and granulocyte colony-
stimulating factor (G-CSF)-mobilized HSC could home to the
injured liver and promote tissue repair. We also examined the
origin of cells (endogenous or HSC) reconstituting liver after
damage. Materials and Methods: Fifty percent orthotopic par-
tial liver transplantation (PLTx) was established. Female SD
rats were used as donors and male SD rats as recipients. The
recipients were repeatedly administered human recombinant G-
CSF for 5 consecutive days before and after 50% PLTx.
Orthotopic whole liver transplantation (WLTx) and 50% partial
hepatectomy (PHx) groups were used as control groups. Blood
and liver samples were collected on days 1, 3, 5, 7 and 14
postoperatively (each n5 6). The quantitative variations of the
peripheral white blood cells with stem cell markers, including
02m /Thy-1.11, CD451/CD341, ﬂt2/31 and c-kit1 mar-
kers, were detected by ﬂow cytometry. The expressions of CD34,
c-kit and Thy-1.1 in liver grafts were detected by immunohis-
tochemistry technique. AST and ALT in serum, mitosis index,
PCNA and BrdU index were employed to evaluate liver injury
and regeneration. Sry gene, a sex-determining region for Y
chromosome, was detected to conﬁrm the origin of proliferating
cells reconstituting liver after injury by in situ hybridization
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in liver sections. Results: Compared with the WLTx groups,
02m /Thy-1.11, CD451/CD341 cells in blood in the 50%
PLTx groups and 50% PHx increased on the ﬁrst day post-
operatively and decreased on the following days and returned to
the normal level on the seventh day postoperatively. In 50%
PLTx, the CD34, c-kit and Thy-1.1 positive cells detected in
portal tract areas peaked during 3–5 days postoperatively.
CD451/CD341 positive cells could be detected. Compared
with WLTx and 50% PHx groups, the survival rate was low
(Po0.05) and liver injury was serious in the 50% PLTx groups.
Compared with the 50% PHx groups, on 3 days postopera-
tively, mitosis index and the expression of PCNA and BrdU
were low in the 50% PLTx groups, after G-CSF administration,
compared with the 50% PLTx and G-CSF150% PLTx groups,
there was a high survival rate in the 50% PLTx1G-CSF groups
(Po0.05). Compared with the 50% PLTx groups, on the third
day postoperatively, the level of AST and ALT were low, and
mitosis index and the expression of PCNA and BrdU were high
(Po0.05) in the 50% PLTx1G-CSF groups and these para-
meters showed no obvious difference from the G-CSF150%
PLTx groups. Compared with the 50% PLTx groups, the
expression of CD341 around the portal tract region increased
on the third day post-transplantation in the G-CSF150% PLTx
groups and on the ﬁfth day post-transplantation in the 50%
PLTx1G-CSF groups. Sry1cells were detected in the G-CSF
mobilized groups, and increased during 3–5 days after trans-
plantation. Conclusions: P2m/Thy 1.11 and CD451/CD341
HSC were mobilized on the ﬁrst day after 50% PLTx. G CSF
treatment after 50% PLTx signiﬁcantly improved survival rate
and liver histology of partial graft, predominantly by promoting
endogenous repair mechanisms. Therefore, mobilization with G
CSF might offer a novel therapeutic approach for the increased
survival of patients of partial liver graft.
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Upregulation of toll-like receptor 7 is essential for serological
clearance of hepatitis B surface antigen in chronic hepatitis B virus
(HBV) infection
Chee-Kin Hui1,2, Haiying Zhang1,2, Nikki P. Lee2,3, Lei Lu1,2,
Nancy Leung4, Benjamin C. Y. Wong1, Chung-Mau Lo2,3,
Sheung-Tat Fan2,3, John M. Luk2,3 and George K. K. Lau1,2
1Department of Medicine,
2Centre for the Study of Liver Diseases, The University of Hong
Kong,
3Surgery, Queen Mary Hospital,
4Department of Medicine, Alice Ho Miu Ling Nethersole
Hospital, Hong Kong SAR, China
Background/Objective: Toll-like receptors (TLRs) play an es-
sential role in innate defence as well as in shaping the adaptive
immune response. We studied the role of TLRs in HBsAg
clearance in chronic HBV patients. Method: We compared the
expression of TLR1-9, by real-time PCR, in PBMCs collected
from chronic HBV patients (HBeAg  ; n5 30/30) and patients
with resolved HBV infection (anti-HBs1 and anti-HBc1,
n5 20). We further studied the TLR7 expression in serial
PBMCs collected from 16 patients treated with pegylated
interferon (IFN)-a2a at baseline, during the 48-week treatment
period and 24 weeks after the end of therapy. HBV-speciﬁc CD4
and CD81 T-cells were enumerated by IFN-g producing
CD41ELISPOT assays and tetramer staining for CD81 T-
cells. Signaling Pathway of TLR7 using Ex Vivo Co-culture
Model: PBMCs of patients with and without HBsAg clearance
were infected with live HBV virus and TLR7 expression, HBV
RNA and cccDNA in the PBMCs quantiﬁed by real-time PCR.
SiRNA was then used to inhibit TLR7 expression on the
PBMCs of patients with spontaneous HBsAg clearance.
MyD88-dependent pathway was studied with Western blotting
and real-time PCR. Results: TLR7 expression in PBMCs was
higher in resolved HBV patients (mean  SD 1.4  0.7) than in
chronic HBV patients (0.9  0.4, P5 0.03). The expression of
TLR7 was higher in chronic HBV patients with HBsAg clear-
ance (n5 4) after pegylated IFN-a2a than those who remained
HBsAg1 at weeks 24 (3.2  1.1 vs. 1.2  0.9, P5 0.02) and 48
(3.0  1.2 vs. 1.8  0.8, P5 0.04) of therapy and 24 weeks after
the end of therapy (2.0  0.7 vs. 0.8  0.2, P5 0.03). In the
ex vivo model, the higher TLR7 expression in PBMCs from
patients with HBsAg clearance is accompanied by up-regulation
of MyD-88, TRAF6 and NFkb expression. HBV-speciﬁc CD81
activity against surface and core peptide was higher in patients
with HBsAg clearance on Day 8 of co-culture. HBV-speciﬁc
CD81 activity was reduced in patients with HBsAg clearance
after SiRNA inhibition of TLR7. Conclusion: Up-regulation of
TLR-7 plays an essential role in HBsAg clearance in patients
with chronic HBV infection.
APASL/Poster/Abstract/185
The incidence and risk factors of renal dysfunction after sponta-
neous bacterial peritonitis in cirrhosis
J. S. Lee, K. I. Park, M. H. Kim, K. A. Kim, J. H. Yang and
Y. S. Moon
Department of Internal Medicine, Inje University Ilsanpaik
Hospital, Gyeonggi-do, Republic of Korea
The deterioration of renal function in patients with cirrhosis and
spontaneous bacterial peritonitis (SBP) is the most sensitive
predictor of in-hospital mortality. A previous randomized, con-
trolled study has shown that for patients with SBP, treatment with
high-dose intravenous albumin in addition to antibiotics reduces
the incidence of renal impairment and improves hospital survival.
But, it would be important to know which patients with SBP may
beneﬁt from albumin infusion or if this treatment should be used
to treat all patients with SBP. Therefore, we conducted a retro-
spective study to elucidate the incidence and risk factors of renal
dysfunction in cirrhotic patients with SBP. All medical records of
136 consecutive episodes of SBP in 100 patients were analyzed.
Renal dysfunction was considered present if any of the following
criteria were met: admission serum creatinine  1.5mg/dl, ad-
mission blood urea nitrogen (BUN)  30mg/dl or a doubling of
serum creatinine or BUN to levels  1.5 and  30mg/dl,
respectively during admission. Of the 136 episodes of SBP, renal
dysfunction was present in 64 (47.1%). Age, serum sodium, Child
class, previous use of antibiotics and previous history of large
volume paracentesis were signiﬁcant risk factors on univariate
analysis. Of these, only age was an independent risk factor on the
logistic regression model. These data show that renal dysfunction
occurs frequently in patients with SBP and only age is an
independent risk factor. Considering the poor prognosis, close
monitoring of renal function is warranted and albumin infusion
with antibiotics should be used in all these SBP patients.
APASL/Free Paper/Abstract/186
Molecular background of HBeAg-negative chronic hepatitis B in
Indonesia (preliminary report)
Martono Roni, Caecilia Sukowati, Meta D. Thedja and
David H. Muljono
Eijkman Institute for Molecular Biology, Jakarta, Indonesia
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Introduction: HBeAg-negative chronic hepatitis B (CHB) is
associated with mutations in pre-core and core promoter regions
of hepatitis B virus (HBV) DNA, and tends to have severe
necroinﬂammatory changes. It was initially reported to prevail
in certain parts of the world (the Mediterranean, the Middle
East and Fareast Asia), but recent studies suggest a much wider
geographical distribution with increasing frequency. Since geo-
graphically HBV has a genetic diversity, the viral characteristics
responsible for this form of disease might vary in different parts
of the world. This is a preliminary study to investigate the
characteristics of HBV DNA in HBeAg-negative CHB patients
in Indonesia and the relationship with the clinical pattern.
Patients and Methods: Sixteen untreated CHB patients and
four patients previously treated with lamivudine who HBeAg
seroconverted were included; all were HBsAg positive for46
months, HBeAg negative, anti-HBe positive, and serum HBV-
DNA4100 000 copies/ml. Clinical and laboratory data were
periodically evaluated. HBV-DNA was sequenced for the core
promoter and pre-core regions and analyzed. Results: Of the 16
untreated patients, four displayed previously reported pre-core
stop mutation, G1896A, and two also showed core promoter
mutations, A1762T and G1764A. Of four treated patients, three
had mutations A1762T and G1764A, and one showed wt HBV
sequence. All patients with core promoter mutations developed
more severe inﬂammation, unresolved by retreatment with
lamivudine. Conclusion: Our study represents one of the ﬁrst
analyses of core promoter and pre-core mutations in HBeAg-
negative CHB patients in Indonesia, revealing the presence of
core promoter and pre-core mutations previously reported in
other geographical regions. Core promoter mutations could
contribute to the severity of the disease.
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APASL/Free Paper/Abstract/188
A study of serum cytokine levels, polymorphisms in interferon-c
promoter and their correlation with treatment outcome of chronic
hepatitis C virus-infected patients
Anila Yasmeen1, Tayyab-Un-Nissa1, Saeed Hamid2, Aniza
Kausar1, Wasim Jafri2 and Anwar Siddiqui1
1Departments of Biological and Biomedical Sciences and Med-
icine,
2The Aga Khan University Karachi, Karachi, Pakistan
A balance between Th1 and Th2 cytokine response to hepatitis
C virus (HCV) may be important in persistence of infection and
response to treatment with antiviral agents. The maximal
capacity of cytokine production varies among individuals and
correlates with the presence of polymorphisms in the cytokine
genes. In particular, interferon gamma (IFN-g) plays an im-
portant role in the elimination of hepatocytes infected
with HCV. Aims: (1) To determine whether the Th1-
and Th2-related cytokine proﬁle of chronic HCV patients is
associated with response to interferon therapy. (2) To correlate
the frequency and association of the single nucleotide poly-
morphism (SNP) in the IFN-g promoter region at  179 bp
between patients with different treatment outcomes and con-
trols.Methods: We studied 100 HCV1 subjects and 100 normal
controls. Patients received interferon a 3MIU thrice weekly1r-
ibavirin 800–1200mg/day for 6 months. Serum levels of IL-4,
IL-6, IL-10, IL-12, IFN-g and TNF-a were determined by
ELISA. The IFN-g promoter region was ampliﬁed by PCR
using genotyping primers from genomic DNA extracted from
peripheral blood lymphocytes. The polymorphic site was iden-
tiﬁed by digestion of PCR product using AvaII restriction
endonucleases. Results: Mean IFN-g levels were signiﬁcantly
elevated in patients compared to controls (78.0  14.9 pg/ml vs
24.7  6.9 pg/ml, Po0.05), and in responders to therapy com-
pared to non-responders (89.3  17.6 pg/ml vs 35.4  10.4 pg/
ml, Po0.05). Polymorphic analysis of IFN-g promoter showed
that the G allele was highly dominant in both patients and
controls. In addition, an extra band of 50 bp was found in 22%
controls and 25% patients, indicating the presence of a new
AvaII restriction site. Linkage association showed no correla-
tion between this polymorphic site and therapy outcome of
patients. Conclusions: High levels of IFN-g were present in
chronic HCV patients, despite the presence of the G allele,
which has been reported as less responsive to pathogens as
compared to the T allele. These ﬁndings suggest that the SNP
 179 G polymorphic site does not have a direct effect on IFN-g
upregulation.
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APASL/Free Paper/Abstract/190
Efﬁcacy and safety of oral N-Acetylcysteine in non-acetamino-
phen-induced acute liver failure
Khalid Mumtaz, Saeed Hamid, Wasim Jafri, Zahid Azam, Sadik
Memon, Zaigham Abbas, Hasnain Shah and Muhammad Islam
The Aga Khan University Hospital, Karachi, Pakistan
Efﬁcacy of N-Acetylcysteine (NAC), although well established
in acetaminophen-induced acute liver failure (ALF), is not yet
clear in non-acetaminophen-induced ALF. Aims: To evaluate
the efﬁcacy and safety of oral NAC in non-acetaminophen-
induced ALF. Methods: A total of 91 adult patients admitted
with non-acetaminophen-related ALF at our hospital from
January 2002 to March 2005 were randomized to receive
NAC (n5 47) or no intervention (n5 44). NAC was started
immediately on admission in an initial dose of 140mg/kg,
followed by 70mg/kg for a total of 17 doses, 4 h apart. In the
absence of a liver transplant facility in our country, all patients
were treated according to a standard medical protocol. Baseline
characteristics were compared in the two groups and mortality
was used as the primary end point. Results: Most baseline
characteristics were comparable in the two groups except for
mean age (27.7  11.8 years in NAC vs 37.5  18.8 in the no
intervention group, P5 0.004), serum bilirubin417.6mg/dl (24
patients in NAC vs 11 in the no intervention group, P5 0.01)
and a viral etiology (35 cases in NAC vs 20 in the no interven-
tion group (P5 0.005). Of the 34 patients who survived, 22
patients received NAC and 12 no intervention (P5 0.054).
Multiple logistic regression analysis showed that use of NAC,
age  40 years, PT  50 s and hyper acute liver failure were
independent predictors of survival. No untoward side effects
were observed with the use of NAC. Conclusions: The use of
NAC is safe and may improve survival in patients with non-
acetaminophen-induced ALF.
APASL/Free Paper/Abstract/191
Hepatitis B and C: prevalence and social factors associated with
sero-positivity among children in Karachi, Pakistan
W. Jafri1, N. Jafri1, J. Yakoob1, M. Islam1, S. F. A. Tirmizi1,
T. Jafar1, S. Akhtar2, S. Hamid1, H. A. Shah1, S. Abid1 and
Q. Nizami3
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1Department of Medicine,
2Department of Community Health Sciences,
3Department of Pediatrics, Aga Khan University Hospital,
Karachi, Pakistan
This cross-sectional study estimated the prevalence and identi-
ﬁed risk factors associated with HCV and HBsAg sero-positivity
among children 1–15 years. It targeted low to middle socio-
economic population comprising 80–85% of the population.
Parents consented for questionnaire and blood sample for anti-
HCV and HBsAg. A total of 3533 children were screened. Of
them, 1862 (52%) were males. Sixty ﬁve (1.8%) were positive for
HBV, mean age 104 years. Fifty ﬁve (1.6%) were positive for
HCV, 32 (58%) boys; mean age 94 years. Four (0.11%) boys
were positive for both HBV and HCV. Sixty (92%) HBV and 51
(93%) HCV-positive children’s parents (P5 0.830) have not
heard of hepatitis viruses (P5 0.815). Forty-ﬁve (69%) HBV-
positive individuals (Po0.04) received therapeutic injections
compared to 28 HCV (51%). Twenty-nine (45%) HBV and 17
(31%) HCV received injections from the local doctor. Forty-ﬁve
(68%) HBV and 28 (51%) HCV patients claimed the use of a
new syringe every time (OR 2.0 CI 1.0–4.2 P5 0.05). Forty-six
(71%) HBV and 33 (60%) HCV patients received vaccination in
the government hospital (OR 4.6 CI 2.6–10.7 Po0.001). A new
syringe was used in 49% (32) HBV and in 82% (45) HCV
patients (OR 1.6 CI 0.08–3.5 P5 0.21). The prevalence of HBV
in the east of the city was 6% (24) (OR 4.8 CI 2.7–8.7 Po0.001)
and in the south 2% (18) (OR 1.8 CI 0.3–3.3 P5 0.08). The odds
of HBV were 2.2 times higher than HCV, with 95% CI 1.1–4.6.
There is a need to educate the lower socio-economic population
regarding HBV and HCV infection and the dangers associated
with unsterilized therapeutic injections.
APASL/Free Paper/Abstract/192
A randomized, open-label, multi-center study comparing the
efﬁcacy and safety of peginterferon a-2a (40 kDa) (PEGASYSs)
with conventional interferon a-2a (ROFERONs-A) in patients
with chronic hepatitis C (CHC) in China
D. Z. Xu1, K. X. Luo2, Z. M. Lu3, J. D. Jia4, Y. M. Wang5,
G. Z. Zhao6, S. L. Zhang7 and D. Z. Zhang8
1Beijing Ditan Hospital,
2Nanfang Hospital, the 1st Military Medical University,
3Shanghai Ruijin Hospital,
4Beijing Friendship Hospital,
5Xi’nan Hospital, The 3rd Military Medical University,
6The 2nd Hospital, China Medical University,
7The 1st Hospital, Xi’an Jiaotong University,
8The 2nd Hospital, Chongqing Medical University, China
Introduction: The prevalence of hepatitis C virus (HCV) infec-
tion in China is 3.2%. In large trials, peginterferon a-2a
(40 kDa) (PEGASYSs) was signiﬁcantly more effective than
conventional interferon a-2a (Roferons-A) in Western patients.
We compared the efﬁcacy and safety of peginterferon
a-2a (40 kDa) and interferon a-2a in Chinese CHC patients.
Methods: Patients were randomized to peginterferon a-2a
(40 kDa) 180 mg/week or interferon a-2a 3MU 3  /week for
24 weeks, with 24 weeks follow-up. HCV RNA was monitored
by COBAS AMPLICOR HCV Monitors Test, v2.0 (limit of
quantiﬁcation5 600 IU/ml). Results: In all, 208 adults were
enrolled. The characteristics of the two groups were similar.
By intent to treat, the overall sustained virological response
(SVR) rates at the end-of-follow-up (week 48) were 41.5% with
peginterferon a-2a (40 kDa) and 16.7% with interferon a-2a
(Po0.0001). The proportion of genotype 1 (35.4% vs 14.5%,
P5 0.003) and non-genotype 1 (66.7% vs 21.7%, P5 0.003)
patients with SVRs was signiﬁcantly higher in the peginterferon
a-2a (40 kDa) than in the interferon a-2a groups. SVR rates in
patients with baseline HCV RNA  8  105 IU/ml were sig-
niﬁcantly higher in the peginterferon a-2a (40 kDa) than in the
interferon a-2a group (41.1% vs 13.1%, Po0.001), but not in
patients with low baseline HCV RNA (42.4% vs 22.0%,
respectively, P5 0.059). No signiﬁcant serious adverse events
(AE) were reported. The frequency and severity of AE were
similar in the two groups, although insomnia was more common
in recipients of peginterferon a-2a (40 kDa) than in recipients of
interferon a-2a (33.0% vs 15.7%, P5 0.004). Conclusion: In
Chinese patients, peginterferon a-2a (40 kDa) (PEGASYSs)
was signiﬁcantly more effective than interferon a-2a and was
well tolerated.
APASL/Free Paper/Abstract/193
Hepatitis B reactivation after withdrawal of preemptive lamivu-
dine in patients with hematological malignancy upon completion of
cytotoxic chemotherapy
Chee-Kin Hui1,2, Winnie W. W. Cheung1, Wing-Yan Au1,
Albert K. W. Lie1, Hai-Ying Zhang1,2, Yui-Hung Yueng1,2,
Benjamin C. Y. Wong1, Nancy Leung3, Yok-Lam Kwong1,
Raymond Liang1 and George K. K. Lau1,2
1Department of Medicine, The University of Hong Kong,
2Centre for The Study of Liver Diseases, The University of
Hong Kong,
3Department of Medicine, Alice Ho Miu Ling Nethersole
Hospital, New Territories, Hong Kong SAR, China
Background: The hepatic outcome of HBsAg1 patients under-
going chemotherapy after withdrawal of preemptive lamivudine
is unknown. Aim: To examine the occurrence of HBV reactiva-
tion after withdrawal of preemptive lamivudine upon immune
recovery post-chemotherapy. Methods: Preemptive lamivudine
was started 1 week before initiation of chemotherapy in 46
consecutive HBsAg(1) patients and continued for the entire
duration of chemotherapy. Preemptive lamivudine was stopped
at a median 3.1 (range 3.0–3.4) months post-chemotherapy.
Patients were longitudinally followed up for a median 25.7
(range 5.7–75.7) months after withdrawal of preemptive lami-
vudine. Serum HBV DNA was monitored with in-house real-
time PCR assay. Results: Eleven (23.9%) patients developed
HBV reactivation after withdrawal of preemptive lamivudine.
The cumulative probability of HBV reactivation after lamivu-
dine withdrawal at 6, 12, 24 and 36 months were 2%, 5%, 16%
and 33%, respectively. Patients with a high prechemotherapy
HBV DNA (4104 copies/ml) were more likely to develop HBV
reactivation (8/16 (50%) vs. 3/30 (10%), Po0.001 on log-rank).
HBeAg(1) patients were also more likely to develop HBV
reactivation (5 of 11 (45.5%) vs. 6 of 35 (17.1%), P5 0.041
on log-rank). A high prechemotherapy HBV DNA (4104 co-
pies/ml) was the most important risk factor for HBV reactiva-
tion after withdrawal of preemptive lamivudine on Cox
proportional hazards analysis (RR 16.13, 95%CI 2.99–87.01,
P5 0.001). Conclusions: HBV reactivation is more likely to
occur in patients with high prechemotherapy HBV DNA after
withdrawal of preemptive lamivudine. A more prolonged course
of antiviral therapy may be necessary in these patients after
completion of chemotherapy in order to reduce post-chemother-
apy HBV reactivation.
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APASL/Poster/Abstract/195
Mucormycosis in patients with cirrhosis
Z. Abbas, S. Rasool, S. Abid, M. Aslam, I. Hameed and
Wasim Jafri
Section of Gastroenterology, Department of Medicine, The Aga
Khan University Hospital, Karachi, Pakistan
Introduction: Oculo-rhino-cerebral mucormycosis occurs in dia-
betics and immunocompromised patients and is associated with
poor prognosis. Antifungal therapy with surgical debridement is
the standard of care. Patients with cirrhosis of liver are more
prone to develop infection. Treatment is difﬁcult due to under-
lying coagulopathy and hepatic dysfunction in patients with
cirrhosis. Little is known about the clinical presentation and
outcome of mucor infection in cirrhosis. Methods: Medical re-
cords of the past 5 years were searched for patients of cirrhosis
with associated diagnosis of mucor or fungal infection. Six
patients with mucor infection were identiﬁed. Results: Out of
six patients, ﬁve were male. The age range was 15–55 years. The
cause of cirrhosis was hepatitis C in four, hepatitis B in one and
autoimmune in one. One patient also had hepatocellular carci-
noma. Four patients were diabetic; of these four, one patient was
also on steroids for autoimmune liver disease. Three patients had
spontaneous bacterial peritonitis. All six patients presented with
rhino-ocular-cerebral mucormycosis with nasal discharge and
upper motor neuron signs. Diagnosis of mucormycosis was
made by culture of biopsy and scrapings taken from the palate
and nasal sinuses. All patients received amphotericin as standard
therapy. Four patients expired in the hospital, while one left
against medical advice. One patient expired 10 days after his
discharge. Conclusion: Mucormycosis in cirrhosis is rare and has
poor prognosis. Patients with advanced cirrhosis and diabetes
mellitus are at risk of developing the infection.
APASL/Free Paper/Abstract/196
Study of seroprevalence of Hbs Ag positive on medical doctors
who underwent medical tests as nominees of Specialist Education
in Dr. Kariadi Hospital Semarang
Hery Djagat Purnomo and Suyatmi Awizar
Division of Gastrohepatology, Department of Internal Medi-
cine, Medical Faculty of Diponegoro University/Dr. Kariadi
Hospital Semarang, Indonesia
Background: Hepatitis B virus (HBV) infection is one of the major
diseases of mankind and is a serious global public health problem.
Health care personnel are at increased risk of occupational acquisi-
tion of hepatitis B virus infection. Medical doctors are one of the
high-risk groups for HBV infection byblood contact. Objecti-
ve: The aim of this study is to determine the prevalence of HbsAg
and the role of duration of time working as a doctor on exposure to
Hbs Ag on medical doctors who underwent medical tests as
nominees of specialist education at Dr. Kariadi Hospital Semarang.
Methods: This study was done retrospectively from 1145 medical
doctors who underwent medical tests as nominees of specialist
education in Dr. Kariadi Hospital Semarang from April 2000 to
October 2004.The HbsAg used as marker of hepatitis B was
measured by the enzyme immunoassay (EIA) method. Results: Of
1145 medical doctors (422 women and 723 men), aged 25–35 years,
mean age 29.34  3.04 nominees of specialist education, more than
3 years as a doctor: 64% (733/1145) persons, less than 3 years as a
doctor: 36% (412/1145) persons. The prevalence of HBsAg positive
among the population was 3.9% (45/1145). The seropositivity
among those more 3 years as a doctor vs those less than 3 years
as a doctor was 5.1% (38/733) vs 1.6% (7/412), Po0,05 consecu-
tively. Conclusion: Prevalence of HBsAg positive among medical
doctors who underwent medical tests as nominees of specialist
education in Dr. Kariadi hospital is 3.9%. HbsAg positive is more
prevalent among doctors who have been working more 3 years.
APASL/Poster/Abstract/197
Co-infection of HIV with HCV and/or HBV in healthy persons
screened for blood donors in Bandung, West Java
Juke R. Saketi1, Chaerul Amri2, Erlina Kartabrata2, S. A.
Abdurachman1, Ali Djumhana1 and D. Girawan1
1Gastroenterology Department Internal Medicine Faculty of Med-
icine Padjadjaran University/Hasan Sadikin Hospital Bandung,
2Indonesian Red Cross, Bandung, Indonesia
Over the past few years, concomitant infection (co-infection) with
human immunodeﬁciency virus (HIV) and hepatitis C virus
(HCV) has emerged as a major public health concern. Co-
infection of HIV with HCV may have a synergistic effect on the
progression of HCV-related liver diseases. Chronic liver disease
from HCV has been recognized as an HIV-associated opportu-
nistic infection. Of additional concern is the rising incidence of
acute hepatitis B in high-risk groups because of poor compliance
with hepatitis B vaccination; thus, HIV-HBV co-infection may
become a growing problem. Co-infection behaves differently and
requires different approaches to screening, diagnosis, manage-
ment, and therapy. According to data from national CITBT
(Contagious Infection through Blood Transfusion) Indonesian
Red Cross, there were 0.06% with anti HIV positive, 0.44% HCV
positive and 1.37% was HbsAg positive among all donors in
Indonesia. The purpose of this study is to examine the prevalence
of co-infection HIV with HCV and/or HBV in healthy persons
screening for blood donors. Data were obtained and analyzed
from all anti-HCV, HbsAg, and anti-HIV reactive from January
to April 2005. The study was conducted in retrospect to serolo-
gical data of donor’s blood with the screening of CITBT reactive
in the Blood Transfusion Unit, Indonesian Red Cross, Bandung,
West Java. In this time period, 23512 donors were tested for their
HbsAg, anti-HCV, and anti-HIV. HbsAg was tested using En-
zyme Immunoassay Murex HbsAg (version 3), anti-HIV by
Enzyme Immunoassay Murex HIV-1.2.0, and anti-HCV by En-
zyme Immunoassay Murex anti-HCV (version 4.0). All are from
ABBOT. The results showed 645 (2.74%) donors were least
reactive to one of these infections. There were 539 (83.8%) males
and 104 (16.2%) females. The most common age group was 20–29
years, 194 (33.7%) persons. The prevalence of anti-HCV was 294
(1.25%), HBsAg was 250 (1.06%), and anti-HIV was 128
(0.54%). One donor was infected with all three (HbsAg, anti-
HCV, and anti-HIV tests) (PEF5 0.203). A total of 12 donors
(4.4%) were reactive to anti-HCV and anti-HIV tests (w25 84.395;
Po0.001); 11 donors (4.4%) were reactive to HbsAg and anti-
HCV tests (w25 279.106; Po0.001); and ﬁve donors (2%) were
reactive to HbsAg and anti-HIV tests (w25 81,724; Po0.001).
The prevalence of co-infection of HCV, HBV, and HIV was
0.04%, co-infection of HCV and HIV was 0.05%, while co-
infectionof HBV and HIV was 0.02% ,and co-infectionof HBV
and HCV was 0.05%. Conclusion: We have to be extra cautious
since this study shows that there are an increasing number of co-
infections of HIV and HCV and/or HBV in blood donors.
APASL/Poster/Abstract/198
Systemic combination chemotherapy (epirubicin, cisplatin, UFT,
leucovorin) in patients with advanced hepatocellular carcinoma
Y. H. Kim, H. J. Chun, Y. T. Jeen, B. R. Keum, Y. S. Kim, H.
S. Lee, S. H. Uhm, S. W. Lee, J. H. Choi, C. D. Kim, H. S. Ryu
and J. H. Hyun
Division of Gastroenterology, Korea University Medical Cen-
ter, Anam-Dong, Sungbuk-Ku, Seoul, South Korea
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Background: Treatment of advanced hepatocellular carcinoma
consists of radiation therapy and chemotherapy. However, results
of these treatments have been disappointing. We administered a
combination of four chemotherapeutic agents (epirubicin, cispla-
tin, UFT, and leucovorin) with different mechanisms to see
whether response rate could be improved through the synergistic
effects of each drug. Methods: We performed a retrospective
study by reviewing the data of patients with advanced hepato-
cellular carcinoma who were treated with EPUL regimen from
January 1995 to December 2004. A total 27 patients were
enrolled. The regimen consisted of epirubicin 50mg/m2 and
cisplatin 60mg/m2 delivered as an intravenous infusion over
5min and over 2 h on day 1, respectively, followed by UFT
and leucovorin administered orally on days 1–21. The chemother-
apy was repeated every 4 weeks. Response to chemotherapy was
evaluated after every two cycles and toxicities were assessed after
each cycle. Results: Among the total of 27 patients, 15 patients
completed more than two cycles of chemotherapy. Twelve
patients only completed one cycle of chemotherapy due to poor
general conditions (11 patients) and cancer progression (one
patient). The treatment response rate of 15 patients was 20%
(95% CI 0–41%) with no complete response and three partial
responses. Median progression-free survival was 4 months. The
most common toxicity was leucopenia (18.5%), which improved
within 1 week. Other toxicities were minimal. Conclusio-
n: Although the toxicities of combination chemotherapy with
EPUL regimen in advanced HCC patients were tolerable, re-
sponse rate was not so high. Thus, this regimen can be considered
as a palliative therapeutic modality.
APASL/Free Paper/Abstract/199
Sustained response off-treatment to entecavir and lamivudine after
48 weeks of treatment in nucleoside-naı¨ve, HBeAg(1) patients:
24-week follow-up results of Phase 3 Study-022
T. T. Chang1, Y. C. Chao2, J Sollano3, K. H. Han4, C. L. Lai5,
N. Akbar6, J. Lao-Tan7, H. Brett-Smith8, L. Fernandes8,
J. Zhu8, A. Cross8 and R. Wilber8
1National Cheng Kung University Hospital, Tainan, Taiwan,
2Tri-Service General Hospital, Taipei, Taiwan,
3University of Santo Tomas, Manila, Philippines,
4Severance Hospital, Yonsei University, Seoul, Korea,
5Queen Mary Hospital, Hong Kong, China,
6Cipto Mangunkusumo National Central General Hospital,
Jakarta,
7Cebu Doctors Hospital, Cebu City, Philippines,
8Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Background: Entecavir (ETV) is a potent and selective
HBV antiviral that demonstrated superior efﬁcacy to lamivu-
dine (LVD) through 48 weeks of treatment in a Phase 3
trial in 709 HBeAg(1), nucleoside-naı¨ve patients with chronic
hepatitis B. Methods: Patients who achieved protocol-deﬁned
response (o0.7MEq/ml by bDNA assay and HBeAg loss) to
ETV (0.5mg QD) and LVD (100mg QD) by week 48 discon-
tinued therapy and were evaluated off-treatment for an addi-
tional 24 weeks according to three sustained response endpoints.
Results: At week 48, more patients in the ETV group than in the
LVD group had serum HBV DNA levels of o0.7MEq/ml
(bDNA: 91% vs 65%, Po0.0001) or o300 copies/ml (PCR:
67% vs 36%, Po0.0001). HBeAg loss rates were similar (ETV
22%, LVD 20%). 21% of ETV patients vs 19% of LVD patients
achieved response and discontinued study medication. The table
below shows the proportion of patients achieving sustained
response endpoints at 24 weeks off treatment. Kaplan–Meier
estimates of the proportion of patients with sustained responses
up to 24 weeks showed a separation among the three endpoints in
favor of ETV that began between weeks 8 and 12 of the follow-up
period. Conclusions: Over 70% of patients with response after 48
weeks of ETV therapy sustained their response when off treat-
ment. By suppressing HBV DNA, causing loss of HBeAg, and
reducing ALT levels with 1 year of treatment, ETV has the
potential to sustain response when therapy is discontinued.
Outcomes at 24 weeks off-treatment
Sustained
response endpoints
ETV
0.5mg – n
(%)
LVD 100mg
– n (%)
HBV DNA o0.7Meq/ml1loss HbeAg 61 (82) 49 (73)
HBV DNA o0.7Meq/ml1loss
HBeAg1ALT o1.25  ULN
54 (73) 38 (57)
ALT o1.25  ULN 56 (76) 39 (58)
APASL/Free Paper/Abstract/200
Sustained response off treatment to entecavir and lamivudine in
nucleoside-naı¨ve, HBeAg(–) patients: 24-week follow-up results of
Phase 3 Study-027
C. L. Lai1, T. T. Chang2, Y. C. Chao3, T. Tanwandee4, S.
Thongsawat5, S. D. Lee6, P. Angus7, Y. Batur8, U. S. Akarca8,
L. Fernandes9, R. Zink9, A. Cross9 and R. Wilber9
1Queen Mary Hospital, Hong Kong, China,
2National Cheng Kung University Hospital, Tainan, Taiwan,
3Tri-Service General Hospital, Taipei, Taiwan,
4Siriraj Hospital, Bangkok, Thailand,
5Maharajnakorn Chiang Mai Hospital, Chiang Mai, Thailand,
6Taipei Veterans General Hospital, Taipei, Taiwan,
7Austin & Repatriation Medical Centre, West Heidelberg, VIC,
Australia,
8Ege University Faculty of Medicine, Izmir, Turkey,
9Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Background: Entecavir (ETV) is a potent and selective HBV
antiviral which was superior to lamivudine (LVD) through 48
weeks of treatment in a Phase 3 trial in 648 HBeAg(–), nucleo-
side-naı¨ve patients with chronic hepatitis B. Methods: Patients
who achieved a protocol-deﬁned response (HBV DNAo0.7 -
Meq/ml by bDNA assay and ALTo1.25  ULN) to ETV (0.5
mg QD) or LVD (100 mg QD) by week 48, discontinued therapy
and were evaluated for sustained response for an additional 24
weeks. Results: At week 48, 85% (275/325) of ETV patients vs
78% (245/313) of LVD patients achieved a protocol-deﬁned
response (P5 0.04). Also, more patients in the ETV than the
LVD group achieved serum HBV DNA levels ofo0.7MEq/ml
(bDNA: 95% vs 89%, P5 0.0053) or o300 copies/ml (PCR:
90% vs 72%, Po0.0001). Of the protocol-deﬁned responders,
259 ETV patients and 220 LVD patients were evaluated for
sustained response. A higher proportion of ETV-treated com-
pared to LVD-treated patients sustained their response; these
data are presented below. Kaplan–Meier estimates of propor-
tions of patients with sustained responses up to 24
weeks showed a separation in favor of ETV for all three
endpoints that began around week 8 during the follow-up
period. Conclusions: Of the 85% of nucleoside-naı¨ve, HBeAg-
negative ETV-treated patients who achieved a protocol-deﬁned
response, 48% sustained that response through 24 weeks off
treatment. By suppressing HBV DNA and reducing ALT levels,
ETV can maintain response when therapy is discontinued.
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Sustained response at 24 weeks off-treatment
ETV 0.5mg
(n5 259)
LVD
100mg
(n5 220)
HBV DNA o0.7MEq/ml (bDNA), % 59 46
ALT o1.25  ULN, % 55 37
HBV DNA o0.7MEq/ml1ALT o1.25  ULN, % 48 35
APASL Bali/Free Paper/Abstract/201
Entecavir (ETV) demonstrates consistent responses throughout
baseline demographic subgroups for the treatment of nucleoside-
naı¨ve, HBeAG(1) and HBeAG(–) patients with chronic hepatitis B
T.T. Chang1, C.L. Lai2, Y.C. Chao3, C.K. Tan4, W. Sievert5,
S.S. Wu6, M. Rosmawati7, D. Oguz8, H. Brett-Smith9, L.
Fernandes9, K. Klesczewski9, A. Cross9 and R. Wilber9
1National Cheng Kung University Hospital, Tainan, Taiwan,
2Queen Mary Hospital, Hong Kong, China,
3Tri-Service General Hospital, Taipei, Taiwan,
4Singapore General Hospital, Singapore,
5Monash Medical Centre, Clayton, VIC, Australia,
6Changhua Christian Hospital, Department of Internal Medi-
cine, Changhua, Taiwan,
7University Malaya Medical Centre, Kuala Lumpur, Malaysia,
8Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey,
9Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Background: ETV was superior to lamivudine (LVD) in Phase 3
studies of nucleoside-naı¨ve, HBeAg(1) (ETV 022) and
HBeAg(-) (ETV-027) patients. This analysis assessed the effect
of baseline demographic subgroups on efﬁcacy outcomes.
Methods: The predictive value of potential prognostic sub-
groups was examined in logistic regression models for the
efﬁcacy endpoints of Histological Improvement [  2-point
decrease in Knodell necroinﬂammatory score and no worsening
of ﬁbrosis (  1-point increase in Knodell ﬁbrosis score)] and
HBV DNA o400 copies/mL. The baseline distribution of sub-
groups was balanced across patient groups but not between
studies (ETV-022 had a higher proportion of Asian patients).
Results: Subset analyses supported the principal analysis about
superiority of ETV over LVD for both endpoints. Across
subgroups, response to ETV was consistent. Conclusions: For
endpoints of Histological Improvement and viral load reduc-
tion, ETV was comparable or superior to LVD across demo-
graphic subgroups. Gender, ethnicity and prior IFN-treatment
did not affect ETV treatment outcome.
Histological improvement
Baseline
variables
ETV-022 HBeAg(1) ETV-027 HBeAg(–)
ETV (%)
n5 314n
LVD (%)
n5 314n
ETV (%)
n5 296n
LVD (%)
n5 287n
IFN-naı¨ve 71 62 70 61
IFN-pretreatedwz 78 62 71 61
Male 71 61 72 59
Femalew 74 65 65 66
Asian 71 64 68 64
Non-Asian
73 60 72 58
nHistologically evaluable.
wSubgroup o100 patients ETV-022.
zSubgroup o100 patients ETV-027.
HBV DNA o400 copies/ml
Baseline
variables
ETV-022 HBeAg(1) ETV-027 HBeAg( )
ETV (%)
n5 354
LVD (%)
n5 355
ETV (%)
n5 325
LVD (%)
n5 313
IFN-naı¨ve 69 36 90 73
IFN-pretreatedn,w 72 49 98 74
Male 67 36 92 74
Female 78 45 91 73
Asian 72 43 93 78
Non-Asian 67 32 90 71
nSubgroup o100 patients ETV-022.
wSubgroup o100 patients ETV-027.
APASL/Poster/Abstract/202
The efﬁcacy of entecavir (ETV) is similar regardless of disease-
related baseline subgroups in treatment of nucleoside-naı¨ve,
HBeAg(1) (Study-022) and HBeAg( ) (Study-027) patients
with chronic hepatitis B
M. Rosmawati1, S. D. Lee2, S. S. Wu3, J. George4, A. Lee5, C.
C. Lim6, F. Zano7, H. Aksu8, H. Brett-Smith9, L. Fernandes9,
K. Klesczewski9, A. Cross9 and R. Wilber9
1University Malaya Medical Centre, Kuala Lumpur, Malaysia,
2Taipei Veterans General Hospital, Taipei, Taiwan,
3Changhua Christian Hospital, Changhua, Taiwan,
4Storr Liver Unit, University of Sydney, Westmead Hospital,
Westmead, NSW Australia,
5Concord Repatriation General Hospital, Concord, NSW,
Australia,
6Tan Tock Seng Hospital, Singapore,
7Philippine General Hospital, Manila, Philippines,
8University of Cukurova, Adana, Turkey,
9Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Background: ETV was superior to lamivudine (LVD) in Phase 3
studies of nucleoside-naı¨ve, HBeAg(1) and HBeAg( ) pa-
tients. This analysis assessed the effect of baseline subgroups
on efﬁcacy outcomes. Methods: Baseline ALT levels and HBV
genotype were chosen as determinants of outcome. The pre-
dictive value of potential prognostic subgroups was examined in
logistic regression models for the efﬁcacy endpoints of
Histological Improvement ( 2-point decrease in Knodell
necroinﬂammatory score and no worsening of ﬁbrosis ( 1-
point increase in Knodell ﬁbrosis score)) and HBV DNA
o400 copies/ml. Baseline ALT levels were similar across treat-
ment groups and between studies. HBV genotypes were
balanced across treatment groups but differed between
studies. Results: Subset analyses supported the principal analy-
sis for superiority of ETV over LVD for both endpoints.
Conclusions: For both endpoints, responses to treatment with
ETV were consistent across ALT strata and HBV genotype
subgroups. Efﬁcacy of ETV was comparable or superior to
LVD across subgroups in these populations.
APASL/Poster/Abstract/203
Alanine aminotransferase (ALT) ﬂares are uncommon both on and
post-treatment in entecavir (ETV)-treated HBeAg(1) patients
J. Sollano1, T. T. Chang2, S. D. Lee3, A. Lee4, I. Merican5,
J. Lao-Tan6, C. K. Tan7, Y. Batur8, H. Brett-Smith9,
L. Fernandes9, R. Hindes9, A. Thiry9, A. Cross9 and R. Wilber9
1University of Santo Tomas, Manila, Philippines,
2National Cheng Kung University Hospital, Tainan, Taiwan,
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4Concord Repatriation General Hospital, Concord, NSW,
Australia,
5Hospital Selayang, Clinical Research Unit, Selayang, Malaysia,
6Cebu Doctors Hospital, Cebu City, Philippines,
7Singapore General Hospital, Singapore,
8Ege University Faculty of Medicine, Izmir, Turkey,
9Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Background: ETV is a potent and selective HBV antiviral. ALT
ﬂares are a concern both on and post-treatment of chronic
hepatitis B.Methods: Flares were analysed in two Phase 3 trials
in HBeAg(1) patients: Study-022 (n5 709 nucleoside naı¨ve):
ETV 0.5mg QD or LVD 100mg QD for up to 96 weeks; Study-
026 (n5 286 LVD-refractory): ETV 1.0mg or LVD 100mg for
up to 96 weeks. Patients with HBV DNA o0.7MEq/ml and
HBeAg loss at week 48 discontinued therapy and were followed
for 24 weeks post-treatment. On and post-treatment ﬂares were
deﬁned as ALT 42  baseline and 410  ULN, and
ALT42  minimum of baseline and end of dosing and
410  ULN, respectively. Results: On-treatment ﬂares were
observed for 12 (3%) ETV and 23 (6%) LVD patients in
Study-022, and 1 (o1%) ETV and 16 (11%) LVD patients in
Study-026. All ETV ﬂares were associated with a  2 log10
reduction in HBV DNA that was maintained during treatment.
12/13 ETV ﬂares resolved on treatment. One patient discon-
tinued ETV due to ﬂare. 12/23 ﬂares on LVD in Study-022 and
all 16 in Study-026 were associated with rising or stable HBV
DNA. Nine patients discontinued LVD due to ﬂare. Of Study-
022 patients with on-treatment ﬂares, 1/12 ETV and 5/23 LVD
patients had a clinical or laboratory abnormality consistent with
hepatic dysfunction and 1 LVD patient died of hepatic failure.
Flares post-treatment were observed in 3 (2%) ETV and 9 (6%)
LVD patients and in 9/12 cases were associated with a return of
serum HBV DNA toward baseline. No post-treatment ETV
ﬂares resulted in hepatic decompensation. Conclusion: ALT
ﬂares on ETV are uncommon and generally associated with
declines in serum HBV DNA and a benign clinical course.
APASL/Poster/Abstract/204
Decline in serum HBV DNA and ALT normalisation is associated
with histological improvement among nucleoside-naı¨ve patients in
entecavir Phase 3 trials
Y. C. Chao1, T. T. Chang2, C. L. Lai3, W. Sievert4, M.
Rosmawati5, H. Simsek6, H. Brett-Smith7, L. Fernandes7, K.
Klesczewski7, A. Cross7 and R. Wilber7
1Tri-Service General Hospital, Taipei, Taiwan,
2National Cheng Kung University Hospital, Tainan, Taiwan,
3Queen Mary Hospital, Hong Kong, China,
4Monash Medical Centre, Clayton, VIC, Australia,
5University Malaya Medical Centre, Kuala Lumpur, Malaysia,
6Hacettepe University Medical School, Ankara, Turkey,
7Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Background: Improvement in liver histology is a principal end-
point in the evaluation of HBV antiviral agents. Methods: This
report investigates if non-invasive measures of response to
entecavir (ETV) could be surrogate markers of histological
improvement (HI):  2-point decrease in Knodell necroinﬂam-
matory score and no worsening of ﬁbrosis (  1-point increase
in the Knodell ﬁbrosis score). Data from two Phase 3 studies
comparing ETV to lamivudine (LVD) in nucleoside-naı¨ve
HBeAg(1) (Study-022, n5 709) and HBeAg( ) (Study-027,
n5 638) patients were analysed. Results: More ETV than LVD
patients achieved HBV DNA o400 copies/ml by PCR (Study-
022: ETV 69%, LVD 38%; Study-027: ETV 91%, LVD 73%).
In Study-022, a higher rate of HI (80%) was observed for ETV
patients with HBV DNA o400 copies/ml compared to those in
higher HBV DNA strata. In Study-027, 95% (252/265) of ETV
patients with HI and PCR data at week 48 achieved HBV DNA
o400 copies/ml, limiting comparison with higher HBV DNA
strata. ETV patients achieving ALTo1  ULN had higher
rates of HI. Conclusions: ETV achieved high proportions of
patients with HBV DNAo400 copies/ml and serum AL-
To1  ULN. Patients achieving these endpoints had higher
rates of HI than those in higher HBV DNA and ALT strata.
APASL/Poster/Abstract/205
Entecavir is well tolerated for the treatment of nucleoside-naı¨ve
and lamivudine-refractory chronic hepatitis B: Phase 2/3 safety
results
J. George1, T. T. Chang2, M. Rosmawati3, J. Sollano4, J. Lao-
Tan5, S. Kaymakoglu6, E. Cooney7, R. Hindes7, J. Yang7,
A. Cross7 and R. Wilber7
1Storr Liver Unit, University of Sydney, Westmead Hospital,
Westmead, NSW Australia,
2National Cheng Kung University Hospital, Tainan, Taiwan,
3University Malaya Medical Centre, Kuala Lumpur, Malaysia,
4University of Santo Tomas, Manila, Philippines,
5Cebu Doctors Hospital, Cebu City, Philippines,
6Istanbul Medical Faculty, Capa, Istanbul, Turkey,
7Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Background: Entecavir (ETV), a potent and selective inhibitor
of HBV polymerase, was well tolerated in Phase 2 trials with a
safety proﬁle similar to lamivudine (LVD). Methods: This
report summarizes data from four studies in which patients
received ETV (nucleoside-naı¨ve: 0.5mg QD; LVD-refractory:
1.0mg QD) or LVD (100mg QD). Nucleoside-naı¨ve patients
(ETV n5 679, LVD n5 668) were from Phase 3 trials Study-022
(HBeAg(1)) and Study-027 (HBeAg( )), and LVD-refractory
patients (ETV n5 183; LVD n5 190) were from Phase 3 trial
Study-026 and Phase 2 trial Study-014. Results: Proportions of
patients experiencing any adverse event (AE) on treatment were
similar for ETV and LVD for both datasets (nucleoside-naı¨ve:
ETV 81%, LVD 82%; LVD-refractory: ETV 85%, LVD 82%).
Incidence of serious AEs was similar between ETV and LVD
(nucleoside-naı¨ve: ETV 7%, LVD 8%; LVD-refractory: ETV
10%, LVD 7%). There were fewer discontinuations due to AEs
in ETV-treated patients (nucleoside-naı¨ve: ETV 1%, LVD 3%;
LVD-refractory: ETV 2%, LVD 7%). On-treatment ALT ﬂares
were less frequent in ETV-treated patients (nucleoside-naı¨ve:
ETV 2%, LVD 4%; LVD-refractory: ETV 2%, LVD 11%).
While on treatment and during the 24-week follow-up, there
were few malignant neoplasms for ETV and LVD (nucleoside-
naı¨ve: ETV 1%, LVD 1%; LVD-refractory: ETV 2%, LVD
1%). Few deaths were reported for ETV and LVD (nucleoside-
naı¨ve: ETV n5 2, LVD n5 4; LVD-refractory: ETV n5 1;
LVD n5 2). Conclusions: ETV has a similar safety proﬁle to
LVD in both nucleoside-naı¨ve and LVD-refractory patients.
Discontinuations due to AEs and on-treatment ALT ﬂares
occur less frequently with ETV than with LVD.
APASL/Free Paper/Abstract/206
Entecavir resistance is absent in nucleoside-naı¨ve patients and
observed infrequently by week 48 in lamivudine-refractory pa-
tients with chronic HBV infection treated with entecavir
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R. J. Colonno, R. E. Rose, S. M. Levine, C. J. Baldick,
K. Pokornowski, M. Plym, C. F. Yu, S. Zhang, A. W. Walsh,
L. Discotto, C. Mazzucco, J. Fang, D. R. Langley and D.
J. Tenney
Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Background: Entecavir (ETV) exhibits potent efﬁcacy in all
HBV patient populations. High-level ETV resistance (ETVr)
requires lamivudine-resistant (LVDr) substitutions (rtM204
with or without rtL180) plus changes at rtT184, rtS202 and/or
rtM250. Methods: Baseline and week 48 genotypes for
4700ETV-treated patients were obtained. All emerging sub-
stitutions identiﬁed, plus samples from all patients experiencing
virologic rebounds ( 1 log increase from nadir by Roche
Cobas Amplicor PCR assay), were phenotyped. Results: No
virologic rebounds due to ETVr were observed and no ETVr-
associated substitutions at residues rtI169, rtT184, rtS202 or
rtM250 emerged among 430 ETV-treated nucleoside-naı¨ve
patients examined. Virologic rebounds due to ETVr were
observed in 1% of ETV-treated LVD-refractory patients.
ETVr-associated substitutions emerged in 6% of ETV-treated
LVD-refractory patients by week 48 and only appeared when
pre-existing LVDr changes were present. ETVr substitutions
were noted in a fraction of LVD-refractory subjects at baseline,
indicating that LVD could select for these changes. Despite the
presence of ETVr substitutions at baseline, ETV treatment did
not lead to rapid virologic rebound or lack of virologic response.
Molecular modeling studies predicted two distinct mechanisms
for ETVr. Conclusions: An extensive genotypic analysis of
ETV-treated patients showed no evidence of ETVr by week 48
in previously nucleoside naı¨ve subjects. Only 1% of ETV-treated
LVD-refractory subjects exhibited virologic rebounds due to
resistance. Clinically relevant ETVr requires the pre-existence of
LVDr substitutions, and at least one additional change at
residues rtT184, rtS202 and/or rtM250.
APASL/Plenary/Abstract/207
Elevated serum level of hepatitis B virus (HBV) DNA is an
independent risk factor for hepatocellular carcinoma: the risk
evaluation of viral load elevation and associated liver disease/
cancer (The R.E.V.E.A.L.–HBV study)
C.-J. Chen1, H.-I. Yang1, J. Su2, C.-L. Jen1, S.-L. You1 and
U. H. Iloeje2
1National Taiwan University, Taiwan,
2Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA
Introduction: HBV DNA is a marker of efﬁcacy for antiviral
treatment of chronic hepatitis B. We examined the independent
effect of HBV DNA on the incidence of HCC in a long-term
study. Methods: A cohort of 3851 asymptomatic HBsAg-posi-
tive subjects was recruited from seven townships in Taiwan
between 1991 and 1992. Serum samples obtained at enrolment
and follow-up examinations were tested for HBsAg, HBeAg,
HBV DNA by PCR (LOQ 300 copies/ml), and ALT. The
diagnosis of HCC was made through data linkage with proﬁles
of the National Cancer Registry and Death Certiﬁcation System
and conﬁrmed by chart review. Multivariable-adjusted relative
risks (RRadj) were derived using Cox proportional hazard
models. Results: During 43 993 person-years of follow-up, 176
subjects were newly diagnosed with HCC. Removing all HCV
co-infected subjects, there were 164 HCC cases among 3653
subjects. In these subjects, the incidence of HCC was strongly
linked with increasing HBV DNA level in a dose–response
manner (test of trend; Po0.001); incidence of HCC was highest
(11.52/1000 PYFU) in subjects with HBV DNA  106 copies/
ml. In a Cox regression model, the RRadj (95% CI) was 7.8 (3.7–
16.2) for HBV DNA levels  106 copies/ml (reference: HBV
DNAoLOQ); in HBeAg negative subjects with normal serum
ALT (N5 2966), the RRadj (95% CI) was 18.6 (8.2–42.2) for
HBV DNA levels  106 copies/ml. Conclusion: Serum HBV
DNA can reliably predict the risk of HCC independent of
HBeAg status and serum ALT level. Persistent elevation of
HBV DNA over time carries the strongest risk of HCC.
APASL/Poster/Abstract/208
Viral load is a strong predictor of hepatocellular carcinoma
(HCC) risk in people chronically infected with hepatitis B virus
(HBV) and with normal serum alanine aminotransaminase level
(ALT): the risk evaluation of viral load elevation and associated
liver disease/cancer (the R.E.V.E.A.L.–HBV study)
H.-I. Yang1, U. H. Iloeje2, J. Su2, C.-L. Jen1, S.-L. You1 and
C.-J. Chen1
1National Taiwan University, Taiwan,
2Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, USA
Background: Treatment guidelines generally recommend therapy
for chronic hepatitis B patients with serum alanine aminotransfer-
ase (ALT)  2  ULN. This study was carried out to examine
the risk of hepatocellular carcinoma (HCC) in this population
with emphasis on the role of serum hepatitis B virus (HBV) DNA
level relative to the role of serum ALT. Methods: A cohort of
3851 participants with chronic HBV infection was recruited from
seven townships in Taiwan between 1991 and 1992. Cohort entry
serum samples were tested for HBsAg, HBeAg, HBV DNA by
PCR (LOQ 300copies/ml), and serum ALT. The diagnosis of
HCC was ascertained through data linkage with computerized
proﬁles of the National Cancer Registry and Death Certiﬁcation
System in Taiwan. Multivariable adjusted relative risks (RRadj)
were derived using Cox proportional hazard models. Results: O-
verall, during 43 993 person-years of follow-up, 176 of the 3851
participants were newly diagnosed with HCC. Of the 3851
participants, 3601 (93%) had a serum ALT level o1  ULN.
Of these, 42% had a serum HBV DNA level  104 copies/ml. Of
the 7% with elevated serum ALT level, 65% had serum HBV
DNA  104 copies/ml at cohort entry. Compared with subjects
with undetectable HBVDNA, subjects with HBVDNA  106 co-
pies/ml had the highest incidence of HCC; RRadj (95%
CI) 12.3 (6.7–22.6). There was a dose-dependent relationship
between HBV DNA and HCC risk in people with normal serum
ALT variably deﬁned as either o1  ULN or o2  ULN.
Conclusion: Elevated serum HBV DNA is a strong predictor of
HCC in chronically infected HBV patients regardless of serum
ALT.
APASL/Poster/Abstract/209
Serum hepatitis B virus (HBV) DNA level predicts the incidence
of liver cirrhosis in persons chronically infected with HBV: the risk
evaluation of viral load elevation and associated liver disease/
cancer (TheR.E.V.E.A.L.–HBV study)
U. H. Iloeje1, H.-I. Yang, J. Su1, C.-L. Jen, S.-L. You2 and
C.-J. Chen2
1Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, CT, USA,
2National Taiwan University, Taiwan
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Introduction: Cirrhosis develops as a result of hepatic inﬂam-
mation and subsequent ﬁbrosis. Chronic hepatitis B (CHB)
subjects are at increased risk of developing liver cirrhosis, as
ongoing viral replication is associated with hepatic inﬂamma-
tory activity. This study examines if increasing levels of
HBV DNA are associated with increasing risk of cirrhosis.
Methods: A cohort of 3851 HBsAg-positive subjects was estab-
lished from seven townships in Taiwan between 1991 and 1992.
Serum samples were tested for HBV DNA by PCR. Cirrhosis
was diagnosed by ultrasonography. Cirrhosis incidence rate per
person-year of follow-up (PYFU) for each HBV DNA strata
was calculated. The multivariable-adjusted relative risk
(RRadj) was derived from Cox proportional hazard models.
Results: Seventy-seven subjects were excluded (two died within
6 months of enrolment, 75 were diagnosed with cirrhosis)
leaving 3774 subjects. During 42 115 PYFU, 395 cirrhosis cases
were newly diagnosed. Cirrhosis incidence rate ranged from
386.1/100 000 PYFU with HBV DNA o300 copies/ml to
2575.7/100 000 PYFU with HBV DNA  106 copies/ml (Po
0.0001) in a dose-dependent manner. With o300 copies/ml as
reference, and adjusting for gender, age, habits of cigarette
smoking and alcohol consumption, and hepatitis C virus anti-
bodies, the risk of cirrhosis began increasing at an HBV DNA
level of 104 copies/ml with a RRadj of 2.2 (95% CI 1.5–3.3) and
was 8.7 (95% CI 6.2–12.3) for those who had HBV DNA
 106 copies/ml. Conclusion: HBV DNA level is a strong
predictor of cirrhosis risk. The incidence of cirrhosis increases
with HBV DNA level in a dose-dependent manner. Conversely,
reducing HBV DNA level is likely to decrease cirrhosis risk in
CHB patients.
APASL/Free Paper/Abstract/210
Viral load is a strong predictor of cirrhosis in CHB infection
regardless of serum ALT and HBeAg status: the risk evaluation of
viral load elevation and associated liver disease/cancer (The
R.E.V.E.A.L.–HBV study)
C.-J. Chen1, H.-I. Yang1, J. Su2, C.-L. Jen1, S.-L. You1 and
U. H. Iloeje2
1National Taiwan University, Taiwan,
2Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, USA
Background: HBeAg status and serum ALT are considered,
respectively, to be markers of active replication and disease
progression. This study examined the impact of HBV DNA level
on the risk of progression to cirrhosis stratiﬁed by HBeAg status
and ALT level. Methods: A cohort of chronic hepatitis B
(CHB)-infected subjects was recruited from seven townships in
Taiwan between 1991 and 1992. Entry serum samples were
tested for HBV DNA by PCR. Subjects were prospectively
followed by clinical examination through 30 June 2004, and
diagnosis of cirrhosis was made by ultrasonography. All cir-
rhosis cases diagnosed within 6 months of enrolment were
excluded from analyses. Multivariable-adjusted relative risks
(RRadj) were derived using Cox proportional hazard models.
Results: Of 3774 subjects, contributing 42 115 person-years of
follow-up data, 3542 (94%) had normal ALT and 3214 (85%)
were HBeAg( ); 395 new cases of cirrhosis were diagnosed.
Increasing HBV DNA was associated with increasing risk of
cirrhosis within each ALT and HBeAg strata after adjusting for
other variables (test of trend Po0.001). With normal ALT and
HBV DNAo104 copies/ml as reference, the RRadj (95% CI) for
subjects with normal ALT and HBV DNA  105 copies/ml was
6.1 (4.8–7.8), and the RRadj (95% CI) for subjects with elevated
ALT and HBV DNA  105 copies/ml was 10.1 (7.0–14.5).
Stratifying by HBeAg status, for subjects with HBV DNA
 105 copies/ml , the RRadj (95% CI) for HBeAg( ) subjects
was 4.9 (3.7–6.4) and for HBeAg(1) subjects was 8.6 (6.6–11.2)
(HBeAg( ) and HBV DNA o104 copies/ml as reference).
Conclusion: Elevated serum HBV DNA is a strong predictor
of cirrhosis in HBV-infected subjects regardless of serum ALT
level and HBeAg status.
APASL/Poster/Abstract/211
Excess mortality associated with chronic hepatitis B virus infec-
tion: the R.E.V.E.A.L.–HBV study
U. H. Iloeje1, H.-I. Yang2, J. Su1, C.-L. Jen2, S.-L. You2 and
C.-J. Chen2
1Global Epidemiology and Outcomes Research, Pharmaceutical
Research Institute, Bristol-Myers Squibb Co., Wallingford, CT,
USA,
2Graduate Institute of Epidemiology, College of Public Health,
National Taiwan University, Taipei, Taiwan
Background: The long-term hepatic sequelae of chronic hepati-
tis B (CHB) infection have been well documented. We evaluated
the mortality risk associated with CHB infection in a large
prospective cohort study. Method: A community-based pro-
spective cohort study was established from seven townships in
Taiwan between 1991 and 1992. Mortality causes were identiﬁed
through computerized data linkage to the Taiwanese National
Cancer Registry, National Death Certiﬁcate Registry and Na-
tional Health Insurance proﬁles through December 31 2002.
Incidence rates were calculated and multivariable-adjusted re-
lative risks (RRadj) derived from Cox proportional hazard
models. Results: Of the 23 820 subjects, 1545 (6.4%) died.
Malignant neoplasms (37%), circulatory system diseases
(20%), injury and poisoning (13%), GI disorders (8%), and
diabetes mellitus (6%) were the ﬁve leading causes of death. Of
the enrolled subjects, 4155 (17.4%) were HbsAg positive; the
RRadj (95% CI) for all cause mortality for the HBsAg-positive
group was 1.7 (1.5–1.9) compared with the HBsAg-negative
group. The RRadj (95% CI) was 10.8 (7.7–15.2) and 5.4 (3.4–8.6)
for liver cancer and chronic liver disease deaths, respectively.
The RRadj (95% CI) for all other causes of mortality was 1.1
(0.9–1.3). Conclusions: CHB-infected subjects had a signiﬁcant
risk of excess mortality compared to non-infected subjects.
Increases in liver-related mortality account for the mortality
differences. Early intervention with appropriate antiviral thera-
pies may decrease liver-related complications and prolong
survival in these individuals.
APASL/Poster/Abstract/212
Valuing health states using utility weights to capture the impact of
disease progression in chronic hepatitis B (CHB)
J. Fang1, Y. Hao1, R. Luo2, Q. Lin1, A. Levy3, S. J. Har-
greaves3, E. Tafesse4, J. Mukherjee4, U. H. Iloeje4 and
A. H. Briggs5
1Department of Medical Statistics and Epidemiology, School of
Public Health, Zhongshan Medical University, China,
2Department of Infectious Diseases, The Third Afﬁliate Hospi-
tal, Sun Yat-Sen University, Guangzhou, China,
3Oxford Outcomes Ltd., Vancouver, Canada,
4Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-
ingford, USA,
5Oxford Outcomes Ltd., London, UK
Background: In mainland China, approximately 9.75% of the
population has chronic hepatitis B (CHB) and, there are an
estimated 280 000 related deaths each year. Without effective
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treatment, patients usually progress through increasingly severe
disease states pre-death. Utility weights are used to estimate the
impact of morbidity and mortality, the quality-adjusted life
years in cost-effective analyses, and for allocation of resources.
We sought to elicit utility weights for six CHB-related health
states. Methods: Utility weights were elicited, by the standard
gamble method and visual analog scale, for six CHB-related
health states (deﬁned by a panel of hepatologists) in patients
(100 CHB subjects) and laypersons (100 uninfected subjects).
Probability wheels with two-color pie charts for the relative
probabilities of perfect health (1) and death (0) were used for the
standard gamble and a ‘feeling’ thermometer was used for the
visual analog scale. Results: For the patient group, mean age
was 42 years (SD: 12.4, range: 20–68 years) and 93.1% were
male. Mean utility weights were 0.41 (95% conﬁdence interval
(CI): 0.35–0.46) for CHB; 0.58 (CI: 0.52–0.64) for compensated
cirrhosis; 0.57 (CI: 0.51–0.63) for subsequent years post liver
transplant; 0.51 (CI: 0.45–0.57) for ﬁrst year post-liver
transplant; 0.31 (CI: 0.26–0.36) for hepatocellular carcinoma
and 0.26 (CI: 0.22–0.31) for decompensated cirrhosis. Mean
utility weights elicited in laypersons followed a similar pattern.
Conclusion: For patients in this population, the health-related
quality of life decreased with progression of disease. In addition,
the utility weights elicited in patients were consistently lower
than those of laypersons.
This research was fully funded by Bristol-Myers Squibb, Wall-
ingford, CT, USA
APASL/Free Paper/Abstract/213
A randomized, placebo-controlled study (etv-056) in China of the
efﬁcacy and safety of entecavir (ETV) in chronic hepatitis B
(CHB) patients who have failed lamivudine (LVD) therapy
Guangbi Yao1, Xiaqiu Zhou2, Daozheng Xu3, Baoen Wang4,
Hong Ren5, Michael Jiang6, Jessica Liu6, Dong Xu7 and
Laurie Macdonald7
1Shanghai Jing An Central Hospital, Shanghai, China,
2Rui Jin Hospital Afﬁliated to Shanghai No.2 Medical Uni-
versity, Shanghai, China,
3Beijing Di Tan Hospital, Beijing, China,
4Beijing Friendship Hospital Afﬁliated to Capital Medical
University, Beijing, China,
5No. 2 Hospital Afﬁliated to Chongqing Medical University,
Chongqing, China,
6Bristol-Myers Squibb Company, Shanghai, China,
7Bristol-Myers Squibb Company, Wallingford, CT, USA
Background: ETV has potent antiviral activity against wild type
and LVD-resistant HBV. Objective: ETV vs. placebo (PBO) for 12
weeks was evaluated in Chinese patients who had failed LVD; long-
term safety and efﬁcacy were assessed in the subsequent 36 weeks
open-label phase.Methods: Eligible patients had documented LVD
failure, stopped LVD for at least 12 weeks, HBV DNA  105 co-
pies/ml by PCR, and ALT  10  ULN. In the double-blind
phase, patients were randomized (4:1) to ETV 1.0mg QD or PBO
for 12 weeks. In the open-label phase, patients received ETV 1.0mg
QD for 36 weeks. The primary endpoint was the change from
baseline in HBVDNA by PCR at week 12. Results: At baseline for
treated patients (N5145), mean HBVDNAwas 8.79 logcopies/ml,
mean ALT was 88.9U/l, and 90% were HBeAg-positive. The mean
change in HBV DNA at W12 was  4.30 logcopies/ml and
 0.15 logcopies/ml for ETV and PBO, respectively (Po0.0001).
In patients with abnormal baseline ALT, 68% ETV vs. 6% PBO
achieved ALT normalization (ALT  1  ULN) (Po0.0001).
The incidence of adverse events (AEs) was comparable: 33% ETV
and 28% PBO patients reported AEs. All patients treated in the
double-blind phase entered open-label dosing. Among patients
initially treated with ETV in the double-blind phase, the mean
change in HBV DNA was  5.08 logcopies/ml, 28% had HBV
DNA levelso400copies/ml and 85% achieved ALT normalization
after 48 weeks ETV. HBeAg loss was achieved in 12 patients (9%)
treated with ETV. No mutations associated with resistance to ETV
were detected. ETV 1.0mg for 48 weeks was generally well tolerated.
Conclusions: The ﬁndings from this study demonstrate the antiviral
activity and safety of ETV in adults with CHB who have failed
LVD.
APASL/Free Paper/Abstract/214
Entecavir is superior to lamivudine for the treatment of chronic
hepatitis B: results of the Phase 3 study ETV-023 in nucleoside-
naı¨ve patients
Guangbi Yao1, Chengwei Chen2, Weilun Lu3, Hong Ren4,
Deming Tan5, Yuming Wang6, Daozheng Xu7, Michael Jiang8,
Jessica Liu8, Dong Xu9 and Laurie Macdonald9
1Shanghai Jing An Central Hospital, Shanghai, China,
2Shanghai Liver Disease Center Of Nangjing Military Area,
Shanghai, China,
3No. 3 Hospital Afﬁliated to Zhongshan Medical University,
Guangzhou, China,
4No. 2 Hospital Afﬁliated to Chongqing Medical University,
Chongqing, China,
5Infectious Disease Department of Xiang Ya Hospital, Chang-
sha, China,
6Xinan Hospital, Chongqing, China,
7Beijing Di Tan Hospital, Beijing, China,
8Bristol-Myers Squibb Company, Shanghai, China,
9Bristol-Myers Squibb Company, Wallingford, CT, USA
Background: Entecavir (ETV) is a potent and selective antiviral
with activity against wild type and lamivudine (LVD)-resistant
hepatitis B virus (HBV). Objective: This study evaluated the
safety and efﬁcacy of ETV 0.5mg QD vs. LVD 100mg QD for
48 weeks in nucleoside-naı¨ve, adult Chinese patients. Method-
s: Patients were randomized 1:1 to receive ETV or LVD. Eligible
patients had HBV DNA  3MEq/ml by bDNA, ALT levels 1.3
to 10  ULN, compensated liver function, and had received no
more than 12 weeks of prior nucleoside therapy. The primary
efﬁcacy endpoint was a composite endpoint of HBV DNA
o0.7MEq/ml by bDNA assay and ALTo1.25  ULN at
week 48. Results: Baseline characteristics were well balanced
between treatment groups; of treated patients (N5 519), 86%
were HbeAg positive at baseline, mean HBV DNA by PCR was
8.56 log copies/ml, and mean ALT was 197U/L. Conclusion-
s: ETV achieves superior virological and biochemical improve-
ments in nucleoside-naı¨ve patients with chronic hepatitis B with a
safety proﬁle comparable to LVD.
APASL/Poster/Abstract/215
Entecavir vs lamivudune and pegylated interferon vs lamivudine:
insights for treating chronic hepatitis B
Y. Shiratori1, M. Omata2, K. H. Han3, Y. F. Liaw4, G. Yao5,
B. Kreter6 and L. Pandey6
1Department of Gastroenterology & Hepatology, Okayama
University, Okayama, Japan,
2Department of Gastroenterology, Tokyo University, Bunkyo-
Ku, Tokyo, Japan,
3Severance Hospital, Yonsei University, Seoul, Korea,
4Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan,
5Shanghai Jingan Hospital, Shanghai, China,
6Bristol-Myers Squibb, Princeton, NJ, USA
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Introduction: Entecavir (ETV) and pegylated interferon a-2a
(pIFN a-2a) are approved treatments for chronic hepatitis B
(CHB): ETV is a nucleoside analog antiviral; pIFN is an
immunomodulator. Phase III trials for ETV, pIFN a-2a and
pIFN a-2b included lamivudine (LVD) as control or part of
combination treatment. Methods: This is a descriptive compar-
ison of ﬁve randomized studies. Among the ETV, pIFN a-2a,
and pIFN a-2b studies of HBeAg(1) patients, baseline HBV
DNA and ALT were comparable, while race and genotype
distributions varied. In the ETV and pIFN a-2a studies of
HBeAg( ) patients, baseline HBV DNA levels were compar-
able, while mean baseline ALT in the ETV trial was higher than
in the pIFN trial. The pIFN trial had more Asian and more
cirrhotic patients.
Results:
HBeAg(1)
Chang (2004)
Fried (2005)/
Lau (2004)
Janssen
(2005)
Endpoint
week
48–52
ETV
(n5 354)
LVD
(n5 355)
pIFN
a-2a
(n5 271)
LVD
(n5 272)
pIFN
a-2a
1LVD
(n5 271)
pIFN
a-2b
(n5 136)
pIFN
a-2b
1LVD
(n5 130)
HBV DNA
o400
copies/ml
(%)
69 38 25 40 68 10 33
HBeAg
seroconversion
(%)
21 18 27 20 24 22 25
ALT
o1.0 
ULN (%)
68n 60n ND ND ND 34 51
HBeAg( )
Endpoint
Week 48
Shouval (2004) Marcellin (2004)
ETV
(n5 325)
LVD
(n5 313)
pIFN a-2a
(n5 177)
LVD
(n5 181)
pIFN a-2a1LVD
(n5 179)
HBV DNAo400
copies/ml (%)
91 73 63 73 87
ALTo1.0 
ULN (%)
78n 71n 38 73 49
nBMS data on ﬁle. In HBeAg(1) and HBeAg(–) patients, histolo-
gical improvement favored ETV over LVD and pIFN.
Conclusions: For virologic endpoints and seroconversion, ETV
was comparable to pIFN a-2a1LVD, and ETV had a higher
proportion of patients with normalized ALT levels and histo-
logical response. LVD performed consistently among trials.
ETV monotherapy and pIFN a-2a1LVD had similar proﬁles
for treatment for CHB.
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APASL/Poster/Abstract/217
Adefovir Dipivoxil for treatment of breakthrough hepatitis caused
by lamivudine-resistant mutants of hepatitis B virus
Chun Kyon Lee, Jeong Hun Suh, Yong Suk Cho, Sun Young
Won, Byung Kyu Park and In Suh Park
Department of Internal Medicine, National Health Insurance
Corporation Ilsan Hospital, Koyang, Korea
Background/Aims: Adefovir dipivoxil (ADV) is a nucleoside
analogue that inhibits wild-type hepatitis B virus (HBV) and
lamivudine-resistant HBV mutants in vitro and in vivo. The aim
of this study was to evaluate the efﬁcacy of ADV against
lamivudine-resistant mutants. Patients and Methods: Twenty-
three patients with breakthrough hepatitis due to lamivudine-
resistant mutants were treated with ADV 10mg daily. We
regularly checked serum HBV DNA, HBeAgand liver function
tests including ALTand serum creatinine every 1–3 months to
evaluate the efﬁcacy and safety of ADV. Results: For 3 to 21
months, the rate of serum HBV DNA loss was 73.3%, 83%,
83% and 100% at 12, 24, 36 and 48 weeks, respectively. The
median serum HBV DNA level was decreased to 0.5 pg/ml from
baseline 247 pg/ml at 12 weeks. The rate of HBe Ag loss was
22.2% at 12 weeks. The rate of serum ALT normalization was
improved, extending the treatment duration by 30.7%, 67.6%,
80.0% and 87.5% at 4, 12, 24 and 36 weeks, respectively. The
median serum ALT level was decreased to 100, 43, 30, 31and
26 IU/l at 4, 12, 24, 36and 48 weeks, respectively, compared to
baseline 148 IU/l. Conclusions: Administration of ADV has
become an effective option for the treatment of patients with
lamivudine-resistant HBV infection.
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Clinical expression of C282Y homozygous HFE haemochroma-
tosis at age 14 years
E. Rossi1, D. F. Wallace2, V. N. Subramaniam2, T. G. St.
Pierre3, C. Mews4 and G. P. Jeffrey5
1Department of Clinical Biochemistry, PathCentre Nedlands,
Western Australia,
2Membrane Transport Laboratory, Cancer and Cell Biology
Division, Queensland Institute of Medical Research, Brisbane,
Queensland, Australia,
3School of Physics, University Of Western Australia, Nedlands,
Western Australia,
4St John of God Medical Clinic, Murdoch, Western Australia,
5Sir Charles Gairdner Hospital Unit, School of Medicine and
Pharmacology, University Of Western Australia, Nedlands,
Western Australia
Clinical symptoms of C282Y homozygous HFE-related haemo-
chromatosis usually manifest in the third to sixth decades of life.
If the onset of symptoms occurs before age twenty years, the
clinical course is typically more severe and is usually due to
mutations genetically distinct from HFE-related haemochroma-
tosis. Juvenile haemochromatosis, a much rarer disease than
HFE haemochromatosis, is characterised by endocrine and
cardiac dysfunction and has been associated with mutations in
either the hepcidin (HAMP) or hemojuvelin (HJV) genes.
Recent reports have also documented that co-inheritance of
mutations in either HAMP or HJV genes causes exacerbation of
phenotypic expression of HFE-related haemochromatosis. We
describe a case of C282Y homozygous HFE-related haemo-
chromatosis in whom clinical symptoms manifested at age 14
and who underwent screening for possible mutations in four
non-HFE haemochromatosis genes. The 14-year-old male pre-
sented with debilitating lethargy. Iron overload was demon-
strated by an elevated liver iron concentration of 59mmol/g
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(paediatric reference rangeo14) measured non-invasively using
proton transverse relaxation rate imaging. The early phenotypic
expression was further investigated by screening genomic DNA
for the presence of co-inherited mutations in genes responsible
for non-HFE haemochromatosis. Previously described muta-
tions in genes encoding hepcidin, hemojuvelin, ferroportin and
transferrin receptor were absent and we conclude that early
expression in this case was possibly controlled by novel muta-
tions or genes.
APASL/Poster/Abstract/220
Chronic hepatitis C (CHC) in patients with end-stage renal
disease on haemodialysis
S. S. Tan1, A. Abdulllah1, F. Mohamed Zawawi2, M. R. Abu
Hassan2 and I. Merican1
1Hospital Selayang, Batu Caves,
2Hospital Alor Star, Alor Star, Malaysia
Introduction: Hepatitis C infection is common in haemodialysis
(HD) patients. Methods: Medical records were reviewed. Data
are reported as mean, range and percentage. Results: Forty-ﬁve
patients (F:M5 15:30) with a mean age of 37.2 years and 55.6%
o40 years (18–59 years). The duration of HD to positive anti-
HCV was 4.6 years (0–18). HBsAg is negative in all of the 36
patients tested. The viral load was 4200 000 IU/ml in 43.6%
ando200 000 IU/ml in 56.4%. Patients with low viral load had
a mean of 40 011 IU/ml (643–19 100). The remaining six patients
had only HCVRNA qualitative tests, which were positive.
Genotyping was done on 25 patients, 76% genotype 1 and
24% genotype 3. ALT was persistently normal in 31.8% and
raised in 68.1% (ALT41 ULN5 50%,42 ULN5 13.6%,43
ULN5 4.5%). Forty had liver biopsy. The ﬁbrosis stage (mod-
iﬁed HAI) was 05 25%, 15 50%, 25 10%, 35 5%, 45 5%,
65 2.5% and not staged5 2.5%. The inﬂammatory grade was
grade 15 2.5%, 25 7.5%, 35 32.5%, 45 22.5%, 55 17.5%,
65 10%, 85 2.5%, 95 2.5% and not graded5 2.5%. Steatosis
was absent in 45%, mild in 37.5%, moderate in 5%, severe in
2.5% and not reported in 10%. Iron stain was reported in 32
biopsies, 10% had increased or minimal load and 70% had none.
Conclusions: This subgroup of CHC was infected after 4.6 years
of HD. HBV co-infection is uncommon. The main genotype is 1
and 43.6% have high viral load. Mildly raised ALT and high
inﬂammatory grade are common. Thepatients are young, 75%
had ﬁbrosis less than 2 and steatosis or iron overload is not
common.
APASL/Poster/Abstract/221
Hepatocellular carcinoma (HCC) in Malaysia: demography,
clinical features, outcome, and a comparison between the Malay
and Chinese
S. S. Tan, A. Abdullah and I. Merican
Hospital Selayang, Batu Caves, Selangor, Malaysia
Introduction: HCC is one of the top 10 cancers in Malaysian
males. Methods: We reviewed HCC cases admitted from April
2003 to December 2004. Sixty-seven of 75 patients have com-
plete data. Results: HCC was diagnosed by imaging with AFP
41000 ng/ml in 42% and two highly suspicious imaging in 58%.
The mean age was 55.4 years (16–81), male to female ratio was
3.16:1 and 58% were Chinese, 33% Malay, 4% Indian and 4%
others. The primary liver disease was 63% CHB, 15% CHC, 3%
anti-HBcore1, 4% co-infection, 6% alcohol and 9% non-B/C/
alcohol. The CPS were 39% A, 33% B and 28% C. The
radiological ﬁndings (n5 60) were 31.3% right lobe single
lesion, 16.4% right lobe multiple lesions, 2.9% left lobe single
lesion and 49.3% bilobar. 18.3% had main portal vein throm-
bosis. 19.4% were alive with mean follow-up 9.65 months (0.25–
23). 28.4% died in hospital at 5.5 months (0.35–18) and 52.2%
defaulted after 4.98 months (0.07–39). 8.9% had resection,
13.4% TACE, 4.5% PEI, 3% chemoinfusion, 1.5% microwave,
1.5% systemic chemotherapy and 67.2% palliative. Comparing
Chinese and Malay, the mean ages were 56.3 years and 55.8
years, respectively (P40.05) There were more male patients,
79.5% in Chinese and 63.6% in Malay (Po0.05). The etiology
in Chinese compared to Malay was 69.2%: 59.1% CHB, 10.3%:
27.3% CHC, 5.2%: none anti-HBcore1, 2.6%: 9% co-infec-
tion, 5.2%: none alcohol and 7.7%: 4.5% non B/C/alcohol. The
CPS for Chinese and Malay were 48.7%: 27.3% A, 28.2%:
45.5% B and 23.1%: 27.3% C (P5 0.003). 54.5% Malay and
43.6% Chinese have bilobar disease. Conclusions: HCC in
Malaysia is mostly associated with males, Chinese and
CHB. Disease at presentation was severe. Although the pre-
valence of HCC is higher in Chinese and similar mean age, the
Malay have more severe disease. These differences warrant
further study.
APASL/Free Paper/Abstract/222
Antiﬁbrotic effects of thalidomide on hepatic stellate cells and
dimethylnitrosamine-intoxicated rats
Lee-Won Chong1,2, Yi-Chao Hsuc3, Kuo-Ching Yang2 and
Yi-Tsau Huang3
1Graduate Institute of Clinical Medicine, School of Medicine,
National Yang-Ming University, Taipei, Taiwan,
2Division of Gastroenterology, Department of Internal Medi-
cine, Shin Kong Wu Ho- Su Memorial Hospital, Taipei,
Taiwan,
3Institute of Traditional Medicine, School of Medicine, Na-
tional Yang-Ming University, Taipei, Taiwan
Tumor necrosis factor alpha (TNFa) plays a central role in
cellular necrosis, apoptosis, organ failure, tissue damage, in-
ﬂammation and ﬁbrosis. These processes, occurring in liver
injury, may lead to cirrhosis. Thalidomide, a-N-phthalidoglu-
tarimide (C13H10N2)4, has been shown to have immunomodu-
latory and anti-inﬂammatory properties, which are possibly
mediated through its anti-TNFa effect. In this study, we
investigated the in vitro and in vivo effects of thalidomide on
hepatic ﬁbrosis. A cell line of rat hepatic stellate cells (HSC-T6)
was stimulated with transforming growth factor b1 (TGF b1) or
TNFa. The inhibitory effects of thalidomide (100–800 nM)
on the NFkB-signaling cascade and ﬁbrosis markers including
a-smooth muscle actin (a-SMA) and collagen, were assessed.
In vivo therapeutic study was conducted in DMN-treated rats,
which were randomly assigned to 1 of 4 groups : vehicle (0.7%
carboxyl methyl cellulose, CMC), thalidomide (40mg/kg), tha-
lidomide (200mg/kg), or silymarin (50mg/kg), each given by
gavages twice daily for 3 weeks starting after 1 week of DMN
administration. Thalidomide (100–800 nM) concentration-de-
pendently inhibited NFkB transcriptional activity induced by
TNFa, including IKKa expression and IkBa´ phosphorylation in
HSC-T6 cells. In addition, thalidomide also suppressed TGF-b1-
induced a-SMA secretion and collagen deposition in HSC-T6
cells. Fibrosis scores of livers from DMN-treated rats receiving
high doses of thalidomide (0.8910.20) were signiﬁcantly reduced
in comparison with DMN-treated rats receiving vehicle (1.561
0.18). Hepatic collagen contents of DMN rats were also signiﬁ-
cantly reduced by either thalidomide or silymarin treatment.
Immunohistochemical double staining results showed that a-
SMA and NFkB-positive cells were decreased in the livers from
DMN rats receiving either thalidomide or silymarin treatment. In
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addition, real-time PCR analysis indicated that mRNA expres-
sions of TGF b1, a-SMA, collagen 1a2 and iNOS genes were
attenuated by thalidomide treatment. In conclusion, our results
showed that thalidomide exerted anti-ﬁbrotic effects in both HSC-
T6 cells and in DMN-intoxicated rats.
APASL/Poster/Abstract/223
Primary hepatocellular carcinoma detected far behind tumor
markers and lymph node metastases – beyond our vision?
Jee-Fu Huang1, Kenichi Takayasu2, Shuichi Okada3, Kazuaki
Shimada4, Yukihiro Nakanishi5 and Masafumi Ikeda2
1Department of Internal Medicine, Fooyin University Hospital,
Pingtung, Taiwan,
2Department of Diagnostic Radiology, National Cancer Center
Hospital, Tokyo, Japan,
3Hepatobiliary and Pancreatic Oncology Division, National
Cancer Center Hospital, Tokyo, Japan,
4Hepatobiliary and Pancreatic Surgery Division, National Can-
cer Center Hospital, Tokyo, Japan,
5Department of Pathology, National Cancer Center Hospital,
Tokyo, Japan
The diverse manifestations of hepatocellular carcinoma (HCC)
often present difﬁculty in early diagnosis due to variability seen
by tumor markers, imaging modalities and clinical presenta-
tions. An asymptomatic 75-year-old man presented with ele-
vated alpha-fetoprotein (AFP) levels in spite of no evidence of
HCC in the liver on ultrasonography, helical CT, MR imaging
and CT angiography (CTA and CTAP). During an 18-month
follow-up, AFP and des-gamma-carboxy prothrombin levels
gradually increased and abdominal lymph nodes were detected
on dynamic CT. Surgical resection was performed and histo-
pathology revealed poorly differentiated HCC with lymph node
metastases (LM). Abrupt decrease of tumor markers was
recognized after surgery. However, postoperative recurrence of
LM, as well as repeat increase of tumor markers was recognized
7 months later. A tumor measuring 1 cm was ﬁnally detected
within the liver on CT one year after surgery. Overall, the times
from abnormal AFP level and LM to HCC detection were 38
and 22 months, respectively. We report the ﬁrst case of identi-
ﬁcation of primary HCC that emerged after LM. Additionally,
this reports the longest lag time between the appearance of
tumor markers and that of primary HCC. It suggests the
limitation of diagnostic modalities as well as the rare and/or
diverse presentations of HCC.
APASL/Free Paper/Abstract/224
Molecular analysis of lamivudine-resistant hepatitis B virus: a
report from Indonesia
Meta D. Thedja1, Suwignyo Sumoharjo2, Widodo1, Caecilia H.
Sukowati1, Martono Roni1 and David H. Muljono1
1Eijkman Institute for Molecular Biology, Jakarta, Indonesia,
2Biomedical Research Unit, Mataram General Hospital,
Mataram, Indonesia
Introduction: Lamivudine (LMV) is a potent antivirus against
hepatitis B virus (HBV). It inhibits reverse transcription and
causes termination of DNA synthesis. Extended treatment is
needed to maintain low viral load and results in higher HBeAg
seroconversion; but is also associated with increased rate of
LMV-resistant-HBV. rtM204 mutation in the YMDD motif, a
conserved region of the C domain in the P gene, is responsible
for LMV resistance. Here, we report the molecular character-
istics of the P gene of HBV DNA in Indonesian LMV non-
responders. Methods: Forty patients positive for HBsAg and
HBeAg with ALT 42ULN were treated with LMV 100mg/
day. Treatment was terminated at week 24 for patients showing
HBeAg seroconversion and normal ALT (group I), and ex-
tended 24 weeks for the others (group II). At week 48, patients
without HBeAg seroconversion and with ALT 42ULN from
group II and those from group I who relapsed were studied. The
P gene of HBV isolated from baseline and end-of-treatment sera
was sequenced and analyzed. Results: At week 48, rtM204V
(YVDD) mutant developed in 4 (10%), with rtL180M and
rtY141F mutations in three cases. One sample had YVDD
mutant at baseline. Other samples showed wt YMDD. Muta-
tions in other parts of the P gene and S gene also occurred in
some samples. Conclusion: rtM204V (YVDD) mutation oc-
curred in our LMV-resistant patients, some accompanied by
rtL180M and a novel rtY141F. This study conﬁrmed that
YMDD mutant may appear independent of LMV treatment,
and LMV resistance is not only due to YMDD mutation.
APASL/Young Investigator/Abstract/225
Genotype B of hepatitis B virus as a marker for Austronesian
population
Neni Nurainy1,2, David H. Muljono1, Herawati Sudoyo1 and
Sangkot Marzuki1
1Eijkman Institute for Molecular Biology, Jakarta, Indonesia,
2Research and Development Department, PT Bio Farma,
Bandung, Indonesia
Background: Genotypes of hepatitis B virus (HBV) have been
suggested as markers of population migration. In this study, we
have examined the distribution of subgenotypes of HBV geno-
types B and C (HBV/B and HBV/C) in the various populations
of the ethnically diverse Southeast Asian archipelago. We report
here the population association of certain subgenotypes, indi-
cating their ancient migration afﬁnity. Material and Method: A
total of 138 HBAg-positive samples were collected from asymp-
tomatic carriers of eight ethnic populations (Batak-Karo,
Dayak Benuaq, Kajang, Makasar, Mandar, Toraja, Alor and
Sumba) and from chronic hepatitis patients from Java and
Chinese ethnic populations of Indonesia. Phylogenetic trees
based on S and Pre-S2 sequences were constructed for genotyp-
ing. Genotype distribution was obtained also from the serotype–
genotype conversion of published Indonesian serotype data
(from 27 cities), and from sequence data obtained from the
Genebank for populations of mainland East Asia. Result: Gen-
otype B was dominant in Indonesia (73.9%), followed by C
(24.6%) and D (1.5%). The existence of subgenotypes of HBV/
B and their population association was conﬁrmed: Bei (East
Indonesia), Bwi (West Indonesia) and Bc (Chinese Indonesian).
Their distribution was consistent with the human ancient
migration pattern in the peopling of the Indonesian archipelago.
HBV/B was dominant in most regions of Indonesia inhabited by
populations speaking Austronesian languages. Dominance of
HBV/C was observed only in Papua, and the neighbouring
Austramelanosid populations. Conclusion: Results of this study
indicate that HBV/B is a marker for Austronesian population
migration, and the population distribution of subgenotypes Bwi
and Bei reﬂects the ancient migration pattern.
APASL/Poster/Abstract/226
The relationship between serotype and genotype of HBV: study of
the East Asian genotypes B and C
Neni Nurainy1,2, David H. Muljono1, Meta D. Thedja1 and
Sangkot Marzuki1
1Eijkman Institute for Molecular Biology, Jakarta, Indonesia,
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dung, Indonesia
Introduction: HBV is classiﬁed into four serological subtypes
(serotypes; adw, adr, ayw and ayr) based on antigenic determi-
nants of surface protein (HBsAg), and into eight genotypes (A–
H). Accumulating evidence suggests the clinical importance of
HBV genotypes and serotypes. The relationship between geno-
types and serotypes has been suggested, but controversies
exist. This study examined the genotype–serotype relationship
of the most common Asian genotypes, B and C. Material and
Method: A total of 110 HBsAg positive samples from various
populations of Indonesia were studied. HBV serotypes were
detected by ELISA, and DNA was sequenced for the PreS2 and
S regions. Genotypes were determined from sequence poly-
morphisms in these regions. Result: We discovered subgeno-
types of HBV genotype B (HBV/B), which are population
associated: Bei (East Indonesia), Bwi (West Indonesia) and Bc
(Chinese Indonesian). Strong correlations between serotypes
and genotypes were observed: serotypes adw to genotypes Bwi
and Bc, ayw1 to Bei, adr and ayr to genotype C, and ayw2 to D.
Certain anomalies were noted (e.g. HBV/B with adr [adr-B] and
HBV/C with adw [adw-C]) and the molecular basis was deter-
mined. adr-B was a result of mixed infection of HBV/B (adw)
and HBV/C (adr); cloning experiment detected more colonies of
HBV/B, but adr was dominant in serological assay. In the
second case, adw-C appeared due to alteration of aminoacid
160 changing r to w, and mutations P127T and C139W in the
vicinity of the a determinant of HBsAg. Conclusion: Strong
correlation between serotype and genotype/subgenotype was
discovered for HBV/B and HBV/C. The ability to convert
serotype data to genotype information would be useful for
further scientiﬁc and clinical studies.
APASL/Poster/Abstract/227
Serological proﬁle and hepatitis B infection in kindergarten
children previously vaccinated in a mass neonatal vaccination in
Mataram, Lombok Island
Syukrini Bahri1,2, Stephanus Gunawan3, Alida R. Harahap1,2,
Suwignyo Sumoharjo3,4, E. Y. Wenny Astuti3,4, David H.
Muljono1
1Eijkman Institute for Molecular Biology, Jakarta, Indonesia,
2Department of Clinical Pathology, Faculty of Medicine, Uni-
versity of Indonesia, Jakarta, Indonesia,
3Biomedical Research Unit, Mataram General Hospital, Ma-
taram, Indonesia,
4Department of Internal Medicine, Mataram General Hospital,
Mataram, Indonesia
Introduction: Following a WHO mass neonatal vaccination in
Lombok Island in 1987–1992, a nationwide hepatitis B vaccina-
tion has been implemented and incorporated into the existing
expanded program of immunization (EPI). The vaccination in
Lombok Island was given to babies at months 0, 1 and 2,
irrespective of the maternal HBsAg status. This study was
performed to evaluate the serological proﬁle and HBV infection
among the kindergarten students previously vaccinated in
Mataram, Lombok Island. Materials and methods: A total of
374 serum samples of kindergarten students aged 4–8 years from
Mataram were assayed for HBsAg, anti-HBs and anti-HBc.
Anti-HBc positive sera were tested for the presence of HBV
DNA by Qiaquick method. The S-region of HBV DNA was
ampliﬁed by nested-PCR, and sequenced and analyzed by
Bioedit and DNAstar softwares. Sera from several correspond-
ing mothers were also investigated. Result: Of 374 samples,
three were HBsAg positive, 280 were anti-HBs positive, and
eight were anti-HBc positive. Children with completed vaccina-
tion had a higher rate of anti-HBs and lower rate of anti-HBc.
All anti-HBc-positive samples were HBV DNA positive, some
with sequences identical to those of the mothers. DNA analysis
of one sample positive for both anti-HBs and anti-HBc revealed
mutations T126I and T143S in the S-gene, both with altered
Jameson–Wolf antigenicity index. Conclusion: HBsAg preva-
lence decreased after a mass vaccination under the EPI program.
Children with completed vaccination had better protection and
less HBV infection. HBV infection still happened despite the
vaccination; some resulted from vertical transmission, and one
was due to escape mutation with altered antigenicity.
APASL/Free Paper/Abstract/228
Viral factors determining ultra good response to 5-year lamivudine
treatment
M. F. Yuen1, D. K. H. Wong1, T. W. C. Leung2, D. Hendricks3,
A. K. C. Leung2, J. C. H. Yuen1, W. Lim2 and C. L. Lai1
1Department of Medicine, The University of Hong Kong,
Queen Mary Hospital, Hong Kong,
2Virology Division, Centre for Health Protection, Department
of Health, Hong Kong,
3Bayer HealthCare LLC, Berkeley, CA, USA
We aimed to determine factors associated with ultra good
response (UGR), deﬁned as HBV DNA ofo2000 copies/ml,
after 5-year lamivudine treatment. The HBV DNA levels at
baseline and various time points over 5 years were measured by
VERSANTs HBV DNA 3.0 assay (Bayer HealthCare LLC,
NY). Part of the nucleotide sequence of reverse transcriptase
(RT) and surface (S) genes were determined by TRUGENEs
HBV Genotyping Kit (Bayer HealthCare LLC). This is an
interim report for 28 out of 50 recruited patients (genotype
B:C 4:24). Eleven patients had UGR. Fifteen patients had
YMDD mutations at year 5 (one had no HBV DNA reduction
at any time point). There were no differences in the baseline
HBV DNA levels (median 8 log copies/ml) between patients
with and without UGR. The patient without HBV DNA
reduction had a baseline S256C mutation at the RT gene
(Ciancio et al, Hepatology 2004). Of the 11 patients with
UGR, two had transient development of YMDD mutations.
Both patients had concurrent mutations at the S gene (L229V
and L229S). The HBV DNA levels of one of them did not drop
below 3  105 copies/ml even with wild-type HBV but de-
creased to 5482 copies/mL when the YMDD mutants disap-
peared. The number of patients with HBV DNA levels
104 copies/ml at different time points are as follows:
Week
2 4 8 12 16 24 48
Patients with UGR (n5 11) 0 3 3 4 5 5 9
Patients without UGR (n5 17) 0 0 0 0 2 3 1
S256C mutation might be associated with poor primary re-
sponse. Patients achieving HBV DNA104 copies/ml at week 12
will have UGR. This prediction could be generalized to the
majority of patients at week 48. Development of YMDD
mutations did not preclude subsequent UGR.
APASL/Poster/Abstract/229
Was the hepatic venous pressure gradient (HVPG) really in-
creased in acute variceal bleeding patients with cirrhosis?
J. B. Kim, T. H. Kim, S. W. Song, T. H. Han, G. H. Baik and
D. J. Kim
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Department of Internal Medicine, Chuncheon Sacred Heart
Hospital, Hallym University, Chuncheon, Korea
March 2004 to March 2005, in order to ascertain whether portal
pressure is really increased in acute variceal bleeding patients, we
measured the HVPG in cirrhotic patients who were admitted to
our hospital because of variceal bleeding and other causes of
cirrhotic complications. With the variceal bleeders, HVPG was
measured after stabilization of vital signs and proper medical
treatment and after resolution of the main cause of admission
with non-variceal bleeders. Of all the 50 patients (M/F:44/6, mean
age 55.3  25.1 years), the causes of cirrhosis were alcohol, HBV,
HCV, alcohol and HBV, and cryptogenic in 29, 8, 3, 5, and 5
patients, respectively. 17 of them were variceal bleeders, and
remained 33 were non-variceal bleeders, in whom the causes of
admission were ascites, hepatic encephalopathy, spontaneous
bacterial peritonitis, ulcer bleeding, worsening of liver function,
and nonspeciﬁc GI symptoms. Between both groups, there was
no statistically signiﬁcant difference in vital signs, serum hemo-
globin concentration, Child–Pugh score, andMELD score. In the
endoscopic workup, F3 varices were more common in variceal
bleeders than in non-variceal bleeders (64.7% vs 33.3%,
P5 0.019). Despite the HVPG being correlated with the Child–
Pugh score (r5 0.552, P5 0.000) and MELD score (r5 0.489,
P5 0.000), there was no statistically signiﬁcant difference in the
HVPG between variceal and non-variceal bleeders (14.53  7.29
vs 14.88  6.74, P5 0.867). This study suggests that other causes
of variceal bleeding, except increased portal pressure, may be
present. But because this study might not reﬂect the accurate
HVPG just before the bleeding, a prospective, large randomized
controlled cohort study is needed.
APASL/Poster/Abstract/230
Budd–Chiari syndrome: a tertiary care hospital experience from
Pakistan
Shahid Rasool, Zaigham Abbas, Khalid Mumtaz, Ashfaq
Ahmed and Wasim Jafri
Department of Medicine, AKUH Karachi, Pakistan
Introduction: Budd–Chiari syndrome (BCS) is a rare disorder
that is characterized by hepatic venous outﬂow obstruction.
Patients with BCS carry poor prognosis without deﬁnitive
treatment such as portal decompressive surgery, TIPS or liver
transplantation. There is no data regarding its presentation and
outcome from Pakistan. Methods: We retrospectively studied
the clinical presentation and outcome of patients with the BCS
admitted to our hospital between 1994 and 2004. Diagnosis was
made on the basis of clinical presentation and imaging studies,
revealing occlusion of the hepatic veins. RESULTS: Only 19
patients, eight (42%) males with a mean age 28.9  9.0 years
were found. Presentation was acute in six (31.5%), sub acute in
seven (37%) and chronic in six (31.5%). Pedal edema in 17
(90%), ascites in 16(84%), right upper quadrant pain and
discomfort in 16 (84%), jaundice in 11 (58%), encephalopathy
in four (21%) and upper GI bleeding in three (16%) were the
main presentations. Imaging studies demonstrated hepatome-
galy in 17 (90%), caudate lobe hypertrophy in 17 (90%), ascites
in 17 (90%) splenomegaly in 11 (58%), intra-abdominal collat-
erals in nine (47%) and portal vein thrombosis in three (16%)
cases. Three patients received anti-coagulation therapy; three
were subjected to angiography, stenting and TIPS while thirteen
patients were managed conservatively. Two patients are alive
while 17 patients are dead, with a median survival of 8 weeks
(mean5 52.5  97.4 weeks). One-month survival was only 34%
with acute presentation compared to 71.5% with sub-acute
presentation and 67% with chronic presentation. Univariate
analysis showed that encephalopathy (P5 0.04) and
hypo-albuminemia (P5 0.02) were bad prognostic factors.
Conclusion: The Budd–Chiari syndrome is uncommon in our
part of the world with poor prognosis in the absence of deﬁnitive
therapeutic options. Encephalopathy and hypo-albuminemia at
presentation are poor prognostic factors.
APASL Bali/Poster/Abstract/231
Detection of hepatitis B virus precore mutant in chronic hepatitis
B patients in pekanbaru (preliminary report)
A. Zainal1, Arﬁanti2, R. Endriani3 and W.A. Fidiawati4
1Department of Internal Medicine, Faculty of Medicine, Uni-
versity of Riau,
2Department of Medical Biology, Faculty of Medicine, Uni-
versity of Riau,
3Department of Microbiology, Faculty of Medicine, University
of Riau,
4Department of Pathology and Anatomy, Faculty of Medicine,
University of Riau
Background: Chronic hepatitis B infection is still one of the
serious public health problem in Indonesia. Chronic hepatitis B
patients have an increased risk for the development of liver
cirrhosis and hepatocellular carcinoma. Hepatitis B e antigen
(HBe Ag) is a marker of hepatitis B virus (HBV) replication in
the liver cells and seroconversion to antibodies to HBeAg (anti-
HBe) usually accompanied by cessation of HBV replication and
remission of liver disease. However in some patients with
chronic hepatitis B infection were reported to have Hbe-negative
but still have HBV replication due to HBV precore mutants.
Objective: The aim of this study was to assess the prevalence of
HBV precore mutants in chronic hepatitis B patients and its
association with chronic hepatitis B clinical manifestation.
Methods: Thirty-four subjects with chronic active hepatitis B
infection and 21subjects with asympthomatic hepatitis B infec-
tion were studied. The study consisted of isolation DNA HBV
from sera and ampliﬁcation of precore region by nested poly-
merase chain reaction (nested-PCR) method. Determination of
precore HBV mutants were carried out by RFLP method.
Result: This study is still in progress. Temporary results show
that HBV DNA was found in 82% of chronic active hepatitis B
patients and 57% of asympthomatic hepatitis B patients. HBV
precore mutants were detected in 96% of chronic active hepatitis
B patients and 67% of asympthomatic hepatitis B patients.
Conclusion: The prevalence of HBV precore mutants in chronic
hepatitis B infection in Pekanbaru was 64%. Further studies
and more samples are needed to determine the association
between HBV precore mutants and chronic hepatitis B clinical
manifestation.
APASL/Young Investigator/Abstract/232
Primary biliary cirrhosis: study of a Singaporean population –
demographics, prognosis and factors involving progression
R. K. M. Wong, L. I. M. Seng-Gee, Y. H. Chan, Myat-Oo
Aung, J. L. Khor and C. T. Wai
Department of Medicine (Gastroenterology Division), National
University Hospital, Singapore
Introduction: Primary biliary cirrhosis (PBC) is a rare disease.
Most natural history studies were performed in Caucasians and
studies among Asians are rare. We aimed to evaluate the natural
history of PBC among Asian patients at our tertiary liver center.
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Methods: All patients with PBC followed at our institution
from 1990 till 2005 were reviewed. Their demographics, bio-
chemical, histology data, and natural history were analyzed.
Factors including demographics, baseline and change of labora-
tory markers were evaluated for their association with hepatic
decompensation. Multivariate analysis was not performed due
to the small number of subjects and multicollinearity amongst
the clinical predictors. Results: Thirty-two patients with PBC,
mean  SD (range) age of 55.1  10.7 (26.7–79.8) years were
identiﬁed, of whom 31 (97%) were female and 29 (91%)
Chinese. Sixteen (50%) were asymptomatic at diagnosis, 14
had bone mineral densitometry performed with a mean T-score
of  1.79 (spine) and  1.99 (hip), and AMA was positive in 26
(81%). Duration of follow-up was 5.3  4.4 (0.02–5.1) years,
and ﬁve (15.6%) had an event of hepatic decompensation within
5 years and at the end, a total of 10 (31%) within 10 years.
Kaplan–Meier analysis showed a mean 9.94 (95% CI, 7.6–12.3)
with median 8.7 years to hepatic decompensation. Signiﬁcant
predictors upon univariate analysis were initial s.bilirubin (14.8
vs.77.6 mmol/l, Po0.001), prothrombin time (11.7 vs.14 s,
P5 0.008), s.albumin (38.3 vs. 31.8 g/l, Po0.001), s.ALP
(271.7 vs. 571.8U/l, P5 0.005) and HDL levels (1.73
vs.0.66mmol/l, P5 0.01) between stable patients and those
with decompensation. Interestingly, rate of change of labora-
tory indices was not a signiﬁcant predictor. Conclusions: The
demographics of PBC in Singapore mirrored the populace’s
ethnic make-up, with a preponderence for females of middle-age
and the rate of decompensation at 5 and 10 years being 15.6%
and 31%. Initial bilirubin, prothrombin time, albumin, ALP
and HDL levels at time of diagnosis have promise as prognostic
indicators for an adverse outcome.
APASL/Poster/Abstract/233
New prognosis prediction system for liver transplantation in
patients with fulminant hepatic failure
Y. Miyake, K. Sakaguchi, R. Terada, A. Takaki, Y. Iwasaki,
H. Kobashi and Y. Shiratori
Department of Gastroenterology & Hepatology, Okayama
University Graduate School of Medicine and Dentistry,
Okayama, Japan
Many patients with fulminant hepatic failure die before receiv-
ing liver transplantation because of the difﬁculty of pinpointing
suitable timing for liver transplantation. The aim of this study
was to establish a new prognostic scoring system useful for
predicting the timing of liver transplantation. The ﬁrst sample
group consisted of 80 patients. We examined 2-week poor
prognostic parameters at the diagnosis of fulminant hepatic
failure (day 1) and on days 4, 8, and 15, and a 2-week prognostic
scoring system was constructed. In order to conﬁrm the accu-
racy of this scoring system, validation was performed in a
second sample group consisting of 26 patients. By using a
stepwise multiple linear regression analysis, the cause of FHF
(hepatitis B virus or indeterminate), hepatic coma grade (III or
IV), systemic inﬂammatory response syndrome (yes) and ratio
of total to direct bilirubin (42.0) were found to be associated
with a 2-week fatal outcome during days 1 to 15. These four
parameters were elicited and scored as11 in this model. The 2-
week survival rate in patients with scoreso3 was 80% in
contrast to less than 30% in patients with scores 3. When this
scoring model was applied to the second sample group, the
sensitivity, speciﬁcity, and positive and negative predictive
values were 87.5%, 90.0%, 93.3%, and 81.8%, respectively.
This 2-week prognostic scoring system may be useful for
predicting a 2-week outcome and determining suitable timing
for liver transplantation.
APASL/Poster/Abstract/234
Regulation of hepatitis B virus X protein expression using
doxycycline-inducible gene expression system
Hong Tang1, Feijun Huang2, Li Liu1, Fang He1, Taoyou Zhou1,
Yong Lin1 and Liansan Zhao1
1Center of Infectious Diseases, Division of Molecular Biology of
Infectious Diseases, State Key Laboratory of Biotherapy (Si-
chuan University), West China Hospital of Sichuan University,
Chengdu, China,
2Department of Forensic Pathology, Medical School of Basic
and Forensic Sciences, Sichuan University, Chengdu, China
Background: Hepatitis B virus X protein (HBx) is a multi-
functional protein, which may play an important role in HBV-
associated pathogenesis, especially hepatocarcinogenesis.
The functions of HBx have been shown to be related to
its location and level of expression. Objective: To establish
in vitro cell line with stable, effective and regulatable HBx
expression using a doxycycline (Dox)-inducible gene expression
system. Methods: A doxycycline-inducible retroviral plasmid
(pBPSTR3-FlagX) was constructed by replacing the tetracy-
cline-controlled transcriptional activator (tTA) gene in
pBPSTR1 with the reverse tTA (rtTA) gene and inserting of
the HBV X gene. Doxycycline-regulated expression of Flag-
HBx in transient transfected HepG2 and Hep3B cells were
analyzed by Western blot. Doxycycline-regulated transactiva-
tion function of HBx was also measured with luciferase reporter
gene assay. Stable HBx expression HepaG2 cell clones were
established through screening with puromycin. Results: The
doxycycline-inducible recombinant plasmid (pBPSTR3-FlagX)
containing the full-length HBV X gene and all the components
of the tetracycline-on (Tet-on) gene expression system was devel-
oped successfully. Expression studies with this vector showed a
Dox dose-dependent induction of Flag-HBx protein expression in
HepG2 and Hep3B cells. The transactivation function of HBx
was also achieved in HepG2 cells in a Dox dose-dependent
manner. After transfecting HepG2 cells with pBPSTR3-FlagX
plasmid, ﬁve puromycin-resistant cell clones with stable HBx
expression were obtained, and two clones showed stable and tight
control of HBx expression by doxycycline.
Conclusion: The doxycycline-inducible HBx expression system
was developed and a stable cell line with effective and regula-
table HBx protein expression was established in this study. The
quantitative regulatory property of this system ensures its great
potential in the functional studies of the HBV X gene. This work
was supported by the National Science Fund for Distinguished
Young Scholars from the National Natural Science Foundation
of China, No. 30325036
APASL/Plenary/Abstract/235
Study on the role of liver-enriched transcription factors in
regulating HBV transcription and replication
Hong Tang1, Song Wang2, Fang He1, Li Liu1, Feijun Huang3,
Taoyou Zhou1, Liansan Zhao1 and Bingjun Lei1
1Center of Infectious Diseases, Division of Molecular Biology of
Infectious Diseases, State Key Laboratory of Biotherapy (Si-
chuan University), West China Hospital of Sichuan University,
Chengdu, China,
2Donghu Hospital, Shenzhen, China,
3Department of Forensic Pathology, Medical School of Basic
and Forensic Sciences, Sichuan University, Chengdu, China
Background: Hepatitis B virus (HBV) replicates by reverse
transcription of the 3.5-kb viral pregenomic RNA. Therefore,
the regulation of the transcription of the pregenomic RNA is a
critical step in the viral life cycle. Objective: To investigate the
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effects of various liver-enriched transcription factors in regulating
HBV transcription and replication, and explore their potential
roles in HBV hepatotrophism. Methods: The replication-compe-
tent HBV recombinant plasmid pHBV4.1 plus different liver-
enriched transcription factor (HNF1, HNF3, HNF4, HNF6, C/
EBP and RXRa/PPARa) expression plasmids were transfected
into nonhepatic cell lines (NIH3T3, HeLa, 293T, SW1353, CV-1
and COS1). The transcription levels of 3.5-kb, 2.4/2.1-kb, 0.7-kb
HBV RNA and HBV replication intermediate DNA were ana-
lyzed by Northern and Southern blot hybridization. Results: In
the absence of cotransfected liver-enriched transcription factor
expression vectors, the 3.5-kb HBV RNA is not transcribed and
HBV DNA replication is not detected after transfecting of NIH
3T3 cells with pHBV4.1. Expression of the liver-enriched tran-
scription factor HNF4 or RXRa/PPARa stimulates transcription
of the 3.5-kb HBV RNA and replication of the HBV DNA. In
contrast, expression of HNF1, HNF3, HNF6 and C/EBP does
not stimulate transcription of the 3.5-kb HBV RNA and there-
fore does not activate viral replication. HNF4 and RXRa/
PPARa were also shown to activate transcription of the 3.5-kb
HBV RNA and viral replication in diverse cell types including
HeLa, 293T, SW1353, CV-1 and COS1 cells. Mutation of the
proximal nucleocapsid HNF4-binding site results in a greatly
decreased level of HNF4 or RXRa/PPARa-dependent HBV
replication. Conclusion: This study demonstrated that the liver-
enriched transcription factors HNF4 and RXRa/PPARa can
support HBV transcription and replication in nonhepatic cells,
indicating liver-speciﬁc gene transcription is one of the determi-
nants of HBV hepatotropism. This work was supported by the
National Science Fund for Distinguished Young Scholars from
the National Natural Science Foundation of China, No.
30325036
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Screening of oesophageal varices with platelet count/spleen dia-
meter ratio in patients with liver cirrhosis
Mabel H. M. Sihombing, Robinson Manurung, Leonardo
Dairi, Gontar Siregar, Juwita Sembiring, Betthin Marpaung,
Sri Soetadi, Lukman Hakim Zain and Pengarapen Tarigan
Division of Gastroentero-Hepatology, Departement of Internal
Medicine/Faculty of Medicine University of North Sumatra, H.
Adam Malik Hospital, Medan, Indonesia
Background and Aim: Portal hypertension commonly accom-
panies the presence of liver cirrhosis, and the development of
oesophageal varices (OV) is one of the major complications of
portal hypertension The prevalence of OV in patients with liver
cirrhosis may range from 24% to 80%, and the reported
mortality from variceal bleeding ranges from 17% to 57%;
therefore, endoscopic screening of OV is recommended in
patients with liver cirrhosis. As endoscopy units and endosco-
pists are not well distributed in hospitals in our country, platelet
count/spleen diameter ratio might be a non-endoscopic tool to
predict the presence of OV in patients with liver cirrhosis.
Methods: We evaluated all the 75 liver cirrhosis patients with
complete biochemical work-up, upper digestive endoscopy,
ultrasonographic measurement of spleen bipolar diameter. Pla-
telet count/spleen diameter ratio was calculated for all patients.
Result: The prevalence rates of OV were 88%. A platelet count/
spleen diameter ratio with a cut off value of 967 had 98.5 %
sensitivity, 88.9% speciﬁcity, 98.5% positive predictive
value, 88.9% negative predictive value and had 8.9 in positive
likelihood ratio and 0.02 in negative likelihood ratio.
Conclusion: Platelet count/spleen diameter ratio could be a
non-endoscopic tool to predict the presence of OV in patients
with liver cirrhosis.
APASL/Poster/Abstract/239
The correlation of anemia parametric with the severity of liver
cirrhosis
Leonardo Dair1, Ida Nancy1, Gontar Siregar1, Juwita Sembir-
ing1, Mabel Sihombing1, Betthin Marpaung1, Sri Sutadi1,
Abiran Nababan1, Lukman H. Zain1, Pengarapen Tarigan1
and Azmi S. Kar2
1Division of Gastroentero-Hepatology,
2Division of Haematology, Department of Internal Medicine,
University of North Sumatra/H Adam Malik Hospital, Medan,
Indonesia
Background: Anemia is a lower than normal hemoglobin in the
blood and is frequently found in liver cirrhosis. The causes of
anemia in liver cirrhosis patients were of multifactorial character
such as suppression of erythropoiesis by alcohol as well as folate
deﬁciency, hemolysis, hypersplenism, and insidious or overt blood
loss from the gastrointestinal tract. Aim of the Study: To study
anemia in liver cirrhosis patients and the correlation of anemia,
including iron deﬁciency anemia and hemolytic anemia, with the
severity of liver cirrhosis patients. Material and Method: The
study was done cross-sectional in 37 liver cirrhosis patients during
June 2003–April 2004. Child–Pugh score was calculated and we
studied anemia parametrics such as hemoglobin, hematocrit,
MCV, MCH and MCHC. Iron deﬁciency anemia examination
by transferrin, feritin serum and hemolytic anemia examination
was done with reticulocyte count.Result: Anemia was found in 28
(76%) patients, 10 (27%) patients with transferrin o16%, three
(8.1%) patients with feritin serumo12% and two (5.4%) patients
with reticulocyte count41.5%. There was no correlation between
degree of anemia, MCV, MCH, MCHC and hemolytic anemia
with the severity of liver cirrhosis. There was correlation only
between iron deﬁciency anemia with the severity of liver cirrhosis
patients (P5 0.0001). Conclusion: Anemia occurred in about
76% cirrhosis hepatic patients and was not correlated with
severity of liver cirrhosis. There was correlation of iron deﬁciency
anemia with the severity of liver cirrhosis. There was no correla-
tion of hemolytic anemia with the severity of liver cirrhosis
APASL/Poster/Abstract/240
The level of thrombopoietin serum in liver cirrhosis patients and
correlation with the severity liver cirrhosis
Juwita Sembiring, Fransiskus Ginting, Leonardo Dairi, Mabel
Sihombing, Betthin Marpaung, Abiran Nababan, Lukman H.
Zain and Pengarapen Tarigan
Division of Gastroentero-Hepatology, Department of Internal
Medicine, University of North Sumatra/H Adam Malik Hospi-
tal, Medan, Indonesia
Background: Thrombopoietin is a thrombopoietic factor
mainly synthesized in the liver. Its production will be decreased
related to the severity of liver disease. Impaired production
thrombopoietin may be responsible for thrombocytopenia in
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liver cirrhosis patients. Aims: To measure serum thrombopoie-
tin levels and to examine the relationship between serum
thrombopoietin concentration and clinical stage of the disease
in patients with liver cirrhosis (Child–Pugh criteria).Method: A
prospective cross-sectional analytic study was conducted invol-
ving 35 liver cirrhosis patients and 39 healthy volunteers. Serum
thrombopoietin levels were measured by enzyme-linked immu-
nosorbent assay. Results: Mean serum thrombopoietin level
was (84 229  44 857) pg/ml in the cirrhotic patients group and
(116 269  75 978) pg/ml in the healthy group (P5 0.033).
In patients with liver cirrhosis serum thrombopoietin levels
were found to be decreased as the disease progressed:
(101  44 455) pg/ml in patients at Child–Pugh stage A,
(98 638  53 058) pg/ml in patients at Child–Pugh stage B and
(57 785  18 957) pg/ml in patients at stage C with P5 0.868
compared thrombopoietin level Child-Pugh stages A and B,
P5 0.019 compared thrombopoietin level Child–Pugh stages A
and C and P5 0.016 compared thrombopoietin level Child–
Pugh stages B and C. Conclusion: The ﬁndings revealed that
serum TPO levels were decreased as degree of cirrhosis pro-
gressed. The impaired production of thrombopoietin may con-
tribute to the development of thrombocytopenia in advanced
liver disease.
APASL/Poster/Abstract/241
Plasma prothrombin time as a diagnostic tool of esophageal
varices due to liver cirrhosis
Hirlan
Gastroenterology Division, Department of Internal Medicine, Di-
ponegoro University, Dr Kariadi Hospital, Semarang, Indonesia
Background: To diagnose esophageal varices (EV) among liver
cirrhosis (LC) patients we usually used endoscopy, but it is not
practical if only the diagnosis of EV serial endoscopy has to be
performed. This study investigated the accuracy of plasma
prothrombin time (PPT) as a tool for VE detection among LC
Methods: In all, 93 patients with LC were allocated to the VE-
positive group (47) and VE-negative group. (46). The diagnosis
of LC was based on clinical, laboratory and ultrasonography
examination. EV was diagnosed by endoscopy and done on the
same day that the liver function test was performed. Diagnostic
test and w2 test were used for statistical analysis. Result: Ab-
normal PPT deﬁned as gradient in patients and controls 4 s or
longer were found in 37 out of 47 patients of the VE-positive
group compared with only seven out of 46 patients of the VE-
negative group (Po0.005). The sensitivity was 78.7% and
speciﬁcity 84.7%. If we use abnormal PPT of 7 s or longer as
the cut off point, the speciﬁcity will be more than 95%.
Conclusion: PPT is a good diagnostic tool for esophageal
varices due to LC.
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Factors to affect serum levels of adipokines in Korean male
patients with nonalcoholic fatty liver disease
S. Y. Oh1, W. Y. Lee1, Y. K. Cho1, B. I. Kim1 and K. W. Oh2
1Department of Internal Medicine, Kangbuk Samsung Hospi-
tal, Sungkyunkwan University School of Medicine, Seoul,
Korea,
2Department of Internal Medicine, College of medicine, Hallym
University, Pyungchon, Korea
Adipokines is known to be associated with metabolic disorders
such as insulin resistance, obesity, and dyslipidemia. The meta-
bolic disorders were also reported to be related with nonalco-
holic fatty liver disease (NAFLD). We aimed to ﬁnd the
relationship between serum adipokine levels and the degrees of
hepatic fat inﬁltration in NAFLD. We also tried to determine
independent factors to inﬂuence the serum adipokine levels in
NAFLD. 65 Korean male patients were classiﬁed into three
groups: Group I: normal liver, Group II: mild fatty liver and
Group III: moderate to severe fatty liver. All subjects were
measured for anthropometric parameters, fasting serum adipo-
kine levels including leptin, adiponectin and resistin. Insulin
resistance was estimated by HOMA-IR. Serum leptin levels
increased with the degree of fatty inﬁltration with signiﬁcance
(mean  SD: Group I; 2.052  1.071, Group II; 2.879  1.016,
Group III; 4.457  1.965 ng/ml, Po0.001), whereas serum
adiponectin and resistin levels were not signiﬁcantly different.
BMI and HOMA-IR were independent factors only for changes
in serum leptin levels (P5 0.029, P5 0.001, respectively), but
not for serum adiponectin and resistin levels. Our study sup-
ports an indirect role for leptin in the pathogenesis of NAFLD,
but not for adiponectin or resistin. BMI and HOMA-IR were
the only independent factors inﬂuencing the serum leptin con-
centrations.
APASL/Poster/Abstract/247
Relations between coagulation parameters and portal vein throm-
bosis in hepatocellular carcinoma
J. W. Yun1, Y. K. Cho2, S. Y. Oh2 and B. I. Kim2
1Department of Internal Medicine, Armed Forces Capital
Hospital, Kyeonggi, Korea,
2Department of Internal Medicine, Kangbuk Samsung Hospi-
tal, Sungkyunkwan University School of Medicine, Seoul,
Korea
Portal vein thrombosis (PVT) is an important complication and
a prognostic factor in cirrhosis and HCC. Although PVT is
mostly associated with portal vein invasion by HCC, the
development of PVT has been reported in association with the
imbalance between clotting activators and inhibitors. The pur-
pose of this study was to evaluate the correlation between
coagulation parameters and PVT in HCC. We divided the
cirrhotic patients ( Child–Pugh Class, B) into three groups:
only cirrhosis (Group A, n5 17), HCC without PVT (Group B,
n5 14) and HCC with PVT (Group C, n5 8). Demographic
information and coagulation parameters (platelet, prothrombin
time, ﬁbrinogen, prothrombin, factor V, VII, IX, X, protein C/S
antigen/activity, lupus anticoagulant, antithrombin III, plasmi-
nogen, tissue type plasminogen activator (tPA), D-dimer, plas-
minogen activator inhibitor type-1 (PAI-1) were compared
between the three groups. Age and aFP level were signiﬁcantly
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higher in HCC with PVT. But, coagulation parameters did not
show any signiﬁcant difference among the groups. The prog-
nosis of HCC is highly dependent on the extent of tumor
invasion and residual liver function. In addition, this study
showed that age and aFP level were highly associated with the
prognosis of HCC with PVT. But the relation between coagula-
tion parameters and PVT did not show any statistical associa-
tion because of the limitation of sample size.
APASL/Free Paper/Abstract/248
Grafts from older donors are associated with decreased recipient
survival after liver transplantation for hepatitis B-related liver
disease
D. Y. Kim, M. S. Choi, K. C. Koh, S. W. Paik, J. H. Lee and
B. C. Yoo
Division of Gastroenterology, Samsung Medical Center, Sung-
kyunkwan University School of Medicine, Seoul, Korea
Introduction: It remains unclear whether donor age inﬂuences
recipient survival in liver transplantation (LT) for hepatitis B
virus (HBV)-related liver diseases. We assessed the effect of
donor age on post-LT outcomes and recipient survival in
patients with HBV infection. Patients and Methods: A total of
217 patients underwent LT for HBV-related liver diseases from
January 1996 to April 2004. Recipients were divided into two
groups according to donor age: older donor group (donor age 40
years, n5 67, median age5 45) and younger donor group (donor
ageo40 years, n5 150, median age5 27). Post-LT outcomes and
patient survival were compared. Results: Baseline characteristics
of recipients (sex, age, MELD score, presence of HCC, HBeAg
positivity, HBV DNA level) and transplantation factors (graft
type, cold/warm ischemia time and graft volume) were similar in
the two groups. Acute rejection occurred in 17.9% of the older
donor group and in 14.7% of the younger donor group
(P5 0.55). The mean ALT at 4 months after LT was similar
(63 IU/l vs. 49 IU/l, P5 0.32). Recurrent HBV infection was
observed in 13.4% of the older donor group and in 6.7% of
the younger donor group (P5 0.12). One- and 5-year survival
rates of the older donor group (76% and 56%) were signiﬁcantly
lower than those of the younger donor group (88% and 80%,
P5 0.02). Hepatic failure was the more common cause of death
in the older donor group, than in the younger donor group (9.0%
vs. 2.0%, P5 0.03). Conclusions: These ﬁndings suggest that
grafts from older donors can be associated with decreased
recipient survival after LT for HBV-related liver diseases.
APASL/Poster/Abstract/249
Usefulness of Milan and UCSF criteria to predict outcomes of
liver transplantation in hepatocellular carcinoma patients receiv-
ing prior transarterial chemoembolization
D. Y. Kim, M. S. Choi, S. W. Paik, J. H. Lee, K. C. Koh and
B. C. Yoo
Division of Gastroenterology, Samsung Medical Center, Sung-
kyunkwan University School of Medicine, Seoul, Korea
Introduction: It remains unclear whether the Milan and/or
UCSF criteria are still valid in hepatocellular carcinoma
(HCC) patients who have received transarterial chemoemboli-
zation (TACE) before liver transplantation (LT). Hence, we
assessed the usefulness of Milan and UCSF criteria in HCC
patients receiving prior TACE, compared with those without
any treatment for HCC before LT. Patients and Methods: From
September 1996 to April 2004, LT was done in 40 HCC patients
who had received prior TACE (TACE-LT group) and in 40
without any previous treatment for HCC (LT group). The
numbers of patients fulﬁlling Milan and UCSF criteria were
36 and 34 in the TACE-LT group, and 33 and 30 in the LT
group. Post-LT outcomes and survival rate were compared
between the patients within the criteria from the two groups.
Results: Baseline characteristics, such as age, sex, etiology of
liver diseases, a-fetoprotein level, MELD score, and graft type
were similar in the two groups. The tumor proﬁles of patients
fulﬁlling Milan and UCSF criteria in each group were also
similar. No signiﬁcant differences were found in post-LT 60-day
mortality (5.6% vs. 12.1%, P5 0.42) and in HCC recurrence
rate (5.6% vs. 6.1%, P5 0.93). Five-year survival rate of
patients fulﬁlling Milan criteria in each group was 65% and
71%, respectively (P5 0.54). Five-year survival rate of patients
fulﬁlling UCSF criteria in each group was 65% and 72%,
respectively (P5 0.73). Conclusion: The Milan and UCSF cri-
teria are useful criteria to predict favorable post-LT outcomes in
HCC patients receiving prior TACE as well as those without
previous anti-cancer treatment.
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DNA-based immunization increased the survival rate of mice
loaded with HBV preS2S antigen expressing myeloma cells
Fang He, Hong Tang, Lian-San Zhao, Li Liu, Tao-You Zhou,
Chong Liu and Bing-Jun Lei
Center of Infectious Diseases, West China Hospital of Sichuan
University; Division of Molecular Biology of Infectious Dis-
eases, State Key Laboratory of Biotherapy (Sichuan Univer-
sity), Chengdu, Sichuan, China
Background: DNA vaccine can induce cell-mediated immunity,
especially CTL responses. It may be a potential therapy for
chronic hepatitis B virus (HBV) infection. We established a
mouse model here, which loaded a myeloma stably expressing
HBV preS2S antigen. This model mimics the status of liver when
it infects HBV chronically. The cells of the myeloma were used
as the targets of the CTL in vivo. Objectives: The goal of this
study was to investigate if the DNA vaccine could increase the
survival rate of the mice model and to observe its probably
therapeutic effects for chronic HBV infection. Methods: The
SP2/O-S2S cell line with stably expressed HBV preS2S was
obtained by transfecting pCMV-S2S into SP2/O cells. BALB/c
mice were subcutaneously inoculated with SP2/O-S2S cells into
the bilateral ﬂanks. One week after loading of the cells, the mice
were divided into four subgroups, and pCMV-S2S, HBSAg,
pCMV or normal saline was injected into the tibial anterior
muscle of each group, respectively; another group was inocu-
lated with SP2/O cells and was injected with pCMV-S2S at the
same time. Two mice of each group were sacriﬁced one week
after injection. HBV preS2S expressing was detected by immu-
nohistochemistry. In vitro CTL activity was detected by the
Cytotoxicity Detection kit. The life span and survival rate were
analyzed by Log-Rank statistics, and Kaplan–Meier Survival
Curve separately. Results: HBV preS2S expression was demon-
strated in muscles injected with pCMV-S2S and SP2/O-S2S cells
formed myelomas. The experimental group got much higher
in vitro preS2S-speciﬁc CTL activity, prolonged life span
(Po0.05) and signiﬁcantly increased survival rate (Po0.05)
than all control groups. Conclusion: This study demonstrates
that HBV preS2S expression construct can generate substantial
HBV preS2S speciﬁcally CTL response and signiﬁcantly in-
crease the survival rate only of mice loaded with a HBV preS2S-
1324
Abstracts
expressing myeloma; thus, it may be a potential immunotherapy
for chronic HBV infection.
APASL/Poster/Abstract/252
HCV core protein may play an important role in the inhibition of
HCV on HBV replication
Fang He, Hong Tang, Li Liu, Shu Wang, Feng-Jun Liu, Tao-
You Zhou and Lian-San Zhao
Center of Infectious Diseases, West China Hospital of Sichuan
University; Division of Molecular Biology of Infectious Dis-
eases, State Key Laboratory of Biotherapy (Sichuan Univer-
sity), Chengdu, Sichuan, China
Background: Both chronic hepatitis B and C virus (HBV, HCV)
infection are major causes of cirrhosis and hepatocellular
carcinoma. It has been shown that HCV may inhibit HBV
replication at superinfection or coinfection status. However, the
mechanism of this phenomenon is still unclear. Objectives: The
aim of this study was to investigate the possible role of HCV
core gene product on the inhibition effect of HCV on HBV
replication. Methods: A series of plasmids were constructed,
which contain HCV full genome, CE2, core, E1, E2, NS2, NS3,
NS4 and NS5 gene, respectively. All of these plasmids and the
empty control vector were transiently transfected into HepG2
2.2.15 cells by calcium phosphate method, separately. About
72 h posttransfection, HBV surface antigen (HBsAg) and e
antigen (HBeAg) in supernatants of the cultured cells were
detected by ELISA, HBV DNA was detected by quantitative
PCR analysis. The replication intermediates of HBV and the
total RNA were extracted from the cells, and they were analyzed
by Southern and Northern hybridization, respectively. Re-
sults: The secretion of HBVviral particles, as well as HBsAg
and HBeAg in the supernatant, was obviously reduced by
thepresence of the HCV full genome, CE2and core genes, but
not by thepresence of other genes. Analysis of the intracellular
HBV replication intermediates and RNA were also shown ob-
viously declined by thepresence of the same genes and not by
thepresence of other genes. Conclusion: These data suggest that
HCV can inhibit the replication of HBV, and the HCV core gene
may play a critical role on this inhibition effect. This work was
supported by the National Science Fund for Distinguished Young
Scholars from the National Natural Science Foundation of China,
No. 30325036, and the Application Fundamental Research Pro-
gram of Sichuan Province, China, No. 04JY029-002-7.
APASL/Free Paper/Abstract/253
Comparison of hepatitis B Virus (HBV) genotyping assays
between TRUGENETM HBV genotyping and RFMPTM HBV
YMDD genotyping
Byung Ik Kim1, Tae Woo Yoo1, Hee-Yeon Woo2, Hyosoon
Park2, Hong Joo Kim1 and Yong Kyun Cho1
1Department of Internal Medicine and
2Department of Laboratory Medicine, Kangbuk Samsung Hospi-
tal, Sungkyunkwan University School of Medicine, Seoul, Korea
Introduction: Many assays for detection of mutations leading to
lamivudine resistance, which were developed by long-term
lamivudine therapy in chronic hepatitis B patients, have been
introduced. However, it is difﬁcult to select one to apply among
these assays. Materials and Methods: HBV DNA was extracted
from the sera of 50 patients with chronic hepatitis B who have
received lamivudine therapy during more than 3 months, and
were analyzed by the TRUGENEt HBV Genotyping (TRU-
GENE), DNA sequencing-based assay, and RFMPt HBV
YMDD Genotyping (RFMP), MALDI-TOF MS-based assay.
We investigated the pattern of mutations in YMDD motif of
HBV polymerase by the TRUGENE and the RFMP. Results:
Among 50 patients, HBV genotypes were all C (100%). Detec-
tion rate of mutation by the RFMP was 74% and that by
the TRUGENE was 68%. The site of mutation detected by the
TRUGENE was V517L, L528M, M552I, and V555I. The
RFMP found mutation in L528M and M552I. The concor-
dance rate between the TRUGENE and the RFMP was 88% in
L528M and 90% in M552I. Conclusion: The TRUGENE
analyzed mutations in more variable sites than the RFMP.
However, the detection rate of mutation by the RFMPwas 6%
higher than that of the TRUGENE. Moreover, high concor-
dance rate between two assays was observed. Therefore, the
RFMP method was thought to be a cost-effective method for
detection of lamivudine resistance.
APASL/Poster/Abstract/254
Comparative analysis of the tolerability of interferon a-2a and
pegylated interferon in the treatment of CHC
L. K. Palgova
Kazakhstan Medical University, Almaty, Kazakhstan
Objective: To compare the tolerability of interferon a-2a and
pegylated interferon a-2a (40 kDa) in combination with riba-
virin in the treatment of chronic hepatitis C. Methods: Sixty
patients with chronic hepatitis C were included with standard
combined therapy: interferon a-2a, 3million IU every day –
eight patients (ﬁrst group), high dose ascertained therapy – 10
patients (second group) and pegylated interferon a-2a(40 kDa)
in standard dosage 180mg once a week – 42 patients (third
group) with ribavirin in doses according to body weight and
genotype of HCV. Results: Flu-like symptoms were recorded in
all patients in the ﬁrst group and second group and in 32
patients (76%) in the third group, hyperthermia was marked in
the ﬁrst group – after 2.8 injections, in the second group – 3.5
injections. In the third group – in 10 patients rise of temperature
was not recorded, in eight cases hyperthermia was recorded
during 52.8h after every one of three injections, in ﬁve cases –
during 60h after each of two ﬁrst injections, in nine patients –
during 48h after the ﬁrst injection, in 10 patients – during 24h
after the ﬁrst injection. Depression was recorded in 90%, 77.7%,
and 64.4% in the corresponding groups. The most evidence of
leukopenia was recorded in the second group, the least in the –
ﬁrst group. Skin eruption and hyperemia on the injection site
were recorded in six patients – ﬁrst group and second group and
10 patients taking pegisis. Cancellation of therapy was required in
ﬁve cases. Causes of cancellation: vasculitis – after 34 weeks of
treatment (ﬁrst group), expressed thrombocytopenia and leuko-
penia – after the ﬁrst injection (third group), anaphylactoid
reaction – after the second injection (third group), thromboem-
bolism of small branches of the pulmonary artery (second group).
Devotion for treatment was highest in those taking pegisis.
Conclusion: In that way, pegisis type of interferon A-2a is
different by the best portability and devotion for treatment,
than interferon A-2a in high dosage ascertained therapy. Port-
ability of therapy by pegisis type of interferon A-2a commensur-
able with portability of standard dosage 3 million IU/day,
devotion for treatment is higher with pegisis type.
APASL/Poster/Abstract/255
The efﬁcacy and tolerability of the combination therapy of CHC
with pegylated interferon a-2a and ribavirin
L. K. Palgova, S. A. Vasiljeva, A. V. Nersesov, V. V. Zeman, E.
A. Kim and K. B. Rashidov
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Kazakhstan Medical University, Republican AIDS Center,
Almaty, Kazakhstan
Objective: To evaluate the efﬁcacy and tolerability of the
antiviral treatment of chronic hepatitis C (CHC) according to
HCV genotype and viral load.Methods: Among 47 HCV RNA-
positive patients were 24 patients with genotype 1b, 11 with
genotype 2 and 10 with genotype 3a, while in two patients
genotype was not determined. The efﬁcacy of the treatment was
analyzed by standard protocol. Side effects and tolerability were
evaluated by general condition, monitoring blood tests every 2
weeks, serum iron, coagulogramma and blood proteins every
month. Results: Normalization of transaminase activity level
was noted after a 4-week therapy in 38 patients, and in eight
patients, transient rising of ALT was seen during the period of
observation. Decreasing of HCV RNA was recorded in all
patients. Currently, 32 patients have ﬁnished their therapy.
Sustained virological response was achieved in 30 patients,
two recurrences were noted (genotypes 1b and 2), the observa-
tion period of 12 patients did not ﬁnish and three patients left
the study. Therapy was cancelled for one patient after the ﬁrst
injection because of a decreasing level of platelets and leuco-
cytes’ lower critical magnitude, in the second case because of
thromboembolism of small branches of pulmonary artery after
28 weeks of treatment. One patient stopped therapy after 30
weeks forpersonal reasons. Positive biochemical and virological
response was noted in two cases. Observation is continuing.
Conclusion: By our observations, a combined therapy of CHC
allowed us to achieve a sustained virological and biochemical
response in 93.7% cases. Side effects led to canceling of therapy
in 4.2% of the observations.
APASL/Free Paper/Abstract/256
Prevalence of viral hepatitis in different population address groups
of Republic of Kazakhstan
L. K. Palgova1, L. Y. Drood2, V. V. Zeman3, S. A. Vasiljeva3,
D. J. Nurgaliev4, J. S. Sheriasdan1, R. K. Kajdarova2, O. B.
Rejman5
1Kazakhstan Medical University,
2Republican Onco-haematology Center RK,
3Republican AIDS Center RK,
4Medical Center ‘‘Shahar’’,
5Medical Center ‘‘Evelina’’, Almaty, Republic of Kazakhstan
Objective: To study the prevalence of viral hepatitis B and C in
different population groups in the Republic of Kazakhstan.
There were no prevalence data in Kazakhstan before. Materials
and Methods: Investigated population groups were as follows:
ﬁrst group – random sampled patients (3336), consulted for the
ﬁrst time for viral hepatitis, second group – asymptomatic
patients (654) with different kind of biliary and liver diseases in
anamnesis, third group – 134 healthy persons, fourth group –
children with leucosis (69), ﬁfth group adult leucosis patients,
sixth group – intravenous drug users (1434), seventh group –
medical staff of hematological center (94), eighth group – blood
donors (1440). Exploration realized by analyzer close-ended
type – Vitros Eci, with test system ‘‘Orto-Clinical Diagnostic’’.
Results: In the ﬁrst group percentage positive markers of viral
hepatitis B was 38.4, and at the same time revealed HBsAg –
11.6%, HBsAb – 35.6%, HBcorAb total – 34.5%, HBcor IGM –
2.5%, HBeAg – 24.9% and HBeGb – 28.9%. In this group, anti-
HCV total was revealed in 18.6%. The second group was
characterized with high levels of positive markers of HCV and
HBV infection (87.3%), with co-infection in 78.9%. In the third
group, 21.5% was revealed with viral hepatitis B and 13.6% with
anti-HCV. Morbidity rate of viral hepatitis in the fourth group in
1998 was 54.6% with a decrease to 37.7% in 3 years, mostly by
CHB. Among children, co-infection of HBV and HCV was
observed in 73%, HBV – in 21% and HCV – 6%. In the ﬁfth
group HBV infection was revealed in 55.8% with acute leukemia
and 70.8% with chronic leucosis. Among them, 11.5% and 8.3%
were HbsAg positive,respectively. In patients with chronic leucosis,
1.2% cases of HDV were revealed. In HIV positive i.v. drug users,
antiHCV was found in 97.5%; among them, 84%were HCVRNA
positive –. In HIV negative i.v. drug users, 77.1% observations
showed antiHCV, and 82% were HCV RNA positive. The seventh
group was different by heterogeneous frequency of markers of
HCV and HBV infection. The most liable to infection were
patient’s mothers, medical and laboratory staff. The prevalence of
antiHCV positive donors come to 2.5%; among them, 89.1% were
HCV RNA positive. Conclusion: A high level of prevalence in
HBV and HCV infection in all groups was accepted to start the
screening program for viral hepatitis in the country.
APASL/Poster/Abstract/257
Hematopoietic stem cell mobilization contributes to liver graft
regeneration after partial orthotopic liver transplantation
Liu Feng1, Pan Xiaoben1, Chen Guodong2, Jiang Dong1, Cong
Xu1, Fei Ran1 and Wei Lai1
1Hepatology Institute,
2Department of Gastroenterology, Peking University People’s
Hospital, Beijing, China
Background: On the basis of the recently recognized potential of
hematopoietic stem cells to give rise to hepatocytes, we inves-
tigated the possibility that auto HSC and granulocyte colony-
stimulating factor (G-CSF)-mobilized HSC could home to
partial liver graft and promote liver repair. Materials and
Methods: Fifty percent sex-mismatched rat partial orthotopic
liver transplantation (PLTx) was established. Female SD rats
were used as donors and male SD as recipients. The recipients
were repeatedly administrated human recombinant G-CSF (rG-
CSF) for ﬁve consecutive days before and after 50% PLTx.
Serum biochemical parameters, mitosis index, PCNA and BrdU
incorporation were employed to estimate liver regeneration and
liver injury. CD34 and c-kit were detected by immunohisto-
chemistry to conﬁrm stem cell migrating to the liver. The SRY
(sex-determining region for Y chromosome) gene was detected
to conﬁrm the origin of cells by in situ hybridization in liver
sections. Results: In 50% PLTx1G-CSF group, G-CSF admin-
istration ameliorated the histological damage and accelerated
the regeneration process. Compared with the 50%PLTx and G-
CSF150%PLTx groups, there was a high survival rate in the
50%PLTx1G-CSF groups (Po0.05). On the third day post-
operatively, the levels of AST and ALT were lower, and mitosis
index, PCNA and BrdU incorporation were higher (Po0.05) in
the 50%PLTx1G-CSF groups, and these parameters showed
no obvious difference between the 50%PLTx and G-
CSF150%PLTx groups. Compared with 50%PLTx groups,
CD341cells around the portal tract region increased on the
third day post-transplantation in the G-CSF150%PLTx groups
and on the ﬁfth day post-transplantation in the 50%PLTx1G-
CSF groups, respectively. SRY, a Y chromosome marker, could
be detected in the G-CSF mobilized groups by in situ hybridiza-
tion, and increased during the 7–14 days after transplantation.
Conclusions: G-CSF treatment after 50%PLTx signiﬁcantly
improved survival rate and liver histology of partial graft,
predominantly by promoting endogenous repair mechanisms.
Therefore, mobilization with G-CSF might offer a novel ther-
apeutic approach for the treatment of liver diseases in
humans.
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APASL/Free Paper/Abstract/258
Interferon-induced protein – ISG20 partially mediating the
inhibitory action of IFN-a on HCV replicon
Yintang Jia, Lai Wei, Dong Jiang, Jianghua Wang, Xu Cong,
Ran Fei
Hepatology Institute, Peking University People’s Hospital,
Beijing, China
One important biological function of interferons (IFNs) is its
antiviral activity. This function is thought to be mediated by the
products of speciﬁc and functionally overlapped cellular genes
induced by interferon in the target cells. Interferon-a has been
used to treat hepatitis C virus infection for more than ten years.
But the mechanisms of its antiviral action are not fully under-
stood. ISG20 is a newly found interferon stimulated gene and
encodes an exonuclease, which can degrade single-stranded
RNA and inhibit some RNA viruses. In this report, we
investigated the effect of ISG20 on HCV replicon replication
by transient and stable overexpression of ISG20 in HCV
replicon cells. The results showed that overexpression of wild
type ISG20 led to the reduction of HCV RNA and NS5A
protein levels, whereas overexpression of mutated ISG20 did not
have an inhibitory effect on HCV replicon and seemed to play a
dominant negative function. Our research ﬁndings suggested
that ISG20 partially mediated the inhibitory effect of interferon-
a on HCV.
APASL/Free Paper/Abstract/259
ISGF3, a critical factor of the IFN-a pathway in the antiviral
action of HBV
Zhang Quan, Wei Lai, Wang Yan, Jiang Dong, Wang Jing Hua,
Fei Ran and Rao Hui Ying
Institute of Hepatology, People’s Hospital, Peking University,
Beijing, China
Objective: To study the mechanism of signal transduction in
anti-HBV with IFN-a. Methods: The HBV DNA in HepG
2.2.15 cell line supernatant with/without IFNa-2b was moni-
tored by ﬂuorescence real-time quantitive PCR. Southern blot
analysis was performed on HBV replicative intermediate DNA
extracted from core particles. Detected STAT1, STAT2,
ISGF3g, PKR 2050-OAS mRNA levels from HepG 2 and
HepG 2.2.15 cell lines were treated with/without IFNa-2b at
different times by semi-quantitive RT-PCR. Also, the STAT1,
P-STAT2, ISGF3g and PKR proteins were measured by means
of Western blot. The same measurements were performed in
cells treated with genistein, which can block the JAK-STAT
pathway. Results: The HBV DNA in HepG 2.2.15 supernatant
that were treated by IFNa-2b for 8 h decreased by
2.07  105 copies/ml. However, similar decreases did not occur
in cells pretreated with genistein. IFN-a2b upregulated the
STAT1, STAT2, ISGF3g 2050-OAS PKR mRNA levels as well
as the STAT1, P-STAT2, ISGF3g and PKR proteins. In cases of
genistein pretreating before IFN, the STAT1, STAT2 and
ISGF3g levels remained unchanged but the 2050-OAS and
PKR mRNA levels decreased. The expressions of the STAT1,
P-STAT2, ISGF3g and PKR protein were also augmented
by IFNa-2b treatment, which was blocked by genistein.
Conclusion: These observations suggested to us that the JAK-
STAT pathway plays a major role in IFNa-2b against HBV,
with ISGF3 being a ‘key factor’.
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Chronic exposure of Mengkudu (Morinda citrifolia) Juice in Balb
C Mice
Al Munawir
Department of Pathology, Jember School of Medicine, Jember,
Indonesia
Mengkudu (Morinda citrifolia) juice was very popular as a food
supplement in the world, but there is little known about side
effects, especially in chronic exposure. This research was conducted
in order to prove the inﬂuence of mengkudu (M. citrifolia) juice to
the percentage of mice liver cells that suffer necrosis. The research
design was The Post Test Only Control Group Design. Animals
being used in this research were 36 2-month male mice of Balb C,
whose average weight was 20–25g. The mice were randomly
divided into four groups. The ﬁrst group (P0) was the control
group which was given aquadest. The second group (P1) was given
mengkudu juice A. The third group (P2) was given mengkudu juice
B. Finally, the fourth group (P3) was given mengkudu juice C. All
four groups were orally given an equal dose of 0.8 cm3 once a day
for 28 days. On the 29th day, the mice livers were taken and made
into histopathology blood smears. LSD test were conducted to
ﬁnd out the difference of liver cells suffering necrosis between all of
the treatment groups. The results of this research show that there
are signiﬁcant differences between the giving of mengkudu juice A,
B, C and the changing (necrosis) of histopathology of mice livers.
The changing is considered signiﬁcant if the signiﬁcant value is less
than 0.05. The result of LSD test shows that treatment P0 is
signiﬁcantly different to treatment P1 and P3 with the value of
P50.000. However, the treatment P0 is insigniﬁcantly different
from treatment P2 (P5 0.057). Treatment P1 is signiﬁcantly
different from treatment P2 (P50.013), but insigniﬁcantly differ-
ent from treatment P3 (P50.069). Treatment P2 is signiﬁcantly
different from treatment P3 (P5 0.000). From these results, it can
be concluded that the giving of mengkudu A, B and C has different
effects on the necrosis of mice liver cells.
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Choledochal cysts – presentation, symptoms and related compli-
cations
S. Y. L. Tan1, N. G. Tan1, Dale L. S. K. Loh2, S. H. Quak2,
A. W. Marion2 and K. Prabhakaran2
1National University of Singapore,
2The Children’s Medical Institute, National University Hospi-
tal, Singapore
Background/Purpose: The study aims to compare the presenta-
tion, diagnostic evaluation and complications in patients with
choledochal cysts in a tertiary hospital. Methods: A retrospec-
tive review of case records of 41 patients, between June 1987 and
May 2005, with known preoperative diagnosis of choledochal
cysts was performed. These patients were operated by and under
the care of the same surgeon. Results: The median age at
presentation was 36 months (range 19 weeks of gestation to 44
years). Of them, 29.3% were male. Six (14.6%) patients were
diagnosed antenatally, three of whom were asymptomatic at the
time of operation. The remaining 38 (92.7%) patients had at
least one presenting symptom; recurrent abdominal pain in 28
(68.3%) and jaundice in 21 (51.2%) patients. In patients with
jaundice, the median age of presentation (30 months) was less
than that of those without jaundice (64 months) (P5 0.09).
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Correspondingly, in those with pain as the main complaint, the
median age at presentation was signiﬁcantly higher (40 months
vs 8.5 months) (P5 0.01). ALP was raised signiﬁcantly as with
any obstructive jaundice. Interestingly, in those without jaun-
dice, the serum median ALP was 194.5 and mean 256.8, all
above the normal range. Amylase was more likely to be raised in
those with abdominal pain (median 151 vs 25) (P5 0.01)
Ultrasound was the most common form of imaging modality
and was performed in 27 (93.1%) patients. CT scan was used as
part of the diagnostic workup in 38 patients (92.7%) andMRCP
in eight patients (19.5%). Excision of the extrahepatic cyst was
performed in 36 (87.8%) patients. There were no cases of
cholangiocarcinoma found at frozen section at the time of
operation or at follow up. Todani Type 1c (51.2%) was type
of choledochal cyst seen most often. The mean duration of
follow-up was 6.4 years, with a median of 5.8 years. Of the 37
patients who already underwent an operation, 33 (89.2%)
underwent an uneventful recovery. Of the four (10.8%) compli-
cated cases, two had postoperative wound infection; one had
postoperative ileus and rising amylase and the last had a viral
fever. Conclusions: Obstruction of the biliary system by the
choledochal cyst resulting in jaundice allows an earlier age of
presentation and diagnosis, unlike those who present with pain
alone. Ultrasound is the main modality for diagnosis, and with
advances in antenatal ultrasound, patients can now be diag-
nosed antenatally. Isolated extrahepatic choledochal cysts make
up the majority of cases and are amenable to early resection with
little postoperative morbidity.
APASL/Free Paper/Abstract/264
The correlation between cyclooxygenase-2 and p53 expression in
hepatocellular carcinoma and the effects of recurrence after
surgery
B. C. Yun, S. U. Lee and B. H. Han
Department of Internal Medicine, Kosin University College of
Medicine, Busan, Korea
Introduction: Overexpression of cyclooxygenase-2 (COX-2) has
been well documented in variable malignancies that develop in the
gastrointestinal tract, breast, cervix, lung, prostate, and hepato-
cellular carcinoma (HCC). The p53 tumor suppressor gene has a
critical role for regulation of cell cycle, cellular growth, and
maintenance of genomic integrity. However, the exact correlation
of COX-2 and p53 expression in HCC is still unclear. We
investigated the expression of COX-2 or p53 and their relation-
ships to clinicopathological variables in patients with HCC and
feasiblity of chemoprevention of hepatocellular carcinoma by
COX-2 inhibitors. Materials and Methods: Formalin-ﬁxed, par-
afﬁn-embedded, archival surgical specimens that had been ob-
tained from 50 patients who had received a diagnosis of primary
HCC were studied. The expression of COX-2 and p53 in tissue
were assessed immunohistochemically. We studied the correlation
between COX-2 or p53 expression and various clinicopathological
variables. Results: The COX-2 overexpression was not signiﬁ-
cantly associated with p53 positivity. High COX-2 expression was
associated with well-differentiated HCC (P5 0.049). Disease-free
survival rates of high COX-2 expressor in peritumoral liver tissue
are signiﬁcantly lower than those of patients with low COX-2
expressor. Conclusion: Our results suggest that the COX-2 may
play a role in the early stage of hepatocarcinogenesis and it
provides preliminary evidence for testing whether COX-2 inhibi-
tors can prevent development of HCC.
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Basal core promoter, precore region mutations of hepatitis B virus
and their association with genotype, e antigen status and severity
of liver disease in chronic hepatitis B patients in India
R. Chauhan, S. N. Kazim, J. Bhattacharjee and S. K. Sarin
Advance Center for Liver Diseases, Department of Gastroen-
terology, G. B. Pant Hospital, New Delhi, India
Background and Aim: Spontaneous mutations of hepatitis B
virus (HBV) could inﬂuence the severity of HBV-related liver
disease. We analyzed the basal core promoter (BCP) and
precore (PC) regions of HBV and correlated these with HBV
genotype, e antigen status and severity of liver disease. Patients
and Methods: In 82 patients (mean age 31  17 years, M:F:
66:16) with histologically proven chronic hepatitis B (CHB), the
BCP and PC regions were sequenced and aligned with known
wild type sequences. Sequence-based HBV genotyping was done
and HBV DNA was quantiﬁed. Results: Thirty-three (40%)
patients had decompensated chronic liver disease (CLD) and the
remaining had CHB. Forty-six (56%) patients were HBeAg
positive. HBV Genotype A was seen in 28%, D in 65% and B/C
in 7.3 %. The PC G1896A mutation was more common in
HbeAg-negative (33% vs. 2%, Po0.01) patients, and was
genotype D speciﬁc. The PC G1862T mutation was more often
detected in HBeAg positive than HbeAg-negative (37% vs.
11%, Po0.01) patients and was genotype A speciﬁc
(Po0.01). BCP mutations at 1762/64 nucleotide positions
were more common in HBeAg negative than in HbeAg-positive
patients (36% vs. 13%, Po0.05) and were equally common in
different genotypes. TA 1–3 region mutations of BCP were more
commonly detected in HBeAg negative than in HbeAg-positive
patients (72% vs. 33%, Po0.01). Patients with BCP 1762, 64
and precore stop codon mutations showed signiﬁcantly higher
histological activity in the liver than the wild type (Po0.05).
HBV DNA levels were signiﬁcantly higher in 1762, 64 and TA1-
3 mutations than in the wild type. Conclusions: PC G1862T is
genotype A speciﬁc but not always conﬁned to e antigen positive
status. TA 1–3 rich mutations of the BCP region are also
associated with e antigen negativity in Indian patients. PC
stop codon and BCP 1762, 64 mutations are associated with
severity of liver disease.
APASL/Poster/Abstract/268
The safety and efﬁcacy of prophylactic endoscopic histoacryl
injection for non-bleeding gastric varices with high risks of
bleeding
Y. J. Chang1, J. J. Park2, Y. S. Seo2, M. S. Lee1, J. Y. Kim2, J. E.
Yeon2, J. S. Kim2, K. S. Byun2, Y. T. Bak2, C. H. Lee3
1Department of Internal Medicine, Hallym University College
of Medicine,
2Department of Internal Medicine, Korea University College of
Medicine,
3Department of Internal Medicine, Konkuk University College
of Medicine, Seoul, Korea
Backgrounds: Gastric varices (GVs) are not uncommon in
patients with portal hypertension. Endoscopic histoacryl injec-
tion (EHI) is reported to be effective treatment for bleeding GVs
but controversial as a prophylactic treatment because efﬁcacy
and safety are undetermined yet. The aim of this study was to
evaluate safety and short-term outcomes of prophylactic
EHI for non-bleeding GVs with high risks of bleeding.
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Methods: Twenty-nine patients (18 males/11 females, mean age
56.9 years) with high risks of gastric variceal bleeding (large
tumorous (22), red color sign (12) or rapidly growing in size (4))
underwent EHI. Five patients had IGV1 type, 17 GOV2, and 7
GOV1, respectively. EHI was performed in a standard method
and repeated injection was done as needed within 3 days.
Follow-up endoscopic examination was performed 1, 3, and 6
months after the procedure and every 6 months thereafter.
Results: Obliteration of GVs was achieved in all of the treated
patients. Twenty-two patients required one session and seven
patients more than two sessions to obliterate GVs. A mean of
1.7 ml of histoacryl was used. As a procedure-related complication,
oozing at the injection site developed in two patients and infection
in one patient. The mean duration of follow-up was 6.3 months
and eradication of GVs was achieved in 16 patients (55.2%). There
was no recurrence of treated GVs but an additional session was
required to obliterate other GVs in two patients.Conclusions: Pro-
phylactic EHI for non-bleeding GVs with high risks of bleeding
was a feasible, safe and effective procedure for eradication.
APASL/Poster/Abstract/269
The clinical characteristics of patients with chronic hepatitis B
who persistently have detectable serum HBV DNA during lami-
vudine therapy
Ji Hoon Kim, Sang Kyun Yu, Yeon Seok Seo, Jong Eun Yeon,
Kwan Soo Byun and Chang Hong Lee
Department of Internal Medicine, Korea University College of
Medicine, Seoul, South Korea
Some patients persistently have detectable serum HBV DNA by
hybridization method despite lamivudine (LAM) therapy. The
aims of this study were to investigate the prevalence and clinical
outcome of patients who persistently have detectable serum
HBV DNA during LAM therapy. Serum HBV DNA, HBeAg/
anti-HBe, and ALT levels were serially monitored. Persistently
detectable HBV DNA was deﬁned as positive serum HBV DNA
by Digene Hybrid Capture II assay until 6 months LAM
therapy. The incidence of patients with persistently detectable
HBV DNA was 7.7% (17/221 cases). In the ﬁrst year of LMV
therapy, viral breakthrough (BT) rate was 21% in group I
(undetectable HBV DNA, n5 204) and 63% in group II
(persistently detectable HBV DNA, n5 17) (Po0.001); HBeAg
loss rate was 38% in group I and 0% in group II (Po0.001);
serum ALT normalization rate was 71% in group I and 28% in
group II (Po0.001). The log10 reduction of serum HBV DNA
after 6 months of LAM therapy was  4.58 log10 in group I and
 1.97 log10 in group II (Po0.001, bDNA assay). There were
no known pretreatment-resistant HBV DNA mutations in the
domains B and C. The chronic hepatitis B patients who
persistently have detectable serum HBV DNA despite 6 months
therapy with LAM have little effect on serum HBV DNA
suppression, higher incidence of viral BT, and low possibility
of HBeAg loss and ALT normalization. Early termination of
LAM therapy in these patients could be advocated.
APASL/Poster/Abstract/270
Ketosis in liver cirrhosis: as biochemical marker for severity of
hepatic dysfunction
Iga Suryadarma, Idn Wibawa and N. Purwadi
Division of Gastroenterology and Hepatology, Department of
Internal Medicine dayana University School of Medicine, San-
glah Hospital, Bali, Indonesia
Background: Ketone bodies are produced by oxidation of fatty
acids especially in the liver, and this process occurs in the
mitochondria as the source of fuel energy in the catabolic state.
In liver cirrhosis (LC) patients, it has been reported to be
associated with insulin resistance and decrease of metabolic
function. The role and mechanism of ketosis in LC is not
known. In the present study, blood ketone bodies (BKB) level
was measured to know the hepatic reserve in LC with Child-A,
B and -C. Methods: Blood concentration of beta-hydroxybuty-
rate (B-OHB) in 48 patients with liver cirrhosis (LC) and 26
healthy volunteers was measured by MediSense Optium Blood
Beta-Ketone Test Strips. Hepatic dysfunctions were classiﬁed
according to Child–Pugh score. Ketone level between two
groups and child class were analyzed by t-test and one-way
ANOVA, respectively. Results: Blood ketone bodies concentra-
tion is signiﬁcantly higher in LC (0.429  0.916 mmol/l)
than in healthy volunteers (0.054  0.076 mmol/l) with
Po0.05). In 48 patients of LC, 13.5% (10) was Child-A,
23.0% (17) Child-B and 28.4%(21) Child-C. B-OHB level
in LC with Child-A (0.100  0.221 mmol/l), Child-B
(0.282  0.354 mmol/l) and Child-C (0.705  1.302 mmol/l) is
signiﬁcantly increased with the progression of LC. Conclu-
sions: We concluded that blood ketone bodies in LC patients
was higher than in the normal population and tended to increase
with the progression of LC. Upregulation of fatty acids oxidation
is required to fulﬁll energy requirement in LC. It is suggested that
BKB may contribute as a biochemical marker of severity of
hepatic dysfunction.
APASL/Poster/Abstract/271
The effect of pretransplantation treatment on the recurrence of
HCC after liver transplantation
J. Y. Choi1, M. S. Kim1, S. H. Bae1, S. H. Cho1, S. K. Yoon1,
J. M. Yang1, Y. S. Lee1, S. G. HONG2 and D. G. Kim2
1Department of Internal Medicine,
2Department of Surgery, College of Medicine, The Catholic
University of Korea, Seoul, Korea
Some hepatocellular carcinoma (HCC) patients exceed meeting
the selection criteria (solitary lesion o5 cm, three lesions o3
cm) for liver transplantation (LT). In addition, about 20% of
patients were dropped from the candidate list because of tumor
progression while waiting for a donor. From May 1997 to
December 2003, 71 consecutive LT patients for HCC in our
transplantation center were enrolled in this analysis to explore
the effect of pretransplantation treatment (TACE or local
therapy) on HCC recurrence. A total of 49 patients were eligible
for pretransplantation treatment for HCC. Twenty-two patients
received living-donor liver transplantation without preoperative
treatment because they already had living donor from relatives.
Twenty-one patients (group 1) met the selection criteria, while
twenty-eight patients (group 2) exceeded the selection criteria.
The mean frequency of pretransplantation treatment was 5.6
cycles (range, 2–15). At the time of LT in group 1, there was no
tumor progression during the median waiting time of 8.1
months. Among group 2 patients, there were 11 cases in
progressive diseases of HCC, six cases in stationary diseases,
and 11 cases down-staging below selection criteria. Among
group 2, during the median follow-up of 26 months (12–89),
the HCC recurrence rates after OLT were 66% (6/9), 33%(2/6),
and 9%(1/11), respectively (Po0.05). There were no HCC
recurrence in the 21 group 1 patients. Pretransplantation treat-
ment in HCC is effective in preventing the progression of HCC
meeting the selection criteria, and downstage HCC exceeding
the selection limit in about one-third. Progressive diseases after
repeated treatment mean a high recurrence of HCC after
transplantation.
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Short-term efﬁcacy of human lymphoblastoid interferon in the
treatment of chronic hepatitis C
W. Y. Tak, Y. D. Park, Y. J. Chung, S. W. Jeon, S. S. Ha, S. U.
Jung, S. K. Kim, B. H. Do, C. M. Cho, Y. O. Kweon, S. K. Kim
and Y. H. Choi
Department of Internal Medicine, Kyungpook National Uni-
versity Hospital, Daegu, Korea
Introduction: Currently, the treatment of chronic hepatitis C is
based on the combination of interferon a with ribavirin. Human
lymphoblastoid interferon is produced from human lympho-
blast cells (BALL-1). A favorable antiviral activity is expected
because it has characteristic composition and makes fewer
neutralizing anti-interferon antibodies. The aim of this study
was to assess the antiviral activity of human lymphoblastoid
interferon in chronic hepatitis C. Methods: Twenty-three pa-
tients with chronic hepatitis C were enrolled. Patients received 5
million U human lymphoblastoid interferon three times weekly
for 24 weeks. Eighteen patients received 800–1000mg/day
ribavirin based on body weight. The primary end point was
end of treatment response (ETR), deﬁned as undetectable HCV
RNA level at the end of treatment. Results: Three patients were
excluded due to side effects. Overall, 70% (14/20) of subjects
achieved ETR. In the interferon only patients (4/23), one with
genotype 2a/c showed ETR and three with genotype 1b showed
nonresponse. In the genotype non-1b group, HCV RNA was
successfully eradicated compared with the genotype 1b group
(100% vs. 50%, P5 0.007). There is no statistical difference
between groups classifying as initial viral load (High vs. low,
88% vs. 58%; P5 0.15), past treatment history (treatment-naı¨ve
vs. relapse, 85% vs. 43%; P5 0.09) and initial ALT level (o2
times vs. 2–5 times vs. 45 times; 75% vs. 73% vs. 60%,
P5 0.87). Conclusion: This study demonstrated that human
lymphoblastoid interferon seem to have a favorable antiviral
response. Further follow-up study is needed to conﬁrm the
sustained virological response.
APASL/Poster/Abstract/274
Clinical course of hepatocellular carcinoma in patients after
seroclearance of HBsAg – a cause for concern
P. E. J. Chang, W. C. Ong and C. K. Tan
Department of Gastroenterology, Singapore General Hospital,
Singapore
Background: Despite HBsAg seroclearance, patients are still at
risk of developing hepatocellular carcinoma (HCC). Whether
they differ from those arising in HBsAg-positive patients remains
unclear. Aim: To examine differences in clinical characteristics
between HCCs in post-HBsAg seroclearance and HBsAg-positive
patients.Materials and Methods: The study population comprised
638 HCC patients seen in our department from 1988 to 1997. Of
these, there were 97 patients negative for HBsAg but with
serological evidence of prior hepatitis B infection, i.e., post-HBsAg
seroclearance (group A), and 344 HBsAg-positive patients (group
B). Clinical and tumor characteristics at presentation and survival
were compared between the two groups. Results: In group A,
93.8% of patients were  45 years old compared to 82.0% in
group B (P50.004). In both groups, the majority was male. There
was no signiﬁcant difference in ethnicity. Child–Pugh score at
diagnosis was comparable in both groups. In group A, 14.6% had
normal AFP levels ( 10mg/l) compared to 9.9% in group B
(P50.198) and median serum AFP was similar. There were no
signiﬁcant differences in TNM stage, portal vein invasion and
presence of extrahepatic spread. Kaplan–Meier survival analysis
showed no signiﬁcant difference in survival (P50.75). Conclusion-
s: Patients who develop HCC after HBsAg seroconversion present
at a later age compared to HBsAg-positive carriers. However, the
severity of underlying liver disease, extent of HCC and survival do
not differ signiﬁcantly from HBsAg-positive patients. Hence,
patients with chronic hepatitis B infection who achieved seroclear-
ance with loss of HBsAg should remain in a surveillance program
for HCC similar to their HBsAg-positive counterparts.
APASL/Poster/Abstract/275
Serum glypican-3 as a predictive biomarker of postoperative
recurrence of hepatocellular carcinoma
K. Watanabe1, Y. Hippo2, T. Asano1, A. Watanabe2, Y.
Midorikawa3, S. Ohnishi1, T. Kodama2, M. Omata1, M. Ma-
kuuchi3 and H. Aburatani2
1Department of Gastroenterology,
2Research Center for Advanced Science and Technology,
3Department of Hepatobiliary Surgery, University of Tokyo,
Japan
Hepatocellular carcinoma (HCC) is an end-result of chronic
infection with hepatitis virus. Although remarkable advances in
treatment have improved the prognosis, high incidence of
intrahepatic recurrence remains a major problem. We have
reported that serum glypican-3 is a potent biomarker especially
for detection of well-to-moderately differentiated HCC (Cancer
Res 2004). The aim of this study is to evaluate usefulness of
glypican-3 as a biomarker of recurrent HCC after curative
surgery. This study includes a total of 99 patients with HCC
treated with curative hepatectomy. Serum glypican-3 was mea-
sured by sandwich ELISA. Patient characteristics, tumor stage,
pathological grade and serum tumor markers were screened for
their prognostic signiﬁcance by univariate analysis, and a Cox
proportional hazard model was used to identify independent
predictors of recurrence. In 99 patients, 44 cases experienced
recurrence in the follow-up period (mean; 18.4 months). Recur-
rence-free survival rates at 6 months and 1 year after surgery
were 78.8% and 65.6%, respectively. In multivariate analysis,
pathological diagnosis of microvascular invasion (HR 2.11,
P5 0.024) and microsatellite lesion (HR 3.09, P5 0.008) and
serum glypican-3 measured after 2 weeks to 2 months post-
operatively (HR 2.45, P5 0.004) and AFP4100ng/ml post-
operatively (HR 3.19, P5 0.01) were signiﬁcant factors
associated with recurrence. Patients with postoperative serum
glypican-3 below 0.3 ng/ml of value was a signiﬁcantly higher
recurrence-free rate than patients with glypican-3  0.3 ng/ml
(86% vs 52% at 6 months, 74% vs 35% at one year, Po0.001).
Serum glypican-3 can be a predictive marker of recurrence after
surgical treatment of HCC.
APASL/Free Paper/Abstract/276
Long-term outcomes of transcatheter arterial chemoembolization
using autologous blood clot for unresectable hepatocellular carci-
noma less than 5 cm in diameter: comparison between autologous
blood clot and gelfoam as embolizing material
K. Watanabe1, T. Gunji1, N. Kawauchi2, M. Akahane3,
M. Omata1, K. Ohtomo3 and S. Ohnishi1
1Department of Gastroenterology, University of Tokyo,
2Tokyo Metropolitan Police Hospital,
3Department of Radiology, University of Tokyo, Tokyo, Japan
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Transcatheter arterial chemoembolization (TACE) has been per-
formed for unresectable hepatocellular carcinoma (HCC). Perma-
nent ischemic occlusion and liver damage by arterial injury with
gelatin particles was a problem, especially for patients with
advanced cirrhosis. We have performed TACE with mild ischemic
effect by using an autologous blood clot as embolizing material
from 1988. The aim of this study is to compare the long-term
survival beneﬁt of short occlusion time TACE (S-TACE) with the
conventional model TACE (C-TACE). Two hundred and thirty-
six patients with unresectable HCC less than 5 cm in diameter
treated with TACE (Child–Pugh A: 112, B: 118, C: 12) were
retrospectively analyzed. One hundred and twenty-three patients
received autoclot and 113 received gelfoam as embolizing mate-
rial. Repeated session was undertaken unless hepatic insufﬁciency
was suspected. Long-term survival and factors associated with
survival were analyzed. Median follow-up period was 29.3
months. 3 and 5-year survival rates were 56% vs 57% and 31%
vs 39%, respectively. Child–Pugh score of the patient who
received S-TAE was signiﬁcantly defective. Hazard ratio was
0.99 (P5 0.94) for long-term prognosis, which treated S-TACE
compared to C-TACE. Low serum albumin, multicentricity, and
AFP were signiﬁcantly associated with poor prognosis by
multivariate analysis. 13 cases (10%) experienced adverse effects
and improved gradually. Overall sessions of treatment were 4.3
(maximum 13) and 2.6 for S-TACE and C-TACE. TACE
with an autologous blood clot can be effective treatment for
patients with HCC under 5 cm. By short duration of occlusion,
mild ischemia and reperfusion can show anticancer effect for
carcinoma, and minimum harmful effect for surrounding cirrhotic
liver.
APASL/Poster/Abstract/277
Comparison of the efﬁcacy and safety of peginterferon a plus
ribavirin and standard interferon a plus ribavirin in Thai patients
with chronic hepatitis C
S. Anyasimaphan1, C. Pramoolsinsup2, T. Tanwandee3, P.
Silapachote4 and A. Chutaputti5
1Department of Pharmacy, Saraburi Hospital,
2Division of Gastroenterology and Tropical Medicine, Depart-
ment of Medicine, Ramathibodi Hospital,
3Division of Gastroenterology, Department of Medicine, Siriraj
Hospital,
4Department of Clinical Pharmacy, Faculty of Pharmaceutical
Sciences, Chulalongkorn University,
5Division of Digestive and Liver Diseases, Department of
Medicine, Phramongkutklao Hospital, Thailand
Objectives: To compare efﬁcacy and safety of peginterferon alfa
(PEG-IFNa) plus ribavirin (RBV) and interferon alfa (IF-
Na)1RBV for treatment of Thai patients with chronic hepatitis
C (CHC). Methods: The data were collected from medical
records of CHC patients who were under care at Phramong-
kutklao hospital, Siriraj hospital, and Ramathibodi hospital
from January 2000 to February 2005. Results: There were
261 CHC patients (139 males, 122 females; mean age5
47.69  10.55 years; genotype 15 91 patients, genotype non-
I5 170 patients); 131 patients received PEG-IFNa1RBV and
130 patients received IFNa1RBV. Sustained virological re-
sponse (SVR) rates for each group were not signiﬁcantly
different (61.1% and 60.8%, respectively) (P5 0.60). According
to HCV genotype, in patients infected with HCV genotype 1,
SVR rates were higher in the PEG-IFNa1RBV group than in
the IFNa1RBV group. (58.2% and 38.9%, respectively)
(P5 0.04). There is no statistical signiﬁcance in other genotypes.
Adverse effects from PEG-IFNa1RBV and IFNa1RBV were
the same except for hematological effects. In the PEG-IF-
Na1RBV group, anemia, neutropenia and thrombocytopenia
were found in 84.7%, 61.1% and 43.5%, and in 69.2%, 21.5%
and 19.1% in the IFNa1RBV group. Mean maximal hemoglo-
bin levels decreased were 3.61  1.32 and 3.24  1.36 g/dl, mean
maximal platelet levels decreased were 62 206  35 755 and
40 903  38 102 cell/mm3 in the PEG-IFNa1RBV group and
the IFNa1RBV group, respectively. (P5 0.03 and Po0.001).
Conclusions: PEG-IFNa1RBV is more effective than conven-
tional IFNa1RBV in Thai patients infected with the HCV
genotype 1. Hematological side effects are more common
in the PEG-IFNa treatment group. CHC genotype non-I
treated with conventional IFNa1RBV is as effective as PEG-
IFNa1RBV.
APASL/Poster/Abstract/278
Evaluation of band ligation in portal hypertensive patients
Sudhir Gupta
Department of Gastroentrology, Government Medical College
& Super Speciality Hospital, Nagpur, India
From September 2001 to May 2005 (44 months), a prospective
study was conducted on the role of band ligation for esophageal
varices. Four hundred and ﬁve patients were enrolled in the
study population either attending OPD or admitted in the ward
of Department of Gastroentreology Government Medical Col-
lege & Super Speciality Hospital, Nagpur, irrespective of disease
etiology. All patients had grade 3–4 varices, except for one who
had grade 2 varices. Of the 405 cases, 233 cases (57.5 %) had
cirrhosis, 162 cases (40 %) had extra hepatic portal vein
obstruction and there were 20 cases of non-cirrhotic portal
ﬁbrosis. Band ligation was successfully done, without any
complications. The age group of patients varied from 10 to 60
years, mean age was 54.5 years. Male to female ratio was
2:1.Successful band ligation criterion was taken as decrease in
the grade of varices by at least one grade, i.e., from grade 4 to 3
or grade 3 to 2. Repeat endoscopy was performed at one month.
At the 1-month follow-up of the 405 cases, 168 cases (41.5 %)
had grade 2 varices, 207 cases (51%) had a very good response
developing grade 1 varices, and in 30 cases (7.5%) no signiﬁcant
response was noted. Overall response to band ligation was
observed in 375 cases (92.5%). Only one patient had massive
upper GI bleed following the band ligation due to an ulcer over
the band ligation site. Conclusion: Band ligation is easier and is
effective for early eradication of varices in portal hypertensive
patients.
APASL/Free Paper/Abstract/279
Clinical applications of various tumor staging systems to predict
long-term survival in hepatocellular carcinoma patients treated
with transcatheter arterial chemoembolization
Jin Hyoung Lee1, Seung Hyoung Kim2, Ja Kyung Kim1, Hyun
Woong Lee1, Jong Tae Lee2, Sang Hoon Ahn1, Yong Han
Paik1, Kwan Sik Lee1, Chae Yoon Chon1, Young Myoung
Moon1 and Kwang-Hyub Han1
1Department of Internal Medicine,
2Department of Radiology, Yonsei Liver Cancer Special Clinic,
Yonsei University College of Medicine, Seoul, Korea
Backgrounds: A clinical tumor staging system to predict long-
term survival is important to provide guidance for patient
assessment and to make therapeutic decisions. The long-term
survival of HCC is related to tumor stage, liver function, and
treatment modality. Currently, there is no consensus as to which
staging system is practically useful in predicting the survival of
patients with HCC. Aims: We investigate which staging system
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is practically useful in predicting the survival of patients with
HCC undergoing the same initial treatment of TACE, to
exclude the confounding effect of the treatment modality.
Patients and Methods: A total of 460 patients with HCC who
had been diagnosed and initially treated with TACE in Sever-
ance hospital between January 1997 and December 2001 were
retrospectively studied. The male to female ratio was 4:1. The
median age of the patients was 55.3 years. HbsAg-positive
patients were 75.7% and anti-HCV-positive patients were
12.0%. Results: The median survival was 20.5 months and
cumulative 1-, 3-, and 5-year survival rates were 66.2%,
33.5%, and 22.1%, respectively. Child–Pugh Class A and B
showed signiﬁcant survival difference, whereas it was not
observed between Class B and C (P5 0.06). TNM stage,
CLIP score and JIS score could generally predict the survival
of HCC patients treated with TACE according to their scoring.
In high scoring groups, such as JIS score 4 and 5, or CLIP score
5 and 6, they did not show signiﬁcant survival differences;
therefore, some other treatment modality (including conserva-
tive care) should be considered. Conclusion: Both CLIP score
and JIS score could predict the survival of HCC patients treated
with TACE. Because JIS score is quite easily calculated, we
propose its use as a prognostic staging system for HCC in
clinical practice.
APASL/Poster/Abstract/280
Clinical outcome of resected hepatocellular carcinoma in relation
to preoperative AFP and PIVKA-II levels
Han Jak Ryu, Sang Hoon Ahn, Ja Kyung Kim, Do Young Kim,
Hyun Woong Lee, Kwang-Hyub Han, Kwan Sik Lee, Yong
Han Paik, Bung Soo Moon, Chae Yoon Chon and Young
Myoung Moon
Department of Internal Medicine, Institute of Gastroenterol-
ogy, Yonsei Liver Cancer Special Clinic, Yonsei University
College of Medicine, Seoul, Korea
Backgrounds: Alpha-fetoprotein (AFP) and prothrombin in-
duced by vitamin K absence or antagonist-II (PIVKA-II) are
widely used for diagnosis of hepatocellular carcinoma (HCC).
But, the clinical difference of AFP and PIVKA-II-producing
HCC is not yet established. Aims: This study was to evaluate
the clinical prognosis of surgically resected HCC in relation to
preoperative AFP and PIVKA-II levels. Patients and Meth-
ods: A total of 109 patients who underwent curative hepatic
resection for primary HCC in Severance hospital between April
2001 and March 2004 were studied. As cut-off values of AFP
and PIVKA-II, two different combinations were used for
analysis: 20 ng/ml and 40mAU/ml, or 50 ng/ml and 100mAU/
ml (Shimada et al. Cancer 1996; 78:2094–2100). Patients were
classiﬁed into four groups according to positivity for AFP and/
or PIVKA-II: Group 1, positive AFP and negative PIVKA-II
levels; Group 2, negative AFP and positive PIVKA-II levels;
Group 3, positive levels of both AFP and PIVKA-II; Group 4,
negative levels of both AFP and PIVKA-II. Disease-free survi-
val was calculated by the Kaplan–Meier method and compared
among four groups using the log-rank test. The predictable
value of tumor marker for recurrence was also calculated with
receiver operating characteristic (ROC) curve. The Cox propor-
tional hazards model was used for multivariate analysis of
prognostic factors. Results: The median age of the patients
was 53 years, and 81 of 109 patients (74%) were male. Under
cut-off values of AFP and PIVKA-II as 20 ng/ml and 40mAU/
ml, the prognosis was not signiﬁcantly different, but disease-free
survival of group 2 was poorer than any other groups using cut-
off values as 50 ng/ml and 100mAU/ml. The negative AFP and
positive PIVKA-II status, Edmonson IV histology, poor UICC
TNM stage, and tumor diameter over 5cm were independent
factors of poor prognosis for disease-free survival. The predict-
able value of PIVKA-II for recurrence after operation was
150mAU/ml, using the ROC curve. Conclusions: The negative
AFP and positive PIVKA-II status and cut-off value of PIVKA-
II over 150 mAU can be prognostic predictors for patients with
HCC after hepatic resection.
APASL/Poster/Abstract/281
Peginterferon a-2a (40 kDa) plus ribavirin (800 or 400 mg/day in
patients with hepatitis C virus (HCV) genotype 2 or 3 infection:
interim results of a prospective randomised multicentre study
P. Ferenci, H. Brunner, H. Laferl, U. Bergholz, M. Rosenbeiger,
R. Stauber, A. Maieron, G. Fischer and P. Steindl-munda
Univ. Klinik fu¨r Innere Medizin IV, Vienna, Austria
Objective: We aimed to determine whether the dose of ribavirin
(RBV) could be reduced from 800 to 400 mg/day in genotype 2 or
3 patients treated with peginterferon a-2a (40 kDa) plus RBV.
Interim results of this prospective, randomised study are reported
herein.Methods: Patients with chronic hepatitis C genotype 2 or 3
infection were randomised to 24 weeks of treatment with RBV 400
or 800 mg/day combined with peginterferon a-2a (40 kDa) 180 mg/
week. Sustained virological response (SVR) was deﬁned as un-
detectable HCV RNA (o50 IU/ml) at the end of a 24 week
untreated follow-up period (week 48).
Results:
Peginterferon a-2a (40 kDa)
180 mg/week plus
RBV 400mg/day
(n5 80)
RBV 800mg/day
(n5 80)
Baseline characteristics
Male, n (%) 49 (61) 45 (56)
Mean age (year) 35 38
HCV genotype 2; 3, n (%) 10 (12); 70 (88) 14 (17); 66 (83)
Virological response at EOT in
pts completing treatment (%)
Overall 66/66 (100) 64/69 (93)
SVR in pts who have completed
treatment and follow-up (%)
Overall 38/47 (81) 37/45 (82)
Genotype 2; 3 3/3 (100); 35/44 (79) 7/7 (100); 30/38 (79)
To date, 207 patients have been randomised and interim data
are available for the ﬁrst 160 patients. SVR rates are similar in
those who have completed follow-up after treatment with RBV
400 (83%) or 800mg/day (79%). During treatment, mean
haemoglobin concentrations were consistently higher in patients
treated with the lower RBV dose. Conclusion: Our interim
analysis suggests that SVR rates are similar in HCV genotype
2 or 3 patients treated for 24 weeks with peginterferon a-2a
(40 kDa) plus RBV 400 or 800 mg/day but that mean haemo-
globin levels are higher in those treated with the lower RBV
dose. Final results are awaited with great interest.
APASL/Poster/Abstract/282
Impact of new legislation on the number of liver transplants in
Singapore
Chun-Tao Wai, How-Cheng Low, Maureen Da Costa, John
Isaac and Seng-Gee Lim
Liver Transplant Program, National University Hospital,
Singapore
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Introduction: Liver transplant is the deﬁnitive treatment of
choice for patients with end-stage liver disease. However, the
number of liver transplants performed in many Asian countries
is low. Singapore has implemented the Human Organ Trans-
plant Act (HOTA) since 1 July 2004, which allows for removal
of the kidneys, liver, heart, and cornea, in the event of death, for
transplantation. Aim: To evaluate the impact of HOTA
on the number of liver transplants performed in Singapore.
Methods: All cases of potential liver organ donors referred to
the Liver Transplant Program from 1 July 2002 to 30 May 2005
were reviewed. The number of referrals, liver retrievals, and liver
transplants were compared between the 24-month pre-HOTA
and the 11-month post-HOTA periods. Results: 240 potential
cadaveric donors were referred over the 35-month period, i.e.
6.86 cases/month: 7.46 vs 5.54 cases/month pre- and post-
HOTA, respectively. Characteristics of donors: age 46  1
years, 168 (70%) male. The commonest causes of death were
intracranial bleeding or stroke 155 (65%), non-trafﬁc accident
trauma 34 (14%), trafﬁc accident trauma 29 (12%). Liver
donation was deemed unsuitable in 175 (73%) of the referrals,
with commonest reasons being disapproval from family 66
(38%) and medical unsuitability 55 (31%). 7 and 4 liver grafts
were eventually transplanted in the pre- and post-HOTA
periods (P5 0.48). Conclusion: The number of cadaveric liver
graft referrals and actual cadaveric liver transplants did not
differ in the pre- and post-HOTA periods.
APASL/Poster/Abstract/283
HBeAg loss and seroconversion treated with adefovir dipivoxil in
HbeAg-positive chronic hepatitis B disease with lamivudine resis-
tance
M. S. Kim, S. Y. Lee, J. W. Jang, S. H. Bae, J. Y. Choi, Y. S.
Lee, C. D. Lee, K. W. Chung and S. K. Yoon
Division of Hepatology-Gastroenterology, Department of In-
ternal Medicine, College of Medicine, The Catholic University
of Korea, Seoul, Korea
Introduction: Adefovir dipivoxil, a nucleoside analogue, inhibits
both wild-type hepatitis B virus and lamivudine-resistant mu-
tants. The aim of this study was to evaluate clinical outcome
achieved by adefovir rescue in HBeAg-positive chronic hepatitis
B (CHB) patients with lamivudine-resistant YMDD mutants.
Patients and Methods: From March 2003 to March 2004,
adefovir was administered in 56 patients with HBeAg-positive
CHB who developed breakthrough hepatitis (increased alanine
aminotransferase (ALT) level over the upper limit of normal
(ULN)) due to lamivudine-resistant YMDD mutant virus. We
assessed virological response and biochemical response at 12
months. HBeAg responses and their determinant factors were
also evaluated. Results: The duration of adefovir administra-
tion ranged from 6 to 24 months with a median of 15 months.
The mean age was 41.3 years (range, 19–67 years) and male to
female ratio was 4:1. At 12 months of therapy, 42 (75.0%) of
patients had a virological response (o105 copies/ml). Biochem-
ical response at the corresponding time point was also 66.6%.
The cumulative HBeAg response rates at 6, 12, and 18 months
were 11.6%, 26.2%, and 42.9% for HBeAg loss, and 10%,
21.9%, and 30.2% for HBeAg seroconversion, respectively.
Baseline ALT level of 410  ULN and 3 log10 decrease in
serum HBV DNA level at 3 months of initiating adefovir were
independent predictors of adefovir-induced HBeAg seroconver-
sion (P5 0.041 and 0.031, respectively). For all patients, the
treatment was well tolerated. Conclusions: Administration of
adefovir for patients with lamivudine resistance showed rela-
tively good virological and biochemical responses. High ALT
and early virological suppression predict better outcome in
patients with lamivudine resistance.
APASL/Poster/Abstract/284
Comparison of viral dynamics between peginterferon a-2b and
interferon a-2b treatment in Chinese patients with HBeAg-posi-
tive chronic hepatitis B virus
Hong Zhao1, Chong-Wen Si1, Lai Wei2, Mo-Bin Wan3,
You-Kuan Ying4, Jin-Lin Hou5 and Jun-Qi Niu6
1First Hospital, Beijing University, Beijing,
2People’s Hospital, Beijing University, Beijing,
3Changhai Hospital, Second military University, Shanghai,
4Huashan Hospital, Fudan University, Shanghai,
5Nanfang Hospital, First military University, Guangzhou,
6First Hospital, Jilin University, Changchun, Jilin, China
Introduction: Few data are available on peginterferon a treat-
ment for patients with chronic hepatitis B virus (HBV). We
compared the change in serum HBV-DNA levels of Chinese
patients with HBeAg-positive chronic HBV, treated with pegin-
terferon a-2b (PEG-IFN a-2b) or interferon a-2b (IFN a-2b).
Patients and methods: Patients with HBeAg-positive (Abbott
KIT) chronic HBV, serum HBV-DNA  105 copies/ml (by real
time PCR, LLQo103 copies/ml) and ALT levels  2  ULN
were included in this study. Following randomization, patients
received PEG-IFN a-2b 1.0 mg/kg/week, or three-times-weekly
IFN a-2b 3MIU for 24 weeks (EOT), with 24 weeks of follow-up.
Results: Two hundred and thirty patients were included. At base-
line, the mean serum HBV-DNA load was 8.06 and 7.99 log10 -
copies/ml for PEG-IFN a-2b and IFN a-2b, respectively, and
mean ALT was 4.17  ULN and 3.77  ULN, respectively. Both
treatments reduced serum HBV-DNA levels during therapy; how-
ever, the reduction was greater with PEG-IFN a-2b at all time-
points. Mean reduction at EOT was signiﬁcantly higher in the
PEG-IFN a-2b group (see table). In patients whose serum HBV-
DNA was48 log10 copies/ml at baseline (PEG-IFN a-2b: n560;
IFN a-2b: n5 59), the proportion of patients whose serum HBV-
DNA levels decreased by42 log 10 copies/ml was greater in PEG-
IFN a-2b than in IFN a-2b recipients at EOT (12% vs 7%) and
follow-up (15% vs 7%), but did not reach statistical signiﬁcance.
Conclusions: PEG-IFN a-2b was associated with a signiﬁcantly
greater decrease in serum HBV-DNA levels at EOT compared
with IFN a-2b. The decrease remained greater with PEG-IFN a-
2b after 24 weeks of follow-up.
Timepoint Mean (SD) decrease in
HBV-DNA from baseline
(log10 copies/ml)
P-value
PEG-IFN a-2b
(n5 115)
IFN
a-2b (n5 115)
12 weeks 1.62 (1.85) 1.27 (1.53) 0.1207
EOT 2.22 (1.91) 1.68 (1.78) 0.0283
Follow-up 1.26 (2.11) 1.19 (2.05) 0.8020
APASL/Poster/Abstract/285
Prevalence of hepatitis B in individuals screened during a country-
wide campaign in Pakistan
Zaigham Abbas1,2,3, Lubna Shazi1,2,3 and Wasim Jafri1,2,3
1Department of Hepatogastroenterology, Sindh Institute of
Urology and Transplantation,
2Liver Stomach Clinic,
3The Aga Khan University Hospital, Karachi, Pakistan
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Introduction: Pakistan is in the area of intermediate endemicity for
hepatitis B. The aim of the present study was to ﬁnd out the
prevalence of hepatitis B in individuals who visited designated
vaccination centers during a countrywide vaccination campaign.
Methods: During October 2003, a vaccination campaign was
initiated. Centers were identiﬁed in the provincial and federal
capital cities (Lahore, Karachi, Peshawer, Quetta, Islamabad)
and Multan, a city in the area known for higher prevalence of
chronic hepatitis in Pakistan. All visitors were screened for HBsAg
andHBeAg using ICT kit (HBsAg/eAg Test by GSK).Result: The
total number of persons screened was 11372 (males57575).
Prevalence of HBsAg positivity was Karachi 3.1%, Islamabad
3.1%, Lahore 3.9%, Quetta 3.9%, Peshawer 5.2%, and Multan
6.7%. Overall prevalence was 4.3% (males 4.4%, females 3.9%).
Most of the HbsAg-positive individuals were young with a median
age of 24 years (range 12–66). HBeAg was positive in 97 persons
(20% of HbsAg-positive individuals). Conclusion: Overall preva-
lence of Hepatitis B in apparently healthy persons visiting vaccina-
tion centres is 3–4% in most cities. However higher prevalence in
Peshawer may be due to settled Afghan refugees, and in Multan
due to known higher endemicity in the ‘‘hepatitis belt’’ involving
southern Punjab and upper Sindh provinces.
APASL/Poster/Abstract/286
Chronic hepatitis B (CHB) patients treated with lamivudine – the
experience of a tertiary referral centre in Malaysia
H. Razlan, S. S. Tan and I. MERICAN
Hospital Selayang, Malaysia
Introduction: Lamivudine is one of the available treatments for
CHB in Malaysia. However, prolonged therapy increases the
risk YMDD mutation and the relapse rate is high after stopping
treatment. Methods: We reviewed all CHB patients on lamivu-
dine from August 2001 to January 2005 in our unit. Results: 123
CHB patients were treated with lamivudine; mean age of 40.8
years (21–73 years), 78% males, 53.6% Chinese, 43% Malays
and 2.4% Indians. At baseline, 65% of patients were eAg1. In
the eAg–CHB group, 72% of patients had HBV DNA level4/
5 10 000 copies/ml. 31.7% patients completed lamivudine treat-
ment after a mean of 19.9 months while 59.3% required
continued treatment with a mean duration of more than 22.2
months. 8.9% either defaulted or died while on treatment. In the
eAg1CHB group with a deﬁned period of therapy, 40.7%
achieved e-seroconversion and 29.6% achieved eAg loss. In
the eAg- CHB group, 75% achieved HBV DNA loss. Of those
who responded and stopped treatment, 56.4% relapsed after a
mean of 6.9 months (2–17). Viral breakthrough occurred in
9.8% after a mean of 24.2 months of therapy. Drug resistance
testing was done on 66.7% of these patients and we found
L180M/M204I/M204V (50%), L180M/M204I (25%), M204I
(12.5%), and L180M, M204V (12.5%). 75% were rescued with
adefovir and 25% were continued on lamivudine therapy.
Conclusions: In our experience, the majority of our patients
responded to treatment with lamivudine. However, relapse rate
is observed in more than half of them and majority required
long-term therapy. The risk of viral breakthrough is low.
APASL/Plenary/Abstract/287
Prevalence and risk factors of gallstone disease in general health
screening people
C. M. Cho1, Y. J. Chung1, S. W. Jeon1, S. S. Ha1, S. U. Jung1,
S. K. Kim1, B. H. Do1, W. Y. Tak1, Y. O. Kweon1, S. K. Kim1,
Y. H. Choi1, J. S. Kim2, H. J. Lee2 and J. M. Chung2
1Department of Internal Medicine,
2Health Promotion Center, Kyungpook National University
Hospital, Daegu, Korea
Gallstone is the most common disease of the biliary system, of
which prevalence, composition, and location have different
demographic characteristics. Recently, the prevalence rate for
gallstones goes on increasing in Korea. Most patients with
gallstones are asymptomatic and are often found incidentally
in a community health survey. Our study was designed to obtain
the prevalence and risk factors for gallstones in people under-
going health screening. A total 36 469 persons, who visited
health promotion center in Kyungpook National University
Hospital from 1998 to 2004, were enrolled in this study. They
were examined using ultrasonography and biochemical tests
such as liver function tests, lipid proﬁles and fasting blood
glucose. Gallstone disease was deﬁned as the presence of poster-
ior shadowing, and echogenic and movable structures within the
gallbladder, as determined by ultrasonography. All subjects
were divided into several groups according to the characteristics,
and the particular prevalence of gallstone disease of each group
was calculated. Among 36 469 persons, comprising 19 429 males
(53.3%) and 17 040 females (46.7%), gallstones were found in
735 persons (2.1%). The male group showed a prevalence of
2.0% (387/19 429) and the female a prevalence of 2.1% (348/
17 040). The annual prevalence for gallstone disease was 1.9% in
1998, 1.5% in 1999, 1.4% in 2000, 1.7% in 2001, 1.6% in 2002,
2.8% in 2003, and 2.7% in 2004. In a univariate analysis, the
risk factors for gallstone disease were older age (P5 0.001),
body mass index (P5 0.001), fasting blood sugar (P5 0.001),
total cholesterol (P5 0.001), LDL-cholesterol (P5 0.018),
triglyceride (P5 0.001), and serum aspartate transferase
(P5 0.005). In a multivariate logistic regression analysis, the
risk factors were older age (OR5 1.54 per age decade), high
body mass index (OR5 1.55), and high fasting blood sugar
(OR5 1.19) in health screening people. The major risk factors
for gallstone disease are older age, high body mass index, high
fasting blood sugar in health screening people. Further studies
will be needed about the prevalence of gallstone disease in the
general population according to the composition of gallstones.
APASL/Poster/Abstract/288
Death related to variceal bleeding and long-term outcome after
balloon-occluded retrograde transvenous obliteration in the pa-
tients with gastric variceal bleeding
Y. S. Choi, D. Y. Kim, M. S. Choi, S. W. Paik, J. H. Lee, K. C.
Koh and B. C. Yoo
Division of Gastroenterology, Samsung Medical Center, Sung-
kyunkwan University School of Medicine, Seoul, Korea
Background and Aims: Balloon-occluded retrograde transve-
nous obliteration (BRTO) has been introduced for the treatment
of gastric variceal bleeding (GVB) in cirrhotic patients with
gastrorenal shunts but its effect remains unclear. Hence, we
evaluated the effectiveness and long-term outcomes of BRTO
for treatment of GVB. Methods: In our institution, from
October 2002 to March 2005, BRTO was performed to control
GVB in 46 cirrhotic patients with documented gastrorenal
shunt. Rates of successful hemostasis and rebleeding, death
related to variceal bleeding (DRVB; death within 6 weeks) and
risk factors, long-term outcome, and complications of BRTO
were analyzed. Results: GVB was successfully controlled in 42
patients (91.3%). Within 6 weeks, seven patients (15.2%) died of
failure to control bleeding (n5 1), bleeding from esophageal
varix (n5 2), and hepatic failure without rebleeding (n5 4).
Multivariate analysis showed that Child–Pugh class C and
impaired renal function were independent risk factors for
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DRVB (relative risk5 7.44, 95% CI5 1.10–99.08; relative
risk5 9.07, 95% CI5 1.77–46.47, respectively). Overall survival
rates were 86.5%, 80.8%, and 71.8% at 6 weeks, 12 months, and
24 months. After BRTO, hemoglobinuria (27.3%), fever
(59.0%), worsening of ascites (43.2%) and pleural effusion
(52.3%) developed but they were mild and transient. Follow-
up endoscopy showed worsening of esophageal varices in 11
(52.0%) of 21 patients but recurrence of gastric varix was not
seen in any patients. Conclusions: Our results suggested that
BRTO can be an effective and safe treatment to control GVB
but rate of DRVB can be high in patients with Child–Pugh class
C and impaired renal function.
APASL/Free Paper/Abstract/289
Expressional diversity and antiapoptotic role of survivin in hepa-
tocellular carcinoma
I. H. Song1, E. Y. Kim1, B. H. Kim1, S. Y. Yun1, S. B. Kim1,
J. E. Shin1, H. J. Kim1 and Y.-H. Chung2
1Department of Internal Medicine, Division of Hepatology and
Gastroenterology, Dankook University College of Medicine,
Cheonan, Korea
2Department of Internal Medicine, Asan Medical Center, Ulsan
University College of Medicine, Seoul, Korea
Survivin, a unique member of inhibitor of apoptosis protein,
is known to be expressed in most human cancers. Because
deregulation of apoptosis results in destruction of cellular
homeostasis including tumor development and growth, we
investigated the survivin expression in hepatocellular carcinoma
(HCC), and analyzed the association of expression pattern of
survivin with NF-kB and caspase-3 expression. Two HCC cell
lines, HepG2 and Hep3B, and four human HCCs revealed the
expression of 439 bp survivin mRNA by reverse transcription-
polymerase chain reaction. Two to three splicing variants of
survivin transcript identiﬁed previously, survivin-deltaEx3
(321 bp), survivin-2B (508 bp), or survivin-3B (604 bp), were
co-expressed with wild type transcript of survivin in two HCC
cell lines and some human HCCs. Adjacent nontumor cirrhotic
livers and two normal livers showed no or little expression of
any survivin transcript. Western blotting analysis was used for
expression of NF-kB (65 kDa) and caspase-3 (35 kDa).
The expression of NF-kB was higher in HCC cell lines and
human HCCs than in adjacent nontumor tissues and
normal livers, but most expressed NF-kB was cytosolic but
not nucleic. The expression of caspase-3 was variable except for
two HCCs which showed lower expression than in the surround-
ing cirrhotic liver. These results suggest the anti-apoptotic
role of survivin in development of HCC. Signiﬁcance of splice
variants and key regulator of survivin expression should be
investigated for the therapeutic target of hepatocellular carci-
noma in the future.
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Hepatitis D virus genotypes: clinical implications and correlation
with hepatitis B virus genotypes
K. C. Chang, C. M. Lee, S. N. Lu, J. H. Wang, C. H. Chen and
C. H. Hung
Division of Hepatogastroenterology, Department of Internal
Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan
Different genotypes of the hepatitis viruses may inﬂuence the
clinical outcome of the disease. The aim of this study was to
evaluate the clinical implications of HDV genotypes IIa and IIb,
and their correlation with HBV genotypes B and C in patients
with chronic hepatitis in Taiwan. Genotyping was performed for
153 patients with chronic hepatitis B and serum anti-HDV
positive antibody. Of them, 40 were asymptomatic carriers, 70
chronic hepatitis, 29 liver cirrhosis, and 14 hepatocelluar carci-
noma. HBV genotyping was performed by PCR–RFLPmethods.
HDV genotyping was performed by RT-PCR, autosequencing,
and phylogenetic analysis. HDV genotype distribution was as
follows: 9 (5.9%) genotype I, 39 (25.2%) genotype IIa, and 54
(33.4%) genotype IIb in 102 patients with positive HDV-RNA.
HBV genotypes also were as follows: 17(11.5%) patients were
genotype A, 87 (56.9%) genotype B, 30 (19.6%) genotype C, and
1 (0.7%) genotype D in 135 patients with HBV DNA positive.
The Kaplan-Meier method showed that chronic dual infection of
HDV genotype II and HBV genotype C patients more frequently
progressed to advanced liver disease (cirrhosis and/or HCC) than
those with chronic HDV genotype II and HBV genotype B dual
infection (P5 0.03). No particular HDV genotype IIa or IIb are
linked to speciﬁc HBV genotype B or C infection. Chronic HDV
genotype II-infected patients coinfected with HBV genotype C
more frequently progressed to advanced liver disease than those
coinfected with HBV genotype B.
APASL/Young Investigator/Abstract/292
Insulin resistance, TNF-a, and adiponectin levels in subjects with
non-alcoholic steatohepatitis (NASH) in Jakarta, Indonesia
C. Rinaldi A. Lesmana1, Nurul Akbar1, Rino Gani1, Maryan-
toro Oemardi1, C. Heriawan Soejono1, La Lesmana1 and
Waldemar Simandjuntak2
1Department of Internal Medicine, Cipto Mangunkusumo
Hospital, Medical Faculty, University of Indonesia,
2Division Gastroenterohepatology, Pusat Pertamina Hospital,
Jakarta, Indonesia
Background: Non-alcoholic steatohepatitis (NASH) is consid-
ered to be the liver component of the metabolic syndrome and is
frequently associated with obesity, abnormal lipid proﬁle, and
type II diabetes mellitus. There is evidence that insulin resistance
(IR) is a major part of a mechanism that has been consistently
associated with NASH. Study about the occurrence of insulin
resistance and adipocytokine level in subjects with NASH in
Indonesia has not been reported. Aim: To investigate the insulin
resistance, TNF-a, and adiponectin in addition to components
of metabolic syndrome in Indonesian subjects with NASH.
Subjects and methods: Seventeen subjects (seven females and
10 males), mean age 45 (14.6) years, with a diagnosis of fatty
liver (ultrasound examination) underwent examination of blood
pressure, anthropometric measurement, and tests for fasting
glucose and insulin levels to deﬁne the insulin resistance by
HOMA-R (homeostasis model assessment) method, lipid pro-
ﬁle, serum TNF-a (ELISA), and adiponectin. Subjects with a
history of excessive alcohol intake, drug abuser, HBsAg posi-
tive, anti HCV positive, and ANA positive were excluded. A
liver biopsy diagnosis was conﬁrmed from every subject, which
has been examined by two experienced pathologists. Fasting
insulin levels and HOMA-IR in eight of 17 subjects with NASH
were compared with 8 matched controls (people with normal
BMI, normal liver function test, normal blood glucose level, and
normal ultrasound). The mean level of adiponectin of nine
subjects with NASH was compared with nine matched controls.
All analyses were performed with SPSS for Windows version 12.
A signiﬁcance level of 5% was used. Results: Of the 17 subjects
studied, all biopsies showed features compatible with NASH,
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mean (SD) HOMA-R was 6.43 (7.5), TNF-a 1.74 (1.14) pg/ml,
adiponectin 4883.5 (4573.2) ng/ml, SGPT level 64.53 (41.15), and
BMI 26.5519 (4.0340). Furthermore, obesity was found in 12
(70%) subjects, hypercholesterolemia in 10 (58.8%) subjects,
diabetes in six (35%) subjects, hypertension in six (35%) subjects,
and hypertriglyceridemia in four (23.5%) subjects. Of the eight
subjects with NASH comparing with controls, we found statis-
tical signiﬁcance (P5 0.012 for the fasting insulin levels and
P5 0.035 for the HOMA-IR). Of the nine subjects with NASH
comparing with controls, we also found statistical signiﬁcance for
adiponectin levels (P5 0.007). Conclusion: Most subjects with
NASH have at least one component of the metabolic syndrome.
Insulin resistance and adiponectin might have a role in subjects
with NASH. Further study is needed to obtain normal values for
TNF-a, and values from subjects with fatty liver. We also need a
larger sample to support this study.
APASL/Plenary/Abstract/293
A randomized placebo-controlled trial of thymosin a-1 and
lymphoblastoid interferon for HBeAg1chronic hepatitis B
Seng Gee Lim1, Chun-Tao Wai1, Yin Mei Lee1, Yock Young
Dan1, Dede Selamat Sutedja1, Aileen Wee2, Shirley Suresh3,
Ying Juan Wu3, David Machin3, Chee Chian Lim4, Kwong
Ming Fock5, Evelyn Koay6, Scott Bowden7, Steven Locarnini7
and Shamsuddin Mohammed Ishaque8
1Division of Gastroenterology, National University Hospital,
Singapore,
2Department of Pathology, National University Hospital, Sin-
gapore,
3Clinical Trials and Epidemiology Research Unit, Singapore,
4Department of Medicine, Tan Tock Seng Hospital, Singapore,
5Department of Medicine, Changi General Hospital, Singapore,
6Molecular Diagnostic Laboratory, National University Hospi-
tal, Singapore,
7Victoria Infectious Diseases Reference Laboratory, Mel-
bourne, Australia,
8Department of Gastrointestinal Liver and Pancreatic Disease,
Bangabandhu Sheikh Mujib Medical University, Bangladesh
Combination therapy between two immunomodulators used for
treatment of chronic hepatitis B was explored based on the
reported therapeutic efﬁcacy of interferon a, and thymosin a-1
as monotherapeutic agents, to determine if combination therapy
was superior to interferon alone. This double–blind, randomized
placebo controlled trial of lymphoblastoid interferon (5MIU three
times per week compares the addition of thymosin a-1, 1.6mg three
times per week for 24 weeks (Combination) with thymosin placebo
(Monotherapy) for the same period. Entry criteria included
positive HBeAg, ALT  1.510  ULN, positive HBV DNA,
absence of cirrhosis, treatment naivety and no co-morbid factors.
A total of 98 HBeAg-positive patients were recruited, of whom 48
were randomized to Combination and 50 to Monotherapy. The
primary endpoint was loss of HBeAg at 72 weeks and secondary
endpoints HBeAg seroconversion, normalization of ALT, loss of
HBV DNA and improvement in histology. The HBeAg loss was
45.8% and 28.0% for Combination and Monotherapy, respec-
tively (difference, 17.8%; 95% CI,  1.2%  35.3%, P-va-
lue50.067). There was no statistically signiﬁcant advantage to
Combination with respect to time to HBeAg loss. There were also
no statistically signiﬁcant differences with respect to the secondary
endpoints of HBeAg seroconversion, changes in histology, normal-
ization of ALT or loss of HBV DNA. In conclusion, this trial
showed a 17.8% improvement in HBeAg loss rates with Combina-
tion over interferon Monotherapy that could indicate a potential
clinically important difference that would need conﬁrmation in
subsequent trials.
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Relationship between cumulative exposure to ribavirin (RBV) and
sustained virological response (SVR) rates in patients with geno-
type 1 chronic hepatitis C receiving peginterferon alfa-2a (40kd)
plus RBV
K.A. Reddy,1 S.J. Hadziyannis,2 M. Diago,3 P. Marcellin,4
T.L. Wright5
1University of Pennsylvania, Philadelphia, PA, USA;
2HippokrationGeneralHospital,HepatologyUnit, Athens,Greece;
3Hospital General De Valencia, Valencia, Spain;
4Hopital Beaujon, Clichy, France;
5University of California, Veterans Affairs Medical Center, San
Francisco, CA, USA
Background: Genotype 1 patients who receive 48 wks of full-dose
peginterferon alfa-2a (40KD) (PEGASYS) plus RBV (COPE-
GUS) have higher SVR rates than patients who undergo dose
reductions. Objective: Assess cumulative drug exposure to RBV
and SVR rates. Methods: Data from two trials in which patients
received peginterferon alfa-2a (40KD) 180mg/wk/RBV 1000/1200
mg/d  48 wks were combined. SVR5undetectable HCV RNA
(o50IU/mL) at end of untreated follow-up (wk72). Cumulative
drug exposure was expressed as a proportion of the planned dose.
Exposure categories were determined using clinic records and
patient diaries. Results: 427/569 randomised patients (75%) com-
pleted treatment. Reductions to o97% of the planned RBV and
peginterferon alfa-2a (40KD) doses occurred in 182 patients (43%)
and 114 patients (27%), respectively. 62 patients (15%) received
o97% of the planned dose of both drugs. Cumulative RBV
exposure during treatment wk1-12 and wk1-48 was signiﬁcantly
and positively correlated with SVR. 325 patients received  97%
of the planned RBV dose during wk1-12 and reductions during
wks13–48 were associated with decreasing SVR rates in patients
receiving o80% of the planned RBV dose. Conclusion: RBV
exposure during wks1–12 of is signiﬁcantly correlated with the
SVR rate in genotype 1 patients receiving 48wks of peginterferon
alfa-2a (40KD) (PEGASYS) plus RBV (COPEGUS) therapy.
Dose reductions too80% during wks13–48 in those who received
full doses during wk1–12 compromised SVR rates. Minimizing
RBV dose reductions at any point in therapy is likely to improve
SVR rates in genotype 1 patients.
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Detection and genotyping of human TT virus in different types of
liver disease from Delhi
P. Kar1, Mohd Asim1, Saket Chatopadhyay1 and B.C Das2
1Department of Medicine, Maulana Azad Medical College,
New Delhi,
2Institute of Cytology and Preventive Oncology, ICMR, Noida,
India
Introduction: In 1997, a novel virus was detected, among the
three Japanese cases with post-transfusional hepatitis by T.
Nishizawa, in patients with fulminant hepatitis and chronic
liver disease of unknown etiology. To look further into the
prevalence of TTV in different types of liver disease and their
prevalent genotypes in Delhi, the present study was designed.
Materials and Methods: A total of 262 serum samples were
collected from patients with different liver diseases. TTV DNA
was detected by semi-nested polymerase chain reaction followed
by direct sequencing and phylogenetic analysis to characterize
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the TTV isolates. Results: TTV DNA was detected in 5 (18.5%)
of the 27 patients with chronic liver disease (CLD) associated
with HBV and HCV, which was signiﬁcantly higher than the
5.4% (2/37) prevalence in non A-G CLD patients. 28.5% (2/7)
TTV prevalence was observed in acute viral hepatitis (AVH)
patients associated with other hepatotrophic viruses, which is
also higher than the 8% (2/25) in non A-G AVH cases. None of
the 23 cases showed TTV DNA in non A-G fulminant hepatic
failure (FHF) cases whereas 8.3% (1/12) TTV prevalence
observed in FHF was associated with HBV, HCV and HEV.
The majority of the cases with TTV DNA positivity showed no
signiﬁcant evidence of biochemical or histological damage of the
liver. Direct sequencing of 25 TTV isolates showed genotype 1a,
which was similar to genotypes found in western India.
Conclusion: TTV prevalence was higher among the CLD pa-
tients, followed by acute and fulminant hepatitis. All the groups
showed genotype 1a. Hence, it is the most prevalent genotype
among patients seen in Delhi.
APASL/Free Paper/Abstract/297
Outcome of paediatric liver transplant – 14 years of experience at
the Children’s Medical Institute, Singapore
N. G. Tan1, S. Y. L. Tan1, Dale L. S. K. Loh2, S. H. Quak2, A.
W. Marion2, K. Prabhakaran2
1National University of Singapore,
2The Children’s Medical Institute, National University Hospi-
tal, Singapore
Background/Objectives: This study summarizes the experience of
a single centre on 47 paediatric liver transplantations
from living and cadaveric donors performed on 44 paediatric
patients. The outcome of transplant surgery, and recipient,
immunosuppression, rejection, and survival rates were reviewed.
Methods: A retrospective case note review of all paediatric
patients who received liver transplantation between March 1991
and January 2005 was carried out. Results: Forty-four cases were
reviewed, of which 21 were boys (47.7%) and 23 were girls
(52.3%). Patients were between 11 months and 14 years of age.
The mean age of the recipients at transplant was 35 months, and
the median age 21 months. Biliary atresia (72.3%), Alagille
syndrome (6.4%) and metabolic liver disease (6.4%) were the
most common indications for liver transplant. Biliary atresia was
signiﬁcantly associated with a good post-transplant outcome.
(P5 0.04). The allografts were distributed as 29 (61.7%) living
related and 18 (38.3%) cadaveric. The retransplant rate was 6.3%
and solely due to hepatic vessel thrombosis. Tacrolimus (FK-506)
was the immunosuppressive agent used in 37 (78.7%) patients.
The other immunosuppressives utilized were corticosteroids
(8.5%) and cyclosporine (8.5%). After transplantation, 37
(78.7%) of the patients, including three retransplants, were well.
There were eight deaths, and the current survival rate of our series
is 83.0%. Conclusions: Liver transplantation is an established
form of intervention for end-stage liver disease and a variety of
extrahepatic metabolic diseases. Good long-term survival rates
comparable to most tertiary centres can be expected. Future
advances in immunosuppression and organ availability are likely
to lead to greater improvements in survival rates.
APASL/Free Paper/Abstract/298
The inﬂuence of HBV-speciﬁc cytotoxic T-lymphocyte stimulated
by dendritic cell in vitro
Gui-Qiang Wang, Heng-Hui Zhang, Yu He, Hong Zhao, Wen-
Hua Piao, Mao-Chang Liu, Hong-Li Xi and Min Yu
Peking University First Hospital, Beijing, China
Objectives: To observe the enhancement of cytotoxic T lym-
phocyte responses in patients with chronic hepatitis B following
vaccination with a dendritic cell stimulated by poly I:C in vitro.
Methods: Peripheral blood mononuclear cells (PBMC) were
isolated from whole blood by density gradient centrifugation
on Ficoll–Hypaque; the non-adherent cells were cultured in the
medium AIM-V containing recombinant human IL-4 and
recombinant human GM-CSF. On day 7, one part of wells
were added with poly I:C. On day 9, mature DC (mDC) were
harvested and used for phenotype analysis. Both of the im-
mature DCs and mature DCs were cocultured with the
auto-T cell for another 2–3 days. Detection of the function
and frequency of HBV-speciﬁc CTL was carried out by enzyme-
linked immunospot assay (Elispot) and tetramer staining.
Results: The dendritic cell was stimulated by poly I:C in vitro,
whose CD83 and CD80 expression increased and became more
mature. The average of percentages of HBV-speciﬁc CD81cells
of total CD81cells was 0.72% (0.43–1.74%) in 12 chronic
hepatitis B patients and the average of the spots of antigen-speciﬁc
IFN-g-releasing effector cells was 17(9–28); stimulated by the the
dendritic cell, the percentages of HBV-speciﬁc CD81cells of total
CD81cells rise to 1.86% (0.78–2.65%) and the average of the
spots of antigen-speciﬁc IFN-g-releasing effector cells was 49 (36–
66); while stimulated by the dendritic cell added with poly I:C, the
percentages of HBV-speciﬁc CD81cells of total CD81cells rise to
3.10% (1.16–4.60%) and the average of the spots was 106 (68–
130). There was statistical difference of conclusion of Elispot and
tetramer in the three groups (Po0.001). Conclusion: The T
lymphocyte of patients with chronic hepatitis B stimulated by
the self-dendritic cell may result in obtaining high percentage and
functional antigen-speciﬁc T lymphocyte. The addition of poly
(I:C), which was used as maturation-promoting factor in DC
culture can enhance the function of DC signiﬁcantly and can get
even higher percentage antigen-speciﬁc T lymphocyte with en-
hanced function.
APASL/Free Paper/Abstract/299
Study of phenotype and function of cord blood dendritic cells
whose mothers are patients with chronic hepatitis B
Heng-Hui Zhang, Hui-Xia Yang, Hong-Li Xi, He Yu, Wen-
Hua Piao, Hong Zhao, Min Yu and Gui-Qiang Wang
Peking University First Hospital, Beijing, China
Objectives: To investigate the phenotype and function of cord
blood dendritic cells in those whose mothers are patients with
chronic hepatitis B, compared to the dendritic cells of healthy
cord blood, healthy adult peripheral blood and adult peripheral
blood with chronic hepatitis B. Methods: Peripheral blood and
cord blood mononuclear cells (PBMC) were isolated from whole
blood by density gradient centrifugation on Ficoll–Hypaque,
and the non-adherent cells were cultured in the medium AIM-V
containing recombinant human IL-4, TNF-a and GM-CSF. On
day 9, mature DC (mDC) were harvested and used in phenotype
analysis; the amounts of IL-12 that dendritic cells produced
were measured; dendritic cells from human cord blood or adult
peripheral blood, which support a mixed leukocyte reaction in
cord blood, and adult T cells have been compared. Results: The
expression rates of CD80 and CD83 on cord blood dendritic
cells in those whose mothers are patients with chronic hepatitis
B were decreased compared with healthy cord blood, healthy
adult peripheral blood and adult peripheral blood with chronic
hepatitis B, Po0.05; The amounts of IL-12 produced by cord
blood dendritic cells in those whose mothers are patients with
chronic hepatitis B were lower than the amounts of IL-12
produced by healthy cord blood, healthy adult peripheral blood
and adult peripheral blood with chronic hepatitis B, Po0.05;
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and the comparison of the ability of dendritic cells inducing T
lymphocyte proliferation was described as the ability of healthy
adult peripheral blood dendritic cells inducing cord blood T
lymphocyte proliferation 4 the ability of healthy adult periph-
eral blood dendritic cells inducing adult T lymphocyte prolif-
eration 4 the ability of healthy cord blood dendritic cells
inducing cord blood T lymphocyte proliferation 4 the ability
of healthy cord blood dendritic cells inducing adult T lympho-
cyte proliferation 4 the ability of healthy cord blood dendritic
cells in those whose mothers are patients with chronic hepatitis
B inducing cord blood T lymphocyte proliferation4 the ability
of cord blood dendritic cells in those whose mothers are patients
with chronic hepatitis B inducing adult T lymphocyte prolifera-
tion. Conclusion: The maturation and function of cord blood
dendritic cells in those whose mothers are patients with chronic
hepatitis B were lower than dendritic cells of healthy cord blood,
healthy adult peripheral blood and adult peripheral blood with
chronic hepatitis B.
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Pathological and clinical analysis of 40 liver failure cases of
hepatitis B
Lin Guoli, Chong Yutian, Gao Zhiliang, Peng Xiaomou and
Zhao Zhixin
China
In order to study the pathological characteristics of the acute on
chronic liver failure (AoCLF) and the decompensated liver
cirrhosis (DCLC) caused by hepatitis B, and the differences
between the AoCLF and the DCLC in the clinical characters, a
pathological analysis of 40 liver failure cases of hepatitis B was
carried out. Thirty-ﬁve males and ﬁve females aged 27–75 years
old from the center of liver transplantation of Zhongshan
University 2003–2005 were the subjects.Orthotopic liver trans-
plantation (OLT) was performed in all 40 cases. Seventeen cases
were diagnosed as AoCLF, and 23 cases as DCLC. Three pieces
of the liver tissue were collected from the left and right lobes of
the liver parenchyma , made into slices stained with hematox-
ylin–eosin and reticular ﬁber, and read by two pathologists
independently. The SPSS 11.0 statistical software was used for
statistical analysis. The measurement data and the enumerations
data were analyzed by Fisher method and T test, respectively.
Probabilities of Po0.05 were recognized as statistically signiﬁ-
cant. Twenty-one of the 40 cases were observed with unaided
eyes and can be divided into three groups: nine cases were
nodular liver cirrhosis, eight cases postnecrosis cirrhosis and
four cases non-cirrhosis. Through microscope examination,
chronic injury and, recently, a big lesion were observed in 17
AoCLF cases; the 23 DCLC cases could be divided into two
groups: one was nodular cirrhosis (four cases) and the other was
postnecrosis cirrhosis (19 cases). The liver lesions were distrib-
uted in the whole liver, but not evenly in all the spots. The two
groups’ clinical data (ALT, TBIL, PTA, etc.) were compared; no
statistical signiﬁcance was found. In summary, the clinical
features of AoCLF were similar to those of decompensated
cirrhosis; the approach to patients with liver failure should be
guided principally on clinical backgrounds, and further
classiﬁcation should be based on pathological and etiologic
considerations. However, histological classiﬁcation and prog-
nosis based on percutaneous biopsy specimens alone may be
misleading.
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Association of vitamin D receptor, CCR5, TNF-a and TNF-b gene
polymorphisms and HBV infection and severity of liver disease
P. V. Suneetha, S. K. Sarin, A. Goyal, G. T. Kumar and S. S.
Hissar
Department of Gastroenterology, GB Pant Hospital, New
Delhi, India
Background and Aims: The role of host factors in persistence of
HBV infection and progression of liver disease is not clear. 1,25-
dihydroxy vitamin D is involved in immune regulation, local
control of cellular growth and differentiation. Expression of
vitamin D receptors in hepatocytes suggests its importance in
the pathophysiology of the liver. We studied the association of
single nucleotide polymorphisms (SNPs) in the genes involved in
immunoregulatory functions of vitamin D with susceptibility
and severity of chronic hepatitis B (CHB). Methods: Five
polymorphisms in vitamin D receptor (intron 8 and exon 9),
CCR5 (32 bp deletion), TNF-a ( 308) and TNF-b (intron 1)
were studied in 214 histologically proven CHB patients and 408
healthy subjects. Genotype frequencies were compared between
patients and controls. Clinical parameters were compared
between patients with a ﬁbrosis score of  2 (mild) or 42
(severe) and histological activity index (HAI) of  5 (mild) or
45 (severe). Results: The frequency of heterozygosity of
CCR5D32 was greater in patients with chronic hepatitis B
than in controls (4.2% vs 0.73%, P5 0.005). Frequency of
VDR a/a and TNF-bA/A was higher in severe than in mild liver
disease based on HAI (19.3% vs 5.4%, P5 0.003 and 18.1% vs
3.8%, P5 0.001, respectively) and ﬁbrosis score (23.7% vs
3.6%, Po0.001 and 18.1% vs 4.4%, P5 0.002, respectively).
Conclusion: CCR5D32 heterozygosity was associated with sus-
ceptibility to HBV infection and VDR a/a, and TNF-b A/A with
severity of liver disease in CHB patients. These results afﬁrm a
role for the immunogenetic factors in chronic hepatitis B.
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Drug-induced acute liver failure in a tertiary liver centre in
Malaysia
A. Abdullah, S. S. Tan, S. Sachithanandan, G. Kanagasabai, L.
S. Velayudham, A. G. Mathew, H. Razlan, R. Ponnudurai and
I. Merican
Selayang Hospital, Selangor, Malaysia
Background: Drug-induced acute liver failure is uncommon and
may be fatal. Objective: To examine the characteristics and the
outcome of patients who are thought to have developed acute
liver failure secondary to drugs.Method: Retrospective analysis
of patients with acute liver failure, as diagnosed according to
King’s College criteria over a 3-year period. Patients are
included if they had used drugs known to be hepatotoxic near
to the time of liver injury. Patients’ demography, category of
liver injury, clinical presentation, liver biopsy results and the
outcome are documented. The patients are scored according
to the Causality-Assessment-of-Adverse-Reaction-To-Drugs,
which categorizes them into highly probable, probable, possible
and unlikely to be drug-induced liver injury (DILI). Results: In
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all, 17 patients were identiﬁed (M:F is 2:15). Mean age is
33.1years(13–66 years). Nine patients were categorized as prob-
able and 8 patients were categorized as possible DILI. Anti-
HBcore (total) was positive in three out of eight patients tested.
Anti-HCV was positive in one out of all 17 patients. ANA was
reactive in one patient but IgG was not signiﬁcantly raised.
Anti-tuberculous drugs were implicated in seven cases. The
other drugs implicated include amoxicillin (n5 2), propylthiour-
acil (n5 2), Chinese/traditional medication (n5 2) lamotrigine
(n5 1), diclofenac (n5 1), paroxetine (n5 1), and ticlopidine
(n5 1). Hepatocellular injury pattern is more common in the
antiTB group (72%) whereas the non anti-TB group has more
cholestatic/mixed injury pattern (60%). Rash and eosinophilia
tend to co-exist and occurred more frequently in the anti-TB
group than the non anti-TB group (86% vs 30%). Mortality rate
is almost equal in both groups (anti-TB5 86%, non anti-
TB5 70%). The mean survival is 0.97 month (0.23–2.5) for
those who died, and the mean follow-up for those who survived
is 7.64 months (3.6–22). Post-mortem liver biopsy in ﬁve
patients showed extensive ﬁbrosis, extensive necrosis or both.
Conclusion: Acute liver failure secondary to drugs has a high
mortality. Careful monitoring of patients started on medications
known to cause liver injury is vital. This is particularly true for
women who seem to be more susceptible.
APASL/Poster/Abstract/306
Acute severe hepatitis B, outlook at two urban centers
A.Ashfaq, JafriWasim, Saleh M. Kashif, K. Ali and M. Shahid
Division of Gastroenterology, Aga Khan University and Ham-
dard University Hospitals, Karachi, Pakistan
Design: Retrospective clinical, serological, biological and fol-
low-up study of 124 patients with severe forms of acute viral
hepatitis B (AVHB). Setting: In-patient service at Aga Khan
University and Hamdard University Hospitals, Karachi, Paki-
stan. Measurements: A total of 124 patients with HepB core
IgM Ab were selected who had follow-up greater than 6 months
and their 70 different parameters, HBsAg conversion rate, Hep
delta co-infections and outcomes were recorded. These para-
meters were compared in seroconverted and in those who
became chronic carriers in a univariate analysis. All signiﬁcant
factors on univariate analysis were entered into a stepwise
logistic regression analysis to identify independent variables of
prognosis. The sensitivity and speciﬁcity of signiﬁcant prognos-
tic factors were then assessed. Results: Out of 168 patients with
acute hepatitis with Hep B core IgM Ab, 41 patients had follow-
up less than 6 months or they could not be approached by
electronic medium. Those with Hep D co-infection and fulmi-
nant course were excluded. In all, 61/124 patients had HepBeAg
positive. Mean follow-up was 6 to 48 months. Ninety-two
patients seroconverted out of the remaining 32 and eight went
on to develop CAH. Four variables differed signiﬁcantly be-
tween seroconverted and chronic carriers on univariate analysis,
includingage less than 20 years and HepBeAg negative; falling
titers of hepatitis BsAg predicted the outcome on multivariate
analysis. Conclusion: Acute severe hepatitis patients are affected
more by Hep BeAg-negative variants and overall spontaneous
seroconversion was 74%, emphasizing the need to look for
therapeutic options for acute severe hepatitis B.
APASL/Poster/Abstract/307
Anti-tuberculous therapy and fulminant hepatic failure: experi-
ence at tertiary care center, non-transplant scenario
A. Ashfaq, J. Wasim, M. Khalid, K. Kashif, M. Shahid and
A. Zahid
Aga Khan University Hospital, Karachi, Pakistan
Background: The incidence of tuberculosis is not decreasing in
this part of the world. On the other hand, there have been
increasing prescriptions of anti tuberculosis medications and at
times empirically, which is exposing a greater number of
patients to the risks of three potentially hepatotoxic drugs:
isoniazid, rifampicin, and pyrazinamide? Thorough awareness
of potentially severe drug hepatotoxic reactions of these medi-
cines is essential because fulminant hepatic failure is a devastat-
ing and often fatal condition without liver transplantation.
Methods: This is a description of 17 cases of fulminant
hepatic failure caused by rifampicin, isoniazid, pyrazinamide
or all. They were admitted to Aga Khan University hospital.
Results: Patients were adults from Karachi, of whom 13 were
females. Nine had pulmonary, four intestinal, two glandular,
one genitourinary and one PUO. Twelve were on three drugs.
One had underlying CLD. Most of the patients were on correct
doses. Eight patients had baseline LFTs and only three had
follow-up LFTs. Only eight had jaundice at the time of
presentation. Most of the patients were of ATT for more than
8 weeks. Fifteen patients died. Six patients died within 48 h of
admission. These cases highlight the dismal outcomes of this
potentially avoidable menace and also elaborate on the lack of
acceptance of current guidelines on liver function tests after
starting anti-tuberculosis therapies.
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Clustering of poor prognostic factors in heavier patients with
chronic hepatitis C (CHC): baseline characteristics and outcomes
with peginterferon a-2a (40 kDa) (PEGASYSs) plus ribavirin
(RBV, COPEGUSs) in randomized, international, Phase III
trials
M. G. Swain1, G. R. Foster2, S. J. Hadziyannis3, E. J. Heath-
cote4, D. Jensen5, S. S. Lee1, P. J. Pockros6, M. Sulkowski7 and
C. Trepo8
1University of Calgary, Calgary, Alberta, Canada,
2Digestive Disease Research Centre, QMUL, London, UK,
3Henry Dunant Hospital, Athens, Greece,
4University of Toronto, Toronto, Ontario, Canada,
5Rush University Medical Center, Chicago, IL, USA,
6The Scripps Clinic, La Jolla, CA, USA,
7Johns Hopkins University, Baltimore MD, USA,
8Hopital de l’Hotel-Dieu, Lyon, France
Introduction: SVR rates decrease as weight increases. This is
apparent in a retrospective subanalysis of a Phase III trial of
pegylated-interferon a-2b (12 kDa)/RBV: the overall SVR of
54% increased to 61% when patients weighing  75.5 kg were
excluded (Lancet 2001; 358:958). Therefore, in this study, we
assessed the complex relationship between body weight and
baseline factors in patients in two Phase III randomized studies,
and between weight and outcomes in patients treated with
peginterferon a-2a (40KD) (PEGASYSs)/RBV (COPEGUSs).
Methods: Data from two studies were combined (N Engl J Med
2002; 347:975; Ann Intern Med 2004; 140:346). Patients were
classiﬁed by weight (  75.5 or475.5 kg) and baseline charac-
teristics of all patients were compared. Outcomes in patients
who were treated for 48weeks with peginterferon alfa-2a
(40 kDa)/RBV 1000/1200mg/day were also compared. Results:
Signiﬁcantly more patients in the 475.5kg group were male,
black, had cirrhosis, genotype 1 or had acquired HCV through
intravenous drug use (IVDU). Heavier patients had signiﬁcantly
higher HCV RNA levels. SVR rates were signiﬁcantly higher in
the lighter patients (odds ratio 1.9, 95%CI, 1.4–2.5). When those
weighing475.5kg were excluded, the SVR rate was 67% (59% in
genotype 1). Serious adverse events (SAEs) were more common
in lighter patients, although there was no difference in withdrawal
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rates for AEs. Conclusion: Body weight has a complex relation-
ship with a range of patient characteristics and outcomes in
patients with CHC. This clustering of poor prognostic character-
istics in heavier patients may explain the lower SVR rates
observed in heavier patients with all interferon-based regimens.
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Effectiveness of pegylated interferon and ribavirin combination
therapy in patients with chronic hepatitis C: an Indian experience
A. Sood1, Vandana1, S. S. Hissar2, M. Kumar1, Chandana1,
Goyal Ankur1, B. C.Sharma1 and S. K. Sarin1
1Department of Gastroenterology, CMC, Ludiana, India,
2Department of Gastroenterology, G.B.Pant Hospital, New
Delhi, India
Background: Chronic hepatitis C (CHC) is an important form
of liver disease in India. Treatment with pegylated-interferon
(PEG-IFN) and ribavirin combination is highly effective in
CHC patients. There is a paucity of data from the Indian
subcontinent. Aim: To study the efﬁcacy of PEG-IFN and
ribavirin combination therapy in patients with CHC. Patients
and Methods: In 124 liver biopsy-proven CHC patients with
ALTlevels41.2  ULN and positive HCV RNA at baseline
were included in the study. All were treated with a combination
of PEG-IFN 1.5mg/kg/week and ribavirin 10mg/kg/day. Pa-
tients with genotypes 1 and 4 were treated for 52 weeks and
other genotypes for 24 weeks and subsequently followed up for
24 weeks. Both end of treatment response (ETR) and sustained
viral response (SVR) were assessed at the end of treatment and
24 weeks after therapy, respectively. Biochemical response
was deﬁned as normalization of ALT (i.e.,  40 IU/L) and
viral response was deﬁned as negativity of HCV RNA. Re-
sults: Of the 124 patients (mean age 41.75  11.75 years and
male:female 104:20), 14 (11.3%) were genotype 1, 103 were
genotype 3, 5 (4%) were genotype 4 and 2 (1.6%) were of
mixed genotypes (more than one genotype). Two patients were
withdrawn due to severe side effects and four patients dropped
out during the study. End therapy and sustained ALT response
was found in 68/124 (54.8%) and 67/124 (54%) patients,
respectively. Overall virological ETR was found in 113/124
(91.1%) and SVR in 101/124 (81.5%). SVR with respect
to genotypes 1, 3, 4 and mixed genotype was 71.4% (10/14),
82.5% (85/103), 80% (4/5), and 100% (2/2), respectively. Con-
clusion: Combination therapy with PEG-IFN and ribavirin is
effective in achieving SVR in more than three quarters of
patients with CHC and the virological response is similar in
all the genotypes.
APASL/Poster/Abstract/312
Effectiveness of mandatory immunization in Mongolian children
Y. Dahgwahdorj, G. Zulkhuu, B. Baigal and O.Baatarkhuu
Health Sciences University of Mongolia, Mongolia
Background: Mongolia is placed on high priority on
universal immunization. However, there has been no systematic
investigation on effectiveness and coverage of vaccination
by the titer against the associated immunization. Objective: To
determine the effectiveness and coverage of HBV vaccination in
rural and urban populations and to compare this with
another vaccine included with mandatory immunization in
Mongolia. Methods and Materials: The design of this study
was cross-sectional. There were 160 children randomly selected,
from Ulaanbaatar (urban) and 433 children from 13 somons
of rural 12 aimaks (province) from 21. All serum samples
were tested for HBsAg, anti-HBs and anti-HBc. In addition,
there was tested for pertussis, tetanus and diphtheria antitoxin
antibody. Results: HBsAg detected was 0–2.5% in urban
children and 3.9–8.7% in rural children of vaccinated groups
and 10.0–19.7% in non-vaccinated groups. Tests for anti-HBs
were positive in 34.0–77.0% in urban and 23.0–31.0% in rural
children of the vaccinated groups, depending on age. Anti-HBc
was detected in 6.4% urban children of vaccinated ages and
35.8% in the same age group in rural settings. Pertussis, tetanus
and diphtheria antitoxin antibody was detected in 84.2–96.1%
of all subjects. There was no signiﬁcant difference between
rural and urban subjects studied for these antitoxin antibodies.
Conclusion: 1. Seroconversion to HBV vaccination is signiﬁ-
cantly lackingcompared to that found in other countries. Also,
the vaccination immunity achieved in rural areas is signiﬁcantly
lower than that of urban areas. 2. Seroconversion to vaccines for
pertussis, tetanus and diphtheria is 86.2–96.1%. Unlike for
HBV, there was no signiﬁcant difference in immunity achieved
between urban and rural areas.
APASL/Poster/Abstract/313
Relationship between HBV DNA levels and presence of PC/BCP
mutation
Heon-Ju Lee, Jun-Hwan Kim, Jong-Ryul Eun, Jung-Hun Lee
and Sun-Taek Choi
Department of Internal Medicine, Yeungnam University,
College of Medicine, Daegu, Korea
HbeAg/anti-HBe seroconversion often coincides with loss of
serum HBV DNA and normalization of liver enzyme, butthe
relationship between HBV DNA levels and precore or basal core
promoter mutation is not clear. We hypothesized that the mutant
group had higher DNA levels than the no mutant group and then
analyzed DNA levels according to the presence of mutation at the
precore and corepromoter regions. We analyzed 67 sera of eAg-
negative chronic hepatitis B patients; male: female, 53:14, lami-
vudine treatment: naı¨ve, 46:21, and 30 patients had achieved eAg
loss after lamivudine treatment. DNA levels were measured by
hybridization capture and bDNA method. Mutant analysis was
done by INNO-LiPA method for 39 patients; it is designed for
detection of G1896A at the precore region, A1762T, and of
G1764A at the core promoter region. Twenty-eight patients were
analyzed by the AFLP method, which is designed for detection of
the precore region mutation. Six cases were PCR negative. At the
core promoter region, wild types were two (5.1%), mutants were
36 (92.3%) and mixture was one (2.6%) in 39 samples. At the
precore region, wild types were 17 (27.9%), mutants were 35
(57.3%) and mixtures were nine (14.8%) in 61 samples. Mean
HBV DNA levels of wild types, mutants, mixtures of the precore
region are 223.4  426.7, 332.3  789.6, and 31.4  45.9pg/ml,
respectively. But there are no statistically signiﬁcant relationships
among DNA levels, presence of mutant, and lamivudine treat-
ment. Single serum HBV DNA test does not determine precore
mutation or wild type in patients with HBeAg/anti-HBe serocon-
version; therefore, genetic analysis is needed in HbeAg-negative
patients to differentiate the precore mutants from wild types.
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The impact of steatosis on treatment response and histological
evolution in chronic hepatitis C patients treated with interferon
a-2b plus ribavirin
Chao-Hung Hung1, Fang-Ying Kuo2, Jing-Houng Wang1,
Sheng-Nan Lu1, Chien-Hung Chen1, Hock-Liew Eng2 and
Chuan-Mo Lee1
1Division of Hepatogastroenterology, Department of Internal
Medicine,
2Department of Pathology, Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung, Taiwan
Background/Aims: We evaluated the impact of steatosis on the
response to antiviral therapy and histological outcome in
patients with chronic hepatitis C. Methods: One hundred and
sixty-one consecutive patients (genotype 1, n5 76; genotype 2,
n5 73) receiving interferon a-2b (3 or 5 million U thrice weekly)
and oral ribavirin (1000–1200mg/day) for 24 or 48 weeks were
included. Ninety patients had paired biopsies obtained a mean
of 29.1  7.1 months apart. Results: Variables associated with
baseline steatosis in logistical regression were higher in body
mass index (  25) (odds ratio (OR): 4.832, P5 0.002) and
higher ﬁbrosis stage (  2) (OR: 3.131, P5 0.019). Neither the
presence nor the severity of steatosis was associated with the
sustained virological response (SVR). Evaluation of paired
biopsies demonstrated that the distribution of steatosis evolu-
tion was not different between patients with and without SVR
(P5 0.374). Among patients achieving SVR, there was a sig-
niﬁcant difference in the ﬁbrosis changes between those with nil
or grade 1 steatosis and with grade 2 or 3 steatosis at posttreat-
ment biopsy ( 0.6  1.2 vs. 0.3  1.3, P5 0.032). Stepwise
logistic regression analysis showed that SVR (OR: 16.33,
P5 0.004), nil or grade 1 steatosis at posttreatment biopsy
(OR: 12.82, P5 0.018), and age o50 years (OR: 6.757,
P5 0.053) were independently associated with ﬁbrosis regres-
sion. Conclusion: Although steatosis is not associated with SVR
in our patients, however, it not only correlates with advanced
ﬁbrosis at baseline but also may affect ﬁbrosis regression after
therapy with interferon and ribavirin.
APASL/Poster/Abstract/315
Risk assessment of hepatocellular carcinoma by transient elasto-
graphy apparatus
R. Masuzaki, R. Tateishi, H. Yoshida, S. Obi, S. Sato,
T. Teratani, N. Kato, F. Kanai, S. Shiina, T. Kawabe and
M. Omata
Department of Gastroenterology, University of Tokyo, Tokyo,
Japan
The prognosis and clinical management of chronic hepatitis C
highly depend on the degree of liver ﬁbrosis. Chronic hepatitis C
with cirrhosis is a major risk factor for hepatocellular carcinoma
(HCC). Until recently, liver biopsy was the only way of assessing
liver ﬁbrosis. However, liver biopsy is an invasive procedure that
is not well accepted by patients. Fibroscan (FS) is a novel, rapid,
non-invasive and reproducible method for measuring liver
stiffness. The aim of this study was to identify the efﬁcacy of
FS as a predictor of HCC development. Consecutive patients
with hepatitis C with or without HCC seen in our institution
between September 2004 and February 2005 were included. FS
was performed on the right lobe of the liver through an
intercostal space. Ten validated measurements were performed
on each patient. Conditional logistic regression analysis was
used to determine risk factors of HCC. Age, total bilirubin,
platelet cell counts, liver stiffness obtained by FS, AST to ALT
ratio, albumin, and age were signiﬁcant factors in the univariate
analysis, and liver stiffness obtained by FS (P5 0.0002) and age
(P5 0.0318) were signiﬁcant factors in the multivariate analysis.
The risk increased by a factor of 13.5 when the FS value
doubled. A prospective study is being conducted to conﬁrm
these results further.
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Manifestation and factors associated with YMDD mutant devel-
opment in lamivudine treatment
S. W. Jung, B. H. Do, S. S. Ha, S. K. Kim, S. W. Jeon, C. M.
Cho, W. Y. Tak, Y. O. Kweon, S. K. Kim and Y. H. Choi
Department of Internal Medicine, Kyungpook National Uni-
versity Hospital, Daegu, Korea
Backgrounds: Lamivudine administration can achieve potent
suppression of HBV replication, normalization of ALT and
improvement in liver histology. However, the emergence of
lamivudine-resistant HBV strains has been reported in long-
term lamivudine therapy. Though factors associated with the
frequency of appearance of YMDD mutant have been much
reported, those with the time of emergence have not been. We
sought to examine the factors associated with the time of
appearance of the YMDD mutant, mutant type and each
one’s characteristics. Patients and Methods: This study included
56 patients with chronic hepatitis B who tested positive for
HBsAg, received long-term lamivudine monotherapy and the
YMDD mutant conﬁrmed by CLIP sequencing method. We
investigated liver function tests and HBVDNA copy at baseline,
3 months and 6 months after treatment, the appearance of
mutant and the type of mutant, genotype. Results: The mean
age of patients was 41  11 and the male:female ratio was 41:15.
All cases were genotype C. The mean time of viral and chemical
breakthrough for the appearance of the YMDD mutant was
21  12 months. Age, sex, ALT and HBV DNA at baseline, 3
months and 6 months after treatment did not inﬂuence the time
of appearance of the YMDD mutant. But the higher the HBV
DNA (log10 copies/ml) at 6 months after treatment, the earlier
the mutant appeared. YIDD type was 34/56 (60%), YVDD type
22/56 (40%) and there was no difference about ALT, HBV
DNA at the appearance of the mutant between the two. L528M
accompanied in 43/56 (77%). Conclusion: HBV DNA (log10
copies/ml) at 6 months after lamivudine treatment was asso-
ciated with a more rapid selection of the YMDD mutant.
L528M usually accompanied it. We must study not only clinical
manifestation and prognosis about the emergence of YMDD
and L528M variants, but also investigate the presence of other
mutant variants.
APASL/Poster/Abstract/318
The factor associated with liver abscess recurrence
Kim Suk Bae, Yun S. E. Young, Kim Byung Ha, Shin Jung
Eun, Kim Hong Ja and Song Il Han
Department of Internal Medicine, DanKook University School
of Medicine, CheonAn, Korea
We studied retrospectively 57 patients who were admitted at
DanKook hospital. Liver abscess recurred in six of 57 patients.
The male:female ratio was 1.3:1 in the nonrecurred group but
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the recurred group consisted of all males. The mean average age
was 58.6 years in both groups. The duration of symptoms was
12.8 days in the nonrecurred group and 21 days in the recurred
group. The right lobe was the most frequent site in both groups.
The mean size of abscess was 6.3 cm in the nonrecurred group
and 3.5 cm in the recurred group. PCD insertion rate was lower
with decreased abscess size, with a statistical signiﬁcance of
Po0.01. PCD insertion duration was 12.2 days in the
nonrecurred group and 8.75 days in the recurred group but
there was no statistical signiﬁcance. Klebesiella pneumoniae
(50%) was the most frequent bacteria in the nonrecurred group
followed by Streptococcus and Escherichia coli. E. coli (60%)
was most frequent in the recurred group followed by K.
pneumoniae. E. coli was more often seen in the recurred
group. Admission period was 22.8 days in the nonrecurred
group and 19.8 days in the recurred group. The nonrecurred
group showed a higher PCD insertion rate and longer duration
than the recurred group. The larger the abscess, the higher was
the PCD insertion rate, leading to a lower recurrence rate. E.
coli was isolated in the recurred group more often than in the
nonrecurred group. Aggressive PCD insertion and thorough
drainage seemed to be helpful to prevent abscess recurrence.
When E. coli is isolated, careful follow-up is necessary.
APASL/Plenary/Abstract/319
Vascular response to vasoconstrictor is increased in rabbit model
of non-cirrhotic portal hypertension (NCPH) at one month
Rizvi Moattar Raza1, Jain Anshu1, Bansal Vishal2, Fahim
Mohammad2 and Sarin Shiv Kumar1
1Department of Gastroenterology, G. B. Pant Hospital, New
Delhi,
2Department of Physiology, V. Patel Chest Institute, Delhi,
India
Background: Pathophysiology of non-cirrhotic portal hyperten-
sion (NCPH), a common cause of portal hypertension (PHT) in
Asia, is obscure. Most studies report a decreased responsiveness
to vasoconstrictors in aortic tissue from partial portal vein-
ligated or cirrhotic rats. Aim: To evaluate the responsiveness of
aorta to vasoconstrictors, phenylephrine, PE (a1 adrenergic
receptor agonist) and potassium chloride (KCl) (a classical
membrane depolarizing agent) in an NCPH model at 1 month.
Animals and Methods: PHT was induced by gastrosplenic vein
(GSV) cannulation and repeated Escherichia coli injection. New
Zealand white rabbits were randomly grouped into experimental
animals (n5 6) receiving 4mg/ml of lipopolysaccharide (LPS)
(from heat-killed E. coli) into the portal circulation through an
indwelling cannula placed in GSV; and sham-operated animals
(n5 5) receiving equivalent amount of saline in similar fashion
at 0, 1, 7, 14 and 28 days. Portal pressure (PP) and splenic
weight were recorded in both the groups of animals. The
reactivity of isolated thoracic aortic rings from NCPH and
sham-operated rabbits at 1 month was evaluated by PE (10 12–
10 4) and KCl (15–75mM). Results: At 1 month, the experi-
mental group rabbits showed a signiﬁcant increase in PP
(14.29  1.32 vs 5.94  0.39mmHg, Po0.001) and splenic
weight (0.91  0.17 vs 0.61  0.16 gm, Po0.01) compared
with the sham-operated rabbits. In vitro tension preparation
showed maximum contractile response to PE in intact
(3.36  1.15 vs 1.97  0.91 g; 10 4M, Po0.001) and denuded
(2.47  0.97 vs 1.87  0.75; 10 4M, P5NS) aortic rings from
NCPH rabbits as compared to the sham-operated group. Con-
tractile response to KCl was similarly increased (3.07  1.04 vs
1.46  0.17 g; 75mM, Po0.001) in NCPH rabbits as compared
to sham-operated rabbits. Conclusion: These results demon-
strate that in NCPH animals, there is a paradoxical increase
in the contractile response to vasoconstrictors. This hyperre-
sponsiveness may be due to up-regulation of a-adrenergic
receptor or an increase in intracellular calcium [Ca21]i at the
initial stage of portal hypertension.
APASL/Poster/Abstract/320
The clinical role of hepatitis B virus genotype in hepatocellular
carcinoma type B
A. S. Sulaiman, A. Sulaiman, R. A. Gani, I. Hasan, N. Akbar,
L. A. Lesmana and U. Budihusido
Division of Hepatology, Department of Internal Medicine,
Faculty of Medicine University of Indonesia, Jakarta, Indonesia
Background: Hepatitis B virus (HBV) is one of the major
causative agents associated with hepatocellular carcinoma
(HCC) in Southeast Asia where the HBV genotype B (HBV/
B) and genotype C (HBV/C) are prevalent. The role of hepatitis
B virus genotypes on the clinical features and prognosis of
patients with hepatocellular carcinoma is currently uncertain.
The aim of the present study was to evaluate the distribution of
HBV genotypes in HCC patients and their clinical relevance.
Methods: A total of 21 patients with HCC were enrolled. HCC
was diagnosed by a combination of a fetoprotein (AFP) and CT
scanning. HBV genotypes were determined by nested polymer-
ase chain reaction (nPCR) using genotype-speciﬁc primers. The
clinical data were analyzed in relation to the HBV genotype
including age, sex, liver function test, Okuda stage, and survival.
Result: HBV genotypes B and C were predominant in this
study, accounting for 16 (76.2%) and 5 (23.8%), respectively.
Genotype B with Okuda criteria 1 or 2 was 4 (25%) and 12
(75%), respectively, whereas Genotype C with Okuda criteria 1
or 2 was 1 (20%) and 4 (80%), respectively. Regardless of
Okuda criteria, median survival rate for genotype B was 166
days and for genotype C was 60 days. However, there were no
statistical differences between those genotypes regarding tumor
staging by Okuda criteria and the overall median survival.
Conclusion: This study could not exhibit the association be-
tween genotypes and other parameters including group of age,
sex, liver function test, AFP, and Okuda criteria. The prognostic
of HCC patients with genotype C may be less than that of
genotype B.
APASL/Plenary/Abstract/321
Viral hepatitis in pregnancy; etiology, clinical course and out-
come: a study of 144 patients
S. Patra1, S. S. Trivedi1, M. Wadhwan2, S. Hissar1, B. C.
Sharma2 and S. K. Sarin2
1Department of Obstetrics and Gynaecology, Lady Hardinge
Medical College,
2Department of Gastroenterology, G. B. Pant Hospital, New
Delhi, India
Background: Severity of viral hepatitis in pregnancy and its
inﬂuence on the mother and the fetus are areas of continued
investigation. There is paucity of data on the etiology, clinical
course and outcome of viral hepatitis in pregnancy. Patients and
Methods: Consecutive pregnant women with viral hepatitis
were included in the study. The etiology, clinical course and
feto-maternal outcome were prospectively assessed. Results: In
all, 144 pregnant women (mean age 22.3  3.1 years) in gesta-
tional ages between 13 and 38 weeks (median gestational age
32.3 weeks), 69% third trimester and 31% in second trimester
were included. The etiology of viral hepatitis was hepatitis E
(HEV) in 58.2%, HBV in 32.6%, hepatitis A (HAV) in 0.6%,
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HCV in 7.6% and co-infection in 1.3%. The maternal compli-
cations were coagulation defect 56%, postpartum hemorrhage
20%, acute renal failure 18%, gastrointestinal bleeding 12.5%
and ascites 17.3%. Of the 144 women, 61 (42.3%) had fulminant
hepatic failure (FHF) (HEV 77%, HBV 23%). Of the 61 FHF
women, 41 (67%) died (HEV 90% and HBV 9.8%, Po0.05).
Maternal mortality was two times higher in the third compared
to the second trimester (28.2% vs 13.1%) (Po0.01). The causes
of death were cerebral edema 48.7%, hepato-renal failure
29.2%, postpartum hemorrhage 21% and multiorgan failure
7%. The perinatal mortality rate was 56.2%. There were 37
(25.6%) live births, 59 (40.9%) stillbirths and 22 (15%) neonatal
deaths. Perinatal mortality was 56% in acute viral hepatitis and
100% in FHF (Po0.01). Perinatal mortality was higher in
women with HEV than in those with HBV (65.4% vs.30.8%,
Po0.01). Conclusion: Based on the results of this very large
prospective study, hepatitis E is found to be the commonest
cause of viral hepatitis and FHF in pregnancy in India. This is
associated with a very high maternal–perinatal morbidity and
mortality, which increases as the gestation advances.
APASL/Poster/Abstract/322
Prompt diagnosis of spontaneous bacterial peritonitis and analysis
of ascitic ﬂuid protein content by reagent strip
J. Jearjesdakul and A. Chutaputti
Division of Gastroenterology and Liver Disease, Department of
Medicine, Phramongkutklao Hospital, Bangkok, Thailand
Introduction: Ascitic ﬂuid PMN count remains a crucial tool in
diagnosing spontaneous bacterial peritonitis (SBP), but may not
be done promptly in some situations. A few studies have shown
the accuracy of reagent strip test for diagnosing SBP. The
objective of this study is to evaluate the use of reagent strip in
Thailand, Combur10TestsM, which is different from that used in
previous studies, for diagnosing SBP and detection of ascitic ﬂuid
with low protein content. Patients and Methods: One hundred
and seventeen ascitic ﬂuid samples of 72 cirrhotic patients were
analyzed by PMN count and 113 samples for protein measure-
ment. Granulocyte esterase strip results for diagnosis of SBP, and
protein strip results for detection of ascitic ﬂuid with low protein
content (o1 g/dl) were compared to the corresponding routine
measurement. Results: Of the 12 samples with ascitic ﬂuid,
PMN4250 cells/mm3, seven samples were diagnosed as SBP by
reagent strip. No samples were diagnosed as SBP by reagent strip
in the samples with PMNo250 cells/mm3. The sensitivity, speci-
ﬁcity, positive predictive value (PPV) and negative predictive
value (NPV) for diagnosis of SBP by reagent strip were 58%,
100%, 100% and 95%, respectively. Of the 13 samples with
ascitic ﬂuid proteino1 g/dl, 18 samples were diagnosed correctly
by reagent strip. Of the remaining 80 samples with ascitic ﬂuid
protein41 g/dl, 57 samples were diagnosed correctly by reagent
strip. The sensitivity, speciﬁcity, PPV and NPV for detecting
ascitic ﬂuid with proteino1 g/dl by reagent strip were 55%, 71%,
44% and 79%, respectively. Conclusion: The reagent strip test
can be used for prompt diagnosis of SBP with speciﬁcity and PPV
of 100%. The clinical application for protein measurement is not
as reliable as conventional laboratory because of low PPV and
NPV.
APASL/Poster/Abstract/323
Comparison of prevalence and clinical features of autoimmune
liver diseases in Japan and other countries
H. Ishibashi1,2,3,4, K. Takegoshi2, Y. Motoo2, T. Morizane3 and
G. Toda4
1National Hospital Organization Nagasaki Medical Center,
Omura, Nagasaki, Japan,
2Fellows’ Association of Japanese Society of Internal Medicine,
3US-Japan Meeting on Autoimmune Liver Diseases,
4Study Group for the Intractable Diseases of the Liver in Japan,
Japan
The prevalence of primary biliary cirrhosis (PBC) and other
autoimmune liver disease (AILD) reportedly varies widely
among countries. The aim of this study is to compare the
prevalence and clinical presentations of AILD between Japan
and other countries by analyzing cases seen during the same
period using the same diagnostic criteria. The design is a
prospective case series of consecutive patients referred to in-
stitutes. Patients with AILD who visited physicians during four
months were enrolled. The number of patients with HBV- or
HCV-chronic liver diseases seen during the same period were
used as a reference. Totally, 24 135 cases were enrolled from 72
institutes in Japan, of which 1960 cases (8.1%) were
AILD, while in total 3501 cases were from outside Japan, of
which 58cases (1.6%) were AILD. The prevalence and the
features of AILD were quite different among countries. The
prevalence of AILD was extremely low in Korea and India. The
prevalence of PBC was higher than AIH in Japan but it was
inverted in Korea, India and Egypt. Less symptomatic cases of
AIH and PBC are more frequent in Japan than in other
countries. Though some bias should exist, the AILD is unevenly
distributed in the world.
APASL/Poster/Abstract/324
PBMC is the home of HBV, or just the hotel?
Hongshan Wei, Qingming Dong, Hui Zhuang, Zhiying Liu,
Sujing Song, Jingjing Guo and Jun Cheng
Institute of Infectious Disease, Ditan Hospital, Beijing, China
It is known that covalently closed circular DNA (cccDNA)
persists throughout the natural history of chronic hepatitis B,
even in patients with serologic evidence of viral clearance. Long-
term antiviral therapy signiﬁcantly decreased cccDNA levels by
a primarily noncytolytic mechanism. At present, the method of
monitoring of HBV cccDNA levels only focuses on infected
human liver biopsies. We presumed that, if the cccDNA
persisted in PBMCs, its levels could be used for monitoring
long-term anti-HBV therapy. Based on this hypothesis, the
present study aims at (i) whether or not there are cccDNA in
PBMCs of HBV DNA positive serum and (ii) and the cccDNA
mainly inhabited CD41T cells, CD81T cells, or other PBMCs.
Methods: A ﬂuorescence quantitative polymerase chain reac-
tion (PCR) for detection of HBV cccDNA in serum was
established using two pairs of primers designed according to
the relatively conservative sequences between the gap upstream
and downstream of HBV DNA plus and minus strands. A
positive reference panel was developed from a HBV recombi-
nant plasmid for the quality control of the assay. PBMCs were
isolated by Ficoll–Hypaque density-gradient centrifugation. BD
FACSCalibur was used to isolate CD41, CD81, T, and other T
cells. Results: The linear correlation equation between thresh-
old cycle value (Ct) and the logarithm of cccDNA initial copies
is as follows: Y5  3.588X155.228; the correlation coefﬁcient is
0.999, and efﬁciency of PCRIS 90.0. The minimum detection
level of the assay is 6  103 copies/ml of cccDNA. The linear
range of the assay is 5  104–5  109 copies/ml of cccDNA. The
range of total HBV DNA/cccDNA ratio detected in serum of
patients with hepatitis B is 66.3  15.2 (2.62–341.98), with a
median of 24.7. HBV cccDNA was detected in CD41 T cells but
not in CD81 T cells. Conclusion: The ﬂuorescence quantitative
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polymerase chain reaction for detection of HBV cccDNA in
serum is simple and highly sensitive, speciﬁc and reproducible. It
can be used for detection of HBV cccDNA in serum to evaluate
the efﬁcacy of antiviral treatment for patients with chronic
hepatitis B. HBV cccDNA in CD41 T cells may be related to
persistence of HBV infection.
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Genotypes of hepatitis B virus infection in the Philippines
J. Sollano1, A. Quino1, T. Sakamoto2, Y. Tanaka2, S. Wong2,
A. Lay1, H. Clavio1 and M.Mizokami2
1Section of Gastroenterology, University of Santo Tomas
Hospital, Manila, Philippines,
2Department of Clinical and Molecular Informative Medicine,
Nagoya City University Graduate School of Medical Sciences,
Nagoya, Japan
Background/Aims: In Asia, the predominant hepatitis B virus
(HBV) genotypes are A, B and C. In Southeast Asia, the most
common genotypes are B and C. There has been no large
population study on hepatitis B virus (HBV) genotypes in the
Philippines to date; thus, the objective of this study is to
determine the predominant HBV genotypes in Filipino patients
with chronic hepatitis B (CHB), liver cirrhosis (LC) and
hepatocellular carcinoma (HCC). Patients and Methods: Betw-
een January 2001 and January 2005, sera from patients with
HBV-associated chronic hepatitis (n5 31), liver cirrhosis
(n5 37) and liver cancer (n5 40) seen in the Liver Clinic of
the UST Hospital were collected and stored in our  80C deep
freeze facility. To determine the genotypes, they were subjected
to restriction fragment length polymorphism (RFLP) described
earlier by Mizokami et al. (FEBS Lett 1999; 450:66–71).
Results: The most common genotypes in all disease forms of
HBV are A, B and C. In chronic hepatitis, the most common
genotypes are A (77%), B (13%) and C (10%). In liver cirrhosis,
the common genotypes are A (41%), C (41%) and B (18%).
Likewise, in hepatocellular carcinoma, the predominant geno-
types are A (38%), B (38%) and C (24%). HBeAg (1) disease is
noted in 82% of genotype A, 85% of genotype B and 79% of
genotype C. Conclusion: Among the Filipino patients, genotype
A is the most predominant HBV genotype. The most common
genotypes noted are genotype A in CHB, genotypes A and C in
liver cirrhosis and genotypes A and B in hepatocellular carci-
noma.
APASL/Free Paper/Abstract/327
cccDNA levels and histologic response in Filipino chronic hepatitis
B patients treated with nucleoside analogues
J. Co, G. Nilo, F. Dy, S.Wong, A.Lay, J.Clavio and J.Sollano
Section of Gastroenterology, University of Santo Tomas
Hospital, Manila, Philippines
Background: Hepatitis B virus (HBV) covalently closed circular
DNA (cccDNA) is a replicative intermediate responsible for
viral persistence and reactivation after treatment withdrawal.
Recently, studies involving nucleoside analogue therapy reveal
substantial reduction of cccDNA and serum HBVDNA post
treatment. Objective: We aim to describe the relationship of
intrahepatic cccDNA concentration with histopathologic changes
in chronic hepatitis B (CHB) before and after nucleoside analogue
treatment. Methods: Liver biopsy was done on 17 consecutive
HbeAg (1) Filipino CHB patients with elevated serum alanine
transaminase (ALT)42  ULN. Intrahepatic cccDNA, total he-
patic and serum hepatitis B virus DNA (HBVDNA) were deter-
mined and correlated with Knodell and Ishak histologic scores
using Pearson’s correlation. Serum and hepatic HBVDNA, in-
cluding ALT, were likewise correlated with cccDNA levels by
linear regression. Results: Mean cccDNA pre-treatment level was
5.7  7.3HGEq as compared to 1.1  1.7HGEq post treatment
(P5 0.025). Mean total hepatic HBVDNA pre-treatment levels of
453.5  558.0HGEq decreased signiﬁcantly to 40.4HGEq post
treatment (P5 0.009). Mean pre-treatment serum HBVDNA
reduced from 411580016956 cpm to 1507 335  4264cpm after
treatment (P5 0.165). Baseline mean Knodell scores were
4.4  3.4 and 2.5  2.1 pre- and post-treatment, respectively
(P5 0.07). Mean Ishak scores pre- and post-treatment were
4.5  3.2 and 3.0  2.4, respectively (P5 0.18). Reduction of
hepatic cccDNA after treatment correlates signiﬁcantly with
lower Knodell and Ishak scores (P5 .003 and 0.024, respectively).
cccDNA levels correlate directly with serum and total hepatic
HBVDNA (P5o0.001). Most patients with pre-treatment
cccDNA levels above 4.38HGEq were found to have higher
Knodell and Ishak scores. Conclusion: Low levels of post-treat-
ment cccDNA are noted in patients with lower serum and total
hepatic HBVDNA, as well as in those with improvement in liver
histology.
APASL/Free Paper/Abstract/328
Baseline factors affecting disease progression in chronic hepatitis
B (CHB) patients with advanced ﬁbrosis or cirrhosis
J. J. Y. Sung1, Y. F. Liaw2, G. Farrell3, W. C. Chow4, J. S.
Dixon5, O. N. Keene5 and J. Sabbat6
1Dept of medicine &Therapeutics, The Chinese University of
Hong Kong, Hong Kong,
2Chang Gung Memorial Hospital and University, Taipei, Tai-
wan,
3Storr Liver Unit, Westmead Millenium Institute, Sydney,
Australia,
4Singapore General Hospital, Singapore,
5GlaxoSmithKline, Greenford, UK,
6GlaxoSmithKline, Singapore
Introduction: Lamivudine reduces disease progression in pa-
tients with advanced CHB (Liaw New Engl J Med 2004).
Additional factors affecting disease progression were investi-
gated.Methods: A total of 651 CHB patients with histologically
conﬁrmed cirrhosis or advanced ﬁbrosis were randomised 2:1
(double-blind) to lamivudine 100mg/day or placebo for  5
years. The primary endpoint was time to disease progression,
deﬁned by  2 points increase in Child–Pugh score or occur-
rence of hepatocellular carcinoma (HCC). The study was
stopped after the second interim analysis showed a clear beneﬁt
for lamivudine. Results were analysed by covariate modelling of
time to disease progression using a Cox’s proportional hazard
model to identify factors which had signiﬁcant impact on
outcome. Results: Endpoints occurred in 34/436 (8%) of pa-
tients on lamivudine and 38/215 (18%) on placebo (hazard ratio
(HR) 0.45, 95%CI 0.28–0.73, P5 0.001). Other factors with a
signiﬁcant impact on outcome included Child–Pugh score 6 vs 5
(Po0.001), Child–Pugh score 7F9 vs 5 (Po0.001), age per 10-
year increase (P5 0.003), ﬁbrosis score 6 vs  4 (P5 0.036). In
another analysis of patients with known HBV genotypes, 68%
had genotype C, 28% B and 4% others. Among patients with
genotype C, endpoints occurred in 5% (15/275) receiving
lamivudine and in 19% (26/137) receiving placebo. Increase in
Child–Pugh score occurred in 4% (10/275) and 9% (12/137),
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respectively, and occurrence of HCC in 2% (5/275) and 8% (11/
137), respectively. For the smaller group with genotype B, there
was no apparent difference in treatment responses. Conclusion-
s: Along with therapy, baseline Child–Pugh score, age and
ﬁbrosis score signiﬁcantly impacted on disease progression.
APASL/Poster/Abstract/329
The accuracy of clinical diagnosis criteria of Korea Liver Cancer
Study Group-National Cancer Center practice guidelines for
hepatocellular carcinoma
J. W. Park, M. An, J. A. Shin, K. W. Park, J. I. Choi, S. H. Kim,
W. J. Lee, S. J. Park, E. K. Hong and C. M. Kim
Center for Liver Cancer, National Cancer Center, Goyang,
South Korea
Background: Pathologic studies are the conﬁrmative diagnosis
of hepatocellular carcinoma (HCC) but have shown that many
small nodules do not correspond to HCC, and tumor seeding
after biopsy is signiﬁcant. Non-pathological (clinical) criteria of
HCC have therefore been suggested by the Barcelona-EASL
conference and Korean guidelines. However, there are no data
to support the usefulness of the clinical criteria of HCC. In this
study, our aim was to validate the accuracy of clinical diagnosis
of the KLCSG-NCC guidelines for HCC in the cohort of
patients admitted to NCC Korea. Method: The database of
232 patients who were examined completely for clinical diag-
nosis criteria and underwent surgical resection or liver biopsy
for hepatic mass in the NCC from 2001 to 2004 were reviewed
retrospectively. Result: One hundred and eighty-six cases of
HCC were conﬁrmed by pathologic examination and 189 cases
of HCC were diagnosed with clinical diagnosis criteria. The
sensitivity, speciﬁcity and positive predictive value of clinical
diagnosis criteria of HCC were 95.1%, 73.9% and 93.7% ,
respectively. There was no statistical difference of sensitivity and
positive predictive value of the criteria for HCC according to
tumor size, stage and the presence of cirrhosis. The sensitivity in
the HBV positive and negative groups was 97.3% and 86.8%,
respectively (Po.001) and the speciﬁcity was 56.5% and 91.3%,
respectively (Po.001). Conclusion: The clinical diagnosis criteria
of KLCSG-NCC for HCC had high sensitivity and positive
predictive value irrespective of the presence of cirrhosis, tumor
size and stage.
APASL/Poster/Abstract/330
Characteristics of HBV genotypes among chronic liver diseases in
the Philippines
Jose Sollano, Jr.1, Alvin Quino1, Jonard Co1, Yasuhito
Tanaka2, Tomoyuki Sakamoto2 and Masashi Mizokami2
1Section of Gastroenterology, University of Santo Tomas Hos-
pital, Manila, Philippines,
2Depatment of Clinical Molecular Informative Medicine, Na-
goya City University Graduate School of Medical Sciences,
Nagoya, Japan
Background/Aim: Hepatitis B virus (HBV) is classiﬁed into
eight genotypes. In Asia, HBV genotype B (HBV/B) and C
predominate, however HBV/A is also found in the Philippines.
Recently, several subtypes, HBV/Aa, Ae, Baand Bj, were
reported and clinical differences between the patients infected
with these subtypes are coming to the fore. In this study, we
investigated HBV genotype distribution among patients with
chronic liver diseases (CLD) in the Philippines. Methods: A
total of 100 sera were obtained from CLD patients, consisting of
32 chronic hepatitis (CH), 37 cirrhosis and 31 hepatocellular
carcinoma (HCC). HBV genotypes and subtypes were mainly
determined by sequencing and molecular evolutionary analyses.
ALT and HBeAg were examined by Integra (Roche) and
Elecsys (Roche), respectively. Results: In the CH patients,
mean age was signiﬁcantly lower and HBeAg positivity was
higher. A phylogenetic analysis showed that 32 HBV/Aa, 37
HBV/Ba and 31 HBV/C strains were found in this study.
Interestingly, the HBV/C strains in the Philippines had the
speciﬁc cluster distinct from previous HBV/C strains from the
database. Comparing age, sex, HBeAg and HBV genotypes
among the CLD patients, only the HBV genotype was asso-
ciated with disease progression; HBV/Ba or C was signiﬁcantly
highly prevalent in cirrhosis or HCC compared to HBV/Aa
(Po0.003). In the HCC patients with the three genotypes (Aa ,.
Ba and C), there were no signiﬁcant differences of age, sex and
HBeAg positivity. Conclusion: In the Philippines, three HBV
genotypes, HBV/Aa, Ba and C, were prevalent, and a possible
novel subtype of HBV/C was found. HBV/Ba or C would be
associated with disease progression.
APASL/Poster/Abstract/331
Hepatocellular carcinoma with hypoglycemia (case series)
Sutanto Maduseno, Siti Nurdjanah, Putut Bayupurnama and
Neneng Ratnasari
Division Gastroenterohepatology, Internal Medicine, Medicine
Faculty, adjah Mada University, Dr. Sardjito Hospital, Yogya-
karta, Indonesia
Introduction: Hypoglycemia is the most frequent endocrine
emergency, which mostly occurred in diabetic patients as the
consequence of treatment and hypoglycemic medication. Hy-
poglycemia that happens in non-diabetic patients needs atten-
tion because it could be serious depending on its cause. Fasting
hypoglycemia is most frequently due to insulinomia, which is an
islet cell tumor that secretes insulin and is rarely caused by a
non-islet tumor, which originates from hematopeotic. Big me-
senchimal tumors that grow in the abdominal retro peritoneum
or chest were involved in half of all cases. Hepatocellular
carcinoma, gastrointestinal carcinoma, carcinoid and carcinoma
adrenocortical frequencies were 25% and of the rest 25% were
other carcinoma. Hypoglycemia frequently occurs in patients
with big hepatocellular carcinoma. A national study in Japan
found 20 cases from 2599 patients with a frequency of 0.8%.
Other authors reported hypoglycemia frequency in hepatocel-
lular carcinoma o0.1%. Method: Case series. Time-line: Jan-
uary 2004to April 2005. Result: We found ﬁve hypoglycemia
cases out of the 57 in the hepatocellular carcinoma cases, with a
frequency of 8.77%. The diagnosis of hepatocellular carcinoma
was established based on biopsy and ﬁne needle aspiration in
four cases and based on USG examination in one case. The
causes of hepatocellular carcinoma were hepatitis B in three
cases, hepatitis C in one case, and unknown in one case . The
blood glucose level varies between 34 and 44mg/dl. Generally,
the patient comes with the most frequent complaint of fatigue
and sweating as hypoglycemic management is by bolous 40%
glucose and maintenance using D 10% infusion. Out of the ﬁve
cases, two of them died due to septic shock and two of them had
repeated hypoglycemic episodes.
APASL/Young Investigator/Abstract/332
Hepatic venous pressure gradient and disease severity in acute-on-
chronic liver disease
K. Das, M. Wadhawan, P. Tyagi, B. C.Sharma and S. K. Sarin
Department Of Gastroenterology, G B Pant Hospital, New
Delhi, India
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Introduction: Hepatic venous pressure gradient (HVPG)
is an important factor in the prediction of variceal hemorrhage.
Due to the paucity of data on portal hemodynamics and disease
severity, indices in acute-on-chronic liver disease (ACLD), we
evaluated the HVPG and disease severity in patients with acute
on chronic liver disease. Patients and Methods: Ninety-nine
patients were recruited, which included compensated chronic
liver disease (CLD) (n5 25), decompensated CLD (n5 48) and
ACLD (n5 26). ACLD was deﬁned as acute deterioration in
liver function in a pre-existing patient of chronic liver disease,
over a period of 2–4 weeks, leading to severe deterioration in
clinical status in the form of ascites, high jaundice and/or
complications of CLD such as hepatic encephalopathy and/or
hepatorenal syndrome (HRS). HVPG was measured by the
standard technique. Liver disease severity was calculated
using the Child–Pugh–Turcot (CPT) score and MELD score.
Results: Of the 99 patients, etiology of CLD was hepatitis B
(n531), alcoholic liver disease (n524), hepatitis C (n57), Wilson
disease (n52), autoimmune hepatitis (n51) and cryptogenic CLD
(n533). Conclusion: HVPG in acute-on chronic liver disease is
similar to compensated CLD but lower than decompensated CLD.
MELD score is signiﬁcantly higher in acute-on chronic liver disease
than in compensated and decompensated CLD.
333
Abstract withdrawn
334
Abstract withdrawn
335
Abstract withdrawn
APASL/Poster/Abstract/337
Prevalence of hepatitis B virus genotypes among patients with
chronic liver disease in Jakarta
Unggul Budihusodo
Hepatology Division, Department of Internal Medicine, Fa-
culty of Medicine, University of Indonesia, Jakarta
Background/Aims: Differences in clinical features and in re-
sponse to antiviral treatments were known among patients
infected with different hepatitis B virus (HBV) genotypes.
Serological HBV-genotyping assays were conducted to observe
the prevalence of HBV genotypes among patients with chronic
liver diseases in Jakarta. Methods: Sera from patients with
chronic hepatitis (CH), liver cirrhosis (LC), and hepatocellular
carcinoma (HCC) were selected at random, and HBV genotypes
were tested by ELISA at The Department of Clinical Molecular
Informative Medicine, Nagoya City University Graduate
School of Medical Science, Nagoya, Japan. (under Professor
Mizokami). Results: One hundred sera collected from 57 patients
(46 males, 11 females) with CH, 32 patients (18 males, 14 females)
with LC, and 11 patients (8 males, 3 females) with HCC, were
tested for HBsAg, anti-HBs, anti-HBc, and HBV genotypes, as
well as anti-HCV. The mean age and age range of CH, LC, and
HCC patients were 39.6 years (19–75 years), 53.4 years (22–71
years) and 53.2 years (26–74 years), respectively. HBsAg was
detected in 36 (36%) sera, while 35 (35%) sera were positive for
anti-HCV, of which 1 (1%) serum was positive for both
markers. It was interesting to note that 89 (89%) of the sera
were anti-HBc-positive. There were 30 (30%) sera that showed
negative results for HBsAg and anti-HCV as well, although most
(26 sera or 87%) of them were anti-HBc-positive, which meant
that there was the possibility that they were suffering from occult
HBV infection. Among the 36 HbsAg-positive sera, HBV geno-
type B was detected in 31 (86%), genotype C in 2 (6%), genotype
D in 1 (3%), and the other 2 (6%) were untypeable. All genotype B
infections were of the Ba (Asia) type; none were of the Bj
(Japan) type. Conclusion: Infection with HBV is common among
patients with chronic liver diseases in Jakarta, and is comparable
with HCV infection. The most prevalent HBV genotype is
genotype B (Ba), while the minor genotypes are genotypes C
and D.
APASL/Free Paper/Abstract/338
Co-infection of HBV, HCV and HIV in Cipto Mangunkusumo
Hospital, Jakarta
Rino A. Gani1, E. V. Y. Yunihastuti2 and Sjamsurizal Djauzi3
1Division of Hepatology, Department of Internal Medicine
Medical Faculty,
2University of Indonesia/Cipto Mangunkusumo Hospital,
Jakarta,
3POKDISUS Cipto Mangunkusumo Hospital, Jakarta
Background: Patients with co-infection of hepatitis C virus
(HCV) and human immunodeﬁcient virus (HIV) tended to be
increased in recent years due to an increased number of injection
drug users (IDU). Co-infection of these viruses has been
reported to worsen the natural history of each other. This has
drawn more attention to explore this condition further. Until
now, there have been few published reports about co-infection
of HIV and hepatitis viruses, especially from developing coun-
tries around Asia–Paciﬁc where hepatitis B viruses (HBV) and
HCV were prevalent.Method: This is a retrospective analysis of
medical records from patients who were treated in our institu-
tion, and tertiary centers in Indonesia, for 1 year (January 2004–
December 2004). Aim: To reveale patients’ proﬁles and clinical
conditions of HCV–HIV co-infected patients and compare it to
non-co-infection patients. Results: In all, 313 patients who are
HIV positive have been examined for HCV infection by means
of anti-HCV. Co-infection of HCV–HIV was detected in 253
(80.8%) cases. Male:female sex ratio in HIV patients was 4:1,
whereas in HCV–HIV co-infection patients it was 27.1:1
(P5 0.0001). Modes of transmission in HIV patients were
mostly through sexual relationships (28/60, 46.7%) and in
HCV-HIV co-infection were mostly through injection drug
users (218/253, 86.2%). Hepatitis B virus infection was detected
in 6 (10%) patients of the HIV group and 17 (6.7%) patients in
the HCV–HIV co-infection group, but the difference were not
signiﬁcant. ALT level in patients with HCV–HIV co-infection
was signiﬁcantly higher than in patients with HIV, which
was 68.8  170.6U/l vs. 44.4  50.7U/l (P5 0.004).
Mean CD4 level in HIV patients was 193.4  230.5 cells/ml,
compared to 182.1  221.4 cells/ml in HCV-HIV patients that
was not signiﬁcantly different. Hepatotoxicity of anti-retroviral
therapy was found in 2/26 patients (7.7%) without HBV or
HCV infections, 1/3 (33.3%) in patients with co-infection
with HBV, 51/127 (40.2%) in patients with co-infection of
HCV and 3/6 (50%) in patients with co-infection of HBV–
HCV (P5 0.014). Conclusion: There is a tendency of more
aggressive HIV prognosis in patients with HCV–HIV co-infec-
tion. Co-infection of hepatitis viruses in HIV patients may
worsen the prognosis because of higher hepatocellular damage
and increase the likelihood of hepatotoxicity in treatment with
ART.
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Genotype of hepatitis B virus in patients with chronic hepatitis B
and hepatocellular carcinoma in RSCM-Jakarta
Irsan hasan, Rino A. Gani, Andri S. Sulaiman, L. A. Lesmana,
Ali sulaiman and Nurul akbar
Hepatology Division, Medical Faculty University of Indonesia,
Indonesia
Eight genotypes of hepatitis B virus (HBV), A–H, have been
described on the basis of the similarity of the complete genome
sequence. Information on HBV genotypes is important, since
many studies reported the relationship between the HBV
genotype and its clinical manifestation, natural course, and
also the response to antiviral treatment. The aim of this study
is to ﬁnd the pattern of genotype in HBV infection in patients
with chronic hepatitis B and hepatocellular carcinoma. A total
of 20 chronic hepatitis B and 29 hepatocellular carcinoma
(HCC) serum samples obtained from patients came to RSCM,
Jakarta. The HBV genotypes were determined in their sera by a
genotyping system based on polymerase chain reaction (PCR)
using type-speciﬁc primers. Only genotypes B and C HBV were
identiﬁed in chronic hepatitis B patients. Eighteen (90%)
patients were infected by genotype B HBV and only 2 (10%)
patients with genotype C. Nineteen (65%) genotype B and 5
(17%) genotype C were found in HCC serum samples. These
results indicate that genotype B is predominant in our chronic
hepatitis B patients; this is similar to previous studies, which
reported that genotypes B and C were conﬁned to populations
with origins in eastern Asia. Genotype C was higher in HCC
than in chronic hepatitis B patients, suggesting that the natural
history of HBV infection with genotype C may be worse than
that with genotype B.
APASL/Poster/Abstract/340
Protective effect of soybean on hepatotoxicity of acetaminophen
induction
Troef Soemarno
Department of Pathology, School of Medicine, Airlangga Uni-
versity, Surabaya, Indonesia
Objective: Soybeans containing lecithin have a protective
effect. Acetaminophen, widely used as a nonprescription an-
algesic and antipyretic, causes hepatic necrosis. Method: As
many as 40 Rattus norvegicus were used. Twenty rats were given
only three times acetaminophen 50mg/body weight for as long
as 10 days, while the 20 remaining rats were given three times
1ml soybean extract followed by acetaminophen, which was
given at a dose similar to the treated group. After 10 days of
observation, the two groups were mechanically scariﬁed, and the
livers were processed for histopathogic examinations. Micro-
scopic ﬁndings from the two groups were compared with
each other. Result: Both groups showed zonal necrotic
hepatic, which visually gave no difference in microscopic
ﬁndings. Conclusion: From this observation it could be con-
cluded that soybean extract, which contains lecithin, has no
function in protection against the hepatotoxic effect of acet-
aminophen.
APASL/Free Paper/Abstract/341
Knowledge of hepatitis C among primary care doctors working in
allied hospitals of Rawalpindi Medical College, Rawalpindi
Z. M. Minhas, M. Umar, A. Rizwan, B. Khar, M. Khurram and
M. Saleem
Rawalpindi Medical College, Rawalpindi, Pakistan
This cross-sectional study was conducted to assess the ‘knowl-
edge of hepatitis C virus among primary care doctors’, of allied
teaching hospitals of Rawalpindi Medical College Rawalpindi,
in December 2004. A self-administered proforma was designed
and pre-tested to conduct the survey. Three trained interviewers
conducted the survey. The response rate was 98%. Simple
frequencies, associations by Pearson w2 test and independent
sample test for continuous variables were analyzed using SPSS
version 10.0. Out of 100 interviewed doctors, 41 (41%) had
completed 1 year after graduation, 29 (29%) 2 years, 26 (26%) 3
years, one (1%) 4 years, and three (3%) 5 years. Twenty-nine
(29%) have seen fewer than 10 patients, 37 (37%) have seen 11–20
patients, and 34 (34%) have seen more than 20 patients in the past
year. Eighty-six (86%) have graduated from Pakistan, while only
14 (14%) graduated from other countries. When asked about
testing of HCV, 56% recommended HCV testing of those with
raised ALT level, 64% those with history of drug abuse, 55%
those with a history of blood transfusion, 42% those with multi-
ple tattooing and 8% recommended HCV testing all the people.
Regarding routine vaccination for HAV (negative for antibodies)
and HBV (negative for antibodies) in HCV-positive patients, 44%
and 78% would vaccinate these patients. In all, 41% recom-
mended vaccination for HCV (negative for antibodies) persons,
while 70% would treat the patients with recommended combina-
tion therapy of a-interferon and ribavarin. Of them, 43% said
that information regarding HCV is not enough. Most of the
primary care residents lack knowledge of recommended guidelines
for the management of HCV infected patients and many do not
test when required and many test in inappropriate situations.
Many do not have an idea of combination treatment. Regular
educational programmes are needed to control the spread, early
diagnosis and proper treatment of the disease.
APASL/Free Paper/Abstract/342
Improved survival with screening for hepatocellular carcinoma in
cirrhosis and chronic hepatitis B
E. Gane, J. Fung, J. Mccall and A. Holden
Background: Hepatocellular carcinoma (HCC) is the ﬁfth
most common malignancy worldwide with the major risk factor
being liver cirrhosis. Survival for patients who present with
symptomatic HCC is poor. We report our experience with HCC
screening in chronic hepatitis B and liver cirrhosis in conjunc-
tion with our National Hepatitis B Screening programme.
Methods: All patients referred for management of HCC
have been followed by the New Zealand Liver Transplant
Unit, including all cases detected through the national
hepatitis B screening programme (since 1999). Demographic,
laboratory, treatment and outcome data were collected in all
patients. Screening was performed with 6-month serum
alpha-fetoprotein (AFP) measurements  ultrasound or CT
imaging. The impact of screening on tumour stage, suitability
for treatment, and survival was determined. Results: A total of
421 cases were reviewed, of which 339 were included in this study.
Patients were excluded if there was incomplete data or if the
tumour was detected following transplant. Of the screen-detected
HCC cases, 72% had a single HCC, 81% had HCC restricted to a
single lobe and 74% had tumour size less than 5 cm.
Of the nonscreen-detected HCC patients, 46% had a single
HCC, 56% had HCC restricted to a single lobe and 19% had
tumour size less than 5 cm (Po0.001, w2 test). In total, 73%
in the screened patients received treatment for their
HCC (transplantation in 40%, resection in 22%, radiofrequency
ablation/transarterial chemoembolisation in 16%) compared to
10% in the non-screened patients (transplantation in 1%, resec-
tion in 6% and radiofrequency ablation/transarterial chemoem-
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bolisation in 3%) (Po0.001). Advance tumour stage
(CLIP score  2) was seen in 90% of the nonscreened HCCs
compared with 29% of the screened HCCs (Po0.001). In all,
46% of the nonscreened tumours had serum AFP of greater than
1000ng/ml compared with 16% in the screened tumours
(Po0.001). Median survival from diagnosis was 1313 days in
screened cases and 83 days in nonscreened cases. One- and 5-year
cumulative survival was 79% and 49% in the screened cases,
compared to 17% and 2% in non-screened cases (Po0.0001;
Logrank Test). Summary: These results suggest that screening
for HCC in high-risk populations (chronic hepatitis B or cirrhosis
of any cause) may improve survival, provided liver transplanta-
tion is available.
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APASL/Poster/Abstract/344
Hepatic arterial infusion chemotherapy by using reservoir for the
treatment of advanced HCC
M. Yoshikawa, M. Sunaga, M. Ebara, H. Fukuda, S. Okabe
and H. Saisho
Gastroenterology, Chiba University School of Medicine, Chiba,
Japan
Introduction: Hepatic resection, percutaneous ethanol injection
(PEI), local ablation, and transcatheter arterial chemo-emboliza-
tion (TACE) are considered as an effective treatment for localized
HCC. Because HCCs are chemotherapy-resistant tumors, in order
to increase the concentration of drug achieved at HCC, hepatic
arterial infusion chemotherapy (HAI) is usually used for the
treatment of multifocal bilobar tumors of the liver or HCCs
combined with tumor thrombi, not amenable to TACE. Recently,
reservoir has been used for HAI in Japan. In this presentation, we
describe the current situation and therapeutic efﬁcacy of HAI by
using reservoir for the treatment of far advanced HCC. Patients
and Methods: Between December 1987 and December 2004, 319
patients with far advanced HCCs were treated by repeated HAI.
All patients were percutaneously implanted with an infusion
catheter connected with a reservoir in the hepatic artery via the
femoral artery or the axillary artery. Epirubicin, pirarubicin, or
carboplatin was administered as a single bolus injection through
the reservoir, and repeated every 4 weeks on an outpatient basis,
until the appearance of disease progression. Results: The mean
number of arterial infusions given during the follow-up period was
10.8. An objective response rate was 35.4% (95% CI 30.1–40.7%).
The mean survival time was 20.7 months (95% CI: 18.4–23.0%).
The cumulative survival rates were 60.9% and 30.1% for the
periods of 12 and 24 months, respectively. Conclusion: Hepatic
arterial infusion chemotherapy using reservoir is active and well
tolerated in patients with far advanced HCC, and may improve
their quality of life.
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APASL/Free Paper/Abstract/348
Single-dose and steady-state pharmacokinetics and safety of
telbivudine following oral administration in healthy Chinese
subjects
P. Hu1, J. Jiang1, H. Wang1, K. Pietropaolo2, G. Chao2,
N. Brown2 and X. J. Zhou2
1Peking Union Medical College Hospital, Beijing, China,
2Idenix Pharmaceuticals, Cambridge, MA, USA
Background: Telbivudine (LdT, b-L-20-deoxythymidine),
an L-nucleoside with potent anti-HBV activity, is being eval-
uated in phase III clinical trials in patients with chronic
hepatitis B. This study assesses the pharmacokinetics (PK) of
telbivudine in healthy Chinese subjects. Patients and Methods: -
Forty-two healthy male and female Chinese subjects were
randomized to receive a single oral dose of telbivudine 200,
400 or 800mg (10 subjects/dose), or multiple doses of 600mg/
day (12 subjects). Single-dose (D1) and steady-state (SS) PK
results are reported. Results: Telbivudine was absorbed
rapidly and exhibited dose-related plasma exposure. PK
parameters including AUC, Cmax, Tmax, T1/2 and renal
clearance (CLR) are summarized below (600mg dose), and
compared to results from previous phase I studies in non-
Chinese subjects.
AUC 24 h
(mg/ml/h)
Cmax
(mg/ml)
Tmax (h) T1/2 (h) CLR
D1 SS D1 SS D1 D1 D1
Chinese
(N5 12)
21.9 (7.7) 26.1 (7.2) 3.7 (1.2) 3.7 (1.2) 2.0 (0.5-3.0) 39.4 (12.1) 6.5 (1.5)
Non-
Chinese
20.5
(6.2, 64)
28.0
(6.2, 64)
3.0
(0.8, 64)
3.4
(0.8, 64)
3.0
(1.0–6.0, 64)
45.6
(23.2, 6)
8.5
(2.5, 14))
Data indicate mean (SD) for Chinese and mean (SD, N) for non-Chinese, except Tmax
where median and range are shown.
Telbivudine was well tolerated, with 15 mild AEs in 8 subjects
and no serious AEs. The nature and frequency of AEs in study
subjects were comparable to those reported in previous telbivu-
dine phase I studies. Conclusions: Telbivudine was well toler-
ated in healthy Chinese subjects with an overall safety and PK
proﬁle similar to that observed in non-Chinese subjects.
APASL/Poster/Abstract/349
Final results of a phase I/II dose escalation trial of valtorcitabine
in patients with chronic hepatitis B
S. G. Lim1, C. L. Lai2, M. Myers3, M. F. Yuen2, C. T. Wai1, D.
Lloyd3, K. Pietropaolo3, X. J. Zhou3, G. Chao3 and N. Brown3
1National University Hospital, Singapore,
2University of Hong Kong,
3Idenix Pharmaceuticals Inc., Cambridge, MA, USA
Introduction: L-deoxycytidine (LdC) and L-thymidine (telbivu-
dine; LdT) are potent inhibitors of hepatitis B virus (HBV)
replication in vitro. Valtorcitabine, a well-absorbed prodrug of
LdC, is synergistic with telbivudine for inhibiting HBV replica-
tion in vitro and in the woodchuck hepadnavirus model. We
evaluated valtorcitabine in chronic hepatitis B (CHB) patients in
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preparation for potential development in combination with
telbivudine. Methods: Antiviral efﬁcacy, safety, and pharmaco-
kinetics of two valyl ester prodrugs of LdC were evaluated in a
phase I/II dose escalation trial. 30,50-divalyl (50, 100, 200, and
400mg/day cohorts) and 30-monovalyl (300, 600, 900, and
1200mg/day cohorts) prodrug forms of valtorcitabine were
investigated. Each cohort comprised seven HBeAg1CHB pa-
tients, randomized 6:1 (drug vs placebo). Serum HBV DNA
levels and safety were evaluated weekly during treatment (28
days), with 12 weeks’ follow-up. Emax modeling assessed the
quantitative relationship between dose and antiviral response
(week 4). Results: Consistent, dose-related HBV DNA reduc-
tions were observed. At day 28, decreases from baseline ranged
from 1.63 log10 (50mg/day) to 3.04 log10 (900mg/day) copies/
ml. Emax modeling conﬁrmed a progressive increase in HBV
DNA suppression toward the theoretical maximum at doses
up to 900mg/day, with a diminished effect thereafter. Safety
appeared comparable to placebo, with no treatment-
related pattern of adverse events or laboratory abnormalities.
Conclusions: Valtorcitabine demonstrated substantial suppres-
sion of serum HBV DNA and was well tolerated in patients with
CHB. A dose of 900mg/day maximized viral suppression and
was selected for ongoing clinical evaluation of valtorcitabine in
combination with telbivudine.
APASL/Poster/Abstract/350
Reactivation of hepatitis B carrier state during cytotoxic che-
motherapy cases: a report
Agus Sudiro Waspodo
Division of Hepatology, Department of Internal Medicine,
Faculty of Medicine, University of Indonesia/Dr. Cipto Man-
gunkusumo Hospital, Jakarta
Hepatitis B virus (HBV) reactivation has been described in
cancer patients who received cytotoxic/immunosuppressive
therapy and may result in liver damage of varying degrees of
severity. Now lamivudine, a nucleoside analogue, has been
known as an effective drug to suppress HBV replication and
to improve histology in chronic carriers of hepatitis B virus. The
outcome of lamivudine therapy (at doses 100 or 150mg/day) in
patients who developed HBV reactivation while receiving cyto-
toxic chemotherapy resulted in clinical improvement. In the
present report, six cancer patients received cytotoxic chemother-
apy treatment. Four of the six patients is a Hepatitis B carrier.
Three patients received 100mg lamivudine for hepatitis B
reactivation treatment and one patient for preemptive lamivu-
dine therapy. Three patients, consisting of 2 male and one
female, had lamivudine treatment, and preemptive treatment
was given in the female patient. Normalizations of ALT and
total bilirubin were achieved in all treated patients, and suppres-
sion of HBV-DNA for preemptive treatment. The patient who
had preemptive treatment discontinued lamivudine treatment
after HBV DNA seroconversion was done. Six months after
discontinuing lamivudine, she had fulminant hepatic failure
after she had cytotoxic drugs. Two patients who had fulminant
hepatic failure after cytotoxic chemotherapy treatments were
dead. In these laboratory tests we found HBsAg seropositive.
They were not those given lamivudine treatment. It is concluded
that early commencement, i.e. at the onset of HBV reactivation
before severe hepatic decompensation, of lamivudine may be
effective in the control of HBV reactivation during chemother-
apy. We suggest screening all cancer patients for hepatitis B
surface antigen before immunosuppressive/cytotoxic therapy,
and closely monitoring liver function of those who are found to
be HBsAg seropositive.
APASL/Poster/Abstract/351
Long-term efﬁcacy of intra-variceal n-butyl-2-cyanoacrylate for
bleeding gastric varices
Yi-Lyn, Tan, Eng Kiong Teo, Kwong Ming Fock, Tay Meng
Ng, Tju Siang Chua, Tiing Leong Ang and Choo Hean Poh
Division of Gastroenterology, Department of Medicine, Changi
General Hospital, Singapore
Introduction: Endoscopic intra-variceal injection of N-butyl-2-
cyanoacrylate (NBC) has been shown to be an effective haemo-
static technique for the treatment of bleeding gastric varices.
However, minimal data is available with regard to its long-term
efﬁcacy. In this study, we evaluated the long-term efﬁcacy of
endoscopic intra-variceal NBC injection as treatment for gastric
varices.
Patients and methods: Patients who presented with actively
bleeding gastric varices from January 1996 to December 2003
and were treated with endoscopic intra-variceal injections of NBC
were included in the study. NBC was injected intra-variceally as a
1:1 mixture with lipiodol. Patients with concomitant oesophageal
varices also underwent band ligation if there was evidence of
stigmata of recent haemorrhage or Grade IV varices. All patients
were treated with intravenous somatostatin in addition to endo-
scopic therapy. Demographic data, Child–Pugh score, presence or
absence of hepatocellular carcinoma (HCC), 1-year survival and
long-term follow-up data were collated.
Results: Eighteen patients were included in the study. In all
cases, the actively bleeding gastric varices were located in the
fundus. Initial haemostasis (no bleeding occurred for 48 h after
intra-variceal NBC injection) was achieved in all 18 patients
(100%). Of these, three patients had HCC, without evidence of
portal vein thrombosis. Five patients (33%) (all three patients
with HCC and a further two patients with Child’s C cirrhosis)
died within the ﬁrst year. There was no mortality due to variceal
bleeding. Three patients were lost to follow-up. The remaining
10 patients who are still on follow-up have a mean survival time
of 39.8 months (range 14–90 months). Conclusion: Endoscopic
intra-variceal NBC injection is highly effective in achieving
haemostasis in actively bleeding gastric varices. Variceal oblit-
eration by intra-variceal NBC injection reduces the risk of
further variceal haemorrhage, thus improving long-term survi-
val. Mortality is mainly due to malignancy or poor liver
function.
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APASL/Poster/Abstract/353
Hepatocellular carcinoma in ectopic liver
Rino Pattiata, J. Wirasmi Marwoto and Saukani Gumay
Department of Anatomical Pathology, Faculty of Medicine,
University of Indonesia, Indonesia
Suspected as an ovarian carcinoma, hysterectomy, bilateral sal-
phingopherectomy and biopsy from omentum were done. Small
nodules were found almost everywhere and bilateral malignant
ovarian tumor was suspected. Microscopically, sections from
endometrium, mesoappendix and omentum showed hepatocellu-
lar carcinoma. No pedicles were seen from those masses to the
main liver. There is no written data at all about the liver condition,
but the clinician said the liver was normal. We concluded that this
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case is one of hepatocellular carcinoma in ectopic liver tissue at the
female genital tract, mesoappendix and omentum.
APASL/Poster/Abstract/354
Efﬁcacy of additional intravenous isosorbid dinitrate in acute
bleeding of oesophageal varices in cirrhotic patients
Sutanto Maduseno, Irsad Andi Arso, Siti Nurdjanah,
Bayu P. Putut and R. Neneng
Subdepartment of Gastrohepatology, Department of Internal
Medicine, Faculty of Medicine/Dr. Sardjito Hospital, Yogya-
karta, Indonesia
Background: Upper gastrointestinal bleeding occurs in 33% of
hepatic cirrhotic patients, 40% of whom die in each episode of
bleeding. Death rate within 2 years reached up to 60%. Seventy-ﬁve
to 93% of upper gastrointestinal bleeding is due to rupture of
oesophageal varices. Isosorbid dinitrate (ISDN), which is an organic
nitrate is a venodilator frequently used as anti-angina medicine.
Recent studies showed that ISDN given orally, sublingual, trans-
dermal or intravenous is proven to lower portal venous pressure in
hepatic cirrhosis patients with portal hypertension. This effect is
equivalent to the effect with vasopressin and somatostatin. Aim of
Study: To investigate the efﬁcacy of intravenous ISDN per drip in
addition to conventional therapy to stop acute bleeding of oeso-
phageal varices in hepatic cirrhotic patients. Method: Prospective,
controlled open trial. Place and Time of Study: Internal Medicine
Ward, Dr. Sardjito Hospital. Period of study: January 1–December
31, 2004. Subjects of Study: Hepatic cirrhotic patients admitted to
hospital due to acute oesophageal bleeding, age above 18 years old,
with systolic pressure 490mmHg, in the absence of shock, en-
cephalopathy and renal function impairment were enrolled. Subjects
were assigned to Group A (receiving conventional therapy and
intravenous ISDN per drip 20mg with the rate of 2mg/h) or Group
B (receiving only conventional therapy). Results: There were 16
patients assigned to each group. Fourteen (87.5%) patients in
Group A stopped bleeding in under 24h, compared to eight
(50%) in Group B (P50.0225). The average time to stopping of
bleeding was 5.42  2.8h (interval 2–11h) in Group A, whereas in
Group B it was 15.12  6.08h (interval 6–20 hours) (Po0.01).
Re-bleeding within 24h occurred in one out of 14 (7.1%) patients
in Group A and none in Group B (P50.7721). No death
occurred in Group A and two (12.5%) occurred in Group B.
Conclusion: Addition of ISDN per drip with 2mg/h to conventional
therapy is more effective in stopping acute oesophageal bleeding
within 24h in hepatic cirrhotic patients compared to conventional
therapy alone.
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APASL/Poster/Abstract/359
Microsatellite instability and methylation pattern of DNA repair
genes in hepatocellular carcinoma
J. H. Park, S. K. Choi, W. S. Lee, C. H. Park, Y. E. Joo, H. S.
Kim, J. S. Rew, S. J. Kim
Department of Internal Medicine, Chonnam Univeristy Medi-
cal School Gwangju, Korea
Background: Epigenetic silencing of DNA repair genes, O6-
methylguanine-DNA methyltransferase (MGMT), hMLH1, and
hMSH3, by promoter hypermethylation have been observed in
various cancers. However, the relationship between microsatel-
lite instability (MSI) and hypermethylation of DNA mismatch
repair genes has not been studied in hepatocellular carcinoma
(HCC). Therefore, MSI and the methylation pattern of CpG
islands of three genes by using methylation-speciﬁc PCR (MSP)
were investigated in 40 paired hepatocellular carcinoma and
associated cirrhosis. Method: MSI status was determined by
ﬂuorescent PCR to amplify loci D2S123, D5S346, D17S250,
BAT 25 and BAT 26. hMSH3 and MGMT were the most
methylated genes both in cirrhosis (70% and 68% respectively)
and in HCC (75% and 73% respectively). Results: The methy-
lation of hMLH1 was rarely found both in cirrhosis (three of 40
cases, 8%) and in HCC (two of 40 cases, 5%). Gene promoters
methylated in cirrhosis were methylated also in HCC, with the
exception of nine cases found to be methylated either in cirrhosis
or in HCC (four for hMSH3, three for hMLH1, and two for
MGMT). Of 40 HCC associated with cirrhosis, three had MSI-
positive phenotype in which two were MSI-low and one was
MSI-high. Immunohistochemically, expression of hMLH1,
MGMT, and hMSH3 protein was 16 (40%), 6 (15%), and 11
(28%) of 40 cases of HCC. Conclusions: These data suggest that
the promoter methylation of MGMT and hMSH3 play an
important role in the pathogenesis of liver cirrhosis and hepa-
tocellular carcinomas as an early event. Therefore, detection of
MGMT and hMSH3 methylation may be useful for screening
patients who may be at risk of developing hepatocellular
carcinoma.
APASL Bali/Abstract/360
Predictors of gastric variceal bleed and results of sclerotherapy
with n-butyl 2 cyanoacrylate
Khalid Mumtaz, Shahid Majid, Hasnain A. Shah, Kashif
Hameed, Saeed Hamid, Wasim Jafri
Section of Gastroenterology, Aga Khan University Hospital,
Karachi, Pakistan
Introduction: Various modalities of treatment have been tried
for bleeding GV but sclerotherapy with N-butyl 2 cyanoacrylate
(NBC) glue injection seems to be the most promising. Aim: To
study the incidence, predictors of bleed and outcome following
NBC sclerotherapy of GV bleed. Methods: Retrospective ana-
lysis of case records of 1436 patients who underwent endoscopy
for portal hypertension (PHTN) in the last 5 years. GV were
classiﬁed according to Sarin’s classiﬁcation. Outcomes with
respect to primary hemostasis i.e., bleeding control within the
ﬁrst 24 h of endoscopy, rebleed i.e., bleed after the ﬁrst 24 h of
endoscopy and in-hospital mortality were analyzed. Re-
sults: The incidence of GV in patients with PHTN was 220/
1436 (15%) and of these, 50 (22.7%) had bled. The main
etiology of PHTN in bleeders was hepatitis C in 34 (68%),
followed by HBV and NBNC in 6 (12%) patients; IGV-I
were observed in 22 (44%), GOV-I in 16 (32%) and GOV-II
in 15 (30%). A comparison of bleeding and non bleeding
GV revealed that IGV-I was seen in 22/50 (44%) patients
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who bled as compared to 39/170 (23%) who never bled
(Po0.003).
Primary hemostasis was achieved with NBC in all patients.
Rebleed occurred in 7 (14%) patients. Secondary hemostasis
with repeat NBC sclerotherapy was achieved in 3 (43%); 2
(28.5%) patients died after repeat sclerotherapy and one each
during TIPSS and surgery. Treatment failure related mortality
rate was 4/50 (8%). Conclusions: GV were observed in 15%
patients presenting with PHTNn and bleed occurred in 22.7%.
There was an increased risk of bleed from IGV-1. NBC was
effective in controlling GV bleed. In hospital, mortality in patients
with bleeding GV was 8%.
APASL Bali/Abstract/361
Abstract withdrawn
APASL Bali/Poster/Abstract/362
Peptic ulcer and helicobacter pylori infection in liver cirrhosis
Nyoman Purwadi
Gastroenterology Division Departement of Internal Medicine,
Medical Faculty University of Udayana Denpasar, Bali
An increased frequency of peptic ulcer is noted in patients with
cirrhosis, but the role of Helicobacter pylori in this condition
remains to be determined. The aim of this study is to know the
prevalence of peptic ulcer in liver cirrhosis and also the role of
H. pylori infection in this condition. We explored medical
records of liver cirrhosis patients who underwent endoscopic
examination in the year 2004. The diagnosis of liver cirrhosis
was conﬁrmed by a combination of clinical, biochemical, radi-
ology and endoscopic examination. Diagnosis of peptic ulcer
was conﬁrmed by endoscopic procedures. H. pylori status was
assessed by serology test from some available stored serum of
these patients. In all, 128 patients was evaluated; there were 103
(80.4%) males and 25 (19.6%) females. We found patients with
peptic ulcer 27/128 (prevalence was 21.1%), of which 13/128
(10.2%) was gastric and 10/128 (7.8%) was duodenal ulcer. The
Helicobacter pylori test was positive in 23/52 (44.2%) in all
cases, 5/15 (33.3%) in gastric ulcer and 3/12 (25%) in duodenal
ulcer patients and the difference was not signiﬁcant (P5 0.7). In
conclusion, the prevalence of peptic ulcer in liver cirrhosis
patients is 21.1% and the role of H. pylori infection in peptic
ulcer disease in liver cirrhosis is weak.
APASL Bali/Poster/Abstract/363
Cost-effective use of antibiotics for the management of sponta-
neous bacterial peritonitis in patients with chronic liver disease
Kashif Anis, Khalid Mumtaz, M. Islam, Hasnain Shah, Saeed
Hamid and Wasim Jafri
Deptartment of Medicine, Section Gastroenterology, Aga Khan
University Hospital, Karachi, Pakistan
Introduction/aim: In a third world country like Pakistan, where
the burden of chronic liver disease (CLD) is enormous with
scarce resources available to patients, there is need for cost
effective management of SBP. Therefore we aimed to assess the
cost effective use of antibiotics in SBP. Methodology: This is a
cross sectional study involving consecutive adult patients. We
compared the efﬁcacy and cost effectiveness of third generation
cephalosporin, Ceftriaxone with the fourth generation cepha-
losporin, Ceﬁpime in patients with SBP. Results: In all, 137
patients records were reviewed from 1 August 2003 to 31
December 2004. Ceﬁpime was used in 69 (group A) and
ceftriaxone used in 68 (group B); 35 (51%) patients underwent
repeat paracentesis in group A and 34 (50%) in group B.
Clinical parameters are shown in Table 1. Conclusion: Efﬁcacy
of both fourth generation cephalosporin, cefepime vs third
generation cephalosporin, Ceftriaxone is almost equal. We
endorse that the cost constraints should be addressed before
selecting the antibiotic.
APASL Bali/Poster/Abstract/364
Chronic hepatitis B virus infection (CHBVI) in pregnant females
H.H. Tan and W.C. Chow
Department of Gastroenterology, Singapore General Hospital,
Singapore
Introduction: Many Asians acquire CHBVI perinatally or dur-
ing early chilhood. Hence, it is important to understand the
natural history of CHBVI in the peripartum period as many
patients may be affected when they reach child-bearing age.
Hence, the aim is to study the clinical outcome of CHBVI in
peripartum females. Method: Clinical and laboratory data of
pregnant female patients, as well as randomly selected (in ratio
1:4) age- and HBe status-matched, non-pregnant, female con-
trols, who were seen in the department for CHBVI between the
years 2000 and 2004, who were studied retrospectively. Clinical
progress of pregnant patients and female controls were observed
up to 6 months postpartum and over a 1-year period, respec-
tively. Results: Nineteen patients and 76 controls, aged (mean)
31.1  4.3 years, were studied. Majority of the patients (68%)
presented during pregnancy, mostly in the second trimester. 12/
19 (63%) were positive for HBeAg at the time of presentation.
13/19 (68%) patients had a clinical event (ie., s.ALT elevation or
loss of HBeAg) vs. 28% among controls (P5 0.001). There was
no signiﬁcant difference in frequency of clinical events between
the HBeAg positive and negative patients. More patients (27%)
than controls (2%) had HBeAg loss by end of the follow-up
(P5 0.003). Among HBeAg negative subjects, more patients (5/
7; 71%) than controls (2/28; 7%) had s.ALT elevation
(Po0.001). None of the clinical event had resulted in hepatic
decompensation clinically. Conclusion: Pregnancy is associated
with s. ALT elevation, and increased HBeAg loss compared to
age-matched female controls, in patients with CHBVI during
the peri-partum period.
APASL Bali/Poster/Abstract/365
Acute exacerbation of chronic hepatitis B (AECHB) post-hepatic
resection for hepatocellular carcinoma (HCC)
T.J.K. Thia1, H.F. Lui1, Y.F.A. Chung2, P. Chow2, L. Ooi2 and
W.C. Chow1
1Department of Gastroenterology
2Department of General Surgery, Singapore General Hospital,
Singapore
Liver resection for HCC often involves patients with chronic
hepatitis B virus infection. To better understand the incidence,
outcomes and risk factors of AECHB post hepatic resection, a
retrospective review of consecutive HepBsAg-positive patients
who underwent liver resection (n5 77) for hepatocellular carci-
noma in our centre between January 2002 to December 2004,
was carried out. The following data were systematically col-
lected: (i) baseline demographic, biochemical, virological and
surgical characteristics, (ii) incidence of postoperative hepatitis
(i.e. ALT 42  baseline or ALT 4200 IU/l between 2 and 24
weeks post-resection) and HBV ﬂares (i.e. postoperative hepa-
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titis associated with detectable HBV DNA), (iii) mortality and
tumour recurrence rate. All results are expressed as median
unless otherwise stated. Results: Seventy-seven patients (87%
male), aged (mean) 58.0 1 12.1 years, underwent 82 liver
resections (70% segmentectomy, 30% hemi-hepatectomy ).
Twenty one (26%) and seven (9%) had postoperative hepatitis
and HBV ﬂares, with peak ALTs of 231.0 & 312 IU/l observed
at day 85 & 84 post-resection, respectively. Hepatic decompen-
sation was more frequent in HBV ﬂare (88% vs 39%, P5 0.03).
Overall mortality rate was signiﬁcantly higher among those with
HBV ﬂare compared with those without postoperative hepatitis
(67% vs 21%, P 5 0.03). Neither postoperative hepatitis nor
HBV ﬂare resulted in higher HCC recurrence. Preoperative
ALT 4100 IU/l was the only risk factor for postoperative
hepatitis but not for HBV ﬂare. Conclusion: HBV ﬂare, or
AECHB, occurred in 9% of HBsAg-positve patients who
underwent liver resection and was associated poorer outcome.
APASL Bali/Poster/Abstract/366
Hepatitis B vaccine with a novel adjuvant, immunostimulatory
phosphorothioate oligonucleotide (1018 ISS), achieves protective
antibody levels more quickly in 40–70-year-old subjects
W.C. Chow1, S.G. Lim2, S. Reading3, A. Freeman3, D. Levitt4
and C. Petersen4
1Singapore General Hospital, Singapore,
2National University Hospital, Singapore,
3Quintiles, Inc. Singapore and Kansas City, USA,
4Dynavax Technologies, Berkeley, CA, USA
Worldwide use of hepatitis B (HB) vaccine has dramatically
decreased cirrhosis and hepatocellular carcinoma due to persis-
tent HB virus infection. However, difﬁcult-to- immunize popu-
lations, including older persons, patients with diabetes, renal
failure, HCV and HIV infection, do not rapidly or completely
develop seroprotective antibody levels when given currently
available vaccines. A new oligonucleotide adjuvant, 1018 ISS,
which mimics microbial DNA patterns recognized as foreign by
the host has shown promise of improving HB vaccine response
in younger individuals. Unmethylated CpG motifs signal
through a Toll-like receptor 9, evoking an innate immune
response and training the adaptive immune response toward a
Th1 path. In this Phase 2 study, 88 healthy, seronegative
subjects aged 40–70 were randomized to receive recombinant
HB surface antigen (rHBsAg) 1 1018 ISS (0, 2, 6 months) or
Engerix-Bs, a licensed HB vaccine with an equivalent dose of
rHBsAg (0, 1, 6 months). Anti-HbsAg antibody concentrations
were assessed 4 weeks after the second immunization. By intent-
to-treat analysis, 91% of the rHBsAg/1018ISS recipients had a
protective antibody response (  10mIU/ml anti-HBsAg) com-
pared with 38% of the Engerix-Bs treated subjects. Median
concentrations of anti-HBsAg antibodies four weeks after the
second immunization were 539mIU/ml for the rHBsAg/1018
ISS group and 1.5mIU/ml for the Engerix-Bs group. In
conclusion, higher antibody levels and greater seroprotection
were achieved after two injections of rHBsAg 1 1018 ISS than
of Engerix-Bs in the 40–70-year-old population. More than
90% of individuals immunized with the experimental vaccine
were protected after the second immunization.
APASL Bali/Poster/Abstract/367
The clinical and histopathology features differences between
NSAID-induced gastropathy patient with positive CLO test and
NSAID-induced gastropathy patient with negative CLO test
Dedy Ismiranto, Niniek Rianty and Harijono Achmad
Indonesia
Background: Nowadays NSAIDs are widely used and often
caused side effects, like dyspepsia, peptic ulcers, bleeding/
perforation, and malignancy of the stomach. Helicobacter
pylori-infected gastric mucosa or duodenum, especially with
previous NSAIDs-induced mucosal injury, were found in almost
100% of chronic gastritis and peptic ulcers, and caused further
mucosal damages. H. pylori produces urease enzyme that
converts urea into ammonia, which makes the microorganism
could live in the gastric acidity. H. pylori infection can be
detected by serologic test, Urea Breath Test, H. pylori stool
antigen test, macroscopic endoscopy, Rapid Urea Test, histo-
pathology, and culture from biopsy specimen. Objective: To
determine whether there are differences in the clinical and
histopathology features of NSAIDs-induced gastropathy pa-
tient with and without H. pylori infection. Methods: This
descriptive analytic study with cross sectional approach was
held in Dr. Saiful Anwar General Hospital Malang. The
samples were collected consecutively during 6 months (Novem-
ber 2003–April 2004) at Rheumatology and Gastroenterohepa-
tology outpatient department, and inpatient of Internal
Medicine Department of Dr. Saiful Anwar General Hospital
Malang. Results: There were 39 patients with chronic dyspepsia
who fulﬁlled the criteria, ages with ranging from 21 to 78 years
old, among whom there were 20 male (46.69  18.10 years) and
19 female patients (47.91  14.74 years). From CLO test, there
were 16 cases with CLO (1) and 23 cases CLO (–). Gastroscopy
revealed 39 cases, as 25 cases of erosive gastritis without gastric
ulcer consisted of six cases CLO positive (three male, three
female) and 19 cases CLO negative (11 male, eight female); and
14 cases of erosive gastritis with anthral gastric ulcer consisted
of nine cases CLO positive (four male and ﬁve female) and 5
cases CLO negative (two male and three female). From 16 cases
with CLO (1), nine cases female and 7 cases male, with clinical
symptoms gradation as four mild, three moderate, and nine
severe cases, while the gastric mucosal damages showed one case
grade I, two cases grade II, seven cases grade III, and six cases
grade IV. From 23 cases with CLO (–), 13 cases were males and
10 cases females, with clinical symptoms gradation as 2 mild, 9
moderate, and 12 severe cases, while the gastric mucosal
damages showed 7 cases grade I, 11 cases grade II, ﬁve cases
grade III, without grade IV cases. Conclusion: This study
showed that the gastric mucosal damages and the gastric ulcers
in NSAIDs-induced gastropathy patients with positive CLO test
were more severe than that in NSAIDs-induced gastropathy
patients with negative CLO test; while the clinical symptoms
were not signiﬁcantly different.
APASL Bali/Poster/Abstract/368
EEG pattern in chronic liver disease patients in Saiful Anwar
General Hospital Malang
Dedi Ismiranto, Harijono Achmad and M. Hariadi
Gastrohepatologi division of RSSA, Malang, Indonesia
Background and Objective: There was high incidence 4 50%
subclinical hepatic encephalopathy (SHE) in Western countries,
according to Reitan Trailmakery test (Zeegen et al. 1970). But
this incidence is not well known in Indonesia. Many tools and
methods are available for SHE, e.g EEG examination. Early
screening and treatment of SHE will be useful in preventing
Hepatic Encephalopathy in the coming days.Methods: Descrip-
tive study, data obtainied from outpatients and inpatients with
chronic liver diseases without any disturbance of consciousness,
from January–March 2005. Chronic Liver diseases are con-
ﬁrmed by history taking, laboratory test and USG. EEG is
performed by Neurofox (EEG 9200 J/K) and read by a
neurologist. The abnormality of EEG if the wave was less
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than 8 cps (Hz). Result: Sixteen patients (61.5%) were diag-
nosed with SHE of 26 patients in study. Ten patients (38.46%)
mild diffuse of hepatic encephalopathy with EEG result of
general intermittent slow acting (frequency 5–8Hz) and 6
patients (23.07%) moderately diffuse of hepatic encephalopathy
with EEG result of general intermittent slow acting (frequency
3–5Hz). EEG pattern patients with Hepatic Encephalopathy
were treated by lactulose. Conclusion: SHE incidence in RSSA
within 3 months of study with EEG examination in Chronic
Liver Diseases Patients is 61.5%. From the preliminary study
was methods that event though there are no sign/symptom of
HE but by EEG SHE could be detected early.
APASL Bali/Poster/Abstract/370
Prospective evaluation of hepatic small nodules: radiographic
ﬁndings and probability of hepatocellular carcinoma
T. Fujishima1, H. Yoshida2, S. Obi3, S. Shiina2, M. Kanda2, R.
Tateishi2, M. Akamatsu2, R. Masuzaki2, Y. Kondo2, N. Mine2,
N. Yamashiki2, T. Teratani2, T. Kawabe2 and M. Omata2
1Department of Internal Medicine, Chosei Hospital, Chiba,
Japan,
2Department of Gastroenterology, Faculty of Medicine, Uni-
versity of Tokyo, Tokyo, Japan,
3Department of Liver Unit, Kyoundo Hospital, Tokyo, Japan
Introduction: Owing to recent progress in imaging techniques,
many small nodules are detected in advanced liver diseases,
including in cirrhosis. But such small nodules are difﬁcult to
distinguish from macrogenerative nodules or other mimicking
lesions. We aimed to determine whether such small nodules are
truly hepatocellular carcinoma (HCC) or not. Patients and
methods: From August 2001 to November 2002, Dynamic-
enhanced CT (CT) and the combination of CT during arterial
portography and CT hepatic arteriography (CTAP/HA) were
performed on 387 consecutive patients suspected of having
HCC. Among them, we enrolled 23 consecutive patients having
small hepatic nodules less than 2 cm detected by CT or CTAP/
HA but not depicted as typical hepatocellular carcinoma by
ultrasonography. The 23 patients had a total of 41 such nodules.
All the patients underwent clinical, biochemical, and ultrasono-
graphic evaluation periodically. Results: The mean follow up
was 12  5 months (range, 4–20 months). Of the 41 nodules,
neoplastic transformation occurred in eight nodules (19.5%)
after 12 months (range, 4–20 months). Edmondson I-II HCC
was conﬁrmed histopathologically by percutaneous needle
biopsy. We compared parameters of transformed and non-
transformed nodules. Baseline size of the nodules was not
related to the transformation. Hypervasculartity on CT was
signiﬁcant. Conclusions: Some hepatic small nodules less than
2 cm were transformed to overt HCC. Hypervascularity of the
nodules should be recognized to be a high risk for transforma-
tion to HCC.
Asia Hep
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Beneﬁts and hazards of long-term lamivudine therapy
Nancy Leung
Alice Ho Miu Ling Nethersole Hospital, and The Chinese
University of Hong Kong, Hong Kong
The ideal goall of CHB therapy is to eradicate HBV infection
and, in doing so, arrest or even revert necroinﬂammation and
ﬁbrosis and restore normal healthy life. Lamivudine is the ﬁrst
available nucleoside analogue shown to bring therapy nearer to
this goal. However, eradication of HBV under long-term
lamivudine therapy is not achieved in majority of CHB patients
who harbor high viral load with serum HBV DNA level around
8–12 log10 copies/ml. Among Asian CHB patients, persistent
viral suppression may be maintainable in a proportion of the
patients, but HBsAg seroconversion is rare. So is there any
beneﬁt in maintaining CHB patients on long-term lamivudine
therapy? What are the hazards during long-term lamivudine
therapy?
To answer the ﬁrst question, there are beneﬁts certain
patients can derive from maintenance of long-term lamivudine
therapy. Data from clinical trials and experience in clinical
setting showed a proportion of patients remaining HBV DNA
negative as measured by sensitive real time PCR assays. Serum
ALT is normalized and remains in low level. Liver histology
showed signiﬁcant improvement not only in necroinﬂammatory
grade, but also reversion in ﬁbrosis stage. Patients with cirrhosis
have occasionally been reported to have histologic reversion of
cirrhosis. The beneﬁt of 3 years of therapy with lamivudine
among patients with advanced ﬁbrosis and cirrhosis has demon-
strated signiﬁcant reduction in disease progression and has
prevented the development of hepatocellular carcinoma when
viral suppression was maintained. Patients with acute exacer-
bation have also been shown to have reduced mortality when
rescued with long-term lamivudine therapy. Post liver transplant
CHB patients also derived beneﬁts.
The answer to the second question regarding hazards in long-
term lamivudine therapy mainly centered on the continued
emergence of lamivudine resistant mutants that result in viral
breakthrough and relapse of hepatitis. Hepatic ﬂare developed
in a signiﬁcant proportion of these patients and a percentage
suffered from fatal decompensation. The risk of transmission of
this mutated HBV species and the global spread of HBV with
resistance to lamivudine that exhibit cross resistance to other
nucleoside analogues is a real threat to the overall control and
prevention of HBV infection and related liver diseases.
In order to maximize the beneﬁt and minimize the risk of
long-term lamivudine therapy, patient selection for therapy need
to be carefully scrutinized and considered. Patients with mild
liver disease and high viral load are unlikely to responsed well
and stand a high risk of developing resistance. Careful monitor-
ing of patients undergoing therapy, including serum HBV DNA
measurement at regular intervals, will detect early emergence of
resistance and timely rescue therapy with adefovir or enticavir.
APASL/Abstract/Asia Hep 2
Current status of adefovir in the treatment of chronic hepatitis B
R. Guan
Mount Elizabeth Medical Centre, Singapore
Adefovir dipivoxil has been a welcome addition to the arma-
mentarium of medications for the treatment of chronic hepatitis
B (CHB) since its availability in 2002. Treatment for 36 months
resulted in higher HBeAg seroconversion in HBeAg positive
CHB patients taking adefovir (43%) than in those taking
lamivudine (33%). Drug resistance was observed in 3.1% of
309 with HBeAg positive CHB patients treated for 144 weeks
with continued inhibition of viral replication and normalization
of liver enzymes. Signiﬁcant and continued reductions of
HBVDNA levels were also documented in HBeAg negative
individuals treated for 144 weeks, HBV DNA became unde-
tected in 71% patients at 96 weeks and 79% at 144 weeks. The
on-therapy response for patients on lamivudine for 36 months
was 40–50%. This difference can be attributed to the low
frequency of drug resistant variants in patients on adefovir
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(5.6%) at three years compared with 55% of patients taking
lamivudine for 3 years. The cumulative probability for devel-
oping adefovir resistance by week 192 was calculated to be 15%.
This compares favorably to the incidence of 67% of patients on
lamivudine for the same period of time. Adefovir is mainly used
for rescue therapy in patients who developed lamivudine resis-
tance. Normalisation of liver enzymes was achieved in 31 to
53% patients with lamivudine resistance after one year of
combination therapy using lamivudine and adefovir. A recent
study showed that adefovir plus lamivudine suppressed
HBVDNA better than adefovir alone in HBeAg negative
CHB patients. No major side effects of adefovir therapy have
been reported to date and the initial concern on renal toxicity
appeared to be unfounded with the 10mg dose.
AsiaHep 3
Pegylated interferon for chronic hepatitis B
A. Chutaputti
Department of Medicine, Section of Digestive and Liver
Diseases Phramongkutlao Hospital
Conventional interferon alpha (IFN-a) has been used for the
treatment of chronic hepatitis B (CHB) for more than 20 years,
with the antiviral and immunomodulatory mechanism. Pegy-
lated interferon alpha (PegIFN-a) is now approved for the
treatment of CHB. The use of conventional IFN-a in the dose
of 5 MIU daily or 5–10MIU three times weekly for 4–6 months
can achieve HBeAg loss in approximately 33% comparing with
12% of control. In a phase II Asian study, a 24-week course of
PegIFN-a 2a (40KD) give a e-seroconversion rate of 33%
(assessed 24 weeks after cessation of the treatment) compared
with conventional IFN-a 2a (25%, P40.05). In the phase III
study, PegIFN-a 2a (40KD) monotherapy 180 mg once weekly
for 48 weeks can achieved HBeAg seroconversion in 32% and
HBsAg seroclearance in 3% when assessed 6 months after end
of therapy. The sustained HBeAg seroconversion rate is quite
similar to that after 6 months therapy even though there is no
head to head comparison between the 6 and 12 months therapy.
A 52-week course of the other PegIFN-a 2b (12KD) trial
(100 mg once weekly for 32 week followed by 50mg weekly for
20 weeks) was well tolerate and gave a 6 month e-seroconversion
in 29% of patients. Conventional IFN-a can achieved biological
and virological response in up to 90% on the patients treatment
but sustained response is low to 10–15% with 4–6 months of
treatment, 22% with 12 months of treatment and 30% with 24
months of treatment. Twelve months of PegIFN-a 2a (180 mg)
monotherapy in 564 HBeAg negative and HBeAb positive CHB
patients showed HBV-DNA level less than 20,000 copies/ml in
43% and HBV-DNA less than 400 copies/ml in 19% with
HBsAg loss in 3% when assessed 6 months after end of the
therapy. However when assessed at the 48 weeks after the end of
therapy, the HBV-DNA less than 20,000 copies/ml is 42%,
HBV-DNA less than 400 copies/ml is 17% with about 30–50%
dropped out rate. Conclusion: Even pharmacological industrial
trying to persuade using of PegIFN-a in CHB patients, new
PegIFN-a cannot achieve dramatically response in patients with
CHB but higher cost of the treatment. Fortunately, the
toxicity is the same with more convenience once a week admin-
istration.
APASL/Abstract/Asia Hep 4
Hepatitis B antiviral drug resistance–problems and prevention
Deepak Amarapurkar
Bombay Hospital andMedical Research Centre, Mumbai, India
For the management of hepatitis B virus (HBV) infection, in
addition to interferon treatment a large number of nucleotide
and nucleoside analogues are available, though currently, and
Lamivudine, Adefovir, Entecavir are licensed. Other drugs like
Tenofovir, Emtricitabine, Telbivudine, Claudine and many
others are in clinical trials.1 Although all these drugs have
potent antiviral activity, successful cure of infection at the end
of 1 year of therapy does not go beyond 20%.1 As we have
learned from Lamivudine treatment long-term use beyond 1
year may improve success rate of cure of HBV infection; but this
is frequently associated with the development of resistance
mutation that affects YMDD motif of HBV polymerase
gene.2 The mutation occurs at the rate of 20% at the end of 1
year which increases beyond 60% at the end of 4 years.3
Appearance of resistance can result in return to pretherapy viral
replication levels, and most importantly, ongoing disease pro-
gression in both hepatitis B e antigen (HbeAg)-positive and
HbeAg-negative patients.4
The molecular target for currently available antiviral drugs
like Lamivudine and Adefovir is the HBV polymerase/reverse
transcriptase (POL/RT).5 POL/RT can be divided into seven
functional subdomains A–G. Mutations in the region of A–D has
been described with various antiviral drugs. Common YMDD
mutation to Lamivudine resistance resides in the domain C
(M204V/I/S). An other mutation that co-exists with M204V/I
have been found predominantly in the B domain and also in the
A domain. Two mutations with Adefovir resistance have been
described, one in the B domain and the other in the D domain.6
For determining the antiviral treatment efﬁcacy, the follow-
ing deﬁnitions are used 7 (1) antiviral treatment effect is deﬁned
as a sustained  1 log10 IU/ml reduction of HBV DNA from
baseline levels during therapy and within 3 months of starting
therapy. A decreased of  1 log10 IU/ml can be used to assess
the early virological response. (2) Primary antiviral treatment
failure is deﬁned as failure of a drug, initially reduced
HBVDNA level by  1 log10 IU/ml within 3 months. (3)
Secondary antiviral treatment failure is deﬁned by rebound of
HBV replication of  1 log10 IU/ml in patients with an initial
antiviral treatment effect who continued to take the drug, as
conﬁrmed by two consecutive laboratory assessment at a 1-
month interval. HBV resistance can be deﬁned as (1) primary or
secondary antiviral treatment failure (as deﬁned previously)
resulting in increase in serum ALT level and development of
symptoms after elimination of non- HBV related causes, (2)
genotypic assay of known mutant and (3) phenotypic assay.
Clinical consequences of resistance can be (1) decreased rate of
HBeAg seroconversion, (2) reversal of histological improvement,
(3) increased rate of disease progression, (4) severe exacerbation
in patients with cirrhosis, (5) risk of graft loss and death in liver
transplant patient, (6) transmission of drug resistant strains and
(7) HBsAg mutations leading to vaccine failure.8
Now, there are several options to monitor HBV drug
resistance.9 They can be divided into (A) genotypic assays e.g.:
(1) direct DNA sequences, (2) clonal analysis, (3) RFLP, (4)
DNA hybridization, and (5) Microchip based assays; (B)
Indirect methods like (1) determination of ALT and (2) quanti-
ﬁcation of HBV DNA; (C) Phenotypic methods. As drug
resistance is a serious clinical problem, predicting drug resis-
tance and monitoring for drug resistance becomes mandatory. It
has been suggested that antiviral drug-resistant HBV mutants
emerge as a function of at least six factors: (1) viral mutation
frequency, (2) intrinsic mutability of antiviral target site, (3)
selection pressures exerted by drugs, (4) magnitude and rate of
viral replication, (5) overall replication ﬁtness of mutant, and (6)
availability of replication space (as determined by the number of
uninfected hepatocytes available). HBV is highly mutagenic,
and there are enough nucleotide substitutions occurring daily to
allow for a broad range of quasi-species. Predictors of resistance
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to Lamivudine therapy are high baseline HBV DNA, elevated
serum ALT, serum HBV DNA4102–103 IU/ml after 6 months
therapy, duration of Lamivudine therapy, high body weight and
BMI and male sex10. In a recently published study, HBe status,
HBV DNA, ALT levels and treatment duration were shown to
be major determinant’s of YMDD mutation.11 As development
of resistance is clinically detrimental, monitoring the patients on
antiviral treatment is recommended. Drug resistance monitoring
is done by assessment of HBV DNA and ALT at baseline and 3
months after the therapy in all patients. Subsequently, in patients
with mild liver diseases assessment is to be repeated for every 6
months for the ﬁrst 2 years and every 3 months thereafter and at
any change of therapy. In patients with advanced liver disease or
cirrhosis, three monthly assessments along with clinical evalua-
tions are recommended.7 Preventing resistance is the best policy.
With currently available nucleotide analogues, there is a modest
ﬁrst phase decline in viral DNA followed by a prolonged second
phase of viral clearance. And hence, there is adequate time for
drug resistant mutants to emerge when monotherapy is used.1
Combination therapy can be used to decrease the risk of drug
resistance with monotherapy. To prevent resistance in (1) com-
pensated liver disease if HBV DNA increases by  1 log10 IU/ml
on Lamivudine addition or switching to Adefovir is recom-
mended. Adefovir is preferred for long-term therapy (2) cirrhosis
and liver transplantation. Adefovir is preferred because of a less
resistance rate, or combination of Adefovir and Lamivudine is
used as there is less likelihood of resistance to either drug. For
management of drug resistance (1) in compensated liver disease a
second drug is added to continued therapy with ﬁrst drug, or
switching to a second drug with 1–2 month over-lap is recom-
mended. Stopping the therapy may be considered if it appears
that the original therapy would not have been started, e.g.
patients with mild disease. (2) In cirrhosis, HIV/HBV co-infection
and liver transplantation, a second drug is added with the
continued use of the ﬁrst drug. The second drug should be
without cross-resistance to the ﬁrst drug and should be started
early, preferably before ALT ﬂare.7
Results of the randomized-controlled trial can prove the
efﬁcacy of the drug; to know the effectiveness of the drug in
real life, one needs to analyse the outcome of research. We
analysed real-life data on our patients receiving long-term
Lamivudine treatment, and development of Lamivudine resis-
tance is the clinical impact and outcome after adding Adefovir
in patients who developed Lamuvidine resistance. Our study
included 82 patients (males 66, age range 5–85 years). Of the 82
patients, 50 patients were HBeAg positive (chronic hepatitis 35,
compensated cirrhosis 7, decompensated cirrhosis 8). These
patients received a mean duration of Lamivudine treatment of
32.44 months. Seventeen out of 50 (34%) developed resistance
to Lamivudine, 32 patients were HBeAg negative (chronic
hepatitis 14, compensated cirrhosis 9, decompensated cirrhosis
9), mean duration of treatment with Lamivudine was 28
months. Eight out of 32 (25%) developed Lamuvidine resis-
tance. Total of 25 out of 82 patients (30.48%) developed
Lamivudine resistance. The presentation of Lamivudine resis-
tance was clinical decompensation 3, sero-reversion 7, ﬂare of
liver enzymes 8, and increased viral load 5. All the patients who
developed resistance were treated with Adefovir in addition to
Lamivudine. Mean period of follow up was 8.5 months; two
patients died because of to decompensation, the remaining
patients are stable with normalized liver function.
APASL/Abstract/AsiaHep 5
New drugs in the pipeline: will promises be fulﬁlled?
L. Sanker V
Liver Unit, Hospital Selayang, Malaysia
Over the last 10 years, the management of chronic hepatitis B
has evolved with better understanding of the virus, changing
disease patterns, new molecular testing techniques like HBV
genotyping and development of novel nucleoside/nucleotide
analogues. Several host and virological factors are associated
with poor response rates to current therapies. Some of these
include insufﬁcient or incompetent host immune responses,
persistence of HBV covalently closed circular (ccc) DNA and
hepatitis B surface antigen in the blood. Trials have been
primarily with monotherapy using interferon alpha or nucleo-
side/nucleotide therapy. Combination therapy of an immune
based therapy with an antiviral agent has shown no added
beneﬁt. This review will focus on some new drugs in the
‘pipeline’, with early efﬁcacy and trial data on these agents.
APASL/Abstract/AsiaHep 7
Management of hepatitis B with normal ALT
M. J. Alexander
Gastroenterology and Hepatology Division, RIPAS Hospital,
Brunei Darussalam
ALT measurement is important in the management of Hepatitis
B. It is an assessment of liver disease and determines the need for
therapy and response to therapy. Pre-treatment ALT level is
helpful but a normal ALT level does not always correlate with
the extent of liver injury. The normal ALT should be interpreted
with speciﬁc reference range in the report. Persistently normal
ALT is considered predictive of histological quiescence and
milder inﬂammation on liver biopsy. Treatment is not war-
ranted in this group as the response to antiviral treatment is
poor. In patients with minimally elevated ALT, treatment not
recommended unless liver biopsy shows moderate to severe
necro-inﬂammation. In gray areas whereby ALT level alone is
unable to determine the decision for treatment liver biopsy
should be considered.
How I do it
APASL/Abstract/How I do it 1
What you should not do in laparoscopic cholecystectomy
W. Y. Lau
Department of Surgery, The Chinese University of Hong Kong,
Prince of Wales Hospital, Shatin, New Territories, Hong Kong
SAR
The lecture starts off with a video recording showing laparo-
scopic cholecystecomy. The operation apparently went on
smoothly but suddenly the common bile duct was transected
and the right hepatic artery was also divided. Why did these
injuries happen? The second part of the lecture is a power point
presentation emphasizing on the proper techniques in laparo-
scopic cholecystectomy.
 Technique of dissection
 – Stay close to gallbladder;
– Conclusive identiﬁcation of cystic duct structures:-
critical view of safety as advocated by Strasberg et al.
 Retraction of gallbladder
– Proper retraction should be with one grasper on the
fundus retracting the gallbladder superiorly and one gras-
per on Hartmann’s porch retracting it laterally. Wrong
direction of gallbladder retraction can lead to the CBD
being mistaken as the cystic duct.
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 Use of diathermy: Injudicious use is hazardous
 – Prolonged application of energy can led to direct injury
to the CBD or indirect by damaging its blood supply;
 – Insulation defects in instruments lead to thermal injury;
 – Capacitative coupling leading to discharge of current to
adjacent tissues;
 – Arcing;
 – Residual heat.
 Operative cholangiogram
 – It is controversial as whether it is able to decrease the
incidence of bile duct injuries. The advantages are early
recognition and limit the damage.
The lecture ends by showing the video recording once again
but stopping at points where mistakes were made that led to the
injuries.
APASL/Abstract/How I do it 2
An aggressive hepatic resection for advanced intrahepatic cholagio-
carcinoma after pre-operative PTBD and portal vein embolization
H. J. Kim
Department of Surgery, College of medicine, Yeungnam
University Daegu, Korea
The development of surgical technique and preoperative man-
agement including PTBD and PTPE has made it possible to
apply aggressive surgical approaches for intrahepaic cholangio-
carcinoma, improving the resectability rate. (Case) A 59 year-
old woman was admitted due to abdominal discomfort and
jaundice. Laboratory studies revealed that total bilirubin
5.4mg/dL, albumin 3.4 g/dL and prothrombin time 10.9 second.
In addition, the retention of indocyanine green at 15min was
2.8%. CEA was 2.8 ng/mL and CA19–9 was 3,032U/mL.
Preoperative imaging study revealed malignant appearing huge
mass located left medial section and causing both side intrahe-
patic duct dilatation. The celiac angiography showed encase-
ment of right main portal vein and hepatic artery. We performed
PTBD through the both dilated IHD and preoperative portal
vein embolization(PVE) for hypertrophy of the future remnant
liver (FRL). Two weeks after PVE, preoperative volumetry
showed hypertrophy of the FRL accounts for 25% of the whole
liver. At operation, there were encasement of right portal vein
and hepatic artery and hardness of conﬂuence of common
hepatic duct. We performed extended right trisectionectomy
(including segment 1, 4, 5, 6, 7, and 8), portal vein segmental
resection and end to end anastomosis, bile duct resection with
Roux-en Y left hepaticojejunostomy and dissection of lymph
nodes. The pathologic diagnosis was intrhepatic cholangiocar-
cinoma with 7 cm sized tumor, invasion of portal vein and
hepatic duct, and involvement of regional lymph nodes. There
was no evidence of recurrence 5 months after operation.
APASL/Abstract/How I do It 3
Laparoscopic common bile duct exploration
Errawan R. Wiradisuria and Barlian Sutedja
Indonesian Society of Endo-Laparoscopic Surgeons (PBEI),
Indonesia
In the era of minimal invasive surgery, the management of
cholecystolithiasis and choledocholithiasis (CBD stone) must
involve not only the techniques themselves but also patient
safety, efﬁciency and cost effectiveness.
Three major options for management of cholelithiasis with
CBD stone are (1) open cholecystectomy1CBD exploration, (2)
endoscopic sphincterotomy and stone extraction1laparoscopic
cholecystectomy (two Stages), and (3) laparoscopic cholecystec-
tomy1laparoscopic CBD exploration (one Stage).
Techniques of laparoscopic CBD exploration: (1) transcystic
approach (transystic laparoscopic CBD exploration), (2) ante-
rior choledochotomy (transcholedochal laparoscopic CBD ex-
ploration).
Laparo scopic common bile duct exploration (LCBDE) will
become an important alternative in treatment of CBD Stone in
the near future, especially in case of failure of ERCP/endoscopic
stone extraction. LCBDE as a minimally invasive procedure has
the advantages of high success rate, low morbidity and mortality
rate and faster postoperative period recovery. LCBDE need
more proper training and longer learning curve.
Breakfast Session
APASL/Abstract/BS I.1
Mechanism of coagulopathy in liver disease
A. H. Reksodiputro
Medical Hematolog- Oncology Division, Internal Medicine
Department, Faculty of Medicine University of Indonesia –
Cipto Mangunkusumo Hospital - RSKD
Hepatic disease, particularly advanced hepatic disease is char-
acterized by a severe coagulopathy after confounded by a
prominent ﬁbrinolytic process and the laboratory manifesta-
tions of a disseminated intravascular coagulation (1–2). The
coexistence of these combined abnormalities of blood clotting
and dissolution create considerable problems for the physicians
caring for, evaluating and treating patients with advanced liver
disease. The phenomenon of blood clotting and dissolution in
individuals with liver disease is only understandable if one is
knowledgeable about the processes of coagulation and ﬁbrino-
lysis as they occur in normal individuals. Liver failure is
characterized by multiple alterations in the hemostatic system
that can range from a clinical problem consisting of a bleeding
disorder to a thrombotic disorder as a consequence of advanced
liver disease, therapeutic interventions, and/or the development
of new complications (varix rupture, spontaneous bacterial
peritonitis, endotoxemia and others). The thrombocytopenia
occurring in advanced liver disease has a multifactorial origin
(5–7). This consists of a combination of reduced synthesis of
TPO, the megakaryocyte growth factor produced exclusively by
the liver, increased splenic sequestration as a consequence of
portal hypertension and the resultant splenomegaly; a reduced
half life of platelets as a result of splenic sequestration and in
certain liver diseases having an autoimmune pathogenic me-
chanism; reduced platelet production as a result of folic acid
deﬁciency which is common in liver disease especially alcoholic
liver disease and those requiring continuous diuretic therapy;
reduced platelet production as a direct consequence of exposure
to a toxin or drug such as ethanol, various H2 antagonists,
proton pump inhibitors and antibiotics used to treat hepatic
encephalopathy and prevent spontaneous bacterial peritonitis
and other infections common to debilitated individuals with
advanced liver disease and ﬁnally a low grade DIC process that
is a remarkably common occurrence in individuals with cirrho-
sis. An additional abnormality seen in cirrhotics is hypoﬁbrino-
genemia occurring as a result of reduced hepatic synthesis as
ﬁbrinogen is synthesized solely in the liver. Reduced ﬁbrinogen
levels are common in very advanced chronic liver disease and in
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cases of acute hepatic failure. A third situation in which
ﬁbrinogen levels may become critical is in the presence of
decompensated DIC. In this later case, it is not reduced
ﬁbrinogen synthesis but rather increased ﬁbrinogen consump-
tion that is responsible for the reduced ﬁbrinogen level. Dysﬁ-
brinogenemia occurs also in individuals with cirrhosis and is a
consequence of excessive sialic acid residues on the ﬁbrinogen
molecule as a result of an abnormal processing of the ﬁbrinogen
molecule prior to hepatic secretion possibly as a result of
intrahepatocyte enhanced glucosyltransferase activity. The
DIC syndrome can occur in both a compensated and decom-
pensated state. In the former, markers of DIC such as d-dimers
and ﬁbrin split products are increased in the plasma but the
majority of the plasma coagulation factors remain in the normal
range or just outside and below the normal range. Moreover, the
platelet count is usually normal but can be reduced in very far-
advanced cirrhotic liver disease. In contrast, in decompensated
DIC, the platelet count is always reduced. Both the PT and
aPTT are abnormal (prolonged) as is the thrombin time. The
plasma levels of factors II, V and VII are reduced and plasma
levels of ﬁbrin split products and d-dimers are increased
markedly. The balance of the coagulation and ﬁbrinolytic
systems in individuals with advanced liver disease is frequently
abnormal. These abnormalities vary as a function of disease
severity, type of liver disease and the presence or absence of the
more common complications of advanced liver disease such as
bleeding, infection, encephalopathy and endotoxemia.The re-
cognition of these abnormalities and their correction are essen-
tial for a normalization of the balance between hemostasis and
bleeding.
APASL/Abstract/BS I.3
Hypercoagulation in NASH and metabolic syndrome
Taned Chitapanarux
Thailand
The metabolic syndrome is characterized by a combination of
obesity, chronic inﬂammation and insulin resistance (1, 2).
Nonalcoholic steatohepatitis (NASH) is a liver disease charac-
terized by steatosis, periportal and lobular inﬂammation. It is
considered to be the liver component in the metabolic syndrome
(3–6). An association of NASH with hyperinsulinemia as well as
with the clinical features of insulin resistance has been fre-
quently reported (3, 7–8). Patients with both clinical and
histological diagnosis of NASH develop metabolic problems
only a few years from diagnosis (9). This metabolic syndrome
also has features of a hypercoagulable state, consisting of
increased levels of clotting factors (tissue factor, factor VII
and ﬁbrinogen) (10–12) as well as inhibition of the ﬁbrinolytic
pathway (increased plasminogen activator inhibitor-1 and de-
creased tissue plasminogen activator activity) (13–15). Simulta-
neously, the presence of endothelial dysfunction and
dyslipidemia triggers platelet aggregability, thus further increas-
ing the risk of thrombotic events both in the arterial and venous
system (16, 17). Although mechanisms of coagulation activation
are well described for other diseases, the precise etiology is not
well known in metabolic syndrome and NASH. So far, only
obesity has been shown to be a modest risk factor for venous
thromboembolic events whereas accurate data for metabolic
syndrome and NASH patients are lacking. Hence, routine
interventions for prevention of venous thromboembolism are
not yet warranted. However, as dyslipidemia is associated with
procoagulant change, this could be a possible target for ther-
apeutic intervention. In view of the rising incidence of metabolic
syndrome even at a young age, both the incidence of venous
thromboembolism and the effect of intervention markers of
hypercoagulability in metabolic syndrome and NASH need
further studies.
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APASL/Abstract/BS II.2
Managing sepsis in liver disease
Syed Sibitul Hasnain
Pakistan
Bacterial infections are present or develop in a third of cirrhotics
admitted to a hospital. In half of the patients admitted with
variceal haemorrhage, bacterial infection is associated, and
contributes adversely towards morbidity and mortality. The
most commonly encountered infection (25%) in cirrhotics is
spontaneous bacterial peritonitis (SBP) followed in frequency by
urinary tract infection (20%), pneumonia (15%), and bacter-
emia (12%). Gram-negative bacteremia predominate in SBP
and UTI while Gram-positive bacteria predominate in pneumo-
nia and bacteremias associated with invasive procedures. The
appropriate and prompt use of antibiotics is the key to success-
ful management. Early recognition and prompt treatment of
SBP has reduced its mortality from 90% to 30%. Regarding the
choice of antibiotics for patients who develop SBP, and are not
on chronic quinolone prophylaxis, patients have shown a very
good response with cefotaxime; equally good results are seen
with ceftriaxone. Ciproﬂoxacin and oﬂoxacin have shown good
results as well. Patients who develop SBP and have been on
quinolone prophylaxis usually have E. Coli infection resistant to
quinolone; they seem to be equally well treated by cefotaxime.
However, if gram-positive organisms are detected, especially
MRSA, then addition of Vancomycin should be considered. In
case of community acquired pneumonia, the newer quinolones
like levoﬂoxacin, moxiﬂoxacin and gatiﬂoxacin have shown
good results in cirrhotic patients. Equally effective however in
such circumstances are cefotaxime and ceftriaxone. It is recom-
mended that after starting empirical therapy with the above,
necessary modiﬁcations be made according to culture and
sensitivity results. Aminoglycosides, though effective, have a
high propensity of causing renal disease or developing during
the course of treatment, do very well with intravenous albumin
transfusions in the range of 1.0 to 1.5 g/kg body weight. Lastly,
good nursing care, prevention of bedsores, prevention of infec-
tion introduced via IV lines catheters go long way overall
control of bacterial sepsis in cirrhotic patients.
APASL/Abstract/BS IV.1
Abnormality of energy metabolism in the skeletal muscle of
patients with liver cirrhosis and change under administration of
glucose and branched-chain amino acid
Koichi Shiraishi, Jun Doi and Shohei Matsuzaki
Gastroenterology Tokai University School of Medicine, Japan
Changes in energy metabolism in the skeletal muscle under
exercise loading in healthy volunteers and patients with liver
cirrhosis were assessed based on the measurement of creatine
phosphate (PCr), inorganic phosphorus (Pi) and changes in
intracellular pH associated with the production of lactic acid
using 31P-magnetic resonance spectroscopy (31P-MRS).
Concurrently, the oxygenation kinetics of intramuscular hemo-
globin/myoglobin were determined using near-infrared spectro-
scopy (NIR) to examine the condition of the oxygen supply to
the muscle under the inﬂuence of blood ﬂow in order to assess
the cause of abnormality of muscular energy metabolism.
Furthermore, causes of intracellular metabolic impairment
were assessed, based on the changes in the parameters under
the administration of glucose and branched-chain amino acid
(BCAA).
As a result, patients with liver cirrhosis had a reduction in
intracellular pH and PCr index (PCr/PCr1Pi) by a markedly
increased variation (DpH, DPCr index) (Po0.05), and aerobic
metabolic impairment in the skeletal muscle after exercise
loading under fasting, compared with healthy volunteers. The
tissue oxygen level, concurrently determined using NIR, sub-
stantiated the absence of difference in the oxygen supply to the
muscle. The ﬁndings indicate declined efﬁcacy of oxygen use by
the muscle, or in other words, ineffective operation of the TCA
cycle in the patients with liver cirrhosis. Under the condition,
glucose-only administration resulted in the insufﬁcient produc-
tion of ATP from the TCA cycle, which increases the percentage
of anaerobic metabolism and the production of lactic acid, and
ineffectively reduces DpH. Meanwhile, it is suggested that the
co-administration of BCAA, which directly acts on the TCA
cycle, markedly reduces DpH compared with the preloading
level (Po0.05) and alleviates the abnormality of energy meta-
bolism in the skeletal muscle. Based on these ﬁndings, it is
suggested that the co-administration of BCAA rather than
glucose-only administration is the key to alleviate abnormality
of the energy metabolism, particularly aerobic metabolic ab-
normality, in patients with liver cirrhosis.
APASL/Abstract/BS V.2
Thymosin alpha 1 in chronic hepatitis B infection
R. Guan
Mt Elizabeth Medical Centre, Singapore
Thymosin alpha 1(Ta1) is a synthetically produced 28-amino acid
polypeptide similar to a molecule found in bovine thymus extract.
This polypeptide molecule increases T cell production and
maturation, stimulates production of Th 1 cytokines like inter-
feron gamma and interleukin-2, and activates natural killer cell-
mediated cytotoxic activity. Several randomized controlled stu-
dies using Ta1 monotherapy showed that a six month treatment
with this agent (1.6mg twice weekly) resulted in signiﬁcantly
higher sustained response rate than untreated controls. A recent
study from Japan involving 316 patients with chronic hepatitis B
infection and comparing 0.8mg Ta1 twice weekly with 1.6mg
twice weekly showed no difference in efﬁcacy between these two
doses except in patients with advanced ﬁbrosis when the 1.6mg
twice weekly dose fare better. The effect of Ta1 therapy is usually
not immediately apparent during therapy, unlike those of inter-
feron or the oral anti-viral agents. Complete virological response
usually occurs up to 12 months after the end of therapy. The drug
is extremely safe with virtually no clinical side effects. No
incidence of liver toxicity has been reported to date. Two small
open labelled studies using Ta1 and interferon combination
showed promising results. Ta1 –interferon combination was
also found to be more effective than interferon monotherapy in
the treatment of chronic hepatitis B. Thymosin a1 and famcy-
clovir combination signiﬁcantly reduced median HBVDNA levels
in immune tolerant patients with normal ALTs when compared
to famcyclovir monotherapy. A study using Ta1 and lamivudine
in combination is ongoing.
APASL/Abstract/BS VI.1
Overview of antiviral resistance in chronic hepatitis B: An update
Scott Bowden
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Victorian Infectious Diseases Reference Laboratory, North
Melbourne, and Department of Microbiology, Monash Uni-
versity, Clayton, Victoria, Australia.
The recent development of safe and effective nucleotide and
nucleoside analogues has been an important advance in the
treatment of chronic hepatitis B. These drugs speciﬁcally inhibit
the hepatitis B virus (HBV) polymerase and result in a sub-
stantial decease in viral load, however, their long-term use is
confounded by the development of resistance. Lamivudine,
adefovir dipivoxil and entecavir have been approved for clinical
use and in vivo resistance to each has been reported. As
demonstrated by sequence analysis, resistance is associated
with nucleotide mutations which produce structurally and
functionally altered polymerases. Interestingly, resistance to
each respective inhibitor requires different mutations in the
polymerase gene. Sequence information, together with results
of in vitro assays and computer modelling, have provided some
insights into the mechanism of action of each drug. To optimize
treatment regimes it will be important to characterize the
patterns of resistance as well as cross-resistance associated
with the various HBV mutants.
APASL/Abstract/BS VI.2
Molecular diagnosis of antiviral resistance in hepatitis B
W. Yoo
GeneMatrix Inc., Bojeong, Guseong, Yongin, Gyeonggido,
Korea
Advances in antiviral therapy such as lamivudine have brought
about an increasing need for sensitive and early detection of
emerging drug-resistant mutants to monitor drug resistance as it
develops and aids early intervention. The identiﬁcation of such
mutations is of increasing importance, especially as alternative
antivirals such as adefovir and entecavir, which are effective
against lamivudine-resistant HBV, have become available.
The detection of HBV variants is largely performed by
sequencing analysis, RFLP and hybridization-based assays.
Sequencing can give information on the majority species present
in the viral populations, but generally cannot detect species
comprising fewer than 15–50% of a viral population. Thus it is
necessary to analyze multiple clones representing viral quasis-
pecies for determining the heterogeneity of a population. For
example, an rtM204V/rtM204I variant mixture could be incor-
rectly scored as rtM204V variant/wild type mixture by direct
sequencing even after visual inspection. This is due to the
inability of the sequencing software to determine the correct
variants present in the sample when the nucleotide mixture at
position 1 (R5A or G) and position 3 (K5T or G) of codon
204 are present. Assays based on RFLP and hybridization have
been contributing to the understanding of the occurrence of the
mutant HBV strains. However, such assays are time consuming,
labor intensive, and are not suitable for a high throughput
screening of large number of samples, as they require multiple
DNA ampliﬁcations and enzyme digestions or complex hybri-
dization steps. Recently we have developed a matrix-assisted
laser desorption/ionization time-of-ﬂight mass spectrometry
(MALDI-TOF MS)-based genotyping assay, termed restriction
fragment mass polymorphism (RFMP), which exploits differ-
ences between wild-type and variant sequences. This assay can
represent an improvement over gel-based assays because it relies
upon precise information about the molecular mass of the
analyte; both DNA strands can be analyzed in parallel and it
can be fully automated.
For clinical application, we established a RFMP assay for
detecting rtL180M and rtM204I/V variants to monitor lamivu-
dine resistance, and also developed a RFMP assay for inter-
rogating rtA181T/V and rtN236T mutations to characterize the
genotypic and phenotypic mutation proﬁles to adefovir in
patients who were treated with adefovir. By comparing the
results from RFMP assays with those of the INNO-LiPA HBV
DR line probe assay, RFLP, and sequencing, the concordance
and ability to identify mixed wild type and mutant viral
populations of different methods were assessed among the
methods. The results showed that the RFMP technology is
very useful for the detection of viral quasispecies and subtle
genetic variations, due to the intrinsic sensitivity of MALDI-
TOF MS. The improved sensitivity and speciﬁcity of the RPMP
assays can help monitor drug resistance as it develops, enabling
early intervention and prevention.
APASL/Abstract/BS VI.3
Clinical impact of early detection for YMDD mutant on the
outcomes of long-term lamivudine therapy in patients with chronic
hepatitis B
K.-H. Han
1Department of Internal Medicine, Yonsei Institute of Gastro-
enterology, Yonsei University College of Medicine, Seoul, Korea
In patients with HBeAg postitive CHB, HBeAg seroconversion
rate increases with increasing duration of lamivudine (LMV)
therapy. However, long-term monotherapy with lamivudine are
often complicated by emergence of drug-resistant YMDD
mutants. Viral breakthrough that is the reappearance of HBV
DNA has been reported to occur usually after 6–9 months of
LMV therapy. However, early emergence of LMV mutant can
be detected very early during or even before lamivudine therapy.
We previously reported that YMDD mutants were detected
within a few weeks during LMV therapy in Korea. However, it
has been unclear whether early detected YMDD mutant may
affect the long-term prognosis of LMV monotherapy in patients
with CHB. We investigated the impact of early detected YMDD
mutation at 3 month on the outcomes of long-term LMV
therapy in HBeAg positive CHB patients. We prospectively
investigated the emergence of YMDD mutation by the nested
PCR at 3 month of LMV therapy in patients with HBeAg
positive CHB. Long-term outcome of LMV therapy was com-
pared between the patients having the early emergence of
YMDDmutation at 3 month and who didn’t. YMDDmutation
was detected in 58% patients at 3 month and only the type of
mutation found was YIDD. Cumulative HBeAg loss rate at 1, 2,
and 3 year was 7%, 14% and 14%, respectively in patients who
had YIDD mutant at 3 month, and 20%, 50% and 60%,
respectively in patients who had only wild type at 3 month
(p5 0.017). Cumulative viral breakthrough rate at 1, 2 and 3
year was 43%, 71% and 71%, respectively in patients who had
YIDD mutant at 3 month, and 0%, 20% and 20%, respectively
in patients who had only wild type at 3 month (p5 0.024).
Conclusions: Our data suggest that early detection for HBV
YMDD mutation at 3 month may be useful to predict the long-
term outcome of LMV therapy in patients with HBeAg positive
CHB. And appropriate treatment strategy such as combination
anti-viral therapy or changing antiviral agent may be needed for
those patients who showed early detection of YMDD mutant.
APASL/Abstract/BS IX.1
HBV genetic diversity and its impact on diagnostic assays
F.B. Hollinger
Department of Medicine, Virology and Epidemiology, Eugene
B. Casey Hepatitis Research Center and Diagnostic Laboratory,
Baylor College of Medicine, Houston, TX, USA
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HBV circulates in blood as closely related, but genetically diverse
molecules called quasispecies. During replication, HBV produc-
tion may approach 1011 molecules/day, although during peak
activity this rate may increase 100–1000 times. Ordinarily, DNA
polymerases have excellent ﬁdelity in reading DNA templates
because they are associated with an exonuclease which removes
incorrectly added nucleotides. However, the HBV DNA polymer-
ase lacks ﬁdelity and proofreading function partly because exo-
nuclease activity is either absent or deﬁcient. Thus, the HBV
genome, and especially the envelope gene, is mutated with
unusually high frequency. These mutations can affect more than
one ORF because of overlapping genes. HBsAg preparations
consist of three polypeptides: S, M and L. These are not
distributed uniformly among the various circulating particles.
The more numerous 20-nm particles (by a factor of 104–106) are
composed primarily of the S protein and essentially no L chains.
Conversely, the virion contains relatively large amounts of the L
chains that contain the recognition site for binding to hepatocytes
and are important for viral assembly and infectivity. The S gene
contains an exposed major hydrophilic region (residues 110–155)
which encompasses the a determinant that is important for
inducing immunity. Nucleotide substitutions in this region are
common and result in reduced binding or failure to detect HBsAg
in diagnostic assays with polyclonal and/or monoclonal antibo-
dies. Adaptive immunity also depends on the recognition of
HBsAg by speciﬁc antibody, and variants pose a threat if they
interfere with binding to antibody. Finally, genomic hypervaria-
bility allows HBV to escape selection pressures imposed by
antiviral therapies, vaccines and the host immune system and is
responsible for creating genotypes, subgenotypes and subtypes.
APASL/Abstract/BS IX.2
The role of hepatic stellate cells in hepatic ﬁbrosis
T. Ueno, M. Sata
Research Center for Innovative Cancer Therapy and Second
Department of Medicine Kurume University, 67 Asahi-machi,
Kurume, 830-0011, Japan
Hepatic ﬁbrosis occurs in chronic liver diseases (CLD) due to
various etiologies such as viral hepatitis, autoimmune hepatitis,
alcoholic liver diseases, nonalcoholic fatty liver diseases and
primary biliary cirrhosis, and develops according to mechanisms
characteristic of the its underlying disease. The most prevalent
mechanisms of hepatic ﬁbrosis in different CLD are chronic
inﬂammation, oxidative stress, direct cytotoxicity, hypoxia and so
on. Hepatic stellate cells (HSC), which are located in the Disse
spaces, are stimulated and activated by various inﬂammatory
cytokines or soluble factors containing platelet-derived endothe-
lial cell growth factor (PDGF), transforming growth factor
(TGF)-b and endothelin (ET)-1. The activated HSC exhibit the
migration, apoptosis, chemoattraction and contraction. Acti-
vated HSC can undergo transformation into proliferative and
ﬁbrogenic myoﬁbroblast-like cells during liver injury. In addition,
speciﬁc lymphocytes and Kupffer cells stimulate ﬁbrogenesis.
Hepatic ﬁbrosis also forms a part of tissue repair, and it proceeds
under condition when ﬁbrogenesis surpasses ﬁbrolysis. Tissue
repair is the recruitment of inﬂammatory cells in order to remove
necrotic space. In this stage of the process, HSC are recruited at
the site of injury in order to synthesize and secrete extracellular
matrix (ECM) components. HSC secrete several chemokines such
as monocyte chemotactic protein (MCP)-1, which is the most
prominent chemotactic factor, and it induces the proliferation of
leukocytes and activated T cells. A cascade of signaling and
transcriptional events in HSC underlies the ﬁbrogenic response to
liver injury, with each step in the cascade being a potential target
for antiﬁbrotic therapy.
APASL/Abstract/BS IX.3
Mitochondrial involvement in hepatitis
David Handojo Muljono
Eijkman Institute for Molecular Biology
A mitochondrion is an organelle found in the cells of most
eukaryotes. Mitochondria are cellular ‘power plants’ because
their primary function is to manufacture adenosine triphosphate
(ATP), which is an essential substance for the life of a cell.
Impaired function of ATP production will cause dysfunction or
death of the cell. The production of ATP is achieved by the Krebs
cycle, electron transport and oxidative phosphorylation. Depend-
ing on energy demands, the amounts of mitochondria vary from
cells to cells. Fat storage cells, which require little energy, have
very few mitochondria, but energy-demanding muscle cells tend
to have many. Human liver cells have around 2000 each.
Two things certain in a cell are cellular life and death.
Mitochondria are not only essential in energy generation and
as key regulators for cellular survival, but also in regulating
physiological cell death. One important function of mitochon-
dria is apoptosis, or programmed cell death, which is a normal
physiological process occurring in senescent or damaged cells,
when speciﬁc cells need to be removed during development or
during normal tissue turnover.
In liver disorders, mitochondrial involvements can be directly
because of intrinsic mitochondrial defects or caused by systemic
disorders that impair its function. Several disorders of different
mechanisms involving mitochondria are alcoholic liver disease,
non-alcoholic fatty liver disease, autoimmune diseases, drug-
induced hepatopathy, and hepatitis because of infectious agents,
such as hepatitis B and hepatitis C viruses (HBV and HCV).
HBV, through the function of its proteins (HBxAg and large
surface protein), induces hepatocyte apoptosis by decreasing the
mitochondrial membrane potential. However, HBx stimulation of
NF-kB protects hepatocytes against apoptosis, as a possible
mechanism to maintain persistent infection. HCV infection is
directly correlated with increased apoptotic activity. The patho-
genesis can be through the direct effect of HCV proteins on
hepatocytes, or through the oxidative stress primarily induced by
the HCV core protein. The apoptosis in hepatitis C may progress
even without the increase of transaminase. Steatosis is also
recognized as a cofactor inﬂuencing the progression of ﬁbrosis in
chronic hepatitis C, while hepatocyte apoptosis itself contributes to
the advancement of fatty liver disease. In the treatment of hepatitis
C, the antiviral effect of interferon may be mediated through
induction of apoptosis. The administration of antiapoptotics, such
as vitamin E, ursodeoxycholic acid, could ameliorate hepatitis C.
APASL/Abstract/BS X.1
Anemia associated with chronic hepatitis C and its treatments
Hyo-Suk Lee
Department of Internal Medicine and Liver Research Institute,
Seoul National University College of Medicine, Seoul, Korea
HCV infection itself can induce autoimmune hemolytic anemia,
leukopenia, and thrombocytopenia. The most effective treat-
ment for HCV infection is combination therapy with (PE-
G)IFN- and ribavirin(RBV). Anemia, neutropenia, leuko-
penia, and thrombocytopenia are among the numerous hema-
tologic disorders frequently observed during HCV treatments.
THESE side effects can inﬂuence HCV treatment and adher-
ence, which is the most important factor in successful eradica-
tion of HCV. Major hematologic side effect of IFN-a and PEG-
IFN-a is bone marrow suppression leading to anemia and
neutropenia; IFN-a-induced anemia can also occur by activa-
tion of apoptosis in erythroid progenitor cells, provocation of
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immune hemolysis, and impairment of renal function. Anemia
tends to occur less frequently with PEG-IFN-a than with non-
pegylated IFN-a. The major side effect of treatment with RBV is
dose-dependent hemolytic anemia. At RBV doses of  800mg/
day, RBV-induced hemolytic anemia causes a dramatic decrease
in hemoglobin levels (of 2–3 g/dL), usually within 4 weeks of
initiation of treatment. In addition to hemolysis, RBV induces
anemia by suppression of erythropoiesis, possibly as a result of
down-regulation of erythropoietin(EPO) receptors. Accordingly,
anemia has been found to be more pronounced with combination
therapy with IFN-a/RBV than with IFN-a monotherapy; hemo-
globin levels o11 g/dL occur in 25%–30% of patients. Actually,
the incidence of dose reductions due to anemia increased from 1%
with PEG-IFN-a monotherapy to 22% with PEG-IFN-a/RBV
therapy. IFN-a/RBV treatment–induced anemia has been called a
‘‘mixed’’ anemia, because patients treated with combination
therapy are subject to RBV-related hemolytic anemia as well as
IFN-related bone marrow suppression, which may impair the
compensatory reticulocytosis that is an expected response to most
hemolytic processes. HCV-infected patients treated with PEG-
IFN/RBV appeared to have inappropriately low levels of endo-
genous EPO for their degree of anemia. Although serum EPO
levels increased, the Hb level did not return to normal, suggesting
that the increase in serum was not sufﬁcient to fully compensate
for the degree of anemia. A recent randomized, double-blind,
placebo-controlled trial suggests that EPO can increase Hb levels,
maintain RBV dosage in a substantial proportion of patients, and
improve patient quality of life signiﬁcantly in this setting. In
summary, currently available HCV treatments induce hematolo-
gic disorders that may exacerbate an already fragile hematologic
state in the HCV-infected individual and may compromise treat-
ment adherence. Reported risks of developing anemia were higher
among Asian studies. Therefore, close monitoring of haemoglobin
levels and judicious adjustment of the RBV dosage are currently
the widely accepted clinical practice to avoid discontinuation of
HCV treatment and to achieve consequent eradication of HCV
infection. Many clinical questions still exist concerning the ad-
junctive use of EPO to ameliorate the anemia associated with
standard combination therapy. There are also economic issues
relating to the long-term costs of therapy. These two clinical issues
will be discussed separately at this BREAKFAST SESSION.
APASL/Abstract/BS XII.1
Laparoscopic pancreatic resection : preliminary results of a
multicenter european study (127 patients)
J.-Y. Mabrut1,2, L. Fernandez-Cruz3, J. S. Azagra4, M. Goer-
gen4, M. Ceuterick5, R. Schockmel5, C. Bassi6, G.- Lmelotti2, G.
Delvaux2, Y. VanNieuwenhove2, J. Weerts7, B. Dallemagne7, J.-
M. Fabre8, J. Boulez1, J.-L. Peix1, J. Baulieux1, M. Adham1, E.
De La Roche1, U. Hesse9, D. Ysebaert10, T. Chapelle10, G.
Roeyen10, R. Aerts11, J. Closset2, A. El Nakadi2, M. Gelin2, B.
Millat8, F. Borie8, C. Arvieux12, J.-L. Faucheron12, C. Letou-
blon12, C. Bertrand13, A. De Neve De Roden2, B. Navez14, J.-P.
Staudt2, A. Dabrowski15, B. Hansson16, C. Gouillat1, J. Mar-
escaux17, B. Sastre18 and J.-F. Gigot2
1Lyon (F), 2Brussels (Be), 3Barcelona (Sp), 4Luxembourg
(Lux),5Montignies-le-Tilleul (Be), 6Verona (I),7Lie`ge (Be),
8Montpellier (F), 9Ghent (Be), 10Antwerp (Be), 11Leuven (Be),
12Grenoble (F), 13Jolimont (Be), 14Gilly (Be), 15Seclin (F),
16Nymegen (NL), 17Strasbourg (F), 18Marseille (F)
Objective: The role of laparoscopy in resection of pancreatic
tumors remain controversial despite an increasing number of
publications reporting laparoscopic pancreatic resections
(LPR). The objective of this study is to assess the feasibility,
safety, and outcome of LPR in a multicenter setting. Methods:
A retrospective study (from 1995 to 2002) was conducted in 25
European surgical centers, collecting a series of 127 patients
operated on an (intent-to-treat) basis of LPR. Results: Final
diagnosis included benign pancreatic diseases in 111 patients
(87%) (insulinoma: 22, neuroendocrine tumor: 20, mucinous
cystadenoma: 26, serous cystadenoma: 21, chronic pancreatitis:
11, others: 11) while 16 patients suffered from malignant pan-
creatic diseases (13%) (insulinoma: 3, neuroendocrine tumor: 5,
ductal adenocarcinoma: 4, cystadenocarcinoma: 2, renal metas-
tases: 2). Five patients with presumed benign pancreatic diseases
had malignancy at ﬁnal pathology. The median tumour size was
30mm (range: 5–120mm). The tumours were located in the left
part of the pancreas in 89%. Laparoscopically successful proce-
dures included 21 enucleations, 24 distal spleno-pancreatec-
tomies, 58 distal pancreatectomies with splenic preservation,
and 3 pancreato-duodenectomies. The overall conversion rate
was 14%. There was no postoperative death. The rate of overall
postoperative pancreatic-related complications was 31%, but
including only 17% of clinical pancreatic ﬁstula. The surgical
reoperation rate was 6.3%. In laparoscopically successful opera-
tions, the median postoperative hospital stay was 7 days (range:
3–67 days), signiﬁcantly reduced in comparison to converted
patients. During a median follow-up of 15 months (range: 3–47
months), 23% of the patients with pancreatic malignancies had
tumour recurrence. No port-site metastases were observed. Late
outcome was satisfactory in all patients with benign diseases.
Conclusions: LPR is feasible and might be safe in selected patients
with presumed benign and distal pancreatic tumours. The best
indication for a laparoscopic approach appears to be the resection
of benign and endocrine tumors without a need for pancreato-
enteric reconstruction (i.e enucleation or distal pancreatectomy).
As in open surgery, the successful management of the pancreatic
stump remains the challenge of this procedure. The role of LPR
for pancreatic malignancies remains controversial.
APASL/Abstract/BS XII.2
Laparoscopy for liver and biliary disease at the Cipto Mangun-
kusumo Hospital
Toar J. M. Lalisang
Digestive division department of surgery, Cipto Mangunku-
sumo Hospital Jakarta, Indonesia
Nowdays laparoscopies was performed on more wider indica-
tion in the ﬁeld of liver and biliary surgery. In the past,
cholecystectomy, appendectomy, diagnostic biopsy and adhe-
siolisis were the common indications.
We report laparoscopic procedures out of the routine indica-
tions, which were performed at our centre in the last 2 years.
There were more than 15 procedures done beside the routi-
nely laparoscopic indication. Most of the cases were women
with an average age at 20–60 years.
Shortage of facilities and learning curve period made these
procedures growth slow.
Five liver cyst cases, ﬁve common bile duct stones, one case
of choledochal cyst and a few liver abcessess were operated
laparoscopically.
In the liver cyst, the unrooﬁng procedure and omentalpexy
were successfully done, in one case, with pathologic result in
situ, cholangiocarcinoma was suggested for wide cyst excision.
The common bile duct stones were ﬁrst explored laparoscopi-
cally in two cases then were converted to open for deﬁnitive
treatment. In the other cases, stone extraction and t-tube were
successfully performed.
Laparoscopic preparations to free the fusiforme cyst and the
gallbladder was performed on the type I choledochal cyst, and
then continued on to laparotomy for total excision and Roux &
Y biliodigestive reconstruction.
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In the liver abcess cases, most were amoebic. Aspiration and
tube drainage were performed, the tube itself being removed 7
days later in out patient clinics.
There was no operative death; length of stay wad less than 3
days and the patient returned routine activity faster. Conclu-
sions: Indication of laparoscopic procedures should be widened
in liver and biliary cases in our institution.
APASL/Abstract/BS XIII.1
Hepatitis B genotypes in South Asia
Z. Abbas
Department of Hepatogastroenterology, Sindh Institute of
Urology and Transplantation, Karachi, Pakistan
Viral hepatitis caused by hepatitis B virus (HBV) infection is a
worldwide disease. The clinical outcome, progression of the
disease and response to the antiviral therapy may depend on
HBV genotypes. HBV isolates even of the same genotype can
differ in virological and clinical characteristics. While genotype
B and C are common in Southeast Asia, this may not be the case
in South Asia. In Karachi, Pakistan, the predominant genotype
is D and about one fourth of the patients have chronic hepatitis
due to HBeAg negative mutants. As most of the patients from
different clinical categories are infected with the same genotype
D, it is difﬁcult to conclude any inﬂuence of the genotype on the
outcome of HBV infection. Genotype D is also the predominant
genotype circulating in the western India (92%), in primitive
tribes of the Andaman and Nicobar Islands, and Calcutta. In
India, this genotype is associated with more severe liver disease
than genotype A and may predict occurrence of HCC in young
patients. Genotypes A and D are the commonest in northern
India and Delhi. Genotype A is more often associated with ALT
elevation, HBeAg positivity, and among those aged 25 years and
above, cirrhosis of liver, than is genotype D. In southern India,
genotype D is detected in 57.3%, genotype A in 18%, and
genotype C in 11.5%. Patients with chronic hepatitis B genotype
C have higher alanine transaminase (ALT) levels than those
who had genotype A or D. Genotype C has a greater potential
for causing disease than other genotypes. Patients with genotype
C have a higher HBeAg-positive rate and a faster progression to
liver ﬁbrosis and hepatocellular carcinoma (HCC) than those
infected by genotype A or B. Subgenotype C1 is common in
Bangladesh. Within the genotype A, the double mutation
(T1762/A1764) in the core promoter is signiﬁcantly more
frequent in Asian isolates (HBV/Aa) than in Eupopean (HBV/
Ae) isolates.There is rational evidence that the duration of the
hepatitis B e antigen (HBeAg) positive replicative phase varies
for the different genotypes, being shorter for A and D which
dominate in South Asia, than for B and C which dominate in
Southeast and East Asia. This may be the reason for vertical
transmission being less common in this region.
Satelite Symposium
APASL/Abstract/SS 1.1
Hepatic encephalopathy
D. Ha¨ussinger
Medizinische Universita¨tsklinik, Moorenstrasse 5, 40225 Du¨s-
seldorf
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome
during the course of acute or chronic liver disease. It is
functional in nature, potentially reversible and precipitated by
rather heterogeneous factors. At the neurophysiological level
HE is characterized by a low-frequent cortico-cortical electrical
coupling, which may explain the cognitive deﬁcits and a low
frequent cortico-muscular coupling, which may explain the ﬁne
motor deﬁcits. Current evidence suggests that HE is the clinical
consequence of a low grade chronic glial edema with subsequent
alterations of astrocyte function, which ﬁnally results in distur-
bances of glioneuronal communication. Modern in vivo brain
imaging techniques have demonstrated this low grade cerebral
edema, whose extent parallels the severity of clinical symptoms.
Different factors, such as ammonia, benzodiazepines, inﬂamma-
tory cytokines can induce or aggravate astrocyte swelling, which
results in oxidative stress, the activation of osmosignaling
cascades, protein modiﬁcations, alterations in gene expression
and neurotransmission. Among the protein modiﬁcations nitra-
tion of critical tyrosine residues in glial proteins may play an
important role. Several proteins, which are nitrated in response
to ammonia, benzodiazepines, hypoosmotic astrocyte swelling or
inﬂammatory cytokines have been identiﬁed, inluding glutamine
synthetase and the peripheral type benzodiazepine receptor.
These ﬁndings not only explain why HE is precipitated in clinical
settings by a variety of factors such as gastrointestinal bleeding,
trauma, protein ingestion, sepsis, diuretics, and sedatives, but
also offer novel potential sites of treatment.
APASL/Abstract/SS 1.3
Inter organ metabolism of ammonia: clues to how LOLA works
R. Jalan
Institute of Hepatology, University College London Medical
School, London
In 1893 members of Pavlov’s group in St. Petersburg described
‘The Meat Intoxication Syndrome’. They described a causal
relationship whereby the shunting of blood from the portal
vein into the vena cava (bypassing the liver), resulted in the liver
not being able to metabolise ammonia into urea leading to
ammonia accumulation in the blood. Within this historical
paradigm, ammonia was thought to be produced in the intestine
and metabolized in the liver. Since then numerous studies have
conﬁrmed a central role for ammonia in the pathogenesis of
Hepatic Encephalopathy. Recent studies in both animals and
also in humans have started to change this historical paradigm
suggesting that when the liver is diseased, the muscle becomes
one of the most important organs involved in the detoxiﬁcation
of ammonia. In keeping with this hypothesis, data accumulated
over the past 30 years have failed to show in a metanalysis a role
for the current ‘gold standard’, i.e Lactulose in the treatment of
Hepatic Encephalopathy. Indeed the metanalysis concluded
that there was insufﬁcient evidence for Lactulose in the treat-
ment of Hepatic Encephalopathy. From the pathophysiological
perspective, LOLA enhances the body’s ability to detoxify
ammonia in the muscle. Clinical and laboratory data have
conﬁrmed that its administration can reduce ammonia concen-
tration. Data in animal models show that administration of
LOLA can reduce ammonia induced brain swelling. Relatively
large clinical trials have shown that compared with standard
medical therapy, LOLA is effective in the treatment of Hepatic
Encephalopathy and a preliminary metaanalysis has also con-
ﬁrmed its efﬁcacy. Large scale clinical trials are underway to
explore the full potential of LOLA for the therapy of hepatic
encephalopathy.
APASL/Abstract/SS 11.3
Abstract withdrawn
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APASL/Abstract/GL 1
Clinical application of recombinant human hepatocyte growth
factor for fulminant hepatic failure
Hirohito Tsubouchi and Akio Ido
Department of Gastroenterology, Kagoshima University Grad-
uate School of Medical and Dental Sciences Translational
Research Center, Kyoto University Hospital
We ﬁrst puriﬁed hepatocyte growth factor (HGF) from patients
with fulminant hepatic failure (FHF) as a hepatotrophic factor
in 1998 (J Clin Invest 88:xxx–xxx, 1998) and succeeded in
cloning HGF cDNA in 1999. The molecular weight of HGF is
approximately 92 kDa, consisting of a heavy chain (62KDa)
and a light chain (34KDa). Measurement of serum HGF levels
is useful in predicting the progress from acute hepatitis to FHF
and the outcome of patients with FHF. HGF treatment stimu-
lates liver regeneration in pigs after partial hepatectomy and
increases the survival rate of rats treated with Jo2 (agonistic
antibody against Fas), in which the mortality is quite high
(490%). HGF treatment also improved demethynitrosamine
(DMN)-induced liver ﬁbrosis in rats. In addition, we recently
found that HGF facilitates the repair of large intestine in
detxran sulfate sodium (DSS) or 2,4,6-trinitrobenzene sulfonic
acid (TNBS)-induced colitis in rats. Many reports of in vivo
experiments indicate that HGF is an extremely important tissue
repair factor for various organs. We have ﬁnished pre-clinical
trials for the clinical application of HGF. The half-life of
intravenously administered HGF in the blood of rats is quite
short - even as short as a few minutes; however, HGF accumu-
lates in the liver, particularly of rats. The phosphorylation of
HGF receptor (c-Met) in the liver of mini-pig with intravenous
treatment of HGF was conﬁrmed. A harmful side effect of HGF
is proteinuria; however, it is reversible, and pathological ﬁnd-
ings of renal tissues at 2 weeks after the cessation of HGF
administration revealed that tissues had fully recovered. We are
going to start phase I and II clinical trials for patients with FHF
using recombinant human HGF.
APASL/Abstract/GL 2
Does hepatic steatosis affect sustained virological response in
chronic hepatitis C genotype 3 infected patients?
S. Rasool, S. Hamid, M. Zubair, K. Mumtaz, H. Shah and W.
Jafri
Hepatic steatosis can be a prominent feature of chronic hepatitis
C virus (HCV) infection, especially in genotype 3 patients, and is
considered to be an independent factor for treatment failure.
However, the association of this observation with different
genotypes is not clear. Prevalence of genotype 3 is very high
among chronic HCV patients in our community (in the range of
85–90%). Objectives: The purpose of this study was to deﬁne
the role of steatosis in sustained virological response (SVR) to
antiviral therapy in chronic hepatitis C genotype 3 patients.
Methods: We analyzed all naı¨ve chronic HCV patients treated
in our department during the last 4 years. Patients were included
in the study only if a pretreatment liver histopathology was
available, were infected with HCV genotype 3 patients, com-
pleted 6 months of therapy with interferon-a and ribavirin and
had follow up available of at least 6 months. Liver biopsies were
graded according to HAI and steatosis according to Brunt et al.
Results: A total of 98 eligible patients were studied. Mean age
was 38.09  9.02 years and 60 (61%) were males. Steatosis was
present in 67/98 (68.3 %) of patients. It was mild in 35/98
(35.7%) and moderate to severe in 32/98 (32.6%) of patients.
End treatment response was achieved in 65/98 (66.3%) and SVR
in 62/98 (63.3%) patients. SVR was associated with stage of
ﬁbrosis (P5 0.02) and pre-treatment platelet count (P5 0.05)
but was not associated with age (P5 0.92), gender (P5 0.39),
BMI (P5 0.74), grade of inﬂammation (0.53) and grade of
steatosis (0.28). Conclusion: Hepatic steatosis is present in a
signiﬁcant number of patients with chronic hepatitis C genotype
3 infection but does not affect sustained virological response.
APASL/Abstract/GL 3
Evidence-based medicine in the treatment of (hepatic encephalo-
pathy)
Peter Ferenci
Medical University of Vienna, Vienna, Austria
A large spectrum of clinical conditions are summarized under the
term (HE) ‘HE’ and include a variety of neuropsychiatric
symptoms ranging from minor not readily discernible signs of
altered brain function, overt psychiatric and/or neurological
symptoms to deep coma. Accordingly, the methods to measure
treatment effects and treatment endpoints are highly variable.
Another variable is the treatment of control groups.Most studies
compare a new drug to ‘standard treatment’ (which by itself
maybe highly effective) or to lactulose (whose efﬁcacy was never
demonstrated by a proper placebo controlled trial) as ‘gold
standard’. However, in view of the natural history of HE the
inclusion of a placebo group is mandatory. In studies comparing
a combination of a test drug with ‘standard treatment’ to
‘standard treatment alone’, an additional effect of the test drug
can be detected only if the sample size is sufﬁciently large.
Author
(Ref)
Test
drug N
HE
better
%
HE
grade
Obser-
vation
time
Exclusion
criteria
Survival
%
(on placebo)
Barbaron (1) Flumazenil III# 265 6 days HR, RF, 97.3 490
IV# 262 acidosis 91.3 490
Kircheis (2) Ornithin-
aspartate
MHE= 27 7 days GI-bleed, 100 0
I= 19
HR, RF
100 22
II# 27 100 44
Strauch (3) Ornithin-
aspartate
MHE= 14 days Unstable pts. 100 0
I1II# 20 100 40
Marchesini (4) BCAA oral I# 34 3 mo Unstable pts. 100 38
Michel (5) L-DOPA I-III= 38 7 days none 61 37
Michel (6) BCAA iv. I-III= 24 5 days Unstable pts. 74 26
Wahren (7) BCAA iv. II-IV= 25 5 days None 80 48
Blanc(8) Neomycin1
lactulose
II-IV= 40 5 days ? 85 70
Strauss (9) Neomycin II-IV= 19 5 days MOF 89.5 89.5
Gentile (10) Acarbose MHE-II 107 2 mo ? ?
Liu (11) Synbiotics
MHE 55 30 days 100 13
HR, hepatorenal syndrome; RF, respiratory failure; MOF, multiorgan failure;
BCAA, branched chain amino acids; MHE, minimal HE. nAll patients on
neomycin. #Test drug better than placebo. =Test drug equal to placebo.
To identify all randomized controlled trials (RCT) in HE, a
MEDLINE search (1966–2005) was conducted using several
terms. A total of 2690 papers, written in English dealt with
treatment of HE; less than 100 were some forms of controlled
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trials. From these, 40 randomized studies had the endpoint
‘improvement of HE’ and included more than 10 patients per
study group. Only 11 placebo RCTs were performed (table
below shows survival rates and improvement of HE in placebo-
treated patients in randomized controlled trials). Only ornithin-
aspartate and synbiotics were superior to placebo in improving
HE. Depending on the stage of HE, spontaneous recovery rates
ranged between 0% in minimal HE (in the absence of clinical
symptoms, a clinical beneﬁt may not be detected) to over 90%
when patients with grades III and IV are studied. By excluding
unstable patients, the short-term mortality was low. Thus,
patient selection is the most powerful predictor of outcome. In
patients with minimal HE, it is impossible to detect a clinical
beneﬁt of a drug. In contrast, in patients with overt HE, the high
spontaneous recovery rate on standard care will make every new
treatment very attractive if no controls are included.
APASL/Abstract/GL 4
Minimally invasive surgery for HPB disease: the present and the
future
W. Y. Lau
Department of Surgery, The Chinese University of Hong Kong,
Prince of Wales Hospital, Shatin, New Territories
Surgery is a form of trauma, and trauma induces local and
systemic responses in a person. If the responses are too ex-
cessive, harm can result. In recent years, the avoidance of
harmful responses by a lesser degree of surgical trauma has
been the subject of intensive research, thus the evolution of the
concept of minimally invasive surgery (MIS). MIS has been
around for many years, but the ﬁrst successful laparoscopic
cholecystectomy in 1987 by Mouret brought a sudden and
dramatic development of MIS. Within a decade, many new
MIS procedures were invented and the medical literature on this
subject increased exponentially. The rapid and wide acceptance
of MIS by the patients and the surgeons is due to the beneﬁts of
the MIS: rapid patient recovery, less pain, short hospital stay
and good cosmetics. However, MIS brought the new problems
of loss of three-dimensional visual ﬁeld, loss of tactile sensation
and operating by looking into the monitor instead of the
patients. These initial problems were solved by good training,
accumulation of experience and technical development in in-
struments. The high costs involved in MIS are partially balanced
by the more rapid recovery of the patients, the shorter hospital
stay and the earlier return to work. As the initial problems of
MIS were solved, more complicated MIS procedures were
carried out. New problems arise such as limited working space
in the peritoneal cavity, poor retraction and exposure, removal
of larger specimens through small wounds and the potential
beneﬁt of the use of MIS in procedures in which the access
trauma forms an insigniﬁcant proportion of the total trauma of
the whole operation. There is no doubt that technological
development will help to develop MIS further in HPB surgery
in the future. At present, there are a number of HPB MIS
procedures which are adopted as a ‘routine’ procedure in
selected centers.
Symposium
APASL/Abstract/S1.2
Clinical relevance of hepatitis B virus genotypes
J.-H. Kao
Hepatitis Research Center, Graduate Institute of Clinical Med-
icine and Department of Internal Medicine National Taiwan
University Hospital and College of Medicine, Taiwan
Hepatitis B virus (HBV) exhibits genetic variability. Based on an
inter-group divergence of 8% or more in the complete genome
nucleotide sequence, HBV has been classiﬁed into at least 8
genotypes. Each genotype has its distinct geographical and
ethnic distribution. Genotypes A and D occur frequently in
Africa, Europe and India, while genotypes B and C are
prevalent in Asia. Genotype E is restricted to West Africa,
and F is found in Central and South America. Genotype G was
reported in France, Germany and the United States. Recently,
the eighth genotype H has been described in Central America.
Even within the Asian-Paciﬁc region, HBV genotype distribu-
tion varies. In addition, subgenotypes are identiﬁed within some
genotypes; however, their clinical signiﬁcance remains to be
examined. The clinical relevance of HBV genotypes has become
increasingly recognized. Because of the preponderance of geno-
types B and C in Asian countries, several studies have clearly
shown that compared to genotype C, genotype B is associated
with spontaneous HBeAg seroconversion at a younger age, less
active liver disease, slower progression to cirrhosis, and less
frequent development of HCC. These data indicate that a
shorter duration of high levels of HBV replication and less
active necroinﬂammation may contribute to a more favorable
clinical outcome among genotype B patients. A study from
India indicated that genotype D is associated with more severe
diseases and may predict the occurrence of HCC in young
patients. HBV genotype has also been shown to correlate with
response to conventional interferon (IFN) therapy in patients
with HBeAg-positive chronic hepatitis B. Two studies found
that genotype B patients have a higher HBeAg seroconversion
rate than genotype C patients. These ﬁndings were conﬁrmed by
recent studies of pegylated interferon, where HBeAg serocon-
version occurred more often in patients with genotypes B
(33  44%) than in those with genotypes C (21  28%).
Regarding the correlation between HBV genotype and response
to lamivudine therapy in patients with HBeAg-positive chronic
hepatitis B, several studies showed that the rates of HBeAg
seroconversion rate and drug resistant YMDD mutation occur
in similar proportions of patients with genotypes B and C.
However, genotype B patients may be more likely to have
sustained response when treatment is discontinued. A clinical
trial of adefovir dipivoxil found that all HBV genotypes (A  G)
resulted in a similar reduction in serum HBV DNA levels, but a
correlation with HBeAg seroconversion or durability of sustained
response has not been determined. The inﬂuence of HBV
genotypes on the response to antiviral treatment among patients
with HBeAg-negative chronic hepatitis B remains less clear. In
summary, there is increasing evidence that HBV genotype affects
clinical outcomes of chronic HBV infection and response to
antiviral therapy. The evidence for the clinical difference is
stronger between genotype B and C, and in response to conven-
tional or pegylated IFN but not lamivudine or adefovir dipivoxil.
Whether HBV genotype guides the choice or duration of therapy,
as is the case of HCV genotype awaits the coming results of
several large randomized controlled studies.
APASL/Abstract/S2.1
Dual liver grafts in living-donor adult liver transplantation
Ki-Hun Kim, Sung-Gyu Lee, Shin Hwang, Chul-Soo Ahn,
Kwang-Min Park, Deok Bog Moon
Department of Surgery, Division of Hepato-Biliary Surgery and
Liver Transplantation, Department of Surgery, Asan Medical
Center, Ulsan University, Seoul, Korea
In Asian countries, the majority of organs for liver transplanta-
tion come from live donations. Because many live liver
donors death has been reported from many centers, the risk is
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not eliminated and remains a major consideration in the potential
donor’s decision. In adult recipients, if a left-lobe graft is selected,
the liver graft volume (GV) is often less than 40% of the standard
liver volume (SLV) of the recipient or 0.8% of the graft-recipient-
weight-ratio (GRWR); therefore, right-lobe liver transplantation
was introduced, and this trend has been spreaded widely.
However, the risk to the donor of the right-lobe graft is
higher than the risk of the left-lobe graft. Recently, dual left-
lobe grafts from two living donors for 1 recipient were obtained
to make up the insufﬁcient graft size and to ensure donor safety,
although it is technically complex and requires long operation
time. Furthermore, if a larger recipient needs a bigger GV than
the sum of dual left-lobes, and the right-lobe hepatectomy from
one potential donor is safe, the combination of a right and a left-
lobe from two donors can be applicable to avoid a small-for-size
graft problem. From March 21, 2000 to December 31, 2004, 150
dual adult living donor liver transplantations (ALDLT)
were performed at the Asan Medical Center. Indications of
DLDLT were the same as the single liver graft LDLT. Dual
liver grafts consisted of 62 two left lobes, 51 a left lobe and a
lateral segment, 21 a right lobe and a left lobe, 10 two lateral
segments, 3 a left lobe and a posterior segment, and 2 a lateral
segment and a posterior segment. There was neither mortality
nor morbidity in donors. In-hospital mortality occurred in 8
patients. Our results suggest that dual ALDLT can be a viable
option to alleviate a small-for-size graft problem and secure
donor safety.
APASL/Abstract/S2.4
Right lateral sector graft for living donor liver transplantation
M. Makuuchi
Artiﬁcial Organ and Transplantation Division, Department of
Surgery, University of Tokyo
The major limitation of living donor liver transplantation
(LDLT) for adult recipients is the size of the graft that can be
procured from a living donor, because a small-for-size graft
might not meet the metabolic demands of an adult recipient.
This problem has been overcome by the use of a right liver graft.
Right hepatectomy, however, imposes an increased surgical risk
on the donor due to the reduced residual liver volume. Our
group was the ﬁrst to design the right lateral sector (RLS) graft,
consisting of segments VI and VII. The indication for harvesting
this type of graft includes a right liver of over 70% of the
estimated total donor liver volume, and an estimated volume of
the two right lateral segments that is greater than that of the left
liver. In addition, this graft needs to be more than 40% of the
recipient’s standard liver volume. The postoperative course in
all donors was uneventful. By the end of 2004, 21 patients
received RLS grafts and 19 patients are still alive with normal
graft function. Clearly RLS graft harvesting techniques will be
of use for expanding the donor pool and minimizing the donor
morbidity rate.
APASL/Abstract/S 3.1
Imaging of choice for difﬁcult biliary stricture
Masayuki Kitano
Department of Gastroenterology and Hepatology, Kinki Uni-
versity, Osaka, Japan
Biliary stricture is caused by various kinds of diseases. We have
to differentiate between biliary cancers, pancreatic cancers,
ampularly tumors, cholangitis including Mirrizi syndrome,
primary sclerosing cholangitis, autoimmune pancreatitis and
so on. Patients with jaundice should ﬁrst undergo transabdom-
inal ultrasonography, computed tomography or MRCP in order
to know whether the cause for jaundice is biliary obstruction.
After conﬁrming the biliary stricture, endoscopic ultrasonogra-
phy (EUS) and endoscopic retrograde cholangio-pancreatogra-
phy (ERCP) provide further information for its ﬁnal diagnosis.
Cytology of bile obtained by ERCP- and EUS-guided ﬁne-
needle aspiration cytology are useful for biliary and panctratic
tumors, respectively.
APASL/Abstract/S 4.2
Management of obstetrical cholestasis
Sibitul Hasnain
Pakistan
Obstetrical cholestasis is intrahepatic interference with bile ﬂow
or formation encountered during the third trimester of preg-
nancy but can also occur in the ﬁrst trimester. Obstetrical
cholestasis is often familial. It is particularly common in
Scandinavia, Northern Europe, Chile, Bolivia and China. Pre-
valence is increasing worldwide. Management aims to ease
symptoms e.g. pruritus, and to reduce complication during
pregnancy. Pruritus is the main symptom of this disease.
General measures include reassuring the patient and advising
her to avoid hot humid environment and wear loose cotton
clothes. Choletyramine is a frequently used medicine in this
condition. Other drug options, including Ursodeoxycholic acid,
Phenobarbitone, Nalmefene, S-adenosyl-L-methionine, are
being evaluated. Steroids have been used for both maternal
pruritus and for helping in fetal lung maturation. An early
delivery from 35 to 38 weeks of gestation has been recom-
mended to eliminate the risk of still birth. Mothers with
obstetric cholestasis are at increased risk of bleeding after birth
because of vitamin K malabsorption. Therefore, vitamin K is
prescribed in this condition. There is a 60–80% chance that
future pregnancy will be affected. Patients are advised to avoid
contraceptive pills in future.
APASL/Abstract/S 5.1
New evidence: primary sclerosing cholangitis
Jenny Heathcote
University of Toronto
The introduction of magnetic resonance cholangiography has
markedly enhanced our ability to make a conﬁdent diagnosis of
sclerosing cholangitis without the need to perform ERC with all
its attendant complications. Thus the diagnosis of sclerosing
cholangitis is made with increasing frequency but it is hard to
tell whether this is a true increase in incidence. There is
documentation that the incidence of primary bile duct cancer
is increasing. The pattern of stricturing and dilatation of the
intrahepatic and/or extrahepatic biliary system typical of pri-
mary sclerosing cholangitis (PSC) is most commonly seen in
association with colonic inﬂammatory bowel disease, although
frequently both conditions are not simultaneous. More recently
a number of other conditions of the extra and sometimes
intrahepatic biliary system which resemble PSC have been
observed in other clinical situations. In children given a diag-
nosis of autoimmune hepatitis 50% show radiographic evidence
of a sclerosing cholangitis. Overlap of PSC with autoimmune
hepatitis may also occur, although less frequently, in adults.
Sometimes the two diseases are simultaneous and at other times
they occur consecutively. Another form of sclerosing cholangitis
is seen in association with autoimmune pancreatitis. Both
respond well to corticosteroid therapy in contrast to the two
previously described forms of cholangitis. Similarly the hyper-
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eosinophilic syndrome may be associated with a sclerosing
cholangitis (and pseudotumors) and responds to treatment with
anti-inﬂammatory agents. Mostly in countries where portal vein
thrombosis (PVT) is not a rarity, a simultaneous portal biliopathy
is described in individuals with PVT. Such individuals may
present with cholangitis and a markedly abnormal biliary tree
can be visualized on MRC. Under these circumstances, it is
assumed but not proven that damage to the biliary tree is
secondary to ischemia. This may also occur in patients who
have a hepatic artery thrombosis following liver transplantation.
There is no evidence that ischemic duct injury is the etiology of
primary sclerosing cholangitis associated with IBD – to date the
cause(s) remain unknown. As many years may separate the two
diagnoses, it is unlikely a ‘‘local’’ effect. Infections of the biliary
tract that may give rise to a radiologic picture similar to that of
PSC. This has been reported with bacterial sepsis of the liver and
in individuals with AIDS and infection with cryptosporidia or
other parasites. However effective therapy leads to resolution of
these biliary changes which simulate PSC.
APASL/Abstract/S5.4
Autoimmune hepatitis and primary biliary cirrhosis: experience
from China
Jidong Jia, Fukui Zhang, Wen Tang and Bao-En Wang
Liver Research Center, Beijing Friendship Hospital and Depart-
ment of Gastroenterology, Capital University of Medical
Sciences, Beijing, 100050, P. R. China
Autoimmune liver diseases including autoimmune hepatitis
(AIH), primary biliary cirrhosis (PBC) and primary sclerosing
cholangitis (PSC) are increasingly reported in world medical
literature, but generally believed, at least in China as ‘‘western
diseases’’ involving predominantly Caucasian peoples. How-
ever, as the awareness and understanding of this group of
diseases has being steadily improved among Chinese hepatolo-
gists, more and more such cases has been diagnosed and a
number of large series published in Chinese literature. For
example, as one of the major centers with special interest in
autoimmune liver diseases in China we diagnosed and managed
more than hundred cases of PBC and more 20 cases of AIH and
some cases of PSC in the last 5 years. To observe the clinical
manifestation and biochemical response to immunosuppressive
therapy in Chinese patients of AIH, we followed 21cases (20
female, 1 male; age ranged from 32 to 78 years, with a mean of
55 years) of probable or deﬁnite cases of autoimmune hepatitis
assessed by IAIHG scoring system. We treated them with
immunosuppressive therapy. The liver function tests were
checked at baseline and 2 weeks, 1 months, 3 months, 6 months
of treatment. Nineteen patients were classiﬁed as type 1 AIH,
one as type 2 AIH, one as type 3 AIH. Three patients had
concurrent diseases, including 1 patient each with sicca syn-
drome, hypothyroidism, and hemochromatosis. Two patients
have AIH-PBC overlap syndrome. Fatigue (65%), anorexia
(47%) and icterus (35%) are the dominant symptoms and signs.
Laboratory investigations showed elevated serum aminotrans-
ferase activities (ALT median 179U/L, AST median 132.5U/L),
elevated serum globulin (median 4.6mg/dl), and positivity of
autoantibodies (ANA 88.2%, SMA 29%, anti-LKM1 6%, anti-
SLA/LP 17.6%, pANCA 17.6%, ds-DNA11.8%). Eighteen
received immunosuppressive therapy (prednisone and/or
azathioprine). Compared with baseline, after 2 weeks of treat-
ment, serum ALT, AST and GLO decreased remarkably, reach-
ing statistical signiﬁcance (Po0.05). After 3 months of
treatment, serum ALP, GGT also decreased, reaching statistical
signiﬁcance (Po0.05). At the time point of 3 months after
treatment, serum levels of TBIL decreased compared with
baseline, reaching statistical signiﬁcance (Po0.05). Most pa-
tients developed mild cosmetic changes during induction period
of the therapy, but usually resolved upon dose reduction.
Conclusion: 1) Autoimmune hepatitis occurred mainly in
women, characterized by elevated serum aminotransferase,
hypergammglobulinemia, and circulating autoantibodies. 2)
Prednisone alone or combined with azathioprine can relieve
symptoms and improve laboratory abnormalities very effec-
tively. PBC has been recognized as a chronic intrahepatic
cholestatic liver disease in Western countries for a half century.
For decades, in China and other Asian countries, PBC had been
less well recognized and less reported. In recent years, however,
more than 600 hundred cases of PBC have been reported in the
mainland China. As in western countries, in China PBC is
predominantly affects women, with a peak age of about 50
years. The earlier series was consisted of mainly older late stage
cases which had not been correctly diagnosed until very late
stage of the disease. Recent series comprised of more earlier and
even asymptomatic cases who has been accidently identiﬁed at
routine health check or workup for other medical reasons. In
our institutel more than 100 cases of PBC have been diagnosed
in the last 5 to 10 years. All 112 patients were either hospitalized
or out-patients at Beijing Friendship Hospital from January,
1991 to August, 2004. The diagnosis of PBC was made accord-
ing to the 2000 Practice Guidelines of AASLD. Ninety-eight
were females (98/112) and mean age at diagnosis was
(52.2  9.7) years. The time interval from initial symptom or
preliminary diagnosis to ﬁnal diagnosis was 21.0  27.6 months.
The most frequent symptom was fatigue (59.8%, 67/112), then
was pruritus (52.7%, 59/112) and jaundice (50%, 56/112).
Forty-ﬁve patients (40.2%) were asymptomatic when they
were diagnosed with PBC. Thirty-three patients (29.5%) were
associated with other auto-immune diseases such as Sjogren’s
syndrome and/ or rheumatoid arthritis. Serum alkaline phos-
phatase and glutamyl transpeptidase levels were markedly
elevated [449.1  378.4 IU/L and 591.0  537.2 IU/L, res-
pectively), whereas alanine aminotransferase and aspartate
aminotransferase levels were mildly to modestly elevated
[(91.5  93.9)IU/L and 103.2  90.2 IU/L, respectively]. Half
patients (50%) had a total bilirubin level X34.2mmol/L. Eighty-
one patients (72.3%) had elevated serum immunoglobin M and
79.5% of the patients (89/112) were anti-mitochondrial antibody
(AMA)/AMA-M2 positive. 38.4% of the patients (43/112) were
serum anti-nuclear antibodies and/or anti-smooth-muscle antibo-
dies positive. Most patients were treated with oral ursodeoxy-
cholic acid and the liver function test ﬁndings were improved.
During a median follow-up of 38 months, there were 13 patients
died from liver failure and/or gastroentestinal bleeding. Five
patients accepted orthotopic liver transplantation and recovered
well. Conclusion: PBC in China is probably much more common
than we thought before, and the clinical characteristics as well as
the biochemical response to UDCA are similar to that reported in
western literature.
APASL/Abstract/S6.3
Management of drug induced hepatotoxicity due to ART
S. R. Shah
Jaslok Hospital and Research Centre, Mumbai, India
Antiretroviral therapy has improved survival in HIV affected
individuals. However simultaneously there has also been an
increased morbidity as a result of ART induced hepatotoxicity.
All the three classes of ART are known to have varying degrees of
hepatotoxicity. AIDS Clinical Trial Groups criteria have classi-
ﬁed the grades of hepatotoxicity (1–4: 4-being severe with ALT4
10  ULN). Severe hepatotoxicity occurs in 5–10%within the ﬁrst
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one year but in the vast majority, it is not associated with
symptomatic hepatitis or adverse outcome and resolves
within a few months. ART will need to be discontinued in
grade 4 hepatotoxicity or symptomatic hepatitis, lactic acidosis
or drug hypersensitivity. Amongst the risk factors for severe
hepatotoxicity are co-infection with B and C viruses, Nevirapine
and high dose Ritonavir based therapy and abnormal baseline
levels of transaminases. Mechanisms of liver injury include mito-
chondrial toxicity and steatosis with NRTI (D4T, DDI, and AZT)
hypersensitivity with Nevirapine and Abacavir, immune reconsti-
tution illness after treatment with nucleoside analogues in HBV co-
infection and virus induced ﬂares due to abrupt withdrawal of
drugs or following drug resistance. Management includes assess-
ment of the severity, exclusion of other causes of acute and chronic
hepatitis and cessation of ART if deemed necessary. Recommence-
ment of ART is done when ALT/AST decline to 2–3  ULN and
symptoms subside with careful monitoring of LFT in case of
rechallenge with implicated agents.
APASL/Abstract/S 7.2
Nonalcoholic steatohepatities in Korea
Dong Jin Suh
Department of Gastroenterology, Asan Medical Center, Uni-
versity of Ulsan College of Medicine, Seoul, Korea
Nonalcoholic fatty liver disease (NAFLD) is increasingly re-
cognized, especially in patients with risk factors such as obesity,
diabetes, hypertriglyceridemia or severe weight loss. As one
spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is
characterized by macrovesicular hepatic steatosis and parench-
ymal inﬂammation in liver biopsy and may ultimately result in
cirrhosis or even hepatocellular carcinoma. Until now no
population-based prospective study has been performed in
Korea partly because of the limited concern of physicians and
the lack of accurate, noninvasive diagnostic measures for screen-
ing. With the increment of obesity and diabetes in general
population, the prevalence and clinical importance of NASH
is expected to increase in Korea. In a cohort study of 1192
factory workers, the prevalence of ultrasonographic fatty liver
was 10.7%, and 51.1% of them had abnormality in liver
function. Among those with abnormal ALT, 21% did not
have history of alcohol or viral hepatitis, which suggested
possible NAFLD. Another recent study including 8379 health
screening subjects who had neither hepatitis virus nor signiﬁcant
alcohol consumption showed moderate-to-severe fatty liver on
ultrasonography in 19%. Men between 20 and 40 years of age,
with high BMI, high triglyceride and ultrasonographic fatty
change more than moderate degree were signiﬁcantly associated
with elevated ALT. A small case–control study of biopsy-
conﬁrmed NAFLD (39 patients) revealed a strong relationship
of high body mass index and NASH. These cases had relatively
progressive ﬁbrosis in comparison with studies from Western
countries and less prominent aminotransferase abnormalities.
Korean physicians are now getting more interested in NASH
and efforts to elucidate the prevalence, natural course and
possible therapeutic modalities of NASH are under way.
APASL/Abstract S 7.5
Non-alcoholic steatohepatitis
Syed Sibitul Hasnain
Pakistan
Non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty
liver disease (NAFLD) is fatty inﬂammation of the liver when it
is not because of excessive use of alcohol. It is the major cause of
cirrhosis of liver. It differs from the simple accumulation of fat
in the liver (fatty liver or hepatic steatosis) in that the inﬂam-
mation of NASH causes damage to the liver cells while simple
fat does not. Recent studies indicate that NASH can result in the
development of liver ﬁbrosis in upto 40% of patients, or
cirrhosis in upto 5–10% of the patients. NASH accounts for
about 10% of newly diagnosed chronic liver disease in USA.
Studies report that the progression to ﬁbrosis or cirrhosis for
NASH is variable but can occasionally occur in less than 20
years, but progresses more so in diabetic and hyper lipidemic
patients above the age of 45 years. NASH occurs worldwide in
both sexes. It has been estimated to affect about 50% morbidly
obese, about 20% of obese and 3% of lean persons. It may
occur in about 2% of children but in 20–50% of obese children.
Diabetes mellitus, insulin resistance, obesity and hyper lipopro-
teinemia are associated with increased risk of NASH. Studies
have shown that in type 2 diabetes mellitus, 90% have fatty
liver, 20% have NASH and 10% have cirrhosis. Currently, there
is no speciﬁc therapy for NASH; however, weight loss if over
weight and correcting elevated cholesterol, triglycerides and
blood sugar are beneﬁcial. Antioxidant drugs and antidiabetics,
which lower insulin resistance, may be advantageous.
APASL/Abstract/S 7.8
Prevalence of metabolic syndrome, severity and treatment of
NASH in Thailand
Chutima Pramoolsinsap
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Non-alcoholic fatty liver disease (NAFLD) is associated with
dyslipidemia, obesity, and insulin resistance, which are the main
features of metabolic syndrome. The prevalence of overweight
(BMI 425kg/m2) and obesity (BMI 430kg/m2) among 18389
Thai population, between 2000 and 2004, were 11–28% and 2.4–
10.5%, respectively. The prevalence of metabolic syndrome
(NCEP-ATP III criteria) by the population-based cross-sectional
survey in 5305 Thai adults aged  35 years was 19% in men and
27% in women. The most important risk factors in the Thai
populations were central adiposity, high triglyceride and low
HDL cholesterol (InterASIA study). The true prevalence of
NASH in the Thai population and in metabolic syndrome
remains unknown. Liver biopsy from 70 patients with ALT
41.5UNL and without other causes of hepatitis, was taken in
the Ramathibodi Hospital, with mean age 45.5 (range 28–68)
years, and of whom 50 (71.4%) were male. Forty-six (65.7%)
patients had features of metabolic syndrome. Liver histological
was graded by Brunt’s classiﬁcation were mild 20 (28.6%),
moderate 46 (65.7%) and severe 4 (5.7%). The degree of ﬁbrosis
in stage 1, 2 and 3 were 44 (62.5%), 24 (34.3%) and 2 (2.9%),
respectively. Obesity, increased abdominal and visceral fat,
insulin resistance, DM, metabolic syndrome, Homar IR 43.5
and high triglyceride levels were signiﬁcantly higher in NASH
than healthy control (P5 0.01). Treatment of NASH in Thailand
mainly focused on the management of associated conditions i.e.
obesity, DM and hyperlipidemia; life-style changes and alcohol
abstinence are implemented before pharmacotherapy included
antioxidants, UDCA, silymarin, and insulin insensitizers.
APASL/Abstract/S8.1
Contrast harmonic ultrasound is a useful technology in the
diagnosis and treatment of hepatic tumors.
Shinpei Sato
Teikyo University Mizonokuchi Hospital, Internal Medicine.
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Recently developing, contrast-enhanced harmonic ultrasonogra-
phy (US) using contrast agent is a new technique that has been
developed to overcome some of the drawbacks of conventional
color Doppler imaging. A dramatic improvement of contrast-
enhanced US brought us the new strategy in the diagnosis and
treatment of hepatic tumors. In this lecture, I would like to talk
about that the present status of US technology and US contrast
agent for hepatic tumors. More accurate diagnosis than conven-
tional color Doppler imaging: Contrast-enhanced harmonic US
using Levovist has proven to be signiﬁcantly more accurate than
color Doppler US in assessing the vascularity of hepatic tumors.
Evaluation of treatment responses after TAE and RFA: We
prospectively analyzed the relationship between detection of
contrast-enhanced Doppler signals in HCC after TAE and
histological conﬁrmation of viable tumor cells in order to
quantify a possible beneﬁcial use of contrast-enhanced harmonic
US. We concluded that tumor blood ﬂow detected by contrast-
enhanced harmonic US indicates the presence of residual viable
tumor cells by biopsy specimens after TAE. Contrast-enhanced
harmonic US is useful in evaluating the effect of TAE. However,
regarding after RFA, It was difﬁcult to evaluate viability because
of unclear the tumor marginal zone to ablate. Distinguishing
Benign and Malignant Focal Liver Lesions by Kupffer Imaging:
We evaluated the differentiability of the late-phase harmonic
sonography (Kupffer imaging) with the contrast agent Levovist
between benign and malignant hepatic tumors. We concluded
that Kupffer imaging is a promising non-invasive technique to
differentiate between benign and malignant hepatic tumors, the
use of which may obviate invasive and expensive further diag-
nostics. Three–Dimensional Power Doppler Ultrasonography: We
assessed clinical usefulness of recently developed three-dimen-
sional power Doppler US for the diagnosis of HCC. We
concluded that three-dimensional power Doppler US provides
deﬁnite diagnosis of HCC in a real-time, non-invasive manner
under certain conditions.
APASL/Abstract/S 8.2
MRI vs CT in detecting small HCC
T. C. Hua
Department of Oncologic Imaging, National Cancer Centre,
Singapore
There are many pitfalls in the imaging of small hepatocellular
carcinoma (HCC). This talk attempts to confront these issues
frustrating the diagnosis of small HCC. The current imaging
criteria of hypervascularity in the hepatic arterial phase with
wash-out in the portal venous phase, the presence of a multi-
nodular or mosaic pattern, the portal venous enhancement of
pseudocapsule and internal sepate; are based on the gross
pathology ﬁndings and the increased vascularity of HCC.
They are more commonly seen in larger HCC. Step-wise
evolution of regenerating nodules into low grade and subse-
quently high grade dysplastic nodule and HCC is recognized.
Radiologic-pathologic studies of these nodules have revealed a
gradual decrease and degeneration of native hepatic arterial
supply and an increase in angiogenesis. In high grade dysplastic
nodules and well differentiated HCC, the increase in angiogen-
esis may balance the normal normal degeneration of hepatic
arterial supply and thus no increase or decrease in vascularity is
noted in the hepatic arterial phase. This makes diagnosis of
these nodules difﬁcult. Arterio-portal shunts or perfusion
anomalies are increasingly recognized as common imaging
ﬁndings which may mimic a small HCC. MRI provides the
best differentiation between a pseudolesion due to shunts and a
small HCC. The modality of choice for imaging small HCC
remains MRI though CT is currently still the workhouse in
many institutions. Recent evidence has shown that Lipiodol-CT
is associated with a high false positive rate. Angiography is less
sensitive compared with dynamic MRI and CT. New MR
contrast agents and FDG PET also have limited success. The
diagnosis of small HCC (1 to 2 cm) still rests on histology.
Presumptive diagnosis of HCC can be made if a hypervascular
lesion (conﬁrmed by 2 modalities and 42 cm) is seen in a
cirrhotic liver according to the EASL criteria.
APASL/Abstract/S 8.3
Prognostic scoring in hepatocellular carcinoma
Tan Chee Kiat1,2
1Department of Gastroenterology and
2Liver Transplant Service, Singapore General Hospital, Singa-
pore
As most patients with hepatocellular carcinoma (HCC) present
at an advanced stage, it is useful to be able to predict their
probability of surviving the next few months. Thus prognostic
scoring is valuable in the management of HCC. Besides estimat-
ing the survival time, prognostic scoring is also useful in
identifying patients suitable for clinical trials. The prognostic
of a patient with HCC is not just dependent on the disease extent
alone. The underlying liver function is of equal, if not greater,
importance as well. Hence a prognostic scoring system should
incorporate liver function in addition to tumour characteristics.
Many prognostic models and scoring systems have been pro-
posed and validated. These models usually require a large
number of data input. Some of these data can only be obtained
by advanced imaging techniques or from a multitude of blood
tests. Our department in the Singapore General Hospital has
developed and validated a simple bedside prognostic model in
contradistinction to the existing models. With so many prog-
nostic models and scoring systems available in the literature, it is
important to select the appropriate one for our patients and to
understand the shortfalls of that particular model. Only then
can we utilize it in a useful manner.
APASL/Abstract/S 9.1
Iron overload with particular reference to the Asian Paciﬁc area
Lawrie W. Powell
The University of Queensland, The Queensland Institute of
Medical Research, Brisbane and The Royal Brisbane and
Women’s Hospital, Brisbane, Australia
Our understanding of the mechanisms by which the body
regulates iron absorption and iron homeostasis has improved
greatly in recent years with the identiﬁcation of key molecules
such as HFE, ferroportin, transferrin receptor 2, hepcidin and
haemojuvelin. Hereditary haemochromatosis, a primary inher-
ited disorder of iron metabolism leading to progressive iron
loading of parenchymal cells of the liver and other organs, can
result from mutations in any of these genes. However, HFE-
associated hereditary haemochromatosis accounts for over 90%
of cases in Caucasian populations. Penetrance is incomplete with
variable clinical expression. The majority of cases demonstrate
biochemical expression but a lower proportion develop advanced
disease. Clinical disease, especially hepatic ﬁbrosis, is related to
the level of body iron stores which is reﬂected primarily in the
liver. The available evidence indicates that adequate screening
and diagnostic strategies can ensure that early case detection and
treatment occur prior to the development of irreversible end-
organ damage. The most cost-effective methods of early case
detection are family (cascade) screening and evaluation of poten-
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tial cases by primary care physicians with a high index of clinical
suspicion. Clearly, HFE-associated haemochromatosis is uncom-
mon in Asian populations. However, inherited iron overload with
similar manifestations can be seen resulting frommutations in the
other key molecules mentioned above as well as secondarily to
iron-loading anaemias.
APASL/Abstract/S 9.2
Neonatal metabolic liver disease
G. Cleghorn
University of Queensland
Metabolic and genetic liver diseases lead to considerable mor-
bidity and account for 30% of liver transplantations performed
in children. It is important for paediatricians and neonatologists
to keep in mind inborn errors of metabolism as a cause of illness
in the neonatal period many disorders are treatable and, in most
cases, successful outcome is dependent on a rapid diagnosis and
early instigation of therapy. Even with untreatable disorders, it
is important to establish the diagnosis in the index case in order
to allow prenatal diagnosis in subsequent pregnancies. Most
babies with an inborn error are born in good condition and of
normal birth weight but a high index of suspicion of metabolic
disease is essential in approaching any sick neonate.
Patterns of Presentation:
 Liver dysfunction
 CNS – encephalopathy & /- seizures
 Metabolic acidosis
 Hypoglycemia
 Cardiac disease
 Dysmorphic features
 Body odour is abnormal or unusual as in Maple Syrup Urine
Disease
 Non immune hydrops fetalis
Timely investigation and where possible intervention is essential
in the management of any of these conditions. When considered
a battery of screening tests should be performed and could
include the following:
 Plasma lactate persistently 4 2.5mmol/l
 plasma lactate : pyruvate 4 20:1
 arterial b-OH butyrate : acetoacetate 4 2:1
 amino acids
–elevatedalanine and proline
 urine organic acids
 plasma acylcarnitine proﬁle
–totaland free carnitine
–FattyAcid Oxidation Defects
 CSF
–Lactateto pyruvate ratio and amino acids measurement
Speciﬁc diagnostic tests are more difﬁcult and are the realm of a
limited number of more specialized centres. Recently, attempts
at developing a regional reference laboratory have been made
with some success using the neonatal dry blood Guthrie card as
a vehicle for providing a sample for analysis via tandem mass
spectroscopy. Using this technique the rapid analysis for amino
acid disorders, urea cycle defects, fatty acid oxidation defects,
organic aciduria’s, peroxisomal defects and possibly congenital
disorders of glycosylation are all possible. This will allow for
rapid assessment and also rapid (within days) reporting of
results which will allow for appropriate therapy where possible.
APASL/Abstract/S 9.3
What does fat do to the children liver: is non-alcoholic steatohe-
patitis a clinical problem?
Quak Seng Hock
Department of Paediatrics, Children’s Medical Institute, Na-
tional University Hospital, Singapore
Non-alcoholic steatohepatitis (NASH) is an entity in the spec-
trum of non-alcoholic fatty liver disease. It is associated with
obesity, diabetes, insulin resistance, and hyperlipidemia. The
prevalence of NASH in children is not known. Generally,
children with NASH presented in the prepubertal age group.
A two-hit hypothesis has been proposed in the pathogenesis of
NASH. The ﬁrst hit is insulin resistance resulting in steatosis.
The second appears to be oxidative stress, which produces lipid
peroxidation and activates inﬂammatory cytokines like TNF –
resulting in NASH. The role of fatty acid oxidation is complex.
Appropriate fatty acid oxidation is essential in order to prevent
accumulation of fat in the liver. On the other hand, excessive fatty
acid oxidation is probably responsible for the generation of
oxidative stress. There is evidence that intact mitochondrial fat
oxidation is required for progression to inﬂammation and ﬁbrosis.
APASL/Abstract/S 11.3
Long-term problems associated with paediatric liver transplanta-
tion
G. Cleghorn
University of Queensland, Brisbane, Australia
Liver transplantation in children has now reached a level of
sophistication and success that it is now timely to consider any
comorbidities that may now be apparent. It is now normal to
consider that in excess of 70% of paediatric liver recipients will
be alive 10 or more years following their transplant. As growth
is the cornerstone of childhood, it is imperative to examine not
only physical, but also psychological growth in these long-term
survivors. It is becoming apparent from many studies and
reports that the catch up linear growth is suboptimal in children
following liver transplant. Our group and others have shown
that there is continuing disparity between height and weight
when compared with age-matched controls. This is at odds with
what is seen with the long-term growth characteristics of
children who have undergone successful Kasai procedures for
extra hepatic biliary atresia which would suggest that there are
some inherent factors arising from the liver transplant itself. It
has been suggested that the use of corticosteroids as part of the
immunosuppressive regime play a large part of this growth
effect but recent studies have suggested that this is not the only
actor at play. Recently, it has been suggested that the degree of
malnutrition prior to transplant and the episodes of rejection
also have some bearing on the outcomes. Psychological out-
comes are also now being examined. Several groups have
suggested that there are subtle abnormalities in psychomotor
development and also cognitive functioning is being seen in
long-term survivors. These outcomes are also being suggested to
having been inﬂuenced by preoperative factors, including nutri-
tion, although, a recent single centre experience from Paris has
shown no effects upon cognitive function and school perfor-
mance. The latest challenges now appear to involve the advent
of increasing incidence of underlying hepatic histological issues.
Increasing ﬁbrosis is being reported in otherwise asymptomatic
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patients but the implications of these ﬁndings are only now
being considered.
APASL/Abstract/S 12.1
HEV replicase: Subcellular localization and interaction with HEV
3’UTR by Fluoresence Resonance Energy Transfer (FRET)
S. Rehman, H. Durgapal, S. K. Panda
Department of Pathology, All India Institute of Medical
Sciences, New Delhi, India
The replication complex of an animal virus consists of a
complex of viral RNA template, replicating strands, viral
RNA polymerase along with cellular proteins and structures.
We investigated the site of replication of HEV by coloclisation
studies using EGFP tagged HEV replicase and organell speciﬁc
ﬂuoroprobes/phores. Further we used the earlier identiﬁed cis-
acting elements at the 3’end of HEV plus strand RNA, which
interacts with the viral replicase (RdRp), in vitro, labeled with
alexa 546-UTP for Fluorescence resonance energy transfer
(FRET) Sensitized Emission in-vivo, using confocal inverted
microscope in living HepG2 cells, permanently transfected with
and expressing replicase-EGFP fusion protein. We observed,
that the HEV replicase localizes to the membranes of endoplas-
mic reticulum. FRET Sensitized emission was performed within
12 hours of RNA transfection. FRET image was generated and
over 50 region of interest (ROIs) were used for calculating
FRET efﬁciency for every cell analysed. Signiﬁcant FRET
efﬁciency values were obtained. We could demonstrate in care-
fully controlled system interaction between the HEV replicase
and the 3’end of HEV genome at the subcellular level on
endoplasmic reticulum.
APASL/Abstract/S 12.3
Hepatitis E virus infection in patients with cirrhosis causes rapid
decompensation and death
S. K. Acharya1, P. K. Sharma1, R. Singh2, S. K. Mohanty3,
K.Madan1, J. Kumar Jha3, S. K. Panda3
1Departments of Gastroenterology,
2Biostatistics
2Pathology and All India Institute of Medical Sciences, New
Delhi, India
Background: In healthy individuals, hepatitis E virus (HEV)
causes self-limiting acute hepatitis with negligible mortality.
Few case series indicate that HEV infection in cirrhosis of liver
may cause rapid decompensation and death. Prospective study
evaluating cirrhotics as high-risk to contract HEV infection and
natural course of HEV infected cirrhotics have not been studied.
Methods: Consecutive patients with cirrhosis liver, and age/sex-
matched healthy blood donors as controls were included in
study. Cirrhotics were categorised into three groups (Group I –
with rapid decompensation, Group II- chronically decompen-
sated, Group III – stable cirrhotics without decompensation).
Sera from cirrhotics and controls were tested for HEV-RNA by
reverse transcriptase polymerase chain reaction. Presence of
HEV-RNA was considered as evidence for HEV infection.
Frequency of HEV-RNA positivity among cirrhotics and con-
trols was compared. Similar comparison was made between the
three groups of cirrhotics. Natural course, mortality and com-
plication frequencies between HEV-infected cirrhotics and cir-
rhotics without HEV infection were assessed. All cirrhotics were
followed up for 12 months. Results: One hundred and seven
consecutive patients with cirrhosis and 200 controls were
included. Thirty (28%) cirrhotics and nine (4.5%) controls
had detectable HEV-RNA (Po0.001). HEV-RNA positivity
among Group I (n5 42), II (n5 32), and III (n5 33) cirrhotics
was 21 (50%), six (19%) and three (10%), respectively
(P5 0.002). Four-week mortality among these three groups
were 21 (50%), six (19%) and 0 (0%), respectively (P5 0.001).
Child–Pugh’s score among HEV-infected cirrhotics (n5 30) was
signiﬁcantly worser (at inclusion and 4 weeks) than cirrhotics
without HEV infection (n5 77) (P5 0.0001). Seventy percent
(21/30) with HEV infection and 27% (21/77) without it had
rapid decompensation (P5 0.001). The former 21 HEV-infected
cirrhotics were asymptomatic before presenting with rapid
decompensation; 13 (64%) of them died within 4 weeks and
all died within 12 months. Mortality among HEV-infected and
non-infected cirrhotics at 4 weeks (43% vs 22%, P5 0.001) and
12 month (70% vs 30%, P5 0.001) was signiﬁcantly different.
Multivariate analysis identiﬁed HEV infection, Child-Pugh’s
score, renal failure and sepsis as independent factors for
mortality. Conclusion: Patients with cirrhosis were prone to
HEV infection, which caused rapid decompensation and death.
Prevention of HEV infection inpatients with cirrhosis may
improve their survival.
APASL/Abstract/S 12.4
The unique riverine ecology of hepatitis E virus transmission in
Southeast Asia
Andrew L. Corwin1, Nguyen T. K. Tien2, Khanthong Bounlu3,
Jarot Winarno4, Maidy P. Putri1, Kanti Laras1, Ria P. Lar-
asati1, Nono Sukri1, Timothy Endy5, H. A. Sulaiman6 and
Kenneth C. Hyams7
lU.S. Naval Medical Research Unit No. 2, Jakarta, Indonesia,
2Pasteur Institute, Ho Chi Minh City, Vietnam,
3Center of National Laboratory and Epidemiolgy, Vientiane,
Lao PDR,
4Provincial Health Service, Sintang District, West Kalimantan,
Indonesia,
5Armed Forces Research Institute of Medical Sciences, Bang-
kok, Thailand,
6Medical Faculty, University of Indonesia, Jakarta, Indonesia
and
7Naval Medical Research Institute, Bethesda, MD
AbstractThe ecology of hepatitis E virus (HEV) transmission in
South-East Asia was assessed from a review of six published and
three unpublished NAMRU-2 reports of hepatitis outbreak
investigations, cross-sectional prevalence studies, and hospital-
based case–control studies. Findings from Indonesia and Viet-
nam show epidemic foci centered in jungle, riverine environ-
ments. In contrast, few cases of acute, clinical hepatitis from
cities in Indonesia, Vietnam and Laos could be attributed to
HEV. When communities in Indonesia were grouped into areas
of low (o40%), medium (40–60%), and high (460%), pre-
valence of anti-HEV antibodies, use of river water for drinking
and cooking, personal washing, and human excreta disposal
were all signiﬁcantly associated with high prevalence of infec-
tion. Conversely, boiling of river drinking water was negatively
associated with higher prevalence (Po0.01). The protective
value of boiling river water was also shown in sporadic HEV
transmission in Indonesia and in epidemic and sporadic spread
in Vietnam. Evidence from Indonesia indicated that the de-
creased dilution of HEV in river water because of unusually dry
weather contributed to the risk of epidemic HEV transmission.
But river ﬂooding conditions and contamination added to the
risk of HEV infection in Vietnam. These ﬁndings attest to a
unique combination of ecological and environmental conditions
in predisposing epidemic HEV spread in South-East Asia.
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APASL/Abstract/S 13.1
Pregnancy and the liver
Nurdan Tozun and Hakan Akin
The liver is the site of many important metabolic and synthetic
functions and two types of liver diseases which may occur at this
phase of life are either directly related to pregnancy or to
common liver disorders which may also affect the liver of a
pregnant woman. In the ﬁrst group of disorders, hyperemesis
gravidarum, intrahepatic cholestasis of pregnancy, acute fatty
liver of pregnancy and hemolysis, elevated liver enzymes and
low platelets syndrome are pregnancy speciﬁc and may either
affect the quality of life of the pregnant woman and/or cause
serious complications in the course of pregnancy.
APASL/Abstract/S14.1
Imaging options in cholangiocarcinoma
Sri Inggriani
Department of Radiology, Medistra Hospital, Jakarta, Indonesia
Tumors of the biliary tract are uncommon but serious problems.
The spectrum of lesions ranges from benign tumor, such as
adenoma, to malignant lesions, such as adenocarcinoma. Most
patients with such lesions present with jaundice due to the
obstruction of the biliary tree by the tumor. The tumors
generally are small and difﬁcult to visualize with the standard
imaging studies such as ultrasonography and computed tomo-
graphy scanning, but these techniques may provide a clue to the
level of the obstruction and help exclude metastatic disease.
Cholangiocarcinoma is the most important primary tumor of
the bile ducts and may involve either the intrahepatic or the
extrahepatic biliary ducts. This tumor variety is the second most
common primary hepatic malignancy after hepatocellular car-
cinoma.
There are several imaging modalities (ultrasonography, CT
scan, MRI and PET), and their diagnostics values for detection
will be discussed. Ultrasonography has been widely accepted as
an initial screening procedure for bile duct dilatation in patients
with jaundice. MRI, MRCP, Contrast Enhanced Computed
Tomography with optimal acquisition timing permits improved
lesion detection and will improve characterizations of lesions.
The role of PET in the diagnostic work up of Cholangio
Carcinoma still remains unclear. PTC and ERCP are helpful in
the unresectable disease based on the palliative procedures to
improve the quality of live.
APASL/Abstract/S 15.2
Booster for hepatitis B vaccination: how long is forever?
M.-H. Chang
Department of Pediatrics, National Taiwan University Hospi-
tal, Taipei, Taiwan
Hepatitis B vaccination in infancy has been proved to be
effective in preventing acute and chronic hepatitis B virus
(HBV) infection, and its complication, e.g. fulminant hepatitis,
and hepatocellular carcinoma. The ﬁrst hepatitis B vaccination
program has been launched since July 1984 in Taiwan. Accord-
ing to the report of World Health Organization (WHO), 147 of
the 192 countries in the world have integrated the HBV
vaccination program in to the infant immunization program
up to the end of 2003. After long term follow-up, the levels of
hepatitis B surface antibody have waned gradually with time.
Yet anamnestic antibody responses to a booster dose were
demonstrated before 15 years of age in previous studies after
primary HBV vaccination in infancy. It is generally accepted
that for immune competent individuals, routine boostering is
not needed before 15 years of age. However, for immune
compromised hosts, regular annual testing for anti-HBs and a
booster dose should be considered when the anti-HBs titer falls
below 10 mIU/mL. For immune competent high risk subjects,
e.g. those with house hold contacts and sex partners of HBV
carriers, and persons with occupational risk, etc. should also be
considered for boostering if the anti-HBs levels fall below
10mIU/mL. As the vaccinees are getting older than 15 years
of age, both the humoral and the cellular immunity to HBV may
decay further. At the mean time, they may become more
sexually active, and expose to more risk of HBV infection.
Theoretically, a booster dose may be considered to be given to
those whose anti-HBs levels fall below 10mIU/mL. On the other
hand, those who are infected by HBV during adulthood hve a
lower risk of becoming chronic carriers (o5%) than those
infected in infancy and earl childhood. In addition, low infection
rates were demonstrated by low anti-HBc rates in vaccines after
long term follow-up. In Taiwan, 4% of anti-HBc was observed
in adolescents 15 to 17 years of age born after the universal HBV
vaccination program in Taiwan. The necessity and the best
timing of boostering therefore need to be analyzed further.
APASL/Abstract/S 17.1
Speciﬁc issues of hepatitis C virus infection in the Asia Paciﬁc
Nancy Leung1,2
1Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong
2The Chinese University of Hong Kong, Shatin, New Terri-
tories, Hong Kong
Hepatitis C viral infection in the Asia Paciﬁc region is char-
acterized by diversity in epidemiology, socio-economic issues
affecting the strategy in identifying and treating infected pa-
tients, and the resources allocated by the government health
organizations to manage the disease burden and health impact.
HCV genotype proﬁle varies in different regions. Genotype 1b
predominates, with 2, 3, 4 and 6 genotypes making up the entire
population. The clinical outcome among these genotypes and its
responsiveness to therapeutic strategy are slowly being recog-
nized. These will contribute to the overall management plan and
design of cost-effective treatment plans. The routes of transmis-
sion of HCV infection in Asia Paciﬁc region are similar to that
in other parts of the world. However, effective preventive
measures are implemented to different degrees of success. For
example, donors of blood, blood products and organs are still
not properly counseled and screened, resulting in new infection
occurring in situations that can be readily prevented. Paid
donors are strongly discouraged but is still practiced in many
regions. Intravenous drug users and substance abusers are well
known to be difﬁcult to control. Health authorities have limited
resources to counsel these individuals, to provide detoxiﬁcation
programs or non-reusable syringe exchange programs. Simi-
larly, sex workers also contribute in spreading the infection and,
in line with the prevention of HIV infection, education of these
sex worker, their client and public as a whole is important. In
many regions, the spread of HCV infection can be traced to
unsafe medical and paramedical practices. Surgical, dental and
medical equipment may not be properly disinfected before being
reused. Reusable syringes or lancet have been found to con-
tribute to major HCV transmission in some health programs for
vaccination or therapy. It is also the practice of some Asian
population to undergo paramedical treatment such as acupunc-
ture, cupping, scarring and rubbing. Tattoo and body piercing
are also popular among the general population. These activities
involve breach of intact skin and HCVs transmitted if universal
precaution is not practiced. Treatment for hepatitis C is ex-
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pensive. Only a small proportion of CHC patients in Asia
Paciﬁc region can afford therapy. The distribution of health
dollars is not even in many regions. The management strategy
for these patients needs to be carefully designed to achieve
meaningful cost-effective results. The same argument applies in
the surveillance for hepatocellular carcinoma. Without a robust
program in oncology and liver transplantation, such exercise
becomes futile. The lack of resource and coordinated effort to
manage hepatitis C infection, high disease burden, morbidity,
and early mortality will be inevitable. The end results are human
misery and indirect negative impact on the countries’ economy.
APASL/Abstract/S17.2
Management of hepatitis C in end-stage renal disease
Chau-Ting Yeh
Chang Gung Medical Center, Taiwan
In chronic hepatitis C patients with end-stage renal disease,
hepatic necroinﬂammation and liver ﬁbrosis deteriorate more
rapidly after renal transplantation (1, 2). This is presumably
attributed to extensive use of immunosuppressants. Increased
risk of glomeruonephritis, ﬁbrosing cholestatic hepatitis, and
possibly diabetes mellitus has been reported (3, 4, 5). Despite
these disadvantages, overall survival is still better for patients
receiving renal transplantation comparing with those receiving
continuous hemodialysis (6, 7). After renal transplantation,
interferon therapy for chronic hepatitis C is associated with a
high risk of rejection and graft loss (8, 9). Management of
chronic hepatitis C in such patients becomes a major challenge
for medical doctors. Pre-transplantation antiviral therapy has
been reported to be beneﬁcial for the patients, although the viral
clearance rate is very low. This is supposedly owing to poor
tolerance of the patients to full dose interferon as well as
occurrence of severe hemolysis when ribavirin is used (10, 11).
In patients who achieved sustained virological response, serum
viral RNA remained negative after renal transplantation in
some studies, arguing for the strategy of pre-transplantation
therapy (12, 13). However, a high recurrence rate post renal
transplantation has been reported in at least one study (14, 15).
An appropriate therapeutic strategy remains to be established.
In conclusion, antiviral therapy is an important issue in chronic
hepatitis C patients with end-stage renal disease. Current
therapeutic regimens are far from satisfactory. New antiviral
agents are needed imperatively.
APASL/Abstract/S 17.3
Treatment of difﬁcult to treat hepatitis C infection
Jenny Heathcote
University of Toronto
The standard of care for chronic hepatitis C is Pegylated Inter-
feron alpha 1 Ribavirin (Peg IFN 1 RBV). Newer targeted
treatments with enzyme inhibitors are still only in phase 1 and
phase 2 trials and thus Peg IFN 1 RBV will likely remain the
standard of care for at least another ﬁve years. Hence the need to
optimize current therapy to enhance the likelihood of achieving a
sustained virologic response (SVR) and improve the cost effec-
tiveness of therapy. Over a lifetime less than 15% of individuals
chronically infected with hepatitis C will die of their liver disease.
Thus there are many individuals infected who do not require
therapy and the current recommendation is that therapy should
be offered to those who on liver biopsy have some evidence of
progressive disease, i.e. ﬁbrosis score of  2 in those infected
with genotype 1 or 4. But for those infected with genotype 2 or 3
pretreatment liver biopsy is not currently recommended because
their response to antiviral therapy is so good, and thus it is
recommended that all receive treatment. In those infected with
genotype 1 and to a lesser extent genotype 4, the chance of a
sustained virological response (SVR) depends on a number of
intumsic and extrimsic inﬂuences. Factors that markedly inﬂu-
ence the likelihood of achieving an SVR are adherence to full
dose therapy given for the appropriate duration of time, viral
factors (genotype, viral load, co-infection with HIV or HBV and
quasispecies development) and host factors (age, gender, degree
of ﬁbrosis and steatosis, BMI and alcohol intake). Thus in order
to optimize therapy, many issues need to be addressed on an
individual basis. Overall approximately 50% of individuals given
Peg IFN 1 RBV fail to respond to antiviral therapy. Likelihood
of non-response may be predicted by the degree of fall in viral
titre upon the introduction of antiviral therapy. It is generally
recommended that in those who fail to have a  2 log drop in
HCV RNA after the ﬁrst 12 weeks of therapy stop treatment as
they have only a 2–3% chance of achieving an SVR should they
persist with therapy. Recent data from examining gene expression
in liver tissue pre-treatment would suggest that non-responders
may be predicted by a speciﬁc 8 gene molecular signature. This
needs to be validated by further studies.
APASL/Abstract/S18.1
Emerging of NASH in the Asia Paciﬁc Region
Diana Payawal
The concept of steatohepatitis as the consequence of two hit
theory was ﬁrst projected by Day and James in 1998. Steatosis is
the recognized ﬁrst and usually reversible hit. The development
of inﬂammation, ultimately leading to cell death and ﬁbrosis is
the less well-deﬁned second hit. NASH is strongly related with
the one or more of the conditions that characterize the meta-
bolic syndrome, including obesity, insulin resistance, hypertri-
glyceridemia, low levels of high density cholesterol and
hypertension. Moreover, there is growing evidence that the
metabolic syndrome is caused by an unbalanced production of
hormones, and cytokines that leads to a chronic inﬂammatory
state that promotes degenerative diseases and cancer in various
tissues including the liver. The Asia-Paciﬁc Region has exposed
itself to an increasing trend of NASH due to the high fat/energy-
excessive diet, apparent urbanization, increasing afﬂuence and
behavioral changes of physical inactivity and, type 2 diabetes.
The rates range from 7–40%, which in countries like Japan
represents a 3–20-fold increase (depending on age) over the last
20 years. The role of obesity in generating the inﬂammatory
process results from events that occur in adipocytes throughout
the body particular within the omental and mesenteric adipose
depots (central obesity). The oxidative process results in lipid
peroxidation resulting in organelle dysfunction, necrotic and
apoptotic cell death. After cancer, cirrhosis from NASH is now
the second most common age-related cause of death in type 2
diabetes. Resolution of histopathologic evidence of steatosis
including regression of ﬁbrosis, inﬂammation remains to be the
ultimate goal of therapy. Unfortunately there are limited large
randomized placebo controlled clinical trials demonstrating
efﬁcacy in achieving all of these aims.
APASL/Abstract/S 18.4
Crucial problems of histopathologic diagnosis in nonalcoholic
steatohepatitis
Vera Damajanti, Wirasmi Marwoto
Department of Anatomical Pathology, Faculty of Medicine,
University of Indonesia, Jakarta, Indonesia
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Nonalcoholic steatohepatitis (NASH) is a chronic liver disease,
with a low risk of progressive ﬁbrosis, cirrhosis and end-stage
liver disease. Another complication is hepatocellular carcinoma
(HCC).
The diagnosis of NASH is a clinicopathologic correlation but
histopathologic evaluation is required because the parenchymal
injury and ﬁbrosis cannot be detected by imaging studies or
laboratory test.
This histopathologic study was based on 18 cases, including
steatosis, ballooning degeneration, lobular inﬂammation (poly-
morphonuclear leukocytes), ﬁbrosis and Mallory bodies.
Our problems are:
1. Statingmild ballooning degeneration is very difﬁcult.
2. Perinuclearﬁbrosis is difﬁcult to evaluate because the histo-
chemistry laboratory in our Department is not
constant.
3. Wewere not very aware in recognizing Mallory bodies
(maybe in Indonesia alcoholic hepatitis is very very low).
4. Notevery center has the beneﬁt of seeing miscellaneous liver
pathology because liver biopsy is difﬁcult to motivate in
patient.
5. Weused to diagnose NASH using previous Brunt classiﬁca-
tion.
And using Kleiner et al., we think, for the time being, adding
simple steatosis and simple steatosis with nonspeciﬁc reaction
took a longer time to adjust to.
APASL/Abstract/S 19.2
Liver transplant for hepatitis C virus cirrhosis
G. Mccaughan
AW Morrow Gastroenterology and Liver Centre, Australian
National Liver Transplant Unit, Royal Prince Alfred Hospital,
and the University of Sydney
Natural history: The hepatitis C virus reinfects the liver allograft
as early as the reperfusion phase during surgery. This is
associated with the return to pre-transplant viral levels, some-
times within 48 hours following transplantation. Virological
replication then reaches a steady state of approximately 1log
higher than in the pre-transplant situation. An additional peak
of viral replication is seen at the time of acute hepatitis in the
allograft at approximately 2–5 months post transplantation.
Progression from acute viral hepatitis to chronic hepatitis over
the next 12 months is associated with a gradual decline back to
levels of virus approximately 1log greater than in the pre-
transplant situation. There is unusual variant of acute hepatitis
that is cholestatic hepatitis C infection. This occurs in 5–10% of
patients, is associated with a cytopathic injury to the allograft
due to extremely high levels of virus and may result in early
allograft loss. Patients with chronic hepatitis C in the allograft
have an increased rate of progression to cirrhosis with cirrhosis
rates of approximately 30% at 5 years and up to 50% at 10 years
following liver transplantation. Predisposing factors to more
severe ﬁbrotic progression in the allograft have been identiﬁed.
These include:
 high levels of virus pre-transplant and at the 4 month period
post-transplant
 donor age
 episode of CMV disease
 pulse corticosteroid therapy
 OKT3 therapy
 There is debate about the role of genotype 1b and genotype 4
and the role of the calcineurin inhibitors (Cyclosporin versus
Tacrolimus) and the continuing use of low-dose Prednisone.
Therapy for HCV in the setting of liver transplantation:
There have been some studies trying to eradicate HCV from the
cirrhotic liver before transplantation. This is associated with the
introduction of low-dose Interferon1 Ribavirin with increasing
doses depending on tolerability. Patients up to Childs Pugh 7
category can be treated, although the sustained virological
response rates for genotype 1 (o15%) and genotypes 3 (30%)
are low on an intention to treat basis. However, it should be
noted that if sustained virological response rate can be obtained
in this situation, then viral recurrence in the allograft does not
occur. Following liver transplantation, there have been various
approaches to treat with Interferon therapy before the episode
of acute hepatitis or once chronic HCV has been established.
Unfortunately, results of treating early are associated with poor
tolerability and sustained virological response rates have only
been achieved in some 10–15% of patients for genotype 1. It has
been claimed from one group that treatment of genotype 3
infection in the early phase is quite successful but the numbers
studied are small. The treatment of established chronic hepatitis
C with Pegylated Interferon 1 Ribavirin are associated with
signiﬁcant reduction in SVRs compared to the non-transplant
situation. SVRs are obtained in approximately 40% of patients
with genotype 3, but only 20% of patients with genotype 1. They
are also associated with signiﬁcant side effects particularly
anaemia, leucopoenia and many centres use Granulocyte Sti-
mulating Factors and Erythropoietin to enable them to continue
therapy. Conclusion: HCV infection in the setting of liver
transplantation arguably is the greatest challenge to liver
transplant units throughout the world, improved treatments in
the cirrhotic state and under immunosuppression are certainly
needed. Furthermore, an understanding of the deleterious
effects of immunosuppression itself on the virus need to be
further studied.
APASL/Abstract/S 19.3
Liver transplantation and nonalcoholic fatty liver disease
Darrell H.G. Crawford
Queensland Liver Transplant Service, Princess Alexandra Hos-
pital, Brisbane, Australia
Nonalcoholic fatty liver disease is an increasingly common
cause of chronic liver disease. There is a concern that this
increased prevalence will translate into an increased demand
for liver transplantation. At present, accurate data on the
proportion of patients undergoing liver transplantation for
non-alcoholic fatty liver disease is not available. However, the
number and proportion of patients who have been transplanted
with a diagnosis of non-alcoholic fatty liver disease or crypto-
genic cirrhosis has not increased in recent years at our centre.
Steatohepatitis causes an increased rate of disease expression in
hepatitis C virus infection and other chronic liver diseases. As
such, the present contribution of steatosis to demand for liver
transplant may be more as a cofactor in disease progression of
other liver diseases rather than as a primary diagnosis. As well
as recipient issues, there are major donor problems related to the
presence of hepatic steatosis. The use of grafts with macrovesci-
cular steatosis is associated with increased rates of primary non-
function and poorer outcome. The mechanisms by which
steatotic livers develop primary non-function are multifactorial,
and include impaired hepatocyte metabolism, physical effects of
lipid and increased sensitivity to oxidative stress. Strategies to
improve the outcomes of patients receiving steatotic grafts are
under investigation and may help redress the balance between
supply and demand for donor livers. Fatty liver disease may
develop following liver transplantation. Patients using standard
immunosuppressive agents are at increased risk of developing
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hypercholesterolaemia, diabetes mellitus hypertension and obe-
sity, and these are recognised risk factors for insulin resistance
syndrome/fatty liver disease. These issues are very important
aspects of care in the postliver transplant patient to reduce the
risk of vascular disease and postliver transplant steatohepatitis.
APASL/Abstract/S 20.2
Chronic hepatitis B; current and future management
Dong Jin Suh
Department of Medicine, Asan Medical Center, University of
Ulsan College of Medicine Seoul, Korea
The primary goal of treatment for chronic hepatitis B is to
eliminate or permanently suppress hepatitis B virus (HBV) replica-
tion before irreversible liver damage develops. Treatment is
indicated for patients in the immune clearance and reactivation
phases. During the last decades, major breakthroughs have been
achieved in treatment of chronic hepatitis B. Currently, three
antiviral agents are approved globally for the treatment of chronic
hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil.
Interferon-alpha has a limited duration of treatment and leads to a
more durable response but side effects are frequent and potentially
serious. Lamivudine is effective and well tolerated, but its efﬁcacy
is limited by the high incidence of resistance during long-term
therapy and the low durability of response after HBeAg serocon-
version. Adefovir has a comparable efﬁcacy with a very low
frequency of resistance in nucleoside-naı¨ve patients. Adefovir is
also effective against lamivudine-resistant strains, but the emer-
gence rate of resistance seems to be relatively high in these patients.
Recently, new immunomodulatory therapies and nucleoside ana-
logues have been evaluated for the treatment of chronic hepatitis
B. This review will summarize the results obtained with current
available treatments and knowledge on the newer antiviral agents
such as pegylated IFNs, entecavir, emtricitabine, tenofovir, telbi-
vudine and clevudine.
APASL/Abstract/S 21.3
Obesity and statins in liver disease
Peter Ferenci
Medical University of Vienna, Vienna, Austria
Baclground: At least in developed countries, obesity is reaching
epidemic proportions, being present in about 30% of young
adults. One of the many sequelae of obesity is hepatic steatosis,
which can be present as the only symptom of this metabolic
syndrome or occur together with other conditions like type 2
diabetes mellitus or coronary heart disease. In obese subjects,
hypercholesterolemia is frequently treated with statins. Cur-
rently, six statins are available for clinical use, all with an
excellent safety proﬁle. As asymptomatic elevations in liver
enzymes are common in patients who are placed on statins,
the issue of using them in patients with fatty liver disease is
relevant. Statin hepatotoxicity: Although some observations in
animals suggested that statins may cause liver disease, no
predictable hepatocellular necrosis occurred in humans. Statins
have no signature pattern of hepatotoxicity as all common
patterns of liver injury (hepatocellular, cholestatic or mixed)
have been reported with all available statins. The most common
clinical hepatic manifestation is asymptomatic elevation in
aminotransferases and this appears to be a class effect of statins.
The incidence is less than 3% and with a minor dose-related
increase. In a meta-analysis evaluating of 49 275 patients who
participated in 13 large, placebo-controlled trials, therapy with
statins at low-to-moderate doses was not associated with a
signiﬁcant increase in liver enzyme elevations compared with
placebo. Very rarely, after initiating statins, liver enzymes can
rise without evidence of liver dysfunction and decrease upon
stopping or reducing the dose. Irreversible liver damage leading
to death or liver transplantation appears to be extremely
uncommon. The estimated risk of fulminant liver failure attri-
butable to lovastatin is two in one million patients. Liver
transplantation was performed for presumably statin induced
acute liver failure in three patients. Statins in patients with
nonalcoholic fatty liver disease: NAFLD is common in patients
with hyperlipidemia and type 2 diabetes (primary targets for
long-term statins) but the presence of fatty liver disease may
itself portray higher cardiovascular risk, necessitating statin
therapy. Furthermore, fatty liver is frequently present in con-
junction with an other liver disease i.e. chronic hepatitis C. The
studies examining the safety of statins in patients with NAFLD
are limited, but the existing data provide some evidence that
they can be used safely. Hyperlipidemic patients with elevated
baseline ALT are at not higher risk for hepatotoxicity than
patients with normal ALT. Some individuals with elevated
baseline liver enzymes have increases in their liver biochemis-
tries, whether or not they receive statins. No worsening of
hepatic histology by statins was found in a few patients with
biopsy-proven NASH treated for about 2 years. Some patients
exhibited an improvement. Unresolved issues: The natural his-
tory of elevated aminotransferases on statins, continued at the
same doses for many years, is unknown. As statins have been
shown to cause various in rodents, concerns about the potential
carcinogenicity of long-term use of statins have been raised. A
meta-analysis of ﬁve large clinical trials demonstrated no
association between statin use over a 5-year period and the
risk of fatal and nonfatal cancers. Conclusion: Unquestionably,
statins are extremely valuable drugs with no evidence to cause
signiﬁcant liver disease.
APASL/Abstract/S22.1
Predictive value of arterial ammonia for clinical outcome and
complications in acute liver failure
Skv Bhatia1, R. Singh2 and Acharya1
1Department of Gastroenterology and
2Biostatistics, All India Institute of Medical Sciences, New Delhi
–110029, India
Background: In acute liver failure (ALF), brain is exposed to
increased amount of ammonia. However, human studies deﬁn-
ing the clinical signiﬁcance of ammonia in ALF are lacking. The
aim of this prospective study was to evaluate the relation of
arterial ammonia levels at admission with survival and compli-
cations among patients with ALF. Methods: 80 consecutive
ALF patients admitted from March 2001 to December 2003
were followed up till death or complete recovery. All had
arterial ammonia estimation at admission (Enzymatic method,
Randox lab, UK). Logistic regression analysis was performed to
identify the independent predictors of mortality. Results: 42
(52.5%) patients died. Non-survivors had signiﬁcantly higher
ammonia levels than the survivors at admission (212  148 vs.
123  128mmol/L, p5 0.005). An arterial ammonia level of X
123.9 mmol/L was found to predict mortality with 81% sensi-
tivity and 79% speciﬁcity. Patients with higher ammonia levels
also developed more complications like deeper encephalopathy
(p5 0.055) cerebral edema (p5 0.020), need for ventilation
(p5o0.001), and seizures (p5 0.006). Logistic regression ana-
lysis showed age, presence of cerebral edema at admission and
arterial ammonia to be independent predictors of mortality
(RR: 1.059, 15.164, 1.008 respectively). Incorporating these
three variables, a risk score for mortality was derived: –3.578
1 0.057 age 1 2.719 edema 1 0.008 ammonia. Conclusion: Ar-
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terial ammonia levels at presentation are predictive of outcome
and can be used for risk stratiﬁcation. Therefore trials evaluat-
ing ammonia lowering therapies are warranted in patients with
ALF.
APASL/Abstract/S22.3
MARS therapy acute-on-chronic liver failure
R. Jalan
Institute of Hepatology, University College London
The vast majority of patients that are referred to a specialist
hepatological centre suffer from acute deterioration of their
chronic liver disease. Yet, this entity of acute-on chronic liver
failure remains poorly deﬁned. With the emergence of newer
liver support strategies, it has become necessary to deﬁne this
entity, its pathophysiology and the short and long term prog-
nosis. Current research focusses upon how a precipitant such as
an episode of gastrointestinal bleeding or sepsis may start a
cascade of events that culminate in end-organ dysfunction and
liver failure. Our current strategy for the management of liver
failure involves supportive therapy for the end-organs with the
hope that the liver function would recover if sufﬁcient time for
such a recovery is allowed. Because, liver failure, whether of the
acute or acute-on-chronic variety, is potentially reversible, the
stage is set for the application of newer liver support strategies
to enhance the recovery process. The molecular adsorbents
recirculating system (MARS), which is based upon the principle
of albumin dialysis may provide an opportunity to create an
environment in which further liver injury can be prevented and
enhanced liver regeneration may occur.
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APASL/Abstract/PGC I.1.2
Hepatitis C virus and malignancy
Arief Suriawinata1 and Swan N. Thung2
1Department of Pathology, Dartmouth Hitchcock Medical
Center, Lebanon, NH, USA
2The Lillian and Henry Stratton-Hans Popper Department of
Pathology, the Mount Sinai Medical Center, New York, NY,
USA
Hepatitis C virus (HCV) is a hepatotropic virus that causes
chronic hepatitis, ﬁbrosis and cirrhosis. HCV is associated with
the development of primary liver tumors, i.e. hepatocellular
carcinoma, cholangiocarcinoma and lymphoma. This article
reviewed HCV-related malignancies, their prevalence and prob-
able oncogenesis.
APASL/Abstract/PGC I.1.3
Early detection in patients with hepatitis C virus infection
F. Moriyasu
The Fourth Department of Internal Medicine, Tokyo Medical
University, Tokyo, Japan
Epidemiology of hepatocellular carcinoma (HCC) in Japan
Eighty percent of HCCs found in Japanese hospitals are
suffering from hepatitis virus infectious diseases. 70% of HCC
patients are suffering from hepatitis C virus (HCV) cirrhosis.
The age is the most important factor when we are dealing
with HCC patients with HCV. The average age of HCV–HCC
patients in Japan is the later half of 60s. This advanced age
tendency is increasing because the of the aging of Japanese
society, in which the average life expectancy is 80 years old.
Therefore, we have to consider their age and the remaining
expectancy after treatment of HCCs, and at the same time, the
higher quality of their lives (QOL).
At the same time we have to remember the existence and
increase of non-B and non-C HCCs. The ratio of non-B and
non-C HCCs between whole HCCs was less than 5% ten years
ago. This ratio has increased up to 30% in the present time
especially in the city area. It is suggested that a part of this
increase is caused by an increase in non-alcoholic steatohepatitis
(NASH). Increase in NASH patients could be explained by the
changes of life style habits in recent Japanese population such as
motorization, computerization and food habits involving cal-
ories and high fat.
Early detection program of HCCs in Japan
Blood test for a-feto-protein (AFP), its lectin fractioning (L3)
and PIVKA2 should be checked every 1 or 2 months.
Imaging diagnosis is the most important method for detec-
tion of HCCs in the high risk group patients. The diagnostic
imaging modalities used in the detection of HCCs are ultra-
sound (US), contrast CT and MRI. PET has been used for
detection of malignancy in the whole body. However, it is a
pessimistic view that FDG–PET can detect HCCs in the liver
because glucose is metabolized actively in the normal liver.
Recently several contrast agents have been developed for
ultrasound of the liver imaging. SonoVue has been launched in
European countries and China. Contrast US has been used for
characterization of the known liver lesions with B-mode US
and/or dynamic CT. Accuracy of HCC diagnosis of contrast
ultrasound is the same between contrast US and CT. Contrast
US is superior to contrast CT in diagnosis of histological
differentiation such as well, moderately and poorly differen-
tiated HCCs. Rapid spreading of contrast US is disturbed by the
necessity of doctors’ skills to make an accurate diagnosis using
contrast study comparing contrast CT.
Next generation contrast agent, Sonazoid is expected to per-
form both detection and characterization of HCCs because of their
ability to make a Kupffer imaging. This microbubble agent could
be phagocytosed by the macrophages in the reticuloendothelial
system such as the liver and spleen. By using these characteristics
we could make more precise diagnosis of liver lesions.
Multi row detector CT (MDCT) has spread rapidly because
of higher spatial resolution and higher throughput. MDCT has
made it possible to detect slight increases in arterial blood ﬂow
and a slight decrease in portal blood ﬂow in the liver lesions seen
in the cirrhosis liver. At the same time, X-ray exposure has been
increased in accordance with a wide use of MDCT.
MRI is useful when the patient has an iodine allergy, and to
avoid further X-ray exposure when the patients are checked
frequently for many years. At the same time, SPIO-MRI is used
for Kupffer imaging, like Sonazoid and Levovist contrast
ultrasound.
Treatment of HCCs
It is important that effective and safe therapeutic methods be
developed when the program for early detection of HCCs in
high risk patients for HCCs works well. Surgical treatment
including liver transplantation has been established. However,
we have to consider that the recurrence ratio in patients with
HCV positive HCCs, after ﬁrst nodule is treated, is very high;
25% per year. It might be right that a curative ratio less than
10% is enough when we take a very high aberrant recurrence
ratio into consideration.
We have several modalities of local ablation therapy: TAE,
PEI, PMCT, RFA and freezing ablation therapy. Recently, high
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intensity focus ultrasound (HIFU) has also been coming up
because it does not need a needle puncture.
Local ablation therapy can display its greatest force when the
HCC lesion is detected in an early stage. Therefore, early
diagnosis is the most important factor governing their prognosis.
Prevention of HCC carcinogenesis
Prevention of HCC carcinogenesis would be the most im-
portant role for hepatologists after early detection and early
treatment of HCCs. Interferon and other chemoprevention
methods should be developed and widely used in Asian countries.
APASL/Abstract/PGC I.1.4
Carcinogenesis of hepatocellular carcinoma with hepatitis B virus
infection
Chia-Ming Chu
Liver Research Unit, Chang Gung Memorial Hospital, Chang
Gung University, Taiwan
Hepatitis B virus (HBV) remains the most important risk factor
for hepatocellular carcinoma (HCC) worldwide. An estimated
300 million individuals worldwide are chronically infected with
HBV. Several risk factors increase the risk of HCC in HBV
carriers, including host factors (older ages, male gender, severity
of underlying liver disease, Asian or African ethnicity, family
history of HCC), viral factors (HBV replication, HBV genotype/
mutant, HCV coinfection), and external factors (exposure to
aﬂatoxin, alcohol, and cigarette). HBV vaccination, antiviral
therapy with sustained suppression of viral replication, and
reduction of exposure to aﬂatoxin are important preventive
measures.
APASL/Abstract/PGC I.2.1
Hepatocellular carcinoma not associated with either hepatitis C or
hepatitis B
M. Isabel Fiel
Mount Sinai School of Medicine, New York, NY, USA
Cirrhosis from any cause predisposes to hepatocellular carci-
noma (HCC). It is quite uncommon to ﬁnd HCC in the absence
of cirrhosis. Cirrhosis related to either hepatitis C virus (HCV)
or hepatitis B virus (HBV) infections represent the major known
risk factors for HCC. Persistent HBV or HCV infection account
for over 80% of HCC cases worldwide.
Although the regenerative activity inherent in cirrhosis is
attributed to predispose to HCC, malignant transformation is
also attributed to a speciﬁc disease state that leads to cirrhosis.
In the absence of cirrhosis, studies have found that HCC almost
always occurs in a histologically abnormal liver and the mere
existence of chronic liver disease represents a potential risk for
HCC development.
APASL/Abstract/PGC I.2.3
Recent progress in imaging of hepatocellular carcinoma from
Ultrasound to PET Scan
Masatoshi Kudo
Department of Gastroenterology and Hepatology, Kinki Uni-
versity School of Medicine, Osaka, Japan
With the recent progress in imaging modalities, detection of
small hepatic nodular lesions has become much easier, but
differential diagnosis still remains difﬁcult. However, a combi-
nation of tomographic imaging techniques and angiography
such as US angiography, CT arteriography (CTA), and CT
during arterial portography (CTAP) has contributed consider-
ably to the differentiation of overt (advanced) hepatocellular
carcinoma (HCC) from benign or premalignant/borderline le-
sions. With such techniques, estimation of the grade of malig-
nancy is also possible.
Recently, non-invasive ultrasonographic vascular imaging
techniques have been developed, such as color Doppler, power
Doppler, and enhanced Doppler imaging. In particular, gray-
scale contrast harmonic imaging proves useful in the manage-
ment of HCC and recently replaced some of the roles of MRI
and CT; ultrasonographic visualization of the vascularity of
viable cancer cells is essential for the US-guided interventional
therapy of HCC.
APASL/Abstract/PGC I.2.4
Pathology of hepatocellualar carcinoma: up-to-date
Masamichi Kojiro
Department of Pathology, Kurume University School of Med-
icine, Kurume, Japan
According to the establishment of follow-up system of the high-
risk populations and the remarkable advance in diagnostic
imagings, increasing number of small hepatocellular carcinoma
(HCC) of the early-stage has been detected and successfully
treated. Extensive studies on small HCC of the early stage have
explored that the majority of early stage HCC is indistinctly
nodular and well differentiated, and it is frequently difﬁcult to
differentiate early-stage HCC from dysplastic nodules. Many of
the early-stage HCCs proliferate with a stepwise process of
dedifferentiation, and a ‘nodule-in-nodule’ appearance morpho-
logically reﬂects the progression of dedifferentiation, process.
However, many of the HCCs are still detected in advanced
stage, and it is also important to understand that HCC some-
times presents unusual morphological features such as sarco-
matous change, intrabile duct or intraatrial tumor growths in
daily practice.
APASL/Abstract/PGC I.2.6
Portal vein tumor thrombosis in HCC: is it really the end of the
road?
Masao Omata, Shuntaro Obi and Shuichiro Shiina
Department of Gastroenterology, University of Tokyo, Tokyo,
Japan
In a previous study by angiograms, the portal vein was shown to
be often used as an outﬂow tract of arterial blood, supplied to
cancer nodules by hepatic artery. This may explain, in part, the
high frequency of portal vein tumor thrombus (PVTT) in
hepatocellular carcinoma. The average life span of patients
with PVTT is only 6 months. Every effort including surgical
removal and liver transplantation failed to reveal that these are
signiﬁcant treatment modalities to prolong patients’ lives. How-
ever, we have recently experienced the success of treating these
patients by the combination of 5FU1Interferon treatment. We
have treated more than 150 cases with PVTT in either the major
trunk or the ﬁrst branch of the portal vein. Among these, more
than 15% of the patients showed complete response (CR) after
the treatment. This is unprecedented, at least for us. In a
previous study, we have revealed that the cases with DCP
positive hepatocellular carcinoma tend to show higher fre-
quency of portal vein tumor invasions (1). In this publication,
those without DCP positivity only developed PVTT in the range
of 1–2%/year, whereas with DCP positivity the range was 20%
(1). DCP is a tumor marker that is produced by tumor cells on
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the condition that Vitamin K is deﬁcient inside hepatocytes.
Therefore, we decided to conduct a study to reveal whether
Vitamin K can prevent the PVTT development in DCP-positive
HCC.We have also attempted to reveal the function of Vitamin K
on tumor growth (2). Among the many signaling systems inside
hepatocytes, we revealed that PKA plays a critical role in
suppression of the tumor gross in vitro. Because of its possible
tumor suppressive effect and ability to prevent portal vein
tumor thrombus, now phase 3 study of the function of Vitamin
K in the prevention of tumor recurrence is ongoing nationwide in
Japan. We also thought of the possibility of pharmacogenomic
measures to predict the treatment effect (3). In this study, we
analyzed hepatocellular cell lines to see whether there is any gene
expression proﬁles which are associated with this treatment effect
(3). In this study, we identiﬁed the genes which may predict
treatment outcome prior to the initiation of chemotherapy (3). In
clinical settings, patients are urgently seeking remedies for of
immediately life threatening disorders and we should continue to
make every effort to treat this condition.
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APASL/Abstract/PGC I.3.1
Liver resection in HCC
Tadatoshi Takayama
Department of Digestive Surgery, Nihon University, Tokyo,
Japan
Introduction: The aim was to deﬁne the evidence-based guide-
line for the surgical treatment in hepatocellular carcinoma
(HCC). Materials and Methods: We searched the papers by
using Medline Dialog System with 4 keywords: HCC, surgery,
English papers, and in the recent 20 years. The clinical evidence
was categorized into 5 levels: level-1 (randomized controlled
trial), level-2 (prospective concurrent cohort study), level-3
(retrospective historical cohort study), level-4 (pre-post study),
and level-5 (case series). Based on the evidence level, we made
the guidelines on 5 surgical issues: surgical indication, proce-
dure, care, prognosis, and adjuvants. Results: We identiﬁed and
reviewed 915 papers, 100 of which were selected as the source of
the guideline. The evidence level comprised level-1 (13%), level-
2 (11%), level-3 (52%), and level-4 (24%). 1) For surgical
indication, Makuuchi’s criteria and ICG clearance test would
be recommended to use. 2) In operative procedure, systematic
segmentectomy would be the most favorable option of choice. 3)
In perioperative care, the nutrition support and hemihepatic
vascular occusion were recommended to use. 4) On prognostic
factor, 3 factors (vascular invasion, HCC stage, and liver
function) were the most powerful prognostic factors. 5) As
postoperative adjuvants, 3 interventions (retinoid, iodine-lipio-
dol, and immunotherapy) had positive effect to reduce HCC
recurrence. Conclusion: We have made a Japanese guideline,
showing that surgery is the primary option of choice for HCC.
APASL/Abstract/PGC I.3.2
Living donor liver transplantation for hepatocellular carcinoma
Deok Bog-Moon, Ki-Hun Kim, Sung-Gyu Lee, Shin Hwang,
Chul-Soo Ahn, Kwang-Min Park
Department of Surgery, Division of Hepato-Biliary Surgery and
Liver Transplantation, Department of Surgery, Asan Medical
Center, Ulsan University, Seoul, Korea.
One million new cases of hepatocellular carcinoma(HCC) occur
each year worldwide, accounting for approximately 1 million
deaths annually. Hepatectomy has been the mainstay of therapy
for these tumor, although 41% of these tumors are nonresectable
due to tumor inaccessibility or extensive cirrhosis with poor
hepatic functional reserve. In recent years, however, progress
has been achieved in the treatment of HCC, and an increasing
number of patients can survive with mwny therapeutic modalities
including transcatheter arterial chemoembolization, percutaneous
alcohol injection, radiofrequency cytoablation, and liver trans-
plantation. Liver transplantation is theoretically an excellent
treatment modality for HCC because this procedure can cure
not only the tumor but also the underlying cirrhosis. Through
most of the 1980s, however, results of liver transplantation for
extensive unresectable HCC were discouraging, with high recur-
rence rates and patients survival of only 30% at 3 years. Because
of the limited supply of cadaveric donor organs and the better
organ allocation, the Milan criteria is widely accepted as patients
selection criteria of liver transplantation for HCC. According to
these criteria, liver transplantation for HCC is limited to patients
with solitary tumor up to 5 cm in diameter or with no more than 3
nodules, each 3 cm or less in diameter. Patients with extrahepatic
spread and/or macrovascular invasion is ineligible. When the
Milan criteria is instituted, the 5-year survival rates have reached
70%. Since living donor liver transplantation has been a successful
and fully accepted treatment for adult patients with end-stage liver
disease, interest in this mpdality as the treatment for HCC has
arisen. The Milan criteria are based on deceased organ allocation.
The situation is quite different from living donor liver transplan-
tation, where the donor comes from self-giving and dedication.
Additionally, many recently published data demonstrate that the
guidelines of the Milan criteria may be too restrictive, potentially
excluding some patients who might beneﬁt from liver transplanta-
tion. The increasing incidence of HCC worldwide ensures that
HCC will continue to be an important and growing indication
especially for living donor liver transplantation. Therefore, it
becomes crucial to establish new patient selection criteria for
living donor liver transplantation
APASL/Abstract/PGC I.3.3
Intraoperative Ultrasound
Keiji Sano, Masatoshi Makuuchi
Hepato-Biliary-Pancreatic Division, Graduate School of Med-
icine, University of Tokyo
Intraoperative ultrasound (IOUS) is now considered to be
indispensable in the diagnosis and the surgical treatment for
liver tumors. In this session we described the basic and novel
techniques of IOUS in liver surgery. The simplest use of IOUS is
detection and diagnosis of the invisible and nonpalpable tumors.
However, especially in patients with chronic viral hepatitis, the
differentiation of classical hepatocellular carcinoma (HCC)
from other precancerous lesions is sometimes difﬁcult in
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IOUS. It is possible that the development of enhanced materials
for ultrasound enables us to make their differential diagnosis.
By injecting contrast materials systemically or via portal vein,
the undetectable tumors by conventional IOUS can be demon-
strated clearly. HCC invades the portal venous branch and
cancer cells detach from the tumor into the portal blood ﬂow,
which would induce intrahepatic metastases in the distal part of
the portal perfusion area. Therefore, systematic resection has
been theoretically considered to be preferable in the resection of
HCC. And it has already been proved clinically that patients
with anatomical resection have signiﬁcantly better prognosis
than those with non-anatomical resection. The technique of
staining portal branches for systematic segmentectomy is de-
monstrated precisely. As for the interventional usage of IOUS,
open biliary drainage for patients with Klatskin tumor should
be introduced. Less involved and less dilated bile duct should be
punctured before resection of the hemiliver which has more
involved and more dilated bile duct. Using this technique we can
puncture 2-mm intrahepatic bile ducts. Doppler ultrasonogra-
phy is another new technique in ultrasound. Doppler ultrasono-
graphy is not only necessary in conﬁrming the ﬂow after
anastomoses but also available in diagnosing hepatic venous
congestion. Just after the dissection of hepatic vein, venous
anastomoses can be detected by Doppler IOUS in only approxi-
mately 20% of the cases. In the other cases, venous anastomoses
cannot be found and the portal branches in the veno-occlusive
area are regurgitated. Doppler IOUS enables us to diagnose the
hepatic congestion and to decide whether or not we reconstruct
the dissected hepatic veins. In summary, the development of
ultrasound has extended the possibility of IOUS in hepato-
biliary surgery and transplantation surgery.
APASL/Abstract/PGC I.3.4
Local ablation therapy: from ethanol injection to radiofrequency
ablation
Shuichiro Shiina
Japan
Backgrounds & aims: In hepatocellular carcinoma, surgical
resection plays a limited role as underlying cirrhosis or multiple
lesions often contraindicates surgery. Furthermore, this cancer
frequently recurs even after apparently curative resection. Con-
sequently, various non-surgical therapies have been developed.
Among them, percutaneous ethanol injection therapy (PEIT)
has been widely used as a standard therapy for small hepato-
cellular carcinoma. On the other hand, percutaneous radio-
frequency ablation (RFA) has recently been introduced in the
treatment of hepatocellular carcinoma. We conducted a rando-
mized controlled trial to compare their survival and recurrence.
Methods: Two hundred and thirty-two patients with hepatocel-
lular carcinoma who had three or fewer lesions, each 3 cm or less
in diameter, and liver function of Child–Pugh class A or B were
entered into a randomized controlled trial. We performed RFA
percutaneously with a cooled-tip electrode. We used the multi-
ple-needle insertion method in PEIT. As a general rule, we
ablated not only the tumor but also some amount of surround-
ing tissue. Two or three days after the treatments, CT was
performed to determine the efﬁcacy. If there were any possible
undestroyed portions, RFA or PEIT was repeated until the
entire tumor necrosis. All patients had CT and US every 4
months to ﬁnd any recurrence. The primary endpoint was
survival, and the secondary endpoints were overall recurrence
and local tumor progression. Results: One hundred and eigh-
teen patients were assigned to RFA and 114 to PEIT. The
number of treatment sessions was smaller (2.1 vs 6.4 times,
Po0.0001) and the length of hospitalization was shorter (10.8
vs 26.1 days, Po0.0001) in RFA than in PEIT. Four-year
survival rate was 74% (95% CI, 65–84%) in RFA and 57%
(95% CI, 45–71%) in PEIT. RFA had a 46% smaller risk of
death (adjusted relative risk 0.54 (95% CI, 0.33–0.89), P5 0.02),
a 43% smaller risk of overall recurrence (adjusted relative risk
0.57 (95% CI, 0.41–0.80), P5 0.0009) and an 88% smaller risk of
local tumor progression (relative risk 0.12 (95% CI, 0.03–0.55),
P5 0.006) than PEIT. The incidence of adverse events was not
different between the two therapies. Discussion: RFA improves
survival of patients with small hepatocellular carcinoma com-
pared with PEIT. This result can probably be explained by the
fact that RFA reduces overall recurrence and local tumor
progression through its more reliable local antitumor effect.
Actually, there was no statistical difference in the recurrence
rates away from the original lesion between the two therapy
groups (P5 0.560), and thus, the difference in overall recurrence
was mainly because of the difference in the local control of the
primary tumor. We have put no restrictions on lesion location.
We have successfully used RFA or PEIT on more than 99% of
patients, some of whom had lesions near the heart, gallbladder,
diaphragm, or on the surface of the liver. In this study, we did not
have any case in which we had to give up treatment because of
tumor location. We have not restricted the number of treatment
sessions. We have repeated RFA or PEIT until CT demonstrates
entire tumor necrosis. As a result, we have successfully ablated
tumors in more than 99% of cases. In this study, we did not have
any case in which the ﬁnal CT demonstrated incomplete tumor
ablation. The incidence of adverse events was not signiﬁcantly
different between the two treatments, although previous compar-
ison studies have suggested that RFA would have higher com-
plication rates than PEIT. Reported mortality rates are 0.3–0.5%
and morbidity rates are 2.2–8.9% in RFA,while they are 0.1%
and 3.2%, respectively, in PEIT. Common complications are
bleeding, biliary injury, and seeding of malignant cells in both
procedures. This study was restricted to tumors 3 cm or less in
diameter, although larger tumors have also been treated with
these procedures. We speculate that the superiority of RFA to
PEIT would be more signiﬁcant in middle-size or large tumors
because of its more reliable local effect. This study was also
restricted to patients with relatively good liver function, although
some patients in Child–Pugh class C have been treated with these
procedures. We are not sure that RFA could achieve better
outcomes in patients with poor liver function, because preserving
liver function might be more important than achieving curative
treatment. Conclusion: Judging from the higher survival but
similar adverse events, RFA is superior to PEIT in the treatment
of small hepatocellular carcinoma.
APASL/Abstract/PGC I.3.5
Abstract withdrawn
APASL/Abstract/PGC I.3.6
Emergent chemoembolization for spontaneous rupture of hepato-
cellular carcinoma
Masatoshi Okazaki
Department of Radiology, Fukuoka University School of
Medicine
Objective: The purpose of this study was to analyze the clinico-
roentogenologic ﬁndings and the prognostic factor of emergent
embolotherapy (E-TAE) for 107 patients with ruptured hepa-
tocellular carcinoma (R-HCC). Materials and Methods: From
1983 to 2003, 107 patients with R-HCC underwent E-TAE. We
evaluate the prognostic factor of E-TAE in these patients. The
patients were divided into two groups. (group A (n5 88):
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hypobilirubinemia less than 3.0mg/dl, group B (n5 19): hyper-
bilirubinemia). Forty-six patients (43%) had portal vein tumor
thrombus (PVTT). Among 61 patients without PVTT, six had
hepatectomy following E-TAE. Chemoembolization with lipio-
dol emulsion and gelatin sponge particles was preferred for
patients without hyperbilirubinemia, while embolization with
particles of gelatin sponge was selected for patients with
extensive tumors or hyperbilirubinemia. Results: Hemorrhage
was stopped immediately after embolization. Progressive jaun-
dice developed in 16 patients who died of hepatic failure and
repeated bleeding within 10 days after E-TAE. Twelve patients
(13.6%) in group A (12/88), and 17 (89.5%) in group B (17/19)
died within 1 month after E-TAE. Fourteen patients (15.9%) in
group A and no patient in group B survived more than 2 years
after E-TAE. Nineteen (41.3%) of 46 patients with PVTT and
10 (16.4%) of 61 patients without PVTT died within 1 month.
Thirteen patients without PVTT (21.3%) and only one patient
with PVTT (2.2%) survived more than 2 years after E-TAE.
Eight patients in group A, including four patients treated by
hepatectomy following E-TAE, survived more than 5 years after
E-TAE. Conclusion: Hyperbilirubinemia is a main factor in
inﬂuencing the risk and prognosis of E-TAE for these patients,
whether PVTT is present or not.
APASL/Abstract/PGC I.3.7
Chemotherapy of advanced stage of hepatocellular carcinoma
Kiwamu Okita
Yamaguchi University School of Medicine, Shimonoseki Koh-
sei Hospital, Shimonoseki, Yamaguchi-Pref., Japan
Hepatocellular carcinoma (HCC) is a major cause of death
among the malignancies in Asia. Early detection of HCC
because of advanced imaging diagnostic technique has contrib-
uted to improving its 5-years survival. However, patients in
early stage of HCC who are the subjects not only of local
therapy such as PEI and RFA, but also of surgical resection, are
so limited. That is, we have to take the huge number of patients
with advanced HCC seriously. In Japan, arterial infusion of low
dose FP(5-FU and CDDP) via hepatic artery and combination
of 5-FU and interferon are performed in 29 of such advanced
patients. Efﬁcacy rate over PR was 48%, while survival rate was
48% in 1-year survival and 15% in 3-year survival.
In this postgraduate course, chemotherapy in advanced stage
of HCC at present will be summarized.
APASL/Abstract/PGC I.4.3
Abstract withdrawn
APASL/Abstract/PGC II.3.1
Abstract withdrawn
APASL/Abstract/PGC III.1.5
Transient elastography: a new non-invasive method for assessment
of hepatic ﬁbrosis
Ryota Masuzaki, Ryosuke Tateishi, Haruhiko Yoshida, Shui-
chiro Shiina, Masao Omata
Department of Gastroenterology, University of Tokyo, Tokyo,
Japan
Background & Aims: The degree of liver ﬁbrosis in chronic liver
disease is classiﬁed into ﬁbrosis stages from F0 (no ﬁbrosis) to
F4 (cirrhosis), which has been found to be well correlated with
the risk of hepatocellular carcinoma. (1–3). However, the
determination of ﬁbrosis stage requires histologic examination
of liver biopsy specimen. Recently developed transient elasto-
graphy apparatus (Fibroscan) provides completely non-invasive
measurement of liver stiffness, and the correlation between the
stiffness thus measured and liver ﬁbrosis stage has been vali-
dated (4–6). Patients & Methods: A total of 137 patients, 127
with chronic liver disease and 10 with normal liver, were
enrolled (Table 1). The stiffness of the liver measured by the
elastography, presented in kPa, was compared with laboratory
tests, etiology of liver disease, liver ﬁbrosis stage, and other
characteristics of patients. Liver biopsy was obtained in 54
patients with hepatitis C, and the correlation was examined.
An ultrasonic transducer (3.5MHz) is mounted on the axis of a
vibrator. The vibrator generates an elastic wave which propa-
gates through the subcutaneous tissues and the liver. During the
propagation of the shear wave, pulse echo ultrasonic signals are
acquired and allow to measure the shear wave velocity. Mea-
surements are totally non-invasive and performed on the right
lobe of the liver through intercostal space between 25 and 45mm
from the skin surface. For each patient, several measurements
(usually 10) were taken. The whole examination duration is
around 5min. Box plots were used to study the liver stiffness
and other laboratory tests distribution according to the ﬁbrosis
stages. The correlation coefﬁcient of Spearman estimated a
trend between liver stiffness, albumin concentration, bilirubin
concentration, platelet cell count, and the ﬁbrosis stages. We
plotted liver stiffness measured by Fibroscan against bilirubin,
albumin concentration, and platelet cell count. Regression
curves were plotted using spline regression. Results: Liver stiff-
ness was well correlated with ﬁbrosis stage (R5 0.688) using the
Spearman rank correlation (Table 2). The stiffness, after loga-
rithmic transformation, was correlated with laboratory tests
including serum total bilirubin concentration , albumin concen-
tration, and platelet count (Fig. 2). Linear correlation with total
bilirubin or albumin was higher in the range over 10 kPa, which
is suggestive of cirrhosis, than in the range below (r5 0.354 vs.
0.014, 0.25 vs. 0.053). In contrast, the correlation with platelet
count was higher in the range below 20 kPa (r5 0.517 vs. 0.085)
(Fig. 3). Conclusions: As compared with laboratory tests, tran-
sient elastography showed wide dynamic range in differentiating
liver stiffness covering both cirrhotic and non-cirrhotic patients.
Sequential determination of liver stiffness may be useful in
assessing progression of chronic liver disease.
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APASL/Abstract/PGC III.1.4
Comparison of Contrast Enhanced US and Histopathologic
Finding in Hepatocellular Carcinoma
S. Sato, S. Shiina, and M. Omata
Department of Internal Medicine, University of Teikyo Mizo-
nokuchi, Department of Gastroenterology, University of To-
kyo, Japan
Distinguishing Benign and Malignant Focal Liver Lesions by
Kupffer Imaging with Sonographic Contrast Agent, Levovist
Purpose: To evaluate the differentiability of the late-phase
harmonic sonography (Kupffer imaging) with the contrast agent
Levovist between benign and malignant liver lesions. Meth-
ods: 150 consecutive patients (102 men and 48 women; mean
age 65 years, range 45–80) with a focal liver lesion suspected of
hepatocellular carcinoma on conventional sonography were
examined with contrast-enhanced harmonic sonography with
Levovist. The Kupffer imaging was generated by stimulated
acoustic emission 5min after intravenous injection of 7ml
Levovist (250mg/dl). The ‘defective’ Kupffer imaging was
deﬁned as no enhancement inside the tumor and the ‘non-
defective’ imaging as otherwise. Ultrasound-guided needle tu-
mor biopsy was performed in each case and histopathology was
evaluated with hematoxylin and eosin staining. Results: 82
(55%) lesions showed ‘defective’ Kupffer imaging while 68
(45%) showed ‘non-defective’ one. On histopathologic exam-
ination, 82/90 (91%) in the former group were either poorly or
moderately differentiated hepatocellular carcinoma, while 57
(95%) out of 60 tumors in the latter group were diagnosed as
dysplasia or well differentiated hepatocellular carcinoma. Ex-
cept 5 cases who chose to receive ablation because of being well
differentiated hepatocellular carcinoma, 52 cases were followed
up with no treatment group. During three years of observation,
only 7 patients of them developed turned out to be classical
hepatocellular carcinoma. Conclusions: Kupffer imaging is a
promising non-invasive technique to differentiate between be-
nign and malignant liver tumors, the use of which may obviate
invasive and expensive further diagnostics.
Using Contrast-Enhanced US to assess the effectiveness of
TAE for HCC: Histological conﬁrmation Objective: The present
study was prospectively performed to elucidate the relationship
between the contrast-enhanced Doppler signals of hepatocellu-
lar carcinoma (HCC) after TAE (transarterial embolization)
and histological conﬁrmation of viable tumor cells. Subjects and
Methods: Between Sep. 2001 and Sep. 2002, 74 nodules in 74
patients were examined. HCC-related Doppler signals were
examined after TAE, and its correlation with tumor viability,
US-guided biopsy specimens was analyzed. We scanned lesions
using contrast-enhanced wideband harmonic US after injection
of a garactose-palmitic acid contrast agent (Levovist). Lesions
were considered to have residual viable tumor if presenting
perfusion images or residual Doppler signals in tumor. Ultra-
sonographic examination was performed with an Advanced
Dynamic Flow system (Toshiba, Japan) with a 3.5MHz convex
probe. Results: After TAE, 50 of the 74 lesions(67%) showed
residual Doppler signals on Contrast-enhanced US. Viable
tumor cells were histologically proven in 43 of 50 nodules(83%)
that presented Doppler signals, while only 3 of the 24 no-
dules(13%) negative for Doppler signals showed viable tumor
cells (Po0.001). Conclusion: Tumor blood ﬂow detected by
contrast-enhanced harmonic US indicates the presence of re-
sidual viable tumor cells after TAE. Contrast-enhanced harmo-
nic US is useful in evaluating the effect of TAE for HCC.
APASL/Abstract/PGC III.2.1
Ultrasound-guided liver biopsy
Hideyuki Tamai
Second Department of Internal Medicine, Wakayama Medical
University, Wakayama, Japan
Diagnostic value: In our department, most liver biopsy is
performed to check for inﬂammatory activity and ﬁbrosis grade
before interferon therapy for chronic hepatitis C. Liver biopsy
should be performed to diagnose the patient with jaundice or
liver injury whose etiology is unknown. Liver biopsy can reveal
the following liver diseases: steatosis or steatohepatitis, auto-
immuno-hepatitis, primary biliary cirrhosis and sclerosing cho-
langitis, idiopathic portal hypertension, congestive liver, and so
on. Biopsy for nodular lesion of the liver can reveal histological
diagnosis or differentiation degree of malignant tumors. Pre-
requisite: Adequate coagulation is required, for example,
thrombocyte count must be more than 50 000/ml; prothrombin
time more than 50%. Also there must be no massive ascites.
Mastery of the technique is needed for safe tumor biopsy. As it
is difﬁcult to direct the biopsy needle to the nodule target of 1 cm
or less, the target nodule must be sonographically visualizable
and it is preferable if the size is more than 1 cm. Although liver
biopsy has a low rate of complication, patient’s cooperativeness
is still required. The patients must be informed of the potential
risks. Written, informed consent should be obtained. Prepar-
ation: Ultrasound equipment which is able to use color Doppler
imaging and tissue harmonic imaging is better for liver biopsy.
Color Doppler can visualize vascular images including vessels to
be avoided. As tissue harmonic imaging can reduce side lobe
artifacts and reverberation, tumor and vessels are visualized
more clearly. A sterile probe sheath or sterilized probe must be
prepared. An exclusive puncture attachment for the probe is
necessary. If the attachment is capable of altering the puncture
angle, tumor biopsy becomes easier. I encourage the use of the
mechanical biopsy needle because of its reliability. Other pre-
parations include intravenous access, premedication, local an-
esthesia and sample preparation. Methods: The ultrasound
equipment we use in our department for liver biopsy or radio
frequency ablation (RFA) is the Hitachi EUB6500 (Hitachi
Medical Corp.). This is a high performance and compact
ultrasound machine, and includes wide band convex probe
and pulse inversion harmonic imaging for both tissue and
contrast. We have newly developed exclusive variable-angle
puncture attachment for this probe. This attachment is ﬁtted
with a needle guide replacement kit (Ultra-Pro IIt; Civco
Medical Instruments Co., Inc.). This kit contains needle sleeves
from 20 to 14G, plastic needle guide and sterile probe sheath.
The probe with a puncture metal attachment is covered with a
sterile sheath and the plastic needle guide is attached outside the
sheath (Figure 1). Numbers 15, 22, 30 and 45 are carved on the
metal attachment in the back view. These numbers indicate the
puncture angle. The puncture angle can be varied according to the
depth of the lesion. Needle sleeves can be exchanged without
changing of the puncture angle (Figure 2). The mechanical biopsy
needle that we use in our department is the Monoptyt (C. R. Bird,
Inc.). Biopsy performed using this needle is speedy and reliable.
This needle is sterilized and disposable and its weight is so light
(only 65g) that needle biopsy can be performed one-handed while
holding probe in the other hand (Figure 3). Sixteen gauge needle for
liver histology and 18G needle for liver tumor is selected. After skin
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disinfection, local anesthesia must be administrated, in a quantity
enough to reduce pain from the skin to the liver capsule. A skin
incision of around 3mm is necessary. For a safe biopsy, the tip of
the needle must be constantly monitored. Making a preliminary
inspection to select a safe puncture line is very important. The
selected puncture line must avoid the bowel, lung, gallbladder,
spleen, large vessels and the bile duct. It is best to approach the
target nodule when it appears clearly and shallowly to achieve this
without taking a deep breath, optimal posture and intercostal plane
factors should be taken into account. For example, sitting position
for lateral segment, or left lateral position for posterior segment is
better. When the biopsy needle runs off from the expected puncture
line in cirrhotic liver or deep lesion, you can tilt the probe to the
right or the left, monitoring the tip of the needle to revise the
direction of the needle (Figure 4). Complication: Bleeding is the
most problematic complication in liver biopsy. Possible bleeding
sites include the intraperitoneal space, under the liver capsule
(Figure 4), the intrathoracic space, and/or the bile duct (Figure 5).
Hemobilia causes abdominal pain and obstructive jaundice. Pneu-
mothorax seldom occurs under ultrasound-guided liver biopsy.
Monitoring after biopsy: In principle, we let the patients take
complete bed rest for at least 4h. After biopsy, monitoring of vital
signs is needed at least once every 30min. Attention should be paid
to any pain or discomfort because these signs may indicate bleeding.
If these signs are observed, subsequent ultrasound, CT or blood
examination must be requested. Antibiotics are administrated for 1
day to prevent infection. In our department, patients must be in
hospital for at least 24h after biopsy.
APASL/Abstract/PGC III.2.2
Local ablation therapy: from ethanol injection to radiofrequency
ablation
Shuichiro Shiina
Japan
Background & Aims: In hepatocellular carcinoma, surgical
resection plays a limited role because underlying cirrhosis or
multiple lesions often contraindicates surgery. Furthermore, this
cancer frequently recurs even after apparently curative resec-
tion. Consequently, various nonsurgical therapies have been
developed. Among them, percutaneous ethanol injection ther-
apy (PEIT) has been widely used as a standard therapy for small
hepatocellular carcinoma. On the other hand, percutaneous
radiofrequency ablation (RFA) has recently been introduced
in the treatment of hepatocellular carcinoma. We conducted a
randomized-controlled trial to compare their survival and
recurrence. Methods: Two hundred and thirty-two patients
with hepatocellular carcinoma who had three or fewer lesions,
each 3 cm or less in diameter, and liver function of Child–Pugh
class A or B were entered into a randomized-controlled trial. We
performed RFA percutaneously with a cooled-tip electrode. We
used the multiple-needle insertion method in PEIT. As a general
rule, we ablated not only the tumor but also some amount of the
surrounding tissue. Two or three days after the treatments,
computed tomography (CT) was performed to determine the
efﬁcacy. If there were any possible undestroyed portions, RFA
or PEIT was repeated until the entire tumor necrosis. All patients
had CT and ultra sonography (US) every 4 months to ﬁnd any
recurrence. The primary endpoint was survival, and the second-
ary endpoints were overall recurrence and local tumor progres-
sion. Results: One hundred and eighteen patients were assigned
to RFA and 114 to PEIT. The number of treatment sessions was
smaller (2.1 vs. 6.4 times, Po0.0001) and the length of hospita-
lization was shorter (10.8 vs. 26.1 days, Po0.0001) in RFA than
in PEIT. Four-year survival rate was 74% (95% conﬁdence
interval (CI) 65–84%) in RFA and 57% (95% CI 45–71%) in
PEIT. RFA had a 46% smaller risk of death (adjusted relative
risk 0.54 (95% CI 0.33–0.89), P5 0.02), a 43% smaller risk of
overall recurrence (adjusted relative risk 0.57 (95%CI 0.41–0.80),
P5 0.0009) and an 88% smaller risk of local tumor progression
(relative risk 0.12 (95% CI 0.03–0.55), P5 0.006) than PEIT. The
incidence of adverse events was not different between the two
therapies. Discussion: RFA improves survival of patients with
small hepatocellular carcinoma compared to PEIT. This result
can probably be explained by the fact that RFA reduces overall
recurrence and local tumor progression through its more reliable
local antitumor effect. Actually, there was no statistical difference
in the recurrence rates away from the original lesion between the
two therapy groups (P5 0.560), and thus the difference in overall
recurrence was mainly because of the difference in the local
control of the primary tumor. We have put no restrictions on
lesion location. We have successfully carried out RFA or PEIT
on more than 99% of the patients, some of whom had lesions
near the heart, gallbladder, diaphragm, or on the surface of the
liver. In this study, we did not have any case in which we had to
give up treatment because of tumor location. We have not
restricted the number of treatment sessions. We have repeated
RFA or PEIT until CT demonstrates entire tumor necrosis. As a
result, we have successfully ablated tumors in more than 99% of
the cases. In this study, we did not have any case in which the
ﬁnal CT demonstrated incomplete tumor ablation. The incidence
of adverse events was not signiﬁcantly different between the two
treatments, although previous comparison studies have suggested
that RFA would have higher complication rates than PEIT.
Reported mortality rates are 0.3–0.5% and morbidity rates are
2.2–8.9% in RFA, while they are 0.1% and 3.2%, respectively, in
PEIT. Common complications are bleeding, biliary injury, and
seeding of malignant cells in both procedures. This study was
restricted to tumors 3 cm or less in diameter, although larger
tumors have also been treated with these procedures. We spec-
ulate that superiority of RFA to PEIT would be more signiﬁcant
in middle-size or large tumors because of its more reliable local
effect. This study was also restricted to patients with relatively
good liver function, although some patients in Child–Pugh class
C have been treated with these procedures. We are not sure that
RFA could achieve better outcomes in patients with poor liver
function, because preserving liver function might be more im-
portant than achieving curative treatment. Conclusion: Judging
from higher survival but similar adverse events, RFA is superior
to PEIT in the treatment of small hepatocellular carcinoma.
APASL/Abstract/PGC III.2.3
Artiﬁcial pleural effusion technique
Hideyuki Tamai
Second Department of Internal Medicine, Wakayama Medical
University, Wakayama, Japan
Deﬁnition: Artiﬁcial pleural effusion is the infusion of 5%
glucose or saline into the thoracic cavity. This method is done
under ultrasound with no special tools. This method is easy and
safe when used. If you can make an artiﬁcial pleural effusion,
the dead space of ultrasound will disappear and the lesion under
the diaphragm dome can be visualized and ablated (Fig. 1). In
addition, safe puncture lines to tumors in posterior segment of
the liver will be available (Fig. 2). Preparation: For making
artiﬁcial pleural effusion, the same preparation used for ultra-
sound guided liver biopsy is needed, that is, ultrasound equip-
ment, a sterile probe sheath or sterilized probe, a puncture
attachment, intravenous access and local anesthesia. In addi-
tion, a bed with a raisable backrest must be prepared, because
radiofrequency ablation (RFA) under artiﬁcial pleural effusion
is performed in the sitting position. We use an exclusive made-
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to-order bed for RFA (Fig. 3). Any position can be maintained
using this bed. The right back of this bed is open for puncture of
the right back. A saturation monitor and oxygen by nasal cannula
are needed for the reason that saturation of oxygen may fall
during instillation of artiﬁcial pleural effusion. The dosage is 500–
1000ml of 5% glucose or saline. A 16 gauges intravenous cannula
(Surﬂo; Terumo, Tokyo, Japan) is used for instillation of artiﬁcial
pleural effusion into the thoracic cavity, in our department. Two
sterile extension tubes to connect the cannula and the route of the
drip are required (Fig. 4). Process: First, the injection site of the
artiﬁcial pleural effusion must be selected. The intercostal plane
where a part of the lung seems to move in time to the breath on the
left side of the ultrasound image, is best for the injection site (Fig.
5). However, the same plane as the target tumor should be
avoided because some air may enter the diaphragm. The entered
air may prevent the observation of the tumor. Second, Local
anesthesia is administrated from the skin to the diaphragm. Third,
20ml of 5% glucose or saline is injected into the diaphragm to
make a space of 1 cm in thickness, to insert an intravenous
cannula (Fig. 6). Fourth, an intravenous cannula is inserted into
the widened diaphragm and is connected to the route of the drip
immediately. The speed of the drops changes in time with the
breath. When the instillation of artiﬁcial pleural effusion is not
effective, the tip of the cannula should be adjusted delicately or a
reinsertion of the cannula should be tried. After instillation of
500ml of 5% glucose or saline, seated position must be main-
tained for observation using ultrasound. If an artiﬁcial pleural
effusion of 500ml is not enough for observation, instillation of
another 500ml is necessary. It is not necessary to drain artiﬁcial
pleural effusion because it will be absorbed in 2–3 days. Compli-
cation: Complications such as bleeding, pnemothorax and pleur-
itis are considered possible, but these complications have never
been experienced in around 150 instances of the artiﬁcial pleural
effusion method being employed in our department. However,
after RFA for large tumors under the diaphragm, artiﬁcial pleural
effusion tends to remain unabsorbed for around 1 month.
State of the Art Lecture
APASL/Abstract/STAL 1
Hepatitis B in 2005
Y.-F. Liaw
Liver Research Unit, Chang Gung Memorial Hospital and
University, Taipei, Taiwan
Key issues on hepatitis B before 2005 have been reviewed in the
APASL consensus update and the European consensus on chronic
hepatitis B and C in HIV co-infected patients, both published in
2005 (Liver Int. 2005;25:472–89 and J Hepatol 2005;42:615–24,
respectively). Existing and emerging data on hepatitis B in 2005
include: (1) Basic studies including molecular biology, HBV mu-
tants, RNA interference and immunology, especially regulatory T
cells; (2) HBsAg seroclearance and occult hepatitis B virus infection;
(3) Association of serum HBV-DNA level and HBV genotype with
the development of liver cirrhosis and hepatocellular carcinoma; (4)
Therapy of chronic hepatitis B with currently available or new
drug(s), including viral kinetic, long-term outcomes, the role of
HBV genotype, the problems and management of drug resistance.
In addition to new ﬁndings, a cost-effectiveness analysis using a
third-party payer perspective has appeared. The analysis has shown
that interferon monotherapy is preferred in health care system with
limited resources, especially in populations with a high prevalence
of HBeAg-negative HBV, and that salvage strategy reserving
adefovir only for lamivuidne resistance my be highly cost-effective
across most health care settings.With the new approval of entecavir
and pegylated interferon 2a for the treatment of hepatitis B, further
studies on cost-effectiveness are needed. In light of these new
developments, the landscape of chronic hepatitis B may change,
including patient selection and drug of choice for initial therapy,
toward better control of chronic HBV infection.
APASL/Abstract/STAL 2
Current status of liver transplantation for hepatocellular carci-
noma from living donor
M. Makuuchi
Artiﬁcial Organ and Transplantation Division, Department of
Surgery, University of Tokyo
It has been generally accepted that the patients with early stage
hepatocellular carcinoma (HCC) and Child C liver cirrhosis are
the best candidate for liver transplantation. HCC develops from
hepatitis B or C (HBV and HCV) cirrhosis, it is important to
control hepatitis virus before and after liver transplantation.
Fortunately, using lamivudine (adephovir) and hepatitis B im-
munoglobulin, we can control HBV almost completely. On the
other hand, HCV is difﬁcult to be controlled by interferon and
ribavirin. HCV infection recurs in all patients and it is the cause of
ﬁbrosing cholestatic hepatitis resulted in graft loss. From the
extension of HCC in the liver, indication of liver transplantation
should be limited toMilan criteria. In our institution, indication of
liver transplant is restricted by the size of the tumor no more than
5 cm and number of nodules no more than 5. Vascular invasion of
the tumor and extrahepatic metastatic lesion are the contraindica-
tion. We have to consider the lower limit of survival in the liver
transplant both in the living and decreased donors. Three-year
survival of the LDLT patients for HCC was 82% (n5 67) in our
institution and 3-year survival was 65% in Japan (n5 316). Even
in advanced HCC, there are patients who can obtain complete
cure. We have to ﬁnd out new indication criteria for HCC.
APASL/Abstract/STAL 5
Recent progress: cholestatic liver injury
J. Heathcote
University of Toronto
Major progress has been made since the mid 1990’s in our
understanding of the control of bile ﬂow as many of the
transporters of the components of bile namely bile acids, inor-
ganic anions and phospholipids as well as cholesterol have now
been cloned. Thus the pattern of disease in children with
progressive familial cholestasis can be subcategorized into types
1, 2 and 3 according to the particular canalicular transporter
defect. It is also possible that in some women who suffer
intrahepatic cholestasis of pregnancy that they too may have a
mutation in the MDR3 transporter responsible for PFIC-3.
Other genetic mutations of transporters have been found in
association with benign recurrent intrahepatic cholestasis and
Dubin Johnson syndrome. Immunohistochemistry studies indi-
cate that compensatory mechanisms may take place once choles-
tasis is established, in that relocation of non-speciﬁc transporters
e.g. MDR3,4 to the basolateral membranes of hepatocytes occurs
thus promoting the transport of bile back into the sinusoid.
Similarly a number of compensatory mechanisms which enhance
bile ﬂow in the presence of cholestasis occur via the nuclear
receptor FXR leading to down regulation of NTCP, CYP7A1,
and CYP8B1 (essential for bile acid synthesis) and up regulation
of BSEP, MDR3 andMRP2 – which enhance bile acid clearance.
Our improved understanding of the mechanisms that control bile
ﬂow will allow for the development of new targeted therapies.
From a clinical standpoint the reversibility of biliary cirrhosis
following relief of extrahepatic biliary strictures is well described.
It remains to be seen whether new drugs may reverse the hepatic
1382
Abstracts
ﬁbrosis that complicates long term intrahepatic cholestasis which
is associated with inﬂammation in the portal tracts. The hydro-
philic, dihydroxy bile acid ursodeoxycholic acid if given early in
the course of chronic cholestatic liver diseases markedly delays
progression of ﬁbrosis, but has not been shown to be associated
with regression of ﬁbrosis. Again, in those patients with inﬂam-
matory diseases of the bile ducts, namely primary biliary cirrho-
sis, Prednisolone and Budesonide have both been shown to delay
progression to cirrhosis in this chronic disease.
Okuda Memorial
APASL/Abstract/Okuda 4
Transjugular intrahepatic portosystemic shunts – the auckland
experience
E. J. Gane,1 A. B. S. Lim,2 A. H. Holden,2 and D. S. Duncan
1New Zealand Liver Transplant Unit,
2Radiology Department, Auckland Hospital.
The New Zealand Liver Transplant Unit provides tertiary
management for the complications of portal hypertension, in-
cluding transjugular intrahepatic portosystemic shunts (TIPS). A
retrospective analysis of TIPS efﬁcacy and clinical outcome at our
centre was undertaken. The clinical records on all patients who
underwent TIPS at Auckland Hospital between September 1998
and May 2005 were reviewed. Clinical indices including aetiology
of liver disease, TIPS indication, Child-Pugh and MELD scores,
pre- and post-procedure serum creatinine and imaging were
documented. Recurrence of gastrointestinal (GI) bleeding, ascites
and hydrothorax, stent patency rates, procedural complication and
mortality rates were analysed. Forty two TIPS procedures were
attempted in 40 patients. Indications were ascites 17 (43%),
variceal bleeding 10 (25%), portal hypertensive bleeding 5
(13%), hydrothorax 2 (5%), hepatopulmonary syndrome 2
(5%), acute Budd Chiari syndrome 1 (2.6%) and severe hypers-
plenism 2 (to allow antiviral treatment for Hepatitis C). Half the
cases were as a bridge to transplantation. Technical success was
achieved in 38 patients (95%). Primary patency was 73%, 50%
and 44% at 3, 6 and 12months respectively. Secondary assisted
patency was 100% at 3, 6 and 12months. Refractory ascites
responded in 16 of 17 patients and control of gastrointestinal
bleeding was provided in 13 of 15 patients. Mean serum creatinine
improved following TIPS (from 0.10 to 0.08mmol/l; p5 0.02).
Cumulative mortality was 7.7% at 1 year, and 12.8% at 6 years.
No procedure-related mortality occurred. Four patients (10.2%)
developed hepatic encephalopathy, 2 were transient and 2 were
intractable (one of whom required listing for liver transplantation).
All TIPS patients awaiting transplantation survived to transplant.
Mean time to transplantation after TIPS was 123days. Expanded
polytetraﬂuoroethylene covered stents were used in 11 patients, of
whom 3 had transient hepatic decompensation, attributed to
partial hepatic venous infarction. Successful TIPS improves
all complications of portal hypertension and may facilitate man-
agement of patients on the waiting list for transplantation. Hepatic
encephalopathy in uncommon and usually responds to lactulose.
Debate
APASL/Abstract/Deb 1
Entecavir as ﬁrst-line treatment for CHB: Pros and Cons
Ching-Lung Lai
Department of Medicine, The University of Hong Kong, Queen
Mary Hospital, Hong Kong
The traditional and pegylated a interferons give the same rate of
hepatitis B e antigen (HbeAg) seroconversion – 32–33% in 1 year,
are associated with a lot of side effects, and are probably less
useful in people who acquire the infection early in life, i.e., the
majority of the Asian hepatitis B carriers. Lamivudine has a high
resistance rate of up to 67–68% after 4 years of therapy. Adefovir,
though associated only with 18% of resistance up to 3 years of
therapy, has potential renal toxicity (3% in 3 years) and is slower
acting than lamivudine. Entecavir is a guanosine nucleoside
analogue. It can inhibit the priming of hepatitis B virus (HBV)
DNA polymerase which involves guanosine triphosphate. Its
EC50 is much lower than those of lamivudine, adefovir, Telbivu-
dine and tenofovir. In large pivotal phase 3 trials involving
HBeAg1 and HBeAg subjects, 81% of patients had o300
copies/ml of HBV DNA after 48 weeks of treatment, compared
with 57% with lamivudine. For lamivudine-refractory patients,
22% had o300 copies/ml of HBV DNA at week 48. For
treatment-naı¨ve subjects, there are no genotypic substitutions
with resistance to entecavir after 48 weeks of therapy. For
lamivudine-refractory subjects with YMDD mutations, 7% of
patients develop entecavir resistance with 1% showing HBVDNA
rebound. Entecavir has safety comparable to that to lamivudine.
With its potency, lack of resistance and side effects, entecavir can
be recommended as a ﬁrst-line agent.
Lunch Symposium
APASL/Abstract/LS 1.3
Appropriate use of interferons in the treatment of hepatitis B
patients
Jia-Horng Kao
Hepatitis Research Center, Graduate Institute of Clinical Med-
icine and Department of Internal Medicine, National Taiwan
University Hospital and College of Medicine, Taipei, Taiwan
Safe and effective treatment strategies for chronic hepatitis B in
order to prevent disease progression into end-stage liver diseases
and hepatocellular carcinoma (HCC) are still needed. Currently,
ﬁve drugs have been approved for the treatment of chronic
hepatitis B: conventional interferon a (IFN-a), lamivudine,
adefovir dipivoxil, pegylated IFN-a and entecavir. The re-
sponses to antiviral therapy are invariably inﬂuenced by both
host and viral factors. Therefore, an understanding of these
factors is important for practicing hepatologists and this may
help design individualized medicine for the treatment of chronic
hepatitis B. Recently, Hepatitis B virus (HBV) genotypes have
attracted increasing attention because they may affect the
disease progression and outcomes of HBV-related chronic liver
disease, as well as the response to antiviral therapies. Although
clinical and pathogenic differences exist among HBV genotypes,
the inﬂuence of HBV genotype on the response to current
antiviral treatments is only partly clariﬁed. Existing data in-
dicate a better sustained response to conventional IFN-a in
genotype B patients than in genotype C patients, and in
genotype A patients than in genotype D patients. Nevertheless,
conﬂicting results exist regarding the response to peginterferon-
a, and more studies are needed. As to HBV genetic polymorph-
isms, our recent data showed that HBV nucleotide consensus
sequence is identical between IFN-a responders and non-
responders. The distribution of nucleotide variations along the
whole HBV genomes is also not different between two groups of
patients. Thus, IFN-a sensitivity-determining region (ISDR)
may not exist within the genome of HBV genotype B, and
host factors as well as virus-host interactions seem more
important than viral factors alone in determining the treatment
outcomes with IFN-a. In fact, our previous study already
demonstrated that certain host genetic background, such as
single nucleotide polymorphisms (SNP) within eukaryotic trans-
lation initiation factor 2, subunit 1 and MxA promoter regions,
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are associated with the responsiveness to IFN-a treatment in
patients with HBeAg-positive chronic hepatitis B. However, the
value of these host genetic polymorphisms in predicting respon-
siveness to peginterferon a-based therapy requires further ex-
aminations. In the foreseeable future, we may need to establish
individualized chronic hepatitis B treatment algorithm tailored
to host (immune status and genomic polymorphisms), virus
(HBeAg status, HBV DNA level, genotype, and precore/basal
core promoter mutants) as well as liver disease status (hepatitis
activity and ﬁbrosis stage).
APASL/Abstract/LS 3.2
What are the goals of therapy that can be achieved?
Nancy Leung1,2
1Alice Ho Miu Ling Nethersole Hospital
2The Chinese University of Hong Kong
Chronic hepatitis B (CHB) virus infection continues to be an
important cause of morbidity, mortality and a source of
potential new infections in many parts of the world. The World
Health Organization (WHO) estimates 400 million individuals
being chronically infected with HBV. HBV is the 10th leading
cause of death worldwide. In China, Southeast Asia, and sub–
Saharan Africa, as many as 10–15% of the population are
chronically infected. Epidemiology is changing as a result of
universal HBV vaccination of newborn being enhanced in Asian
countries, aiming to prevent mother-to-child transmission. Im-
proved socioeconomic situation will also promote better pre-
vention programs. However, population movement with
migrants from high endemicity regions may introduce infection
among those in low endemicity regions. Therapeutic advances
have been shown to have signiﬁcant impact on the incidence of
liver-related morbidity and mortality.
It is clear that sustained viral suppression is the key to the
reduction or prevention of hepatic injury and disease progres-
sion. The ultimate goal of therapy is to prevent hepatic decom-
pensation, to reduce or prevent progression to cirrhosis and/or
HCC, and to prolong survival (durable response). Therefore, the
primary goal of treatment for chronic hepatitis B is to eliminate
or permanently suppress HBV. This will decrease pathogenicity
and infectivity, and thereby stop or reduce hepatic necroin-
ﬂammation. In clinical terms, the short-term goal of treatment is
to ensure HBV DNA sustained suppression, ALT normalization
and prevent the development of decompensation (initial re-
sponse), to reduce hepatic necroimﬂammation and ﬁbrosis
during and after therapy (maintained and substained response).
The ﬁrst goal of therapy for patients with compensated
hepatitis Be antigen (HBeAg) positive CHB is HBeAg loss, or
better still, HBeAg seroconversion, together with, persistent un-
detectable serum HBV DNA as measured with sensitive real time
PCR assays. For patients with HBeAg-negative CHB, persistent
undetectable serum HBV DNA is the main goal. Biochemical and
histological response will follow. The long- term serious sequelae
of CHB such as cirrhosis and hepatocellular carcinoma can be
prevented. Durability of viral responses off therapy is another
goal that we should aim for along with health and economic
considerations. However, without hepatitis B surface antigen
(HBsAg) loss or HBsAg seroconversion, the durability rate is
not guaranteed. Similarly, patients with cirrhosis undergoing
antiviral therapy should aim for these goals; however, the com-
plications from cirrhosis require additional management pro-
grams. The risk of hepatocellular carcinoma might be lowered
but not eliminated. It has become recognized that are HBsAg-
positive patient in immune compromised state or when under-
going immune suppression will experience viral rebound. Prophy-
lactic antiviral therapy will prevent hepatitis ﬂare and
decompensation because of viral rebound and enable patient to
undergo these therapy uneventfully.
Advances in therapy for CHB have abled the goal of therapy
being achieved in higher proportion of the patients. The
eradication of the virus and its deep- seated hold in the
hepatocytes as cccDNA is a goal that may be realized if there
are more potent antiviral therapies that have low rate of
emergence resistant mutants. Combination therapy with im-
mune modulator is an area that requires further investigation.
IASL Symposium
APASL/Abstract/IASL 2
Management of ascites and bacterial infections in patients with
cirrhosis
Patrick S. Kamath
Advanced Liver Diseases Study Group, Division of Gastroen-
terology and Hepatology Mayo Clinic, Rochester, MN, USA
ASCITES Ascites is the most common major complication in
cirrhosis of the liver. It is associated with increased morbidity
from complicating spontaneous bacterial peritonitis and hepa-
torenal syndrome. The median survival of patients with ascites is
2–5 years; patients with refractory ascites have a median
survival rate of 6 months, and those with type 1 hepatorenal
syndrome have survival a rate of approximately 2 weeks.
Management of cirrhotic ascites Ascites results from renal
retention of sodium and water. Therefore, treatment is aimed
at achieving a negative sodium balance. This may be achieved as
follows:
1. Low sodium diet.
2. Fluid restriction.
3. Diuretics.
4. Therapeutic paracentesis.
Complications of large volume paracentesis are unusual and
include abdominal wall hematomas, hemoperitoneum and bo-
wel perforation. These, however, occur in fewer than 1 in 1000
paracentesis.
Management of Refractory Ascites and Hepatorenal Syndrome
1. Large volume paracentesis.
2. Transjugular intrahepatic portosystemic shunts.
3. Systemic vasoconstrictors.
4. Orthotopic liver transplantation.
Management of Spontaneous Bacterial Peritonitis
Antibiotic therapy is recommended with cefotaxime 2 g intra-
venously every 12 h for a period of at least 5 days. Forty-eight
hours after initiation of cefotaxime therapy, a repeat paracent-
esis should be carried out. If there is a 425% decrease in
neutrophil count, then the patient is responding to treatment
and antibiotics are continued for a total of 5 days. On the other
hand, if the neutrophil count has not decreased, one should
suspect secondary bacterial peritonitis and carry out a CT scan
with oral contrast.
In addition to antibiotics, albumin is administered and this is
associated with improved survival. Albumin is initially adminis-
tered in a dose of 1.5 g/kg body weight on day 1 and repeated in
a dose of 1 g/kg body weight on day 3.
Patients who have had SBP should be kept on antibiotic
prophylaxis long term or until liver transplantation. The usual
antibiotic recommended is norﬂoxacin in a dose of 400mg/day.
The only other indication for antibiotic prophylaxis against SBP
is in a patient with cirrhosis and gastrointestinal bleeding. In
these patients, norﬂoxacin 400mg is given once daily for a
period of 7 days. Intravenous antibiotics such as ceftriaxone
may be preferable in this group.
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